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Abstract 
 Dietary macronutrients are an important and controllable factor in health. Current 
research best practices use memory-based dietary assessments (MBDA) to estimate nutrient 
intake. However, there is evidence of bias in information obtained from MBDA as subjects over 
or under report energy and macronutrient intake. Metabolomics is a powerful tool to used 
identify molecular biomarkers of disease risk, not only can provide mechanistic insights into 
macronutrient metabolism but also can inform our understanding of accuracy and precision of 
MBDA. Metabolomics uses high throughput profiling to identify small metabolites in an 
organism. Lipidomics is a subset of metabolomics that primarily identifies lipids. .Here, I 
describe the use of plasma lipidomic profiling to determine the temporal changes in the plasma 
lipidome of healthy male and female adult participants provided high fat or high carbohydrate 
diets and objectively identify dietary macronutrient content. 
 The PUFA study provided a high polyunsaturated fat diet (40-50% fat, 80% 
polyunsaturated fats) for 3 weeks followed by a high carbohydrate diet (75% carbohydrates - 
CHO) to 12 individuals. After 2 days of PUFA, 16% of 480 lipids showed significant changes 
and 27% changed after 21 days. After switching to CHO, 27% percent of lipids changed after 2 
days and 30% after 21 days. This demonstrated that a high PUFA diet produced a rapid turnover 
of the plasma lipidome. Next, we provided a standard diet for 3 days to 24 individuals then 
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randomized to a high fat diet (60% fat, HF) or a high carbohydrate diet (75% carbohydrates, HC) 
for 3 weeks. Fewer lipidomic changes were apparent within group over 21 days, but significant 
differences between experimental groups were apparent. We identified a set of ‘sentinel’ lipids 
comprising mostly plasmalogens and phosphatidylcholines that classified the participants in both 
studies with 87% predictive value. A significant correlation between macronutrient intake and 
predictions in lipidomics data from a study of 102 individuals with known diets highlighted the 
potential use of sentinel lipids to identify dietary intake in free-living population. 
 In parallel with the MEAL study, we compared known diets of subjects with 
reported diets during the study. Participants reported kCal intake accurately but over-reported 
protein intake in all diets. In the high fat diets, fat was under-reported by 6.3% and carbohydrate 
over-reported by 19.8%. In the high carbohydrate diet, carbohydrate under-reported by 10.8% 
and fat over-reported by 66%. These results suggest 24HR estimate energy well in controlled 
feeding studies. However, estimation of extreme macronutrient intakes in the context of a 
feeding study was poor.  
 To assess dynamic changes in the metabolome from acute intravenous glucose 
and insulin, we collected plasma samples from a cohort of obese, metabolically healthy and lean 
individuals during hyperinsulinemic-euglycemic clamps. Targeted profiles of amino acids, fatty 
acids and small organic compounds demonstrated changes associated with glucose infusion rate 
(GIR), rather than obesity. Lean and obese subjects with low glucose infusion rate showed 
greater suppression of plasma fatty acids and increased levels of branched-chain amino acids 
 xvii   
 
throughout the clamp. Paradoxically, insulin suppressed long chain fatty acids while their 
cognate acylcarnitines were unchanged but not shorter chained species. This novel finding 
suggests a clearance difference of acylcarnitines by chain length. 
These studies collectively demonstrate the utility of metabolomics and lipidomics to 
identify macronutrient intake. The development of objective biomarkers of intake could produce 
complementary diagnostic tools for nutritional studies. The identification of differential dynamic 
changes due to macronutrient exposures and insulin sensitivity has the potential to identify 
unknown physiological effects of diet.
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Chapter 1: Introduction 
 
The Role of Diet and Nutrition in Health 
The rise of chronic diet-related disease due to overconsumption has accelerated greatly in 
the last century with 40% of adults and 19% of children and youth in the United States classified 
as obese increasing their risk for heart disease, type 2 diabetes, and some cancers (1). In 2008, 
the estimated costs of medical treatment of disease related to obesity were $147 billion and per 
person was $1,429 higher than for normal weight individuals (2, 3). This rise in obesity is 
indicative of dietary patterns of overconsumption of calories and is evidenced by the under 
consumption of healthy foods such as fruits and vegetables and overconsumption of added 
sugars and saturated fats (2).  
The Current State of Dietary Analysis 
Diet, and in particular macronutrient intake, is an important and controllable factor in 
health (4). Specifically, over-consumption of calories has been associated with diseases such as 
cardiovascular disease and type 2 diabetes mellitus (5, 6), though total nutrient intake seems to 
be more important belied by the preeminence of obesity to the risk of diabetes. In order to 
provide effective advice about nutrition, nutritional science researchers and epidemiologists 
require data about dietary intake of individuals that is both valid and unbiased. However, 
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collecting unbiased dietary intake data proves to be a difficult challenge (7). Current information 
about macronutrient intake depends on large epidemiological studies that is comprised of data 
collected using memory-based dietary assessment methods (MBDA) (2, 8-10). The accuracy and 
precision of the data obtained using MBDA is questionable due to demonstrable underreporting 
and misreporting of energy and macronutrient intake (11-17). 
 In 2015, the United States Dietary Guidelines Advisory Committee released the latest 
dietary guidelines for the country (2). This report contains a dietary component from the 
National Health and Examination Survey (NHANES) entitled ‘What We Eat in America’ 
(WWEIA), which comprises data estimated from memory-based dietary assessment methods 
such as food frequency questionnaires (FFQ) and 24-hour dietary recalls (24HR) (2, 8). This 
report informs both national nutritional policy and dietary guidelines (2). FFQ and 24HR are 
used throughout nutrition research, with perhaps WWEIA being the largest example of the use of 
MBDA (8, 18).  
Collecting dietary intake data proves to be challenging because of the subjective nature of 
data collection inherent with FFQs, DR, and dietary journals (19). MBDAs do not directly 
measure nutrient intake but rather require subjects to remember either foodstuffs that are 
commonly consumed, in the case of FFQs, or food that have been eaten within the last 24 hours 
in the case of 24HR (8, 20). The strength of FFQs is that they provide glimpses into habitual 
intake while 24HR typically assess dietary consumption from the most recent days or weeks 
(19). Research suggests that data obtained using MBDAs exhibit both underreporting and over 
reporting of caloric and macronutrient intake (8, 21-30).  
One difficulty with using MBDA to draw conclusions about actual dietary intake is that 
there is evidence they do not align well with actual dietary intake (31, 32). MBDAs require a 
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certain level of subject literacy and are subject to possible recall bias and withholding of 
information, either intentional or unintentional (8, 33, 34). FFQs tend to have low accuracy, 
under-report energy intake (EI) and have poor generalizability while 24HR under-reported high 
intakes and over-reported lower intakes under-estimate carbohydrates, vitamins, and alcohol (12, 
22, 33, 35). One criticism of the use of MBDAs is that the range of caloric intake reported are so 
large that the lower bounds may not be biologically plausible because they would be lower than 
required for life (36, 37).  
Despite the flaws inherent with MBDA, they continue to be widely used for assessing 
dietary intake and are the best-known source of this information at this point (38). MBDAs are 
relatively inexpensive to administer, are non-invasive, do not require trained health workers to 
draw blood, and do not require laboratory analysis (8, 33). There has been a recent call from the 
Institutes of Medicine (IOM) to fill the knowledge gap in nutritional research through the 
development of objective biomarkers of dietary intake (7). One suggestion to solve this dilemma 
would be the merging of data-driven approaches for dietary analysis such as metabolomics with 
traditional MBDAs such as FFQ and DR (7, 39, 40). 
 
Metabolomics as a Possible Solution 
 The inaccuracies of nutrient intake based solely on MBDAs has led to a call for objective 
measures of dietary intake to be developed (41-44). Metabolomics is a promising technology that 
could provide such measures (41-44). Metabolomics is the comprehensive analytical chemistry 
approach to provide a global description of all metabolites present in biofluids such as a blood 
serum and urine (44, 45). The metabolites found in these fluids is defined as the “metabolome” 
(45, 46) and reflect the downstream products of the genome and proteome and may provide 
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important information about the biological state of organisms (47). The metabolomic analysis is 
used to study alterations in metabolism under different conditions or to find correlations between 
metabolites that might provide insight into biological connections between metabolites (43). 
Metabolomics primarily uses nuclear magnetic resonance spectroscopy or mass spectroscopy to 
identify small metabolites in these samples (48). Once samples are analyzed, they produce very 
large datasets that must be analyzed using advanced statistical methods for high dimensional data 
(42).  
 Metabolomics follows a specific pipeline that starts with sample acquisition, followed by 
sample preparation, sample analysis, and data analysis (43, 46). Sample acquisition in dietary 
analysis usually involves blood plasma or urine collection (41, 43, 49). The goal of sample 
preparation is the isolation of metabolites from larger macromolecules such as proteins and 
larger lipids (46). Sample analysis involves identification of metabolites within the biofluids 
(50).  
Currently, no one technology is best at measuring the entire metabolome. Some analysis 
techniques may be more appropriate for certain metabolites; for example, GC-MS is most 
appropriate for polar, easy to volatilize metabolites (45, 46). Often, parallel and/or redundant 
methods of measurement are used. Nuclear magnetic resonance (NMR) as well as mass 
spectrometry methods such as gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-mass spectrometry (LC-MS) are the most commonly used techniques currently 
used to identify metabolites present in biofluids (43, 45). GC-MS and LC-MS rely upon 
ionization of the gas phase of the sample and then separation of the molecules by mass: charge 
ratio (m/z) and retention times while NMR does not rely upon separation of the analytes (46). 
The advantage of using NMR is its reproducibility and simplicity of sample preparation, but 
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NMR suffers from low sensitivity that limits analysis to only the most abundant metabolites in 
the sample (50). Conversely, MS methods have higher sensitivity but may be more difficult to 
quantitate than NMR and suffer from problems from contamination due to this high sensitivity 
(50). 
Assessment of plasma samples using metabolomics is performed one of two basic 
profiling methods, either a targeted or an untargeted profiling. Targeted profiling uses a small 
group of predefined metabolites chosen for analysis while untargeted profiling obtains a broader 
picture and identifies all metabolites within the sample (41, 51). Untargeted profiling produces a 
much larger metabolome picture and is often used as a hypothesis-generating approach while 
targeted profiling uses known information or assumptions about metabolism and is regarded as a 
more hypothesis-driven approach (46). Depending on the research question, strategies for 
metabolite analysis may include selection of either targeted metabolomics, untargeted 
metabolomics, or both (43). With the advent of metabolomics as a reliable and commonly used 
technology, and problems with the reliability of MBDAs, there have been calls to exploit this 
technology to assess dietary exposure (42).  
Processing of most MS and NMR data begins initially with software specific to each 
machine or manufacturer for analysis or with freely available software for peak detection and 
integration (52). Targeted metabolomics uses isotope-labeled authentic standards, so processing 
is straightforward. Untargeted metabolomics requires that software is capable of peak selection, 
evaluation, and relative quantification (52). After peak detection, researchers conduct library 
searches for presumptive peak identification (53, 54). Missing data is not often a problem with 
small sample sets or experiments, especially in a targeted approach, however in untargeted 
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metabolomics missing data must be imputed using statistical procedures such as a nearest 
neighbor procedure or imputing the minimum detection level (51, 52). 
 
Lipidomics 
While metabolomics is the systematic study of metabolites produced during biological 
processes, lipidomics is a subset of metabolomics which focuses on lipids as the metabolites of 
interest (55). Lipidomics, more than just characterizing the complete lipidome, is the complete 
understanding of how lipids influce biological systems (47). Initially thought only as storage 
molecules and membrane constituents, lipids have proven to have important physiological roles 
including cell signaling, protein modification, and membrane anchoring (47).  
Lipids have classicaly been defined as biological molecules which are generally 
hydrophobic and usually soluble in organic solvents and the presence of long hydrocarbon chains 
(47, 56). Some lipids, such as phosphoinositol, are often soluble in water and steroids do not 
posess the typical hydrocarbon chains (47). Recent work has attempted to develop a 
comprehensive classification and nomenclature system for lipids (47, 56, 57). These lipids have 
been divided into 8 classes: 1) fatty acyls (FA), 2) glycerolipids, 3) glycerophospholipids, 4) 
sphingolipids, 5) sterol lipids, 6) prenol lipids, 7) saccharaolipids, and 8) polyketides (56, 57). 
Recent clarification of naming glycerophospholipids has also added nomenclature to identify 
specific head group moeties including phosphatidylcholines (PC), phosphatidylethanolamines 
(PE), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylglycerols (PG), 
cardiolipins (CL) (57). Furthermore, nomenclature to identify the monoglycerphospholipids may 
use a lyso- prefix for identificiation (i.e. lysophosphatidylcholine uses LPC) and the plasmalogen 
forms of these are identified with an O- prefix to identify the ether bonded to the sn-1 alkenyl 
7 
 
group (PlsCho or PlsEth) (57, 58). Finally, two numbers separated by a colon indicate the total 
hydrocarbon length and total number of double bonded carbons in that chain (56, 57). For 
example, a phosphatidylcholine with 36 carbons and two double bonds would be indicated by PC 
36:2. 
Because of their hydrophobic nature, lipids are not readily transported in the blood 
throughout the body. Instead, they are bound into lipoproteins which are protein/lipid complexes 
which allow transport of the hydrophobic lipids in the aqueus blood plasma (59). There are 5 
types of lipoproteins named according to the density of their lipid constituents: chylomicrons 
(ultra low density lipoproteins; ULDL), very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IPL), low density lipoproteins (LDL), and high density lipoproteins (HDL) 
(60). These lipoproteins all have interiors containing hydrophobic lipids with surface monolayers 
consisting of the hydrophilic heads of phosopholipids and cholesterols (60). Various lipid 
binding apolipoprotein serve to stabilize lipoproteins and act as interact with lipoprotein 
receptors on organelles and cells for uptake and transport (60, 61). 
Lipidomics has been used recently to understand the dysregulation of lipid metabolism in 
diseases such as diabetes (62) and hypertension (63). Hu et al. found that PC and Triacylglycerol 
(TG) were elevated in hypertensive while CE were decreased (64). Lipidomics has also been 
used to find biomarkers of disease such as pre-eclampsia (65). A recent study has shown that 
metabolomics can be effectively used to monitor the dietary intake of phenylalanine in 
individuals with phenylketonuria (66). The work of this dissertation seeks to use lipidomics to 




Statistical Challenges with High Dimensional Metabolomics Data 
Because thousands of metabolite features are produced after analysis with LC-MS and 
GC-MS identification of metabolites which are associated with each feature is challenge and 
often require the use of advanced statistical methods to analyze (46, 51). The number of features 
produced using metabolomics can number in the thousands with many being redundant or 
adducts of known metabolites. Pearson’s correlations overlap between metabolites detected in 
positive and negative mode, and database searching can help to eliminate redundant features and 
limit the size of the data (52). Feature lists are compared to known databases to help identify 
metabolites, but some metabolites may remain unknown (53, 54). False discovery rate (FDR) 
and family-wise error rate methods are used to decrease feature redundancy (52). 
To compare two separate metabolomes, for example a treated group compared to a 
control group, univariate methods such as student’s t-tests (parametric), rank sums 
(nonparametric), and ANOVA (parametric, multiple classes) can be used (51, 52). However, the 
effect of potential confounding variables such as sex, BMI, and age are not taken account by 
these methods and multivariate methods should be used instead (51). Multivariate methods take 
into account all of the metabolomic features simultaneously and are useful at identifying 
relationship patterns between these features (51). Unsupervised methods, such as principal 
component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) are used in 
many studies of metabolomics to identify patterns of metabolite differences between groups (43, 
51, 67-69). Other unsupervised methods such as hierarchical clustering analysis (HCA) have 
been used with metabolomic data to identify non-linear relationships not always discovered with 
PCA (51). In these studies we use univariate methods (student’s t-tests and ANOVA), 
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multivariate methods (linear and non-linear regression), and unsupervised methods (PCA and 
machine learning) 
 
Dynamic Change in the Metabolome 
 Measuring metabolomic differences at several time points during a study allows for the 
identification of dynamic changes in the metabolome. Variations in the metabolome can be 
particularly important for understanding the etiology of both short-term and long-term changes 
due to diet. The dynamics of the metabolome, and lipidome, have only recently been studied. 
Dynamic changes have been used to understand metabolite trajectories associated with early life 
growth between the ages of 6 months and 4 years in humans (69). In this study, 30 children 
provided urine samples which were analyzed using NMR (69). Higher levels of trimethylamine 
N-oxide (TMAO) and betaine were found at the 6 month time period (69). Glycine and 
glutamine were decreased after 6 months along with increases in creatine and creatinine (69).  
With regard to diet, targeted metabolomics has been useful in defining metabolite 
signatures associated with high fat diet (70), the ‘prudent diet’ (71), and the “Western diet” (71). 
In the Krug et al. study, 15 healthy male participants provided several time course plasma and 
urine samples for targeted metabolomics (191 metabolites). Participants’ metabolomes were 
analyzed using NMR to reflect several physiological tests: 1) a single day fast, 2) consumption of 
a standard liquid diet, 3) during an oral glucose tolerance test (OGTT), and 4) physical exercise. 
The finding of this study was that these physiological challenges provided many interindividual 
differences despite physiological similarities (70).  
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Changes in the metabolome due to circadian cycles under different nutritional challenges, 
specifically a high fat diet and high carbohydrate diet, have also been identified (72). Participants 
(8 males) were randomized and consumed one day of a standard diet, a high fat diet (HFD), and 
a high carbohydrate diet. Untargeted plasma metabolomics were analyzed with ultra-high-
performance liquid chromatography-tandem MS at two time points, 8 am and 7 pm. The results 
of the study show differences in metabolomics due to time of day in all subjects (72).  
Dynamic changes in the metabolome have been identified using nutritional challenges 
used to measure insulin resistance such as the hyperinsulinemic-euglycemic clamp (HEIC) (73). 
In this study, 12 women with polycystic ovarian syndrome (PCOS) and 10 age matched controls 
underwent an 8 week exercise program at 60% VO2max. Participants underwent a 
hyperinsulinemic-euglycemic clamp (HEIC) to assess insulin resistance before and after the 
intervention. Plasma samples were provided at three points: before the HEIC, 120 minutes after 
saline drip, and after the HEIC. Metabolomics was assessed using LC-MS/MS (Triple Q) in an 
targeted fashion (163 targets). A decrease in several amino acids (leucine/isoleucine, glutamate, 
methionine, ornithine, phenylalanine, tyrosine, and proline) in PCOS subjects which was not 
seen in control subjects. The were no differences in amino acid profiles between controls and 
subjects after exercise, suggesting that exercise can normalize insulin resistance (73).  
 
Current Uses of Metabolomics in Dietary Analysis 
The use of high-throughput profiling of metabolites in biological fluids has emerged as a 
potential method to provide an objective measure of dietary intake and could supplement MBDA 
in dietary research (19, 41, 43, 44, 74). Multiple studies have identified relationships between 
MBDAs and blood metabolites levels (75, 76). Recent studies using metabolomics to analyze 
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data fall into two basic groups, epidemiological studies using large data sets, and controlled 
feeding studies. The epidemiological studies use large cohort studies to identify specific 
biomarkers of dietary intake while the controlled feeding studies use feeding trials to identify 
biomarkers of intake (44).  
 A few epidemiological studies have identified metabolomics patterns that correspond 
with specific dietary patterns. Bouchard-Mercier et al. were able to identify an increase in plasma 
amino acids and short-chain acylcarnitines (ACAR) in subjects who eat a Western diet when 
compared to those that eat a Prudent diet composed of high levels of fruits, vegetables, and lean 
meats and low in fat and cholesterol (77). McCullough et al. found identified biomarkers for 4 
healthy dietary patterns in post-menopausal woman in the United States were associated with 
consumption of fish (78). Peré-Trepat et al. using an FFQ found that individuals who reported 
eating an animal-based food diet had higher concentrations of lysine, arginine, glutamine and 
glutamate, threonine, aspartate and asparagine, citrate, and polyol compounds in plasma when 
compared to individuals who report a plant-based diet (79). An epidemiological study by Floegal 
et al. used cross-sectional data to identify metabolites from serum showing habitual intake of 
butter (acylcarnitines, acyl-alkyl-phosphatidylcholines, lysophosphatidylcholines, and hydroxy-
sphingomylines), red meat, and fish (hexose and phosphatidylcholines) using a targeted profiling 
approach (80). Habitual potato, dairy product, and corn flake ingestion was identified by this 
study (80). Habitual citrus intake indicated by the metabolite proline betaine when compared to 
FFQs by Heinzmann et al. in 2010 (81). One particular interesting study looked at dietary 
exposures based upon habitual diets (vegan, vegetarian, and omnivorous) then used metabolomic 
data obtained from 1-H-nuclear magnetic resonance to predict habitual intake of meat and other 
animal products (82).  
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While these epidemiological studies are thought provoking and provide evidence that 
metabolomics can be a useful tool for identifying biomarkers of habitual intake, their reliance on 
MBDAs draws into question the accuracy and precision of effect estimates of associations.   
Controlled feeding trials in conjunction with metabolomics could be a potentially be used to 
understand and increase the validity and reliability of MBDAs, especially 24HR (83, 84). 
Metabolomics is used with controlled feeding trials to identify specific biomarkers of dietary 
intake. These fall into three categories: acute feeding trials, short term feeding trials, and habitual 
feeding trials.  
Heinzmann et al. fed 7 subjects a standardized diet for 6 days with different standardized 
meals fed each day (85). The urine metabolome was assessed at 4 points in each day (85). A 
clear metabolite profile exists for fruit and wine ingestion (tartrate, proline betaine, hippurate, 
and 4-hydroxyhippurate (85). Metabolome patterns between subjects also shifted in conjunction 
from diet to diet (85). Metabolite profiles have been identified following acute consumption of 
cocoa (metabolites of cocoa-phytochemicals, alkaloid derivatives, polyphenol metabolites and 
processing-derived products such as diketopiperazines) (86), sugar sweetened beverages 
(formate, citrulline, taurine, and iso-citrate) (49), tea extract (hippuric acid, 4-hydroxyhippuric 
acid, and 1,3-dihydroxyphenyl-2-O-sulfate) (87), salmon (trimethylamine-N-oxide and 1-
methylhistidine) (88), raspberries (ascorbate, sulphonated caffeic acid and sulphonated methyl-
epicatechin) (88), broccoli (ascorbate) (88), coffee (dihydrocaffeic acid-3-O-sulfate and 
feruloylglycine) (89), polyphenols (hesperetin, quercetin, & naringenin) (90), and red meat (2-
aminoadipic acid, β-alaninine, and 4-hydroxyproline) (91).  
Short-term feeding trials tend to be longer than 24 hours but are still controlled feeding 
trials. Using short term feeding, biomarkers for soy feeding, specifically isoflavones have been 
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identified (92). A 12-week feeding trial in individuals with metabolic syndrome of mixed nuts 
was able to identify discernable difference between those who ingested nuts and those who did 
not (93). An 8-week feeding trial of milk and meat protein was able to identify a specific 
metabolic profile in individuals who were given milk but not in those who were fed meat (94). 
Whey protein was found to produce distinct metabolic profiles compared to gelatin protein in 
women with type 2 diabetes over an 8-week weight loss program (95). Another 12-week study 
found specific biomarkers of cheese and butter intake in 23 subjects (96). Cruciferous vegetables 
(97) and dark chocolate (98) consumption biomarkers have been identified using short term 
feeding trials and metabolomics. Several studies have also identified biomarkers of meat intake 
using short term feeding trials and metabolomics (99, 100). Animal studies have shown 
identifiable metabolic changes after 12-week high-fat diets (101).  
 
Metabolomic Response to Standard Diet 
 While biomarkers of specific food intake have been identified using metabolomics, there 
is a gap in the literature in which controlled feeding studies identify dynamic changes in the 
metabolome. A few acute or short-term feeding trials have elucidated convergence of 
metabolomics patterns. Heinzmann et al. performed a study in which subject’s metabolomics 
patterns shifted in parallel relative to different standardized diets (85).  Winnike et al. fed 10 
healthy volunteers a standardized diet for 2 weeks and found that both urine and serum 
metabolite patterns were most diverse on the first day and converged significantly over time 
(76). The metabolome convergence was most pronounced after day 1 and much less so over time 
(76). In a more acute feeding study of standard diet, Favé et al. fed subjects a standardized meal 
the night before a standard breakfast and collected urine up to 4 times (102). It was found that 
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the metabolomics patterns of all subjects converged to a similar pattern soon after the test 
breakfast (102).  
 Habitual feeding studies using metabolomics tend to focus on drawing together 
information from MBDAs and combining that with GC-MS, LC-MS and/or NMR to identify 
dietary patterns in larger populations and/or over longer periods (44). These studies have applied 
metabolomics to samples using food diaries (43, 103), FFQs (44, 104), and 24HR (104). These 
studies have identified metabolite profiles among habitual cocoa drinkers (105, 106). Habitual fat 
intake has been associated with specific lipidomic profile (107). Specifically, habitual saturated 
fat intake is identifiable through detection of phospholipids (108). Habitual milk ingestion is 
associated with specific biomarkers, specifically uridine and trimethyl-N-aminovalerate, in a 
large twin study in the UK (109).  
In one very large study comparing Western diets (United States and United Kingdom) 
with Asian diets (Japan and China) metabolomic profiling was able to identify a Western diet 
from an Eastern diet using urine metabolites (67). Holmes et al. conducted a particularly large 
study using a metabolomics approach and was able to distinguish Eastern Asian diet consumers 
from UK and USA Western diet consumers based upon their blood serum metabolite profiles 
(67). This study involved 4630 participants from the INTERMAP epidemiological study from 17 
populations from China, Japan, UK, and the USA (67). Four 24HRs were conducted to establish 
eating patterns as well as metabolomics profiling of two 24hr urine specimens (67). Using 
hierarchical cluster analysis (HCA) of metabolites, there appeared two clear dietary patterns 
which were grouped into Western (UK and USA) and Asian (Japan and China) (67). These HCA 
results were then confirmed using principal components analysis (PCA) (67). 
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 The TwinsUK cohort is a large epidemiological study involving 3262 monozygotic 
female twins and has been used to establish dietary patterns using urinary metabolomics which 
were used to be modeled using regression analysis and structural equation modelling (112-114). 
Teucher et al. found that dietary patterns determined using FFQs showed a strong heritable 
component for food choice (113). This was followed by a targeted metabolomic analysis of these 
same subjects and it was found that dietary pattern was able to be statistically modeled using 
regression analysis and structural equation modeling (112). In a recent study by Pallister and 
Jennings et al. habitual food intake of this same population was determined using FFQ and then 
71 reported food groups were assessed against 601 identified metabolites (114). This study 
identified 180 significant associations with 39 food groups that contained 106 different 
metabolites (114). Ergothioneine was found to be a biomarker for mushroom intake, trans-4-
hydroxyproline for red meat, and 3-phenypropionate, indoleproprionate, and threitol for fruit 
intake (114). Recently, this same group also found trimethyl-N-aminovalerate, 
hydroxyphingomyelin, and diacylphosphatidylcholine 28:1 are associated with milk intake with 
this same group of subjects (109).  
Recent work has proven that metabolomics holds promise for use in dietary recall. 
Metabolomic profiles successfully classified subjects according to their diets with very high 
accuracy (115). Urinary metabolites have been used to classify individuals into “healthy” or 
“unhealthy” dietary patterns based on metabolomics patterns (49). Lipidomic pattern dynamics 
in a high fat diet following a high carbohydrate diet has recently been investigated by feeding 46 
heathy, non-obese pair twins (116). In this study, subjects were given a high carbohydrate diet 
(15% protein, 30% fat, 55% carbohydrate) for six weeks followed by six weeks of a high fat diet 
(15% protein, 45% fat, 40% carbohydrate) (116). Lipidomic analysis revealed five distinct lipid 
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patterns, a) no reaction, b) a monotonous increase, c) an acute increase followed by plateau, d) 
stable concentration for one week followed by a delayed reaction, and e) a counter regulation 
with an acute response in one direction for one week followed by a rebound in the opposite 
direction after this (116).  
Nutritional metabolomics has been able to identify specific foods biomarkers for dietary 
intake (41-44, 110, 111). However, with the exception of studies in habitual fat intakes (107, 
108), little has been reported on metabolite changes due to controlled changes in macronutrient 
content of food. The Holmes study which identified subjects who consumed either a Western or 
an Eastern diet based upon their metabolome is promising because of the inherent difference in 
these diets (67), but this study was not a controlled feeding study. This leads us to a particular 
gap in the literature. We were not able to find many studies using metabolomics to identify 
specific differences in the metabolome that used a feeding study in which the macronutrient 
content of diet was identified and well controlled. 
 
The Use of Metabolomics during the Hyperinsulinemic-euglycemic Clamp 
Metabolomics elucidated differences in metabolism between insulin resistant and insulin 
sensitive individuals. Several studies have identified changes in plasma levels of amino acids, 
TCA cycle intermediates, and fatty acids (117, 118). Metabolomic analysis has shown that that 
circulating branched-chain amino acids (BCAA) correlate negatively with insulin sensitivity and 
T2DM due to obesity when compared to lean, healthy individuals (119). Metabolomic analysis 
identified elevations in plasma BCAAs, aromatic amino acids, 2-aminoadipic acid, and lipids of 




These findings highlight the use of metabolomics to enhance our knowledge and 
understanding of metabolic disorders like insulin resistance and T2DM and their causes (118, 
125-128). Recent metabolomics studies have identified biomarkers and metabolites associated 
with cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. The phospholipid 
phosphatidylcholine 34:2 has a positive correlation in patients with metabolic syndrome (MetS) 
and comorbidities such as waist circumference, plasma glucose, free fatty acid and triglyceride 
levels (129). The BCAA isoleucine positively correlates with MetS while lysine is negatively 
correlated (130). It has long been known that insulin resistance is positively correlated with the 
BCAAs, tyrosine, phenylalanine and negatively correlated with glycine (131), but recent work 
using the more sensitive metabolomics methods has identified a glutamine (positive correlation) 
and glutamate (negative correlation) as potential identifiers of insulin resistance (132). To 
strengthen these findings, a recent large population study of Finnish men identifies nine amino 
acids are associated with insulin resistance and T2DM (133); these were phenylalanine, 
tryptophan, tyrosine, alanine, isoleucine, leucine, valine, aspartate, and glutamate.  
 This dissertation utilized high throughput metabolomic and lipidomic methodologies to 
understand dynamic changes in the metabolome and lipidome due to changes in dietary intake 
using two modalities. First was a 24-day feeding study of a standard diet followed by very high 
carbohydrate and very high fat diets. Second, we compared the plasma metabolomic profiles of 
individuals collected during a hyperinsulinemic-euglycemic clamp (HEIC) which involved 
intravenous glucose administered over the course of an hour.  
In the study of insulin resistance, the use of metabolomics is new and provides great 
promise both in finding predictive biomarkers as understanding the physiological implications 
and actions of the disease (118, 134). Metabolomics elucidates differences between insulin 
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resistant and insulin sensitive individual’s levels of amino acids, TCA cycle intermediates, and 
fatty acids (117, 118). Acylcarnitines have been implicated, through metabolomic profiling, as a 
possible cause of insulin resistance (135). Acylcarnitines are thought to be incompletely oxidized 
through muscle fatty acid ß-oxidation and could play a role in muscle insulin resistance (136). 
Incomplete fatty acid oxidation (FAO) outpacing the tricarboxylic acid cycle could result in the 
accumulation of excess acylcarnitines that interferes with insulin sensitivity (135). However, 
whether insulin sensitivity is caused by an increase in acylcarnitines or results in an increase in 
acylcarnitines is not understood (137).  
In a metabolomics study during an oral glucose tolerance test (OGTT), medium chain 
acylcarnitines, CAR 10:0 and 12:0, were found to be associated with insulin resistance in a large 
(n=470) study of older men (age 70.6±0.6) while these associations were not found in longer 
chained and shorter chained acylcarnitines (138). While metabolomics has used to study 
dynamic changes in the metabolome during glucose tolerance test, these dynamics are poorly 
studied in the HEIC. This is of interest because the HEIC is considered the gold standard in the 
measurement of insulin resistance. One study did find that insulin stimulation lowered most 
medium- and long-chained acylcarnitines compared to basal levels in healthy individuals and 
that leucine, isoleucine, and lysine negatively correlate with insulin sensitivity (139).  
One aim of this dissertation work is to elucidate the dynamic changes in metabolite 
profiles using metabolomics during the HEIC. In particular, obese metabolically healthy 
individuals were studied who were either more or less insulin sensitive based on their glucose 




Currently in nutritional research, dietary intake of both individuals and populations is 
established using MBDAs. However useful, the validity of estimates of dietary intake based 
solely on MBDAs is in question (140). Metabolomics has emerged as a tool that could provide 
an objective measurement of dietary intake (43, 74, 141). With the emergence of metabolomics 
and subsequent use in nutritional analysis, there has been significant use in the identification of 
biomarkers of specific food intake. There has also been much of use of metabolomics to identify 
both dietary patterns as well as biomarkers of intake using MBDAs. However, because both 
reliability and validity of MBDAs has come into question, there is a significant gap in the 
literature and the science in using metabolomics as an indicator of objective macronutrient 
intake. Furthermore, there has been a recent call for the merging of data-driven approaches for 
dietary analysis such as metabolomics with traditional MBDAs such as FFQ and DR (39, 40). 
Secondly, there have been several acute and short term controlled feeding trials using 
metabolomics that determined biomarkers of dietary intake of specific nutrients (141). Despite, 
this there has been little work done on changes in metabolomics patterns using controlled feeding 
trials of macronutrient intake.  
Study Population 
This study utilized four distinct adult study populations. The first feeding study 
population was a group of 12 healthy controls in a high polyunsaturated fat (PUFA)/high 
carbohydrate (CHO) feeding study. The second feeding study population was a group of 23 
healthy individuals who took part in a 24-day high fat/high carbohydrate feeding study (MEAL). 
A third population of subjects tested against the training populations of the PUFA/CHO and 
MEAL and was a group of 46 healthy controls in a bipolar feeding study. This population came 
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from the community as a whole and we refer to as the Community population (Community). The 
final population was for the hyperinsulinemic-euglycemic clamp study and involved 18 subjects. 
 The PUFA/CHO study was initially designed to look at the efficacy of a high PUFA diet 
to change the viral load in individuals with hepatitis C. Here, we analyze the data from the 12 
healthy controls recruited for the study. The subjects were fed a high PUFA diet for three weeks 
followed by an immediate switch to a high CHO diet for three weeks. Plasma samples were 
collected from these subjects for comparison at baseline and then on days 2, 7, and 21 of each 
experimental diet for a total of 7 samples. 
 The high carbohydrate/high fat study (MEAL) was designed to identify dynamic changes 
in the metabolome of subjects during a 24-day feeding study. 23 subjects (11 ♀/12 ♂) were fed a 
standard diet (12% protein/ 35% fat/ and 50% CHO) for 3 days followed by either a high CHO 
diet (15% protein/ 10% fat/ 75% CHO) or a high fat (15% protein/60% fat/25% CHO) for 21 
days following the standard diet. Plasma samples were collected at baseline, after the standard 
diet, and at 4 points during the experimental diet for a total of 6 time points. 
 In the Community population, 43 healthy control subjects from a bipolar study were 
selected. These individuals were not bipolar. These individuals gave one plasma sample at the 
end of one week in which their diets were ascertained with 7 consecutive days of dietary 
journals. 
 In the hyperinsulinemic-euglycemic clamp study, there were 18 individuals; 6 lean 
controls, 6 metabolically healthy obese individuals who were more insulin sensitive, and 6 
metabolically healthy obese individuals who were less insulin resistant. These subjects all took 
part in a larger study conducted by the lab of Dr. Jeffrey F. Horowitz at the University of 
21 
 
Michigan. Each underwent a hyperinsulinemic-euglycemic clamp with 7 plasma samples taken 
during the clamp and analyzed for metabolomic differences between groups. 
 
Thesis Aims 
This leads us to the specific aims of this dissertation work: 1a) determine dynamic 
changes in the lipidome due to high carbohydrate and high fat diet. 1b) identify diet as either 
high fat or high carbohydrate based on biomarkers determined using lipidomics. 2) Compare the 
recalled macronutrient intake with the actual macronutrient intake of subjects in a controlled 
feeding study. 3) Compare the metabolomic profiles of a) obese but metabolically healthy 
individuals who are more insulin sensitive, b) less insulin sensitive, and c) lean control (fig. 1.1). 
Thesis Overview 
 Chapter 2 identifies dynamic changes in the lipidome due to high fat and high 
carbohydrate diets. Furthermore, 54 lipid classifiers (Sentinel lipids) were used to successfully 
classify subjects as either high carbohydrate or high fat eaters. Lastly, “real-world” diets were 
successfully classified as either high fat or high carbohydrate based using these sentinel lipids. 
 Chapter 3 compared recalled diet using 24-hour recalls (24HR) with provided diet for the 
23 subjects in the MEAL study. The goal of chapter 3 is to ascertain the reliability of 24HR in a 
controlled feeding. 
Chapter 4 investigated the metabolomic changes in metabolically healthy obese 
individuals and lean control individuals who were either more insulin sensitive or resistant.  
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Chapter 5 summarizes the work of this dissertation and offers recommendations and 
future directions for research on expanding the scope of this research to increase the 








Figure 1.1 Overview of the aims of this dissertation. 
 
 
Schematic overview of the aims of this dissertation. The overall research question is: “How 
does macronutrient intake effect the metabolomic profile after high fat or high carbohydrate 
diet?” The PUFA/CHO and MEAL studies’ macronutrient proportions are indicated on the 
right with protein, fat (PUFA/MUFA/SFA) and carbohydrate. Aim 1 focuses on development 
of a biomarker that differentiates between high fat and high carbohydrate diet. Aim 1a 
focuses on the dynamic changes in the lipidome and Aim 1b on identifying and testing 
biomarkers that differentiate between high fat and high carbohydrate intake. Aim 2 compares 
actual diet and 24HR reported macronutrient and EI. Aim 3 identifies dynamic metabolomic 
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Chapter 2: Towards Unbiased Assessment of Nutrient Intake: 
Dynamic Response of the Plasma Lipidome to Macronutrient Intake 





Nutrition researchers use several forms of memory based dietary analysis (MBDA) to estimate 
dietary intake. However, dietary intake information that comes from MBDAs is flawed as 
subjects misreport both energy intake and macronutrient intake. Given these limitations, 
developing lipidomics as a tool to assess objective dietary intake would provide a significant 
addition to epidemiological studies in assessing diet and understanding dynamic changes in 
lipidome as a risk for chronic diseases.  
Objective:  
The first aim of this study was to elucidate the dynamic changes in the lipidome in humans on a 
very high fat and very high carbohydrate feeding diet. The second aim was to identify lipidomic 
biomarkers that would discriminate high fat and high carbohydrate diets and to validate these 




We used two controlled diets in this study. The first was a 21-day PUFA/21-day CHO study with 
12 subjects. The second study fed 24 subjects a standard diet for 3 days followed by 3 weeks of 
either a very high fat (HF) or very high carbohydrate diet (HC). We conducted plasma lipidomic 
analysis on samples from these studies to identify lipid differences and similarities. Statistical 
analysis identified 12 “Sentinel Lipids” which were significantly different between PUFA/CHO 
and HF/HC. Support Vector Machine learning (SVM) produced ROC curves using Monte-Carlo 
cross validation, identify important features, and produce predictive probabilities of a validation 
test set.  
Results:  
We elucidated dynamic changes in the lipidome of the PUFA/CHO study and HF/HC study. In 
the PUFA/CHO, we observed rapid changes in lipid levels with 41% changing after 2 days of 
changing to a PUFA diet and 64% within 2 days of changing of a CHO diet. Plasmalogens, 
LPCs, and LPEs changed in a slower fashion. Approximately 200 lipids were statistically 
different between CHO and PUFA at tested days. After 3 days of a standard diet, variation in the 
lipidome decreased significantly in the MEAL study. The MEAL study showed similar patterns 
to PUFA/CHO but with much less significant differences. After ROC analysis, selected 
important features were able to discriminate between plasma samples of high fat and high 
carbohydrate with an AUC of 0.873.  
Conclusion:  
The lipidome is very responsive to diet. Variation decreased after 3 days of a standard diet 
highlighting the need for feeding studies to begin a standard diet to normalize the lipidome. 
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Several lipids showed an adaptive response to feeding which demonstrates that lipids change 
quickly after a HC or HF feeding, but this difference is blunted (but still significant) over 3 
weeks. Several lipids also showed a monotonous and stable response providing evidence that 
finding an objective measure of macronutrient intake is possible. We also identified a small 
panel of lipids that discriminate between very high fat and very high carbohydrate diets. While 
quite preliminary, and limited by small sample size, these sentinel lipids perhaps hold promise 
for identification of macronutrient intake in free-living populations.  
 
Introduction 
Diet, and in particular macronutrient intake, is an important and modifiable lifestyle behavior (1). 
Specifically, macronutrient intake has been associated with cardiovascular health and type 2 
diabetes mellitus (2, 3). Current recommendations about energy and macronutrient intake are 
based on large cross-sectional studies such as What We Eat in America which utilizes data from 
the National Health and Nutrition Examination Survey (NHANES) (4, 5). Several forms of 
memory based dietary analyses (MBDA), such as food frequency questionnaires, 24-hour recalls, 
and food diaries are routinely used to estimate actual food intake (4, 5).  
Despite their widespread use, there is abundant evidence that dietary intake information obtained 
from surveys and recalls are biased as subjects misreport both energy and macronutrient intake 
(6-12). As a result, epidemiological studies use well-established methods of adjustment to 
account for these inconsistencies (13-16). Associations between diet and disease in the context of 
nutritional intake are often drawn from information obtained via MBDAs (17, 18). The use of 
biased dietary information could potentially lead to inaccurate estimation of the effects of diet on 
42 
 
health (19-23). Despite the known limitations with MBDAs, they remain the primary approach to 
estimate dietary intake (4, 5, 11).  
Metabolomics is an emerging technology that could be used in conjunction with epidemiological 
studies to provide an objective method for measuring dietary intake and relating it to chronic risk 
for disease (24-27). Current uses of metabolomics in dietary research tend to fall into two basic 
categories, epidemiological studies that rely on large data sets and controlled feeding studies. 
Epidemiological studies use large cohorts to identify specific biomarkers of intake and relate 
these biomarkers to health outcomes (28), while the smaller feeding trials use controlled feeding 
trials to identify biomarkers of intake of specific foods (29). For example, a diet characterized by 
higher intakes of red meat and lower intake of whole-grain bread and tea was identified in the 
large EPIC-Potsdam cohort was associated with hexose and PCs in serum (30). Wellington, et. 
al., used metabolomics to successfully identify human dietary patterns, specifically “Western” 
and “Prudent” dietary patterns (31). Another study identified the association of the blood 
metabolite betaine with citrus fruit consumption in a feeding study and validated these findings 
in a larger cohort (32). A few studies have identified relationships between blood metabolites 
and MBDA data (33, 34).  
Research into dynamic time course changes in the metabolome following diet have also 
been examined in a handful of studies (31, 35, 36). The first study by Pellis, et. al.,  performed 
metabolomic and proteomic analysis following a postprandial challenge test (PCT) comprised of 
59% lipids, 30% carbohydrates, and 12% protein as a percentage of total kCal (35). Thirty-six 
overweight subjects were given a PCT before and 5 weeks after following an anti-inflammatory 
supplement mix in a crossover design. These authors were able to identify differences in 
metabolites associated with amino acid, oxidative stress, inflammation, and endocrine 
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metabolism before and after supplementation (35). In a study involving 46 healthy, non-obese 
twin pairs, Frahnow, et. al., performed lipipomic profiling on subjects at baseline, after 1 week, 
and after 5 weeks after switching from a low fat to high fat eucaloric diets. They found that lipid 
profiles diverged after only 1 week of the change to a high fat diet and further after 5 weeks (36). 
In the final study, 42 subjects were provided a eucaloric Prudent or Western diet for 2 weeks and 
targeted and untargeted metabolomic profiling was performed on both plasma and urine (31). 
Several small metabolites were identified which were associated with consumption of these diets 
including linoleic acid, α-linoleic acid, and linoelaidic acid (Western diet) and ketoleucine, 
ketovaline, nad hydroxypipecolic acid (Prudent diet) (31).  
The aim of this study was three-fold: 1) Description of dynamic metabolomic changes that occur 
after a 3-day diet followed by 3-week high fat or high carbohydrate diet, 2) identification of 
lipidomic patterns which differentiate between very high carbohydrate diets and very high fat 
diets and development of a training set of metabolites, 3) classification of subjects on “typical” 
or “normal” diets as either high carbohydrate or high fat using patterns based on metabolites 
identified in aim 2. 
Methods 
 
Controlled Feeding studies:  
Two controlled feeding studies and one cross-sectional study were used to conduct this research. 
The first was a high polyunsaturated fatty acid diet (PUFA) followed immediately by a high 
carbohydrate diet (CHO) and is referred to as the PUFA/CHO study. The second controlled 
feeding study was a standard diet followed by either a high fat (HF) or a high carbohydrate (HC) 
diet and is referred to as the MEtabolomic AnaLysis of Diet study (MEAL). The test study 
(Community) was a cross-sectional study of control subjects from another study of healthy 
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controls from the community who were taking part in a study of bipolar disorder. Subjects in the 
Community study completed 7 consecutive days of dietary journals so their diets are relatively 
well characterized.  
Recruitment and Ethics:  
The Michigan Institutional Review Board approved all procedures involved in this study 
(HUM00006248, HUM000110543 and HUM00045653) and we obtained informed consent 
forms from all participants before beginning any portion of the study. All recruitment of 
participants for each of the studies described used umclinicalresearch.org and local 
advertisements. 
PUFA/CHO Study:  
The first controlled feeding study used a longitudinal paired study design without crossover 
involving 12 (6 male, 6 female) subjects. These subjects consumed a very high PUFA diet (10-
15% Protein, 25-50% carbohydrate, & 40-50% fat; 10% MUFA, 10% SFA) for 21 days 
immediately followed by 21 days of a high carbohydrate diet (10-15% protein, 70-80% 
carbohydrate, & 10-15% fat; <10% SFA) (Figure S2.1). Recruitment criteria were between the 
ages of 19 and 50, no history of metabolic disorders, no recent changes in weight, and no current 
use of metabolism altering medications.  There was no washout period between diets. On the 
initial day (Day 0), subjects were consented, weighed and measured, and provided with food for 
the first 2 days. Subjects returned to the metabolic kitchen twice per week during the study to 






Blood collection:  
 
We collected 7 overnight-fasted blood samples in 10.0 mL EDTA treated vacutainers 
(www.bd.com) on days 0, day 2 of the PUFA diet (P2), P7, P21, day 2 of the CHO diet (C2), C7, 
and C21. Samples were immediately inverted 7 times and placed on ice to be processed in ≤1 hr. 
Plasma was frozen at -800C for later LC/MS analysis.  
MEAL Study:  
The MEAL study used a parallel randomized block design blocked by sex and involved 23 
participants randomized to 2 experimental diets, high fat (HF) and high carbohydrate (HC), 13 
HC (7 male, 6 female) & 10 HF (5 male, 5 female) (Figure S2). Recruitment criteria included 
subjects between the ages of 19 to 40, BMI 18.5 to 25, no history of metabolic disorders, no 
recent change in weight, and no use of metabolism altering medications. Initial protocol called 
for 24 subjects. One HC participant was removed for non-adherence to the assigned diet that was 
recognized in the data and was confirmed by a post-study questionnaire administered to the 
participants. This reduced the total number of subjects in the analytic sample to 23. 
 
Study design summary and randomization scheme:  
 
Participants completed baseline assessments, consumed a ‘standard’ diet for 3 days, and 
randomly assigned to experimental diet groups for the following 21 days (Figure S2). We 
randomized subjects into study groups based upon date of consent and blocked by sex. A random 
number generator (Microsoft Excel 2016) was used to assign subjects into diet groups. 
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Participants returned to the study location every 2-4 days for repeated assessments and to pick-up 
food.  
Body composition and anthropometry:  
 
Baseline height was measured in duplicate to the nearest 0.5 cm using a wall-mounted 
stadiometer (Easy-Glide Bearing Stadiometer, Perspective Enterprises, Portage, MI). Weight was 
measured in light clothing to the nearest 0.1 kg using a calibrated electronic scale (Scale-Tronix 
Model 6002, White Plains, NY). At each food pick-up current weight was measured. If body 
weight fluctuated more than 1 kg, the total kcal provided were adjusted to maintain baseline 
body weight.  
Blood collection:  
 
Fasted blood samples were collected in EDTA treated vacutainers ((www.bd.com)) on days -3, 
0, 2, 7, 14 and 21. Samples were immediately inverted 7 times and placed on ice and processed 
in ≤1 hr. Plasma aliquots were frozen at -800C. Lipidomics:  
Untargeted LC/MS-based shotgun lipidomics was performed on -800C frozen, once-thawed, and 
single-aliquot plasma samples in a manner detailed in Afshinnia et al (37), including sample 
extraction and preparation on plasma samples. Mass spectroscopy data acquisition for each 
sample was performed in both positive and negative ion mode using a TripleTOF 5600 equipped 
with a DuoSpray Ion Source as performed earlier by Kregel, et. al. (38). 605 lipids and 563 lipids 
combined in positive and negative mode were annotated for the PUFA/CHO and MEAL studies 
respectively. Lipidomics data were normalized to remove batch and run order effects. Each lipid 
was normalized individually, without the use of internal standards. Positive and Negative modes 
were treated separately, until the final step of removing redundant duplicate lipids. 
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Pooled samples were derived from combining of small aliquots of experimental samples and 
were dependent on each experiment (PUFA/CHO, MEAL, or Community). Lipids missing more 
than 30% of data from either the pooled samples or the experimental data were removed. Robust 
regression on the pooled data was used to calculate an adjustment ratio between batches within 
each experiment; this ratio was then used to remove batch effects. For each lipid i, we calculate a 
batch-adjustment factor βi. If there were two batches, this adjustment factor was the slope from 
the robust regression of one batch on the other, without an intercept. If there were more than two 
batches, one batch was selected as the reference, and all other batches were regressed against the 
reference batch individually. We calculated the adjustment ration between batches using the 
lmrob function from the R package robustbase. Once the adjustment factors were calculated, 
missing data were imputed using the knn function from the R pamr package. Imputation 
considers the batch number, run order and sample label. Loess smoothing was used to remove 
the remaining effects of run order. Once all batch and run order effects had been adjusted, data 
from positive and negative modes were combined and redundant lipids removed. If a lipid was 
present in only one mode, but with multiple ions, the ion with lowest variability as measured by 
relative standard deviation (RSD) was retained. If a lipid was present in both modes, we picked 
the mode that had the most lipids of that lipid’s class and kept the ion w/ the lowest RSD within 
that mode. If a lipid is present in both modes with identical number of ions/lipids present, we 
retained the ion with the lowest RSD across both modes. After normalization and the elimination 
of duplicates, there remained 480 lipids in the PUFA/CHO study, 571 in the MEAL study, and 
549 in the Community study (Supplemental Tables S2.1 to S2.7).  
 For each subject in both PUFA/CHO and MEAL, we calculated log2 fold difference from 
baseline and between time points using Microsoft Excel 2016 as the log2 (resultant lipid 
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AUC/initial lipid AUC) (Redmond, WA, USA). We calculated fold difference for the time 
intervals 0 to P2, P2 to P7, P7 to P21, & 0 to P21 in the PUFA/CHO study and for 0 to 2, 2 to 7, 
7 to 14, 7 to 21, and 0 to 21 in the MEAL study. Statistical significance between time points was 
determined using an FDR correction of 0.1 (Figures 2.1 & 2.2). Because these samples were 
from 2 different studies, extracted at different times, and run on LC/MS at different times, all 
lipids were median scaled to the MEAL samples, which contained the greatest number of lipids. 
Median scaling involved multiplying all lipids by a ratio of the median of pooled samples for 
each lipid (MEAL pooled lipid/Pooled lipid). The average AUC for all studies was more 
abundant in the MEAL study so we used the MEAL study lipids as the numerator. 
Analysis of Variation of Lipids between Days:  
To demonstrate the reduction of variation in all lipids after a standard diet, we calculated the 
variance in each lipid during each day in the MEAL study. For each day in the MEAL studies 
mean, standard deviation and variance in z-scores for each lipid was calculated using Microsoft 
Excel. Using SAS 9.4 software one-way analysis of variance (ANOVA) with Tukey’s post-hoc 
analysis was used to determine differences in variance between days with a Bonferroni-Hochman 
correction for all lipids. Mean variance scores for each day were plotted for each day of the 
MEAL study (Figure 2.2D) (SAS Institute Inc., Cary, NC, USA). Principle component analysis 
(PCA) to help explain the unsupervised variance in the dataset was performed using the 
statistical analysis feature in Metaboanalyst (http://metaboanalyst.ca) (39, 40) for each day in the 
PUFA/CHO and MEAL study (fig. S2.3). All data was normalized using log transformation and 
auto-scaling. There were only significant differences during experimental days for both 
PUFA/CHO (days 2,7,21) and MEAL (days 2,7,14,21) so principal component 1 was compared 
to principle compenent 2 (fig. S2.3). 
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 Sentinel Lipids:  
From lipids identified in the PUFA/CHO and MEAL studies, Metaboanalyst 
(http://metaboanalyst.ca) (39, 40) was used to determine significant differences between diet 
groups (PUFA/CHO and HC/HF) at any experimental time point using Student’s t-tests 
(FDR<0.1) and which overlapped between the MEAL and PUFA/CHO studies. From an initial 
480 lipids in PUFA/CHO and 571 lipids in MEAL, a total of 311 and 82 were significantly 
different at any experimental time point, respectively. The overlap of significantly different 
lipids between datasets produced 54 initial sentinel lipids. (Figure 2.3).  
Sentinel Lipid classification of macronutrient intake in PUFA/CHO and MEAL Subjects:  
The predictive power of the MEAL and PUFA/CHO was determined using the 12 sentinel lipids. 
The biomarker analysis feature of Metaboanalyst was used to produce ROC curves for 
identifying discriminating biomarkers (Figure 2.4A). Missing features in all datasets the data 
were imputed using K-nearest neighbors (KNN). Linear support vectors machines (SVM) was 
used as a machine learning classification method and feature ranking method to rank features 
from most discriminating to least discriminating (Figure 2.4D). A natural break occurred at 60% 
selection frequency and the 12 lipids with the highest selection frequency were used to generate 
multivariate ROC using Monte-Carlo cross validation (MCCV) using balanced sub-sampling 
(Figure 2.3).  
For each MCCV, 2/3 of the samples were used to evaluate the discriminating features and 
tested on the other 1/3 of sample; this process was iterated 100 times to improve performance. 
(39). Confusion matrices were produced, and sensitivity and specificity were calculated using 
high carbohydrate consumption as positive and high fat as negative (Figure 2.4B&2.4C). 
Sensitivity was calculated as the number of HC eaters who were identified as HC/total number of 
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HC eaters and specificity was calculated as the number of HF eaters who were positively 
identified/total number of HF eaters. Accuracy was calculated as (true carbohydrates + true 
fat)/(true carbohydrate + true fat + false carbohydrate + false fat). Plots of lipid changes over the 
course of the study were produced in GraphPad Prism 8 for Windows version 8.1.1 (220) (San 
Diego, CA). A correlation matrix of all sentinel lipids with one another was produced in an in-
house R package called Coolmap and presented as a heat map (Figure S2.5).  
Community Study: 
Subjects for the Community study wear comprised of 43 healthy control subjects and 59 
euthymic subjects from the Heinze C. Prechter Longitudinal Study of Bipolar Disorder (41).  
Subjects were between the ages of 25 and 60. All bipolar subjects were not expressing bipolar 
systems (euthymic) for several weeks before and during the study period. 
Application of Sentinel lipids in estimating dietary intake:  
Lipidomics profiles from the Community study were generated using fasting blood samples. 
Blood samples were taken following an overnight fast of at least 8 hours. All subjects provided 7 
consecutive dietary journals to the registered dietitians at the Michigan Nutrition and Obesity 
Center. Nutrition Data System for Research software (NDSR), version 2016 developed by the 
Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis, MN (42), was 
used to estimate the energy, macronutrient and micronutrient content of the reported diet.  A 
ratio of %carbohydrate: %fat was used to classify subjects as either high fat reporters (>1.43) or 
high carbohydrate reporters (<1.43). The value 1.43 was selected as a cut-off because this was 
the ratio of % carbohydrate: % fat in the MEAL standard diet (50% cho: 35% fat). Plasma 
samples were also obtained from these subjects on the last day of their dietary journals. Plasma 
was extracted and frozen in the same manner and the same lab as the PUFA/CHO and MEAL 
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samples. Lipidomics analysis was performed in the same manner as the PUFA/CHO and MEAL 
samples and median scaling performed as described earlier. Using the subset of 12 
discriminating from the 54 sentinel lipids as a test set and the MEAL & PUFA/CHO 
experimental days as a training set a predicted diet score was produced. A score of 0 to 0.5 
indicated a prediction of HC and a score of 0.5 to 1.0 indicated a prediction of HF.  Scores 
farther away from 0.5 are indicative of higher confidence. Predicted scores were plotted against 
reported CHO:Fat in GraphPad Prism 8 for Windows version 8.1.1 (220) (San Diego, CA). 
Linear regression was also calculated in Prism with a calculation for significance of a slope of 
non-zero. (Figure 2.5). 
Results 
 
To create a potential objective blood marker of carbohydrate and fat macronutrient intake in 
people, we performed two independent controlled feeding studies in healthy subjects. Dietitians 
designed and provided custom meals with known macronutrient composition to healthy 
volunteers. Weight was monitored and total energy intake adjusted every 2-3 days to maintain 
the subjects’ starting weight.  
PUFA/CHO study  
 
To provoke a significant change in the lipidome, participants were initially provided a eucaloric 
diet high in polyunsaturated fatty acids for 3 weeks followed immediately by a high carbohydrate 
diet (70-80% CHO) for an additional 3 weeks (Figure 2.S2.1). We performed plasma lipidomics 
profiling after an overnight fast at baseline and on days 2, 7 and 21 days (PUFA) and days 23, 28 
and 42 (CHO). Subject weights varied less than 1% over the course of the study (Table 2.1A).  
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 A significant proportion of the 480 annotated lipids showed robust changes and were observed 
across most of the 23 lipid classes (Table 2.S2.1-S2). At Day 21 of PUFA, 128 lipids exhibited 
statistically significant changes (FDR adjusted p-value < 0:1) compared to Baseline and 145 
lipids changed at Day 42 (CHO) compared to Day 21 (Figure 2.1A and 2.2B, Table S2A to 
2.S2.4A). Of the 85 lipid species that showed reciprocal changes.  These lipids were largely 
decreased at Day 21 compared to baseline and increased to Day 42 (n=81). Not surprisingly, 
lipid species comprised of saturated fatty acids fell following the PUFA diet and rose following 
the CHO diet.  
Lipid change rapidly after 21 days following either diet with 52 of 128 lipids (41%) changing 
after 2 days of PUFA and 93 of 145 (64%) changing after 2 days of CHO diets (‘Fast”, Figure 
2.1C). LPC and LPEs composed of polyunsaturated fatty acids showed a slower change 
following PUFA diet but was rapid after a CHO diet. This is likely due to the greater variety of 
fatty acids entering the pool following PUFA as compared to relatively restricted fatty acid 
species (saturated and monounsaturated fatty acid) in the CHO dietary period. Plasmalogens also 
showed relatively slow changes following dietary change (Figure 2.1A). Finally, we note that the 
TGs with lipids containing fatty acids with the longest chains and most double bonds showed 
significant increases 2 days following consumption of either the PUFA or CHO diet, but rapidly 
returned to baseline and mostly did not differ between the diets at 21 days.  
To identify lipids that could potentially discriminate macronutrient intake, we assessed the 
differences in the levels of lipids at each time point following dietary changes (Figure 2.1B & 
Tables S2 to 2.S2.4). Approximately 200 lipids at each time point showed differential expression 
but distinct patterns appear. Plasmenyl-PCs and plasmenyl-PEs stood out, showing significant 
differences at day 2, with only a subset showing differences between , suggesting that these 
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lipids, which are primarily found in membranes (43-45), adapt to dietary changes ( Figure 2.1 & 
Tables S2 to 2.S2.4). This is similar to the pattern seen in TG with long chain polyunsaturated 
fatty acid, described above. Approximately half of the lipid species (218) were not significantly 
different between PUFA and CHO at any time point (Tables S2 to 2.S2.4), suggesting that these 
lipids turn over slowly, have high variability or may be under control.  
MEAL Study 
  
The high polyunsaturated fatty acid diet allowed us to assess lipid turnover and showed a rapid 
divergence in the levels of lipid species (Figure 2.1 & Tables S2A to 2.S2.4A). However, the 
polyunsaturated fatty acid levels used in the PUFA/CHO study were more abundant than in the 
typical ranges consumed in US adults. The metabolites which show differences may not be 
useful to objectively assess macronutrient intake in a population consuming lower amounts of 
polyunsaturated fatty acids. For this reason, we performed a second controlled feeding study to 
assess the effect of a more representative mixture of fatty acid intake in 12 men and 12 women 
(data from one woman was dropped due to admission of dietary non-adherence) using a different 
feeding paradigm (Figure S2).  
Age, weight change, caloric intake, BMI, total mass, and DEXA measurements did not reach 
statistical difference between groups (p<0.05). Energy consumed was similar between both study 
groups. Study participants weight was stable during the 24-day feeding study, showing less than 
1 kg in weight change from baseline. 
In plasma samples, 571 lipids were identified. At Baseline and after Standard Diet, no significant 
differences were seen in the lipidome between the individuals randomized to either HF or HC 
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diets (Figure 2.2B, Tables S2.3 – S2.5). As was the goal, the metabolite variability decreased 
from Baseline to Standard Diet (Figure 2.2D).  
There were very few statistically significant changes within each group following either the HF 
or HC interventions (Figure 2.2A, Tables 2.S2.5 to 2.S2.7). These results were expected because 
the HF, compared to the PUFA diet did not supply large amounts of PUFA to the lipidome. 
When CHO diet group was compared to the PUFA diet group here were significant changes in 
the levels of lipids species between groups (Figure 2.2B, Tables 2.S2.5 to 2.S2.7). At Day 2, 22 
lipids were differential in their plasma concentrations, and this increased to 58 lipids showing 
expression changes by Day 21 (Figure 2.2B, Tables 2.S2.5 to 2.S2.7). As with the PUFA/CHO 
study, at day 7 there appears to be an adaptation to diet change as only 5 lipids are differentially 
expressed. As seen in the PUFA/CHO results, the differentially expressed lipids were enriched in 
O-PCs, O-PEs as well as SM and TGs with Cer species showing differential expression in the 
MEAL study group. 
 
Identification of lipids that discriminate dietary intake: 
  
As described in methods, we identified a subset of 54 initial sentinel lipids that fulfilled the 
criteria of significant change in any experimental time point in both the PUFA/CHO and MEAL 
study, of those we used the 12 with the highest selection frequency to discriminate between high 
fat and high carbohydrate diets as sentinel lipids. In order to show the ability of these sentinel 
lipids (Figure 2.4) to predict unknown diets, we classified all samples from both diets as either 
high fat (PUFA & HF) or high carbohydrate (CHO & HC). 
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ROC curves were generated from all experimental days of the PUFA/CHO and MEAL studies 
(days 2, 7, 14, & 21). Using the 12 sentinel lipids, ROC area under the curve was estimated to be 
0.873, which indicates excellent discrimination (Figure 2.4A). Of 70 HC subjects, 55 were 
classified as high carb which produced a sensitivity of 0.753 (0.639 – 0.847) while 59 of the 77 
high fat subjects were classified as which is a specificity of 0.797 (0.688 – 0.882) (Figure 5C & 
D). Predictive accuracy was also determined to be excellent at 0.776 (0.699 – 0.840) (Figure 
2.4D). To illustrate that this score was similar during all experimental days, AUC’s from ROCs 
were calculated by day x diet (Figure 2.4C) and were comparable to the overall ROC. This 
indicates that these sentinel lipids may be relatively agnostic to short-term dietary changes. 
Next to further illustrate the power of the sentinel lipids to separate HC and HF diets, principal 
component analysis (PCA) was performed on both the PUFA/CHO diet and the MEAL diet 
separately. PC1 vs PC2 graphs on the PUFA/CHO illustrate separation which is most clear after 
day 2 and may diminish slightly by day 21 (Figure S2.3). This pattern is similar in the MEAL 
study, but PCA analysis also included baseline and standard measurements (day -3 and day 0) 
which shows no separation, followed by clear separation on days 2 through 21 (Figure S2.3). 
Testing Sentinel Lipids using the Community Study 
 
Finally, to test and demonstrate the predictive power of the sentinel lipids on a “real world” 
population we used the biomarker analysis on the subjects from the Community study. 
Lipidomics analysis from this group identified 527 lipid species. The 102 individuals (Table 
2.1A) provided diet journals over 7 consecutive days and average ratio of carbohydrate to fat was 
calculated (Table 2.1B) (see methods). These values were then regressed with predictive 
probabilities generated using the sentinel lipids and resultant assigned class scores (either HC or 
HF) (Figure 2.6). When compared to the reported CHO/FAT ratio of these test subjects (n=102), 
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linear regression showed linearity and a significant negative slope (p<0.05) which is indicative of 
correct predictions (Figure 2.6). This is despite the narrow range of reported dietary intake that is 
closer to the standard diet than to the HC or HF diets (Figure 2.6).  
Discussion 
 
Dynamic response of the lipidome to diet: 
 
Food provides a complex mixture of organic and inorganic materials that are digested into 
constituent metabolites, exposing cells to a constant supply of nutrients. Alterations in the ability 
to effectively metabolize ingested nutrients can lead to a wide variety of diseases. Indeed, diet is 
likely the primary environmental factor in gene-environment interactions that increases risk of 
the major diseases of modern times (47). Allelic variations across the genome are associated with 
changes in an array of blood metabolites and contribute to variation in the metabolome (48) as 
well as a proportion the risk attributable for different diseases (49). As accumulating evidence 
demonstrates that blood metabolite levels can potentially enhance the prediction of a variety of 
diseases (50-53), determining the effect of diet on metabolites is a necessary step in order to 
disentangle diet and genetics while moving towards individualized intervention with diet 
therapy.  
Effects of a standard diet: 
 
It is important to note that the MEAL study utilized a standard diet, while the PUFA/CHO study 
did not. In the MEAL study we found that the lipidome of subjects at baseline, entering the study 
on their habitual diets, were had more variability between subjects than after just 3 days of 
consuming a standard diet (Figure 2.5B). Winnike, Busby, Watkins, and O’Connell performed a 
similar study (n=10) and found normalization occurring in both urine and serum metabolomics 
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occurring after one day of a standardized diet (33). Similarly, Favé et al found that subjects fed a 
standardized meal the night before an experimental diet protocol clustered together when 
analyzed by PCA indicating a standardized diet is necessary and sufficient to draw subject’s 
metabolomes together at the beginning of a feeding study (54). Our results are further supported 
by the lack of significant differences between HC and HF subjects at baseline and after the 
standard diet, but many differences after just two days of experimental diets (Figure 2.2). Our 
results, along with those of Winnike and Favé highlight the importance of a standard diet to 
“wash out” lipid differences in plasma between subjects and normalize all subjects lipidome 
profiles at the beginning of feeding studies (33, 54).  
 
Adaptive response of the lipidome after a diet change: 
 
Plasma lipidomics appear to be a useful platform to classify individuals according to their 
relative intake of carbohydrates and fat, irrespective of the amount of polyunsaturated fatty acids 
in the diet. While the lipidome is diverse, polyunsaturated fatty acids are derived from dietary 
intake while saturated and monounsaturated fatty acids and others are derived from both dietary 
and endogenous production through de novo lipogenesis. Through the administration of a very 
high polyunsaturated fat diet, induced changes in about 30% of lipids after two days (Figure 
3.1A, Tables 3.S2 to S2.4). There is adaptation to the high PUFA diet with as about a 1/3 of 
lipids which were significantly changed after Day 2 of PUFA were not different at Day 21. This 
indicates a homeostatic adaptive response to high PUFA intake. This indicates a homeostatic 
adaptive response to high PUFA intake. This may be due to reduction in elongase and desaturase 
enzyme activity which are regulated transcriptionally by carbohydrate-responsive element-
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binding protein (ChREBP) (55, 56) liver X receptor α (LXRα) (57) and sterol regulator element-
binding proteins 1c (SREBP-1c) (58), each of which are suppressed following high fat feeding. 
The adaptive response pattern seen in lipids could potentially be due to a lagged increase in 
SCD-1 activity. SCD-1 is an endoplasmic reticulum enzyme that catalyzes one of the rate 
limiting steps in the formation of monounsaturated fatty acids such as oleate (FFA 18:1) and 
palmitoleate (FFA 16:1) from 18:0-CoA and 18:1-CoA (59, 60). SCD-1 is necessary for 
endogenous MUFA synthesis from saturated fatty acids (61). Increased SCD-1 and de novo 
lipogenesis activity has been associated with high carbohydrate diets, such as the HC and CHO 
diets in the MEAL and PUFA/CHO studies (62-64) whereas high PUFA diets are associated with 
suppression of the transcription of the SCD-1 gene (64). This PUFA intake mediated repression 
of hepatic SCD1 and MUFA synthesis may have evolved as a mechanism to maintain cellular 
unsaturated fatty acid balance (63). Additionally, diets high in cholesterol upregulate SREBP-1c 
expression that overrides the PUFA mediated SCD-1 suppression (58). It is also been shown that, 
in humans, a high carbohydrate diet will increase free fatty acid synthesis (65), potentially 
through an increase in SCD-1 activity and increased insulin (62, 63). One possibility for the 
adaptive response pattern that we are seeing in lipids (Figures 1 & 2) is due to an acute increase 
in SCD-1 that is blunted over longer-term high fat/high carbohydrate feedings. 
The significant rise in longer, polyunsaturated fatty acid containing lipid species after Day 2 of 
CHO diet in DG and TG could be due to several reasons: increased oxidation of carbohydrate 
with sparing of fatty acid oxidation (66), rapid induction of elongases and desaturases (67), and 
an increase in the levels of shorter chain, saturated and monounsaturated derived from de novo 
lipogenesis, competing for oxidation of polyunsaturated fatty acids (68). The amount of lipids 
produced by hepatic de novo lipogenesis may also be playing a role in the rise we see in PUFA 
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containing lipid species; Wilke et al. (69) found that after a 3-day higher-fat diet, healthy 
subjects had higher rates of de novo lipogenesis than those on a lower-fat diet.  
Differences between dynamic responses in the PUFA/CHO and MEAL studies: 
 
The MEAL study showed a smaller number of significant changes to the overall metabolome 
within each diet group (Figure 1A & 1C). However, as seen in the PUFA/CHO diet, there were 
more lipids significantly different at day 2 than at day 7 (Figure 2B), again suggesting an 
adaptation to the diet in these individuals. Another feeding study has found a similar adaptive 
response in sterols and DGs (36) while we found it other species as well. The MEAL study 
perhaps identified more adaptive responsive lipids because we collected plasma in much smaller 
intervals (2 days, 7 days, 14 days, & 21 days) while the former study was collected 5 weeks apart  
Discriminatory power of the sentinel lipids: 
 
We identified a small subset of the lipids that showed the ability to classify the individuals 
consuming high fat or high carbohydrate diet (Figure 2.3 & 2.44). These sentinel lipids were 
primarily composed of phosphatidylcholines, and ethanolamine-containing plasmalogens (Figure 
2.3). The discriminating sentinel lipids tended to change slower and in general, increased 
following a high carbohydrate diet, despite the fact that most of them showed increased 
unsaturation in their fatty acid side chains. Within class, the lipids tended to be correlated across 
subjects and time (Figure S2.4), but across classes, there was lower correlation.  
Plasmalogens are a major subclass of choline and ethanolamine glycerophospholipids that have a 
long chain fatty alcohol attached at the sn-1 position through a vinyl ether bond. These lipids can 
compose up to 20% of lipids in plasma membranes (44, 45) and are ascribed to act as 
antioxidants (43). Ethanolamine-containing plasmalogens (PlsEth) have other activities. These 
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lipids are synthesized initially in peroxisomes with the final, rate-limiting step is by the enzyme 
Fatty Acid Synthase 1 (Far1) which attached to the outer membrane of the peroxisome. The 
levels of PlsEth in cells appear to be strictly regulated by modulating the stability of the rate-
limiting enzyme Far1; low levels of PlsEth (but not choline containing plasmalogens (PlsCho) 
increase the stability of the Far1 protein and higher levels stimulation degradation of Far1 (70). 
PlsCho which are also increased following carbohydrate diets are thought to be synthesized 
through the hydrolysis of PlsEth and condensation of the alkenylglycerol with phosphocholine 
(43). The levels of PlsEth and PlsCho are highly correlated (Figure 2.S2.4). We speculate that in 
the presence of higher levels of saturated fatty acids in PlsEth synthesis may be increased as 
these lipids prefer polyunsaturated fatty acids in the sn2 positon of the lipid (71). 
Another, non-physiological possibility is that subjects became less compliant in consuming the 
provided diets over the course of the study. Noncompliance in the MEAL diet is unlikely as we 
report in chapter 3 using dietary recall from this study; our data indicates that subjects were very 
compliant throughout the study. 
Strengths/Limitations 
 
This study has several strengths. First, we used state of the art high throughput targeted lipidomic 
techniques which provided an objective measure of lipidomic changes due to diet. Using 2 
longitudinal well-controlled feeding studies elucidates dynamic changes in the lipidome due to 
high fat and high carbohydrate diet. Further, the use of a 3-day standard diet in the MEAL study 
demonstrated the rapid change in the lipidome due to diet and convergence of the lipidomes of 
our participants. Unsupervised machine learning techniques allow for unbiased prediction of as 
well as identification of biomarkers of dietary intake. Finally, use of the Community study which 
61 
 
relied upon 7-day dietary diaries provides insight into the value of our sentinel lipids for 
identifying macronutrient intake in free-living populations. 
Findings also must be interpreted in light of certain limitations.  First, we used extreme test diets 
which provided ~+/-3SD carbohydrate and fat intake compared to adults’ dietary intake reported 
in NHANES (46). While the experimental protocol produced a set of lipids that discriminated 
between the test diets, our assessment was based on the dietary recall of these participants. 
Future tests on diets which are less extreme and closer approximate the reported habitual intake 
of the population by NHANES should be conducted to probe and hone the discriminatory ability 
of the sentinel lipids to identify macronutrient intake.  
Secondly, the populations used in this study were fairly small. Further testing with larger 
populations could inform the generalization of these findings to the population as a whole. Also, 
these controlled feeding studies and Community group were conducted in healthy, mainly 
Caucasian individuals, but did include both women and men. Confirmation of the performance 
of the sentinel lipids to identify macronutrient intake will need to be done in populations with 
more diversity in terms of age, ethnicity, and health status. . Finally, protein levels were held 
constant when deriving the sentinel lipids. The average protein intake reported in the Community 
study was similar the PUFA/CHO and MEAL studies, but had a much larger standard deviation.  
(Table 2.1B). Perhaps better discriminators may be identified in controlled feeding studies across 
a broader range of protein intake.   
Conclusions 
In our studies, the lipidome was highly responsive to diet with but is also able to adapt to 
significant increases in fatty acid and carbohydrate intake (Figures 1 & 2). This suggests that 
using lipidomics profiles to assess individual differences in metabolism not directly related to 
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diet, it may be prudent use a short intervention with a standard diet to achieve greater 
homogeneity in the lipidome prior to initiating the study and to keep the diet consistent during 
the study. These caveats should be added to circadian changes in the lipidome (72) in designing 
lipidomics studies. Finally, we developed a panel of “sentinel” lipids and in particular, a subset 
of 12 lipids that do an excellent job of discriminating between very high fat and very high 
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Figure 2.1(A-C). PUFA/CHO study Log2 differences within and between diet comparisons. 
 
 
Here we show only lipids significant within or between diets at any time point. Lipids are 
organized from the top to bottom from shortest chain length and most saturated to longest 
chain length and least saturated within each lipid class. A) Data represented as Log2 
difference of area under the curve (AUC) within each diet. For PUFA this is in the time 
course between Baseline (B) to day 2 PUFA diet (P2), P2 to P7, P7 to P21, & B to P21 that 
represents the total change during the course of the PUFA diet. This pattern repeated for the 
CHO diet starting with P21 (P21 to C2, C2 to C7, C7 to C21, & P21 to C21). Light blue 
represents a decrease and pink an increase, dark blue and red are significant (FDR <0.1). 
Black bars between PUFA and CHO data indicate Sentinel Lipids with red indicating 
Sentinel Lipids chosen as the 12 Selected Important Features by SVM ROC analysis. B) 
Black is significant (FDR <0.1) between PUFA and CHO at corresponding diet days (P2 v 
C2, P7 v C7, and P21 v C21). Grey is not significant. C) This matrix is representative of the 
rapidity of significant lipid changes. Fast is a significant change at day 2 PUFA or CHO and 
a significant difference at B to P21 or P21 to C21. Slow is a significant change at day 21 and 
again at B to P21 or P21 to C21. No dietary effect (No DE) is representative of no significant 






Figure 2.2(A-D). MEAL study Log2 differences within and between diet comparisons. 
 
Here we show only lipids significant within or between diets at any time point. Lipids are 
organized from the top to bottom from shortest chain length and most saturated to longest 
chain length and least saturated within each lipid class. A) Data represented as Log2 
difference of area under the curve (AUC) within each diet. On the left are subjects on the HF 
diet from B to S, S to 2, 2 to 7, 7 to 14, 14 to 21, & B to 21 that represents the total difference 
during the experimental diet. This pattern repeats for the HC. Light blue represents a decrease 
and pink an increase, dark blue and red are significant (FDR <0.1). Black bars between HF 
and HC data indicate Sentinel Lipids with red indicating Sentinel Lipids chosen as the 12 
Selected Important Features by SVM ROC analysis. B) Black is significant (FDR <0.1) 
between PUFA and CHO at corresponding diet days (2v2, 7v7, 14v14, and 21v21). Grey is 
not significant. C) This matrix is representative of the rapidity of significant lipid changes. 
Fast is a significant change at day 2 HF or HC and a significant difference at B to 21 in each 
diet. Slow is a significant change at day 21 and again at B to 21. No dietary effect (No DE) is 
representative of no significant change at B to 21. D) Variances were computed for all lipid 
measures in both groups at each experimental day, ANOVA with a Tukey’s post-hoc 









Figure 2.3 (A-E) Description of determination of Sentinel Lipids 
 
 
Sentinel lipids were determined using the following method. A) 480 annotated in lipids in 
the PUFA/CHO study were compared and 311 which were significantly different at any 
experimental time point (P2, P7, P21, C2, C7, or C21) between PUFA and CHO diets. B) 
571 annotated lipids in the MEAL study compared and 82 were significantly different at any 
experimental time point (2, 7, 14, or 21). (FDR <0.1). C) Of the significantly different lipids, 
54 overlapped between studies and selected as Sentinel Lipids. D) SVM machine learning 
used as a classification method using the sentinel lipids. There was a natural break point 
above the 60% selection criterion with 12 were chosen as E) 54 initial sentinel lipids with 






Figure 2.4 (A-D). ROC analysis using Sentinel Lipids on the MEAL and PUFA dataset. 
 
 
A) ROC graph plotting sensitivity (true positive rate) against 1-specificity (false positive 
rate) for PUFA/CHO and MEAL samples (blue line). AUC indicated as 0.873 which 
indicates excellent discrimination by the 12 Selected Important Features from the Sentinel 
Lipids. This data also includes 14 randomly selected and balanced holdout samples for 
validation (purple line) which had a comparable AUC of 0.872. B) Shows predicted class 
probabilities for each sample (black filled circles are HF and open are HC) using 12 
Selected Important Features. Red circles are holdout samples. C) AUCs from ROC 
analysis for each day shows good discrimination by day and as such identifies these 
features as agnostic by day. D) Confusion matrices for training and holdout samples along 





















Figure S2.1. Study design for the PUFA/CHO Study 
 
The PUFA/CHO study was a 42-day longitudinal paired study design without 
crossover involving 12 subjects (6♀, 6♂). A high polyunsaturated diet provided for 
the first 21 days immediately followed by 21 days of a high carbohydrate diet. 























Figure S2.2 Study design for the MEAL Study 
 
The MEAL study followed a parallel-randomized block study design blocked by sex. 
It involved a cohort of 23 subjects (11♀, 12♂). The first 3 days subjects were given a 
standard diet (15% Protein/35% Fat/50% Carbohydrate) which was followed by 21 
days of either a high carbohydrate (15% Protein/10% Fat/75% Carbohydrate) or high 
fat diet (15% Protein/60% Fat/25% Carbohydrate). Blood was drawn for plasma on 
days -3 (B), 0 (STD), 2, 7, 14, & 21. 24HR recalls were given on days -3, 0, and once 
per week during the experimental diet. On the first day, written and oral consent, 
DNA, height & weight, and an FFQ was also collected. Subjects picked up food and 











Figure 2.5. Predicted carbohydrate/fat ratios from TEST study subjects using the “Sentinel 
Lipids” 
 
Subject predicted class (either HC or HF) using SVM based on 12 highest selected important 
features from the Sentinel lipids to predict plasma samples as either high carb (red) or high 
fat (green). A score of 0.0 to 0.5 is indicative of a high carbohydrate prediction and a score of 
0.5 to 1.0 is indicative of high fat. Values closer to 0.5 are less confident than those that are 
closer to 0.0 and 1.0. The Y-axis indicates the average carbohydrate percentage to fat 
percentage ratio reported by these subjects in seven dietary journals on consecutive days. The 
dashed lines labeled HC, Standard, and HF are there to reference the carbohydrate/fat ratios 
in the MEAL study HC = 7.5, Standard = 1.43, and HF = 0.42. The linear regression line 
formula is indicated on the right and the p value is significant for deviance from a slope of 
zero indicating that there is a significant relationship between lower Carb/Fat ratio and higher 
probability scores (p<0.05). 
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B) MEAL Study C) TEST Study 
n= 12 HF n=10 HC n=13 
102 (59 BP,  
46 controls) 
 Sex distribution 6 ♀, 6 ♂ 5 ♂,6 ♀ 7 ♂,6 ♀ 41 ♂,61 ♀ 
Age in yrs. (SD) 28.2(5.8) 23.9 (2.6) 24.9 (4.0) *44.1(14.1) 
Weight Change (Δkg) -0.8 (1.2) 0.30 (0.9) -0.05 (1.0) N/A 
Caloric Intake (kCal/day) 2687 (676.8) 2740 (502.2) 2825 (521.4) 2024.4 (638.5) 
BMI kg/m2 24.5(4.2) 23.2 (3.1) 23.1(2.8) 26.3(4.7) 
All subject characteristic represented as average (SD). Caloric intake for PUFA/CHO studies were 
amount of kCal food provided and Community study was average kCal/day reported via food 



















a Reported intake from 7 consecutive food journals as % 
of total energy, mean (SD) 
Total Protein 15.5(3.2) 
Total Carb 48.6(8.6) 
Total Fat 33.6(6.4) 
Total Calories 2024.4 (638.5) 
Data represented as average percent data reported in 7 








PCA analysis of all 54 sentinel lipids during the time course of PUFA/CHO (top) and MEAL 
(bottom) studies. In these graphs green circles represent PUFA/HF and red represent 
CHO/HC with 95% confidence intervals represented by the large green and red ovals. This 
graphs primary component 1 (PC1) vs primary component 2 (PC2). Discrimination is nearly 
immediate and persistent in PUFA/CHO while discrimination occurs after the beginning of 





Figure S2.4. Correlation heat map of 54 Sentinel Lipids. 
 
Correlation heat map of 54 Sentinel Lipids with the range of correlation running from Red = 
1.0 to Green -1.0. Important Selected Features are highlighted in light red. This shows that 























Table S2.1. Annotated lipids in PUFA/CHO, MEAL, and TEST studies. 
 
This table represents all lipids annotated in each study. Data represented as number of lipids 
and the range of lipid species from shortest chain length to longest. 
Lipid Species PUFA/CHO Study
Class Name Abbreviation
Species, 
n= Range of Species
Species, 
n= Range of Species
Species, 
n= Range of Species
Cholesteryl Ester CE 12 [16:0] to [22:6] 12 [16:0] to [22:6] 15 [16:0] to [22:6]
Acylcarnitine ACAR 12 [10:0] to [26:0] 13 [10:0] to [26:0] 13 [10:0] to [24:0]
Ceramide [AS] Cer [AS] 1 [34:1] 2 [34:1] to [42:2] 1 [34:1]
Ceramide [ADS] Cer [ADS] 0 -- 0 -- 1 [38:0]
Ceramide [EODS] Cer [EODS] 1 [58:0] 3 [57:2] to [60:0] 4 [57:1] to [59:2]
Ceramide [NDS] Cer [NDS] 6 [34:0] to [42:1] 10 [34:0] to [43:0] 7 [34:0] to [42:1]
Ceramide [NP] Cer [NP] 3 [34:0] to [42:1] 6 [34:0] to [42:1] 2 [34:0] to [42:0]
Ceramide [NS] Cer [NS] 21 [32:1] to [43:2] 28 [32:1] to [46:5] 23 [32:1] to [45:1]
Diacylglycerol DG 27 [30:0] to [40:7] 28 [30:0] to [40:7] 36 [30:0] to [42:0]
Free Fatty Acids FFA 16 [16:0] to [24:3] 16 [16:0] to [24:3] 16 [16:0] to [24:3]
Glucoceramide [NS] GluCer[AS] 6 [34:1] to [42:2] 6 [34:1] to [42:2] 5 [34:1] to [42:1]
Lysophosphatidylcholine LPC 26 [14:0] to [26:1] 26 [14:0] to [26:1] 26 [14:0] to [24:1]
Lysophosphatidylethanolamine LPE 10 [16:0] to [22:6] 15 [16:0] to [24:0] 11 [16:0] to [22:6]
Phosphatidic Acid PA 1 [34:2] 7 [34:1] to [38:6] 0 --
Phostphatidylecholine PC 73 [26:0] to [44:4] 86 [24:0] to [46:4] 79 [26:0] to [44:4]
Phosphatidylethanolamine PE 29 [32:1] to [40:8] 34 [30:0] to [42:10] 23 [30:0] to [40:7]
Phophatidylglycerol PG 5 [33:0] to [36:3] 7 [33:0] to [38:4] 2 [33:0] to [36:0]
Phostphatidylinositol PI 9 [34:2] to [40:6] 12 [25:0] to [40:6] 9 [32:1] to [38:6]
Plasmenyl-phosphatidylcholine PlsCho 47 [24:0] to [46:4] 52 [24:0] to [46:4] 51 [24:0] to [46:4]
Plasmenyl-phosphatidylethanolamine PlsEtn 39 [32:1] to [44:6] 47 [32:0] to [44:6] 34 [32:1] to [42:6]
Phosphatidylserine PS 0 -- 2 [36:1] to [38:4] 5 [34:0] to [40:6]
Sphingomyelin SM 51 [30:0] to [44:6] 52 [30:1] to [45:7] 64 [28:1] to [46:7]
Triacylglycerol TG 85 [38:0] to [60:12] 107 [36:0] to [62:12] 100 [36:0] to [64:17]
Total -- 480 -- 571 -- 527 --
MEAL Study TEST Study
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Table S2.2A: PUFA/CHO study significant differences for within and between diet 
comparisons for all lipids (16:0 Cholesterol ester to Ceramide [NS] 42:1) 
 Mean Log2 AUC Values For Each Lipid Species 
   PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
16:0 CE 15.4341 15.5099 15.7852 15.5495 15.4463 15.2095 15.3436 
16:1 CE 13.4622 13.1963 13.4501 13.2436 13.5638 13.2153 14.1224 
18:0 CE 14.4033 14.1994 14.5798 14.2584 14.3243 14.3748 14.2262 
18:1 CE 18.1682 18.0362 18.2756 18.0411 18.2224 18.1644 18.2224 
18:2 CE 21.0659 21.0790 21.1136 21.1332 21.0205 21.0942 21.0999 
18:3 CE 18.3468 18.0519 18.2255 18.2713 18.3171 18.2798 18.1504 
20:3 CE 18.0490 17.9988 17.8033 17.8057 18.0321 17.9513 18.0754 
20:4 CE 20.1003 20.5156 20.0205 20.1046 20.2032 20.0714 19.9252 
20:5 CE 16.8851 17.0804 16.3761 16.2744 16.5337 16.8252 16.1858 
22:4 CE 14.1059 14.4420 14.0699 13.9857 14.2339 13.9640 14.1167 
22:5 CE 15.1060 15.4812 15.0179 14.8508 15.1790 15.1154 15.0836 
22:6 CE 18.3000 18.6137 18.2404 18.2098 18.3862 18.3475 18.1653 
ACAR 10:0 13.3492 13.0555 12.6641 13.1027 13.0142 13.1392 13.3443 
ACAR 10:1 12.4621 12.3978 12.3553 12.8495 12.3441 12.2360 12.5165 
ACAR 12:0 13.4597 12.8835 13.2838 13.5791 13.2436 13.0980 13.3251 
ACAR 14:0 13.6567 13.0695 13.1503 13.7341 13.2551 13.2594 13.5408 
ACAR 14:1 14.5802 14.0114 14.3027 14.7991 14.2620 14.2828 14.7164 
ACAR 14:2 13.7877 13.1589 13.6134 14.4539 13.5136 13.6268 14.0939 
ACAR 16:0 15.9190 15.3644 15.6543 15.6912 15.4559 15.4752 15.8242 
ACAR 18:0 14.4009 13.9119 14.2122 14.3708 14.1983 14.3267 14.0926 
ACAR 18:1 16.4888 16.2522 16.3722 16.5541 16.1309 16.1114 16.6379 
ACAR 18:2 16.2886 16.1841 16.2509 16.7773 16.0873 16.1903 16.3747 
ACAR 24:0 12.9768 11.9392 12.8535 12.9467 12.6737 12.6354 12.7412 
ACAR 26:0 12.5097 12.0304 12.1837 12.9665 12.2561 12.2207 12.4377 
Cer[AS] 34:1 12.1429 12.3923 12.1703 12.2578 12.2568 12.4043 12.4281 
Cer[EODS] 58:0 12.5432 12.4759 12.6235 12.2838 12.4834 12.3352 12.2244 
Cer[NDS] 34:0 16.2186 16.2164 16.5037 16.2213 16.1882 16.1463 16.2273 
Cer[NDS] 36:0 14.5785 14.9324 14.6831 13.5209 14.4791 14.3054 14.6443 
Cer[NDS] 38:0 11.3980 10.9287 11.4542 10.9172 11.0821 10.9589 11.1524 
Cer[NDS] 40:0 17.6723 17.0808 17.8786 17.1533 17.3668 17.2410 17.3893 
Cer[NDS] 42:0 15.2266 14.7051 15.2587 14.9780 15.2252 14.9395 15.1202 
Cer[NDS] 42:1 18.2605 17.7557 18.0587 18.0145 18.1130 18.0648 17.8975 
Cer[NP] 34:0 12.7327 12.4515 12.9196 12.5704 12.3443 12.3841 12.1476 
Cer[NP] 42:0 16.4170 15.7440 16.2909 16.1486 15.9742 15.9874 15.8973 
Cer[NP] 42:1 15.8596 15.4965 16.0642 16.0975 15.8205 15.9111 15.8471 
Cer[NS] 32:1 14.1568 13.6005 14.0239 13.5816 13.6823 13.9373 13.8792 
Cer[NS] 33:1 15.1139 15.2099 15.3278 14.8350 14.9446 14.9790 15.0989 
Cer[NS] 34:1 19.9253 19.9588 20.0006 20.0158 19.9226 19.8812 19.8991 
Cer[NS] 34:2 14.4849 14.8935 14.4792 14.2698 14.1238 14.4146 14.3633 
Cer[NS] 35:1 19.0252 19.0338 19.0905 19.0441 18.9710 19.0130 19.0533 
Cer[NS] 36:1 16.7724 17.0696 16.6459 16.0937 16.5397 16.5156 16.6933 
Cer[NS] 36:2 14.5995 15.2348 14.4772 14.0735 14.3792 14.4870 14.6963 
Cer[NS] 37:1 15.4510 15.6329 15.3921 15.2814 15.3239 15.3442 15.4162 
Cer[NS] 38:1 17.3338 17.0820 17.2101 16.8981 16.8598 16.7736 16.9323 
Cer[NS] 38:2 14.7598 15.0067 14.5444 14.5557 14.5133 14.1064 14.6715 
Cer[NS] 39:1 12.8768 12.6230 12.5998 12.7851 12.5197 12.7840 12.7912 
Cer[NS] 40:1 16.6642 16.2094 16.4567 16.2758 16.3647 16.3525 16.2915 
Cer[NS] 40:2 17.7241 17.3830 17.4973 17.4168 17.2645 17.2322 17.3459 
Cer[NS] 40:3 13.6829 13.7548 13.5651 13.1585 13.6332 13.2209 13.6915 
Cer[NS] 41:1 16.6771 16.1908 16.4428 16.3584 16.4581 16.4699 16.3503 
Cer[NS] 41:2 18.1577 17.9501 17.9342 18.0924 17.9250 17.8002 17.9057 
Cer[NS] 42:1 21.4834 20.9353 21.2748 21.2221 21.1871 21.0899 20.9374 
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Table S2.2B: PUFA/CHO study significant differences for within and between diet comparisons 
for all lipids (Ceramide [NS] 42:2 to Lysophosphatidylcholine 14:0) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet    CHO Diet  
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
Cer[NS] 42:2 17.3154 17.0444 17.1320 17.2326 17.1447 17.1647 17.2347 
Cer[NS] 42:3 17.7285 17.7316 17.6075 17.7539 17.5323 17.3418 17.6770 
Cer[NS] 43:1 18.9684 18.4032 18.7926 18.6924 18.7962 18.5572 18.3718 
Cer[NS] 43:2 14.0785 13.7449 13.9592 13.9781 14.1602 13.7685 13.8595 
DG 30:0 13.1456 12.6078 12.9096 12.7223 12.8453 12.9258 13.0172 
DG 30:1 10.8027 9.8727 10.4568 10.5719 10.5194 10.4818 10.8858 
DG 32:0 18.3548 18.3724 18.5016 18.4859 18.3525 18.3911 18.4662 
DG 32:1 14.1418 13.0987 14.0251 13.5095 13.9429 13.7858 14.3001 
DG 32:2 12.0332 11.7884 12.5106 11.6961 12.4983 12.0835 12.7990 
DG 33:0 15.1634 15.1705 15.2236 15.2010 15.0911 15.1002 15.2224 
DG 33:1 11.3827 10.6504 11.4196 11.1917 11.3222 11.3499 11.6308 
DG 34:0 22.2416 22.0726 22.3208 22.3286 22.2157 22.2316 22.2377 
DG 34:2 16.3911 16.3795 16.8596 16.4687 16.3158 15.9959 16.8878 
DG 34:3 13.8543 13.7983 14.4027 13.7902 14.4188 13.9167 14.7210 
DG 35:1 12.8067 12.4886 12.9097 12.1992 12.5293 12.7357 12.7513 
DG 35:2 12.2221 11.5728 12.2875 11.7880 12.0023 12.1202 12.4838 
DG 35:3 11.4645 11.1808 11.7142 10.9676 11.7710 11.5519 11.9856 
DG 36:0 23.0698 22.7611 23.1701 23.2853 23.1233 23.0483 23.0481 
DG 36:1 18.8686 18.7707 18.9332 18.9222 18.8580 18.8998 18.9221 
DG 36:2 17.9225 17.6665 18.4194 17.8835 18.0510 17.9078 18.2765 
DG 36:3 17.2988 17.2384 17.9473 17.5157 17.5399 17.2942 17.8374 
DG 36:4 16.9750 17.0897 17.9237 17.5874 17.3750 17.1599 17.7618 
DG 36:5 13.0643 13.0843 13.7410 13.4910 14.2018 13.8688 14.1233 
DG 38:1 12.6731 12.4634 12.6901 12.5945 12.8263 12.6718 12.5583 
DG 38:2 12.6710 12.3570 12.9418 12.1363 12.4954 12.6141 13.0524 
DG 38:3 13.1480 12.9627 13.4374 13.4275 13.2561 13.0235 13.6431 
DG 38:4 14.1693 13.8757 14.1547 14.0972 14.2772 13.6336 14.4653 
DG 38:5 14.6116 14.6843 14.9398 14.6979 14.9319 14.3921 14.8455 
DG 38:6 14.1889 14.2391 14.3746 14.1689 14.5744 14.2157 14.5162 
DG 40:6 12.5704 12.1826 12.2839 11.9832 12.8109 12.3384 12.7313 
DG 40:7 13.0335 13.0729 13.2232 13.1113 13.4019 13.3619 13.5097 
FFA(16:0) 24.8597 24.8942 24.8068 24.7943 24.6327 24.6328 24.8653 
FFA(18:0) 24.5469 24.4764 24.5286 24.5878 24.5271 24.4481 24.4301 
FFA(18:1) 24.9922 25.0033 24.8083 24.6831 24.3854 24.5146 24.9970 
FFA(18:2) 24.2924 24.5494 24.3168 24.2575 23.7622 24.0686 24.5303 
FFA(20:0) 19.3237 19.2070 19.4400 19.4493 19.3125 19.2182 19.2533 
FFA(20:1) 19.1763 19.1143 18.8347 18.9061 18.5502 18.6696 19.1888 
FFA(20:2) 18.7766 18.9668 18.4873 18.6193 18.2770 18.3969 18.9922 
FFA(20:4) 20.7488 20.6123 20.4927 20.2678 20.1834 20.1504 20.5579 
FFA(22:0) 17.6006 17.3910 17.7405 17.7012 17.4381 17.4670 17.5666 
FFA(22:1) 16.3341 16.0329 16.1076 16.4935 16.0711 16.0966 16.1950 
FFA(22:2) 14.7002 14.5073 14.4822 14.4645 14.2886 14.2722 14.5835 
FFA(22:3) 15.2519 15.1771 14.9000 15.1094 14.6603 14.6865 15.3224 
FFA(24:0) 17.5507 17.4720 17.5282 17.5491 17.3030 17.5041 17.2704 
FFA(24:1) 17.1782 17.0917 17.3669 17.3874 16.8594 16.9402 17.2385 
FFA(24:2) 15.4807 15.5602 15.5667 15.4303 15.0658 14.9688 15.5665 
FFA(24:3) 13.0845 12.8322 12.8585 12.8112 12.4936 12.5305 12.8754 
GlcCer[NS] 34:1 13.5381 13.7684 13.5973 13.3584 13.4819 13.3557 13.3402 
GlcCer[NS] 34:2 10.6009 10.1950 10.8994 10.3261 10.2931 9.6427 10.5623 
GlcCer[NS] 40:1 15.1024 15.0604 14.9514 15.2016 14.9572 14.7028 14.9905 
GlcCer[NS] 41:1 14.5057 14.4874 14.1976 14.5003 14.3217 14.0783 14.4258 
GlcCer[NS] 42:1 15.8246 15.6915 15.6597 15.8918 15.7555 15.5046 15.8034 
GlcCer[NS] 42:2 15.2015 15.3042 15.2647 15.4513 15.3470 15.0803 15.2966 




Table S2.2C: PUFA/CHO study significant differences for within and between diet comparisons 
for all lipids (Lysophosphatidylcholine 15:0 to Phosphatidylcholine 34:5) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
LysoPC 15:0 15.0506 14.6372 14.8903 15.2056 14.8637 14.8746 14.9943 
LysoPC 15:1 15.3941 14.8060 15.4779 15.6740 15.0656 15.2370 15.4833 
LysoPC 16:0 23.0260 22.6593 22.9745 23.0214 22.8921 22.7842 22.8949 
LysoPC 16:1 17.4435 17.1130 17.5135 17.4135 17.3535 17.1982 17.6015 
LysoPC 17:1 14.7376 14.3064 14.5348 14.5070 14.5007 14.4821 14.4968 
LysoPC 18:0 22.0595 21.6663 22.1760 21.8505 21.7786 21.9451 21.7397 
LysoPC 18:1 21.0995 20.7233 21.0445 21.0684 20.7578 20.7699 20.9397 
LysoPC 18:2 21.9356 21.6363 21.8753 22.3194 21.6843 21.6817 21.8082 
LysoPC 18:3 15.6827 15.1170 15.5090 15.5652 15.2514 15.3640 15.2284 
LysoPC 19:0 14.7073 14.4121 14.8335 14.9294 14.5083 14.7562 14.7015 
LysoPC 19:1 13.2802 12.9154 13.3304 13.2941 13.1274 13.0348 13.1071 
LysoPC 20:0 14.3592 14.0115 14.5397 14.7782 14.2197 14.3874 14.2986 
LysoPC 20:1 15.0866 14.6170 14.9334 15.2999 14.7512 14.8198 14.9685 
LysoPC 20:2 15.5473 15.3746 15.5405 15.9865 15.4579 15.4968 15.6958 
LysoPC 20:3 17.8987 17.4568 17.5729 17.9071 17.6264 17.4838 17.8624 
LysoPC 20:4 18.5209 18.5129 18.3673 18.3757 18.2447 18.0237 18.0673 
LysoPC 20:5 17.9945 17.7431 17.9837 18.4394 17.8052 17.8491 17.9448 
LysoPC 22:0 12.7826 12.4128 12.6859 12.9595 12.6675 12.6528 12.6630 
LysoPC 22:4 14.3349 13.9226 14.2878 14.1062 14.0424 13.8090 14.2882 
LysoPC 22:5 15.9951 15.6532 15.8161 15.5861 15.5742 15.3031 15.6536 
LysoPC 22:6 16.3507 16.3686 16.2273 16.2538 16.0604 15.8354 16.0770 
LysoPC 23:0 10.9046 9.9134 10.8292 11.1495 10.6135 10.6176 10.5149 
LysoPC 24:0 13.5165 13.1270 13.5396 13.9560 13.4425 13.6393 13.5068 
LysoPC 24:1 12.0328 11.7441 12.2243 12.5759 12.1204 12.0846 12.2088 
LysoPC 26:1 10.6134 10.0702 10.4728 10.6588 10.1006 10.2573 10.6154 
LysoPE 16:0 14.7211 14.0794 14.6704 15.1141 14.7502 14.5093 15.0607 
LysoPE 18:0 15.8126 15.2495 15.7798 15.8341 15.6524 15.5417 15.8482 
LysoPE 18:1 16.4085 15.3152 16.3772 16.4073 15.7963 15.7489 16.0832 
LysoPE 18:2 16.2814 15.7798 16.4856 16.7435 15.9580 16.0539 16.4141 
LysoPE 20:3 13.4341 12.9975 12.8344 13.3748 13.0866 12.9874 13.5229 
LysoPE 20:4 15.9447 15.6073 15.7868 15.8173 15.7360 15.5352 15.8265 
LysoPE 20:5 11.6560 10.7188 11.2660 11.2566 11.4140 11.4983 11.5579 
LysoPE 22:4 12.2595 11.5866 12.4051 11.7633 12.1340 11.6074 12.3251 
LysoPE 22:5 13.7978 13.2361 13.4298 13.3016 13.3377 12.9650 13.9577 
LysoPE 22:6 15.6269 15.5593 15.4808 15.4034 15.4832 15.2097 15.6630 
PA 34:2 12.0610 12.2918 11.9612 11.9994 11.8965 11.8006 12.1680 
PC 26:0 10.5024 8.5085 9.7334 9.8268 10.1339 10.1198 10.0781 
PC 29:0 12.5867 10.9910 11.6652 12.1988 12.2547 12.1129 12.4329 
PC 30:0 15.6312 14.6621 15.0617 15.1234 15.3514 14.9963 15.5991 
PC 30:2 12.3302 10.6301 11.5946 11.9749 12.0516 11.8130 12.3830 
PC 31:0 14.9039 14.0130 14.4565 14.5836 14.6303 14.4911 14.7155 
PC 31:1 14.1107 13.3514 14.0839 14.1421 14.0862 13.7063 14.7292 
PC 32:0 19.7533 19.2790 19.6533 19.9112 19.6652 19.4520 19.9411 
PC 32:1 17.1928 16.1292 16.9125 17.1049 17.0950 16.8218 17.5353 
PC 32:2 18.8191 18.0022 18.5008 18.8258 18.6286 18.4622 19.0029 
PC 32:3 13.8330 13.0658 13.1912 13.5594 13.4920 13.3232 13.7461 
PC 33:0 15.4463 14.7905 15.0092 15.2315 15.2194 15.0406 15.3506 
PC 33:1 17.6358 16.8037 17.3182 17.4134 17.5555 17.4547 17.5887 
PC 33:2 18.4074 17.6703 18.1781 18.5573 18.3877 18.1851 18.4911 
PC 33:3 13.7404 13.0422 13.5630 13.6915 13.6772 13.6425 13.7529 
PC 34:1 23.5746 23.1121 23.4520 23.5693 23.4570 23.2610 23.6502 
PC 34:2 21.8777 21.4117 21.8280 22.1305 21.7982 21.6324 21.9559 
PC 34:3 18.2038 17.8446 18.2797 18.4646 18.2470 17.9626 18.5851 
PC 34:4 15.8827 15.1432 15.5074 15.5864 15.6679 15.4238 15.7439 
PC 34:5 13.0868 12.9839 12.9319 13.1254 12.7553 13.1521 13.2528 
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Table S2.2D: PUFA/CHO study significant differences for within and between diet comparisons 
for all lipids (Phosphatidylcholine 35:0 to Phosphatidylethanolamine 32:1) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
PC 35:0 13.8225 13.1468 13.6672 13.6973 13.3307 13.4745 13.7801 
PC 35:1 15.8061 15.3849 15.6337 15.7501 15.7456 15.6857 15.8593 
PC 35:2 19.5321 18.9191 19.5135 19.6912 19.3704 19.4141 19.5555 
PC 35:3 15.1829 14.8200 15.4411 15.6878 14.8966 15.1348 15.5110 
PC 35:4 16.5822 16.2072 16.3501 16.4967 16.6432 16.4945 16.5641 
PC 35:5 13.3563 12.6924 12.6329 12.8931 13.2542 13.2651 13.0200 
PC 36:0 14.8159 14.6687 14.8316 14.7918 14.5061 14.7429 14.7572 
PC 36:1 20.5871 19.9745 20.5953 20.2551 20.2845 20.3973 20.4266 
PC 36:2 24.0233 23.6832 24.1303 24.0914 23.8693 23.9374 24.0109 
PC 36:3 20.5912 20.1694 20.5994 20.7300 20.5059 20.3427 20.6462 
PC 36:4 20.4393 20.1711 20.2922 20.2196 20.3101 20.1344 20.3903 
PC 36:5 19.7572 19.5940 19.5779 19.5078 19.7715 19.7910 19.7430 
PC 36:6 15.7492 15.2265 15.3487 15.5650 15.7279 15.4783 15.8101 
PC 37:1 14.4093 13.8810 14.3265 14.3398 14.3808 14.2633 14.2384 
PC 37:2 16.1915 15.5961 16.2386 16.4942 16.0892 16.0877 16.2228 
PC 37:3 17.1669 16.7328 17.0340 17.1869 17.1005 17.0697 17.2646 
PC 37:4 18.3405 18.1681 18.1751 18.1207 18.2429 18.1947 18.1410 
PC 37:5 16.4725 16.3220 16.5988 16.2630 16.3931 16.3083 16.3979 
PC 37:6 14.7070 14.6595 14.8542 14.7459 14.7495 14.6306 14.7643 
PC 37:7 14.7449 14.5856 14.6528 15.3073 15.0114 14.4228 15.3416 
PC 38:1 15.0832 14.6662 15.1361 15.0797 15.0325 14.9923 15.0423 
PC 38:2 18.4923 18.0053 18.7111 18.7024 18.4567 18.5360 18.6756 
PC 38:3 21.1857 20.7304 21.1707 20.8713 21.1093 21.1171 21.2629 
PC 38:4 22.7591 22.9346 22.7700 22.2400 22.7506 22.6665 22.5301 
PC 38:5 21.9527 21.9141 22.0171 21.5290 21.8349 21.6649 21.7885 
PC 38:6 22.4078 22.4610 22.5695 22.3644 22.5292 22.2405 22.4881 
PC 38:7 17.7460 17.5242 17.7975 17.6092 17.7124 17.7088 17.8044 
PC 39:3 13.9703 13.4469 14.1172 14.0785 14.0505 13.8506 14.1877 
PC 39:4 15.2959 15.0817 15.2207 15.2922 15.1889 15.1327 15.2412 
PC 39:5 15.9200 15.6625 15.8120 15.5846 15.8627 15.7563 15.6701 
PC 39:6 16.4966 16.4813 16.3777 16.2638 16.4639 16.4502 16.3330 
PC 39:7 13.7020 13.5941 13.9302 13.8324 13.8460 13.6722 13.6520 
PC 40:1 12.9468 12.4919 12.5152 12.8675 12.7946 12.6484 12.6992 
PC 40:2 13.9821 13.6273 14.1099 14.4502 13.9767 13.9127 14.2811 
PC 40:3 15.1674 14.8103 15.1089 15.4023 15.0679 15.0484 15.3431 
PC 40:4 16.2596 15.9992 16.5176 16.0105 16.1709 16.0297 16.2021 
PC 40:5 17.0769 16.9775 17.3135 16.6473 17.0500 16.8875 17.0985 
PC 40:6 19.9883 20.1464 20.2869 19.5269 20.0913 19.9973 20.0215 
PC 40:7 18.3406 18.4175 18.5075 18.2939 18.3576 18.2053 18.4070 
PC 40:8 15.2061 15.3767 15.3108 15.6218 15.1168 15.2845 15.5232 
PC 40:9 12.4534 11.2977 12.2230 12.0502 12.1696 12.4806 11.9897 
PC 41:6 11.6554 12.3812 12.2355 11.8255 12.2743 12.5147 12.0673 
PC 41:7 10.1650 11.3106 11.3777 11.2244 11.1748 11.4201 10.9379 
PC 42:1 12.2569 11.5320 11.7310 12.3688 11.9031 11.8150 12.4475 
PC 42:10 14.5122 14.1728 14.4904 14.4629 14.4105 14.4037 14.2768 
PC 42:2 12.9854 11.9651 13.2876 13.2933 12.7587 12.6590 13.1814 
PC 42:3 12.7637 12.7116 13.0694 13.5647 12.8688 12.8929 13.3144 
PC 42:4 13.5223 12.7988 13.3488 13.7932 13.2036 13.1101 13.8750 
PC 42:5 14.5252 13.6418 14.5407 14.3435 14.4582 14.1146 14.6688 
PC 42:6 14.1239 13.9570 14.3435 13.7569 14.1797 13.9055 14.4197 
PC 42:7 14.1382 13.9435 14.1211 14.4162 14.1496 13.7687 14.3247 
PC 42:8 14.1140 13.9644 14.2283 14.5286 14.0121 14.0454 14.3806 
PC 42:9 14.0807 13.4963 13.9146 13.7341 13.7241 13.7130 13.7679 
PC 44:4 12.6018 11.7300 12.8295 12.7864 12.7445 12.5122 12.7469 
PE 32:1 12.7744 11.7523 12.5625 12.7270 12.8045 12.2779 13.3919 
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Table S2.2E: PUFA/CHO study significant differences for within and between diet comparisons 
for all lipids (Phosphatidylethanolamine 32:2 to Plasmenyl-phosphatidylcholine 36:2) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
PE 32:2 10.8398 10.3072 10.3227 10.6473 10.7812 10.6655 11.2484 
PE 33:0 11.1837 11.4161 11.5629 11.8669 11.2610 11.4911 11.4783 
PE 33:1 10.7058 10.2169 9.9078 11.0513 11.1295 10.9160 11.2951 
PE 33:2 12.2536 11.1758 11.6560 12.9319 11.6219 11.8848 13.0170 
PE 34:0 18.6807 18.5979 18.7295 18.7619 18.6391 18.6306 18.8398 
PE 34:1 14.1667 13.3864 14.1083 14.1763 14.0679 13.6738 14.7009 
PE 34:2 16.2009 15.7024 16.2308 17.0404 16.1780 15.7236 17.0150 
PE 34:3 14.5077 13.6978 14.4372 14.9236 14.6565 14.4440 15.1570 
PE 35:1 12.0500 11.8808 12.5096 12.6848 12.3498 12.2266 12.8539 
PE 35:2 13.2966 12.4871 13.2584 13.8660 13.6422 12.9921 13.9489 
PE 35:4 12.1931 11.8119 11.9014 12.5777 12.2500 11.9958 12.6848 
PE 36:0 14.1722 14.0775 14.1932 14.3078 14.0525 14.1683 14.1969 
PE 36:1 15.4442 15.0139 15.5936 15.3960 15.0732 15.2593 15.6997 
PE 36:2 16.9031 16.3213 17.1364 17.4026 16.8447 16.7219 17.4502 
PE 36:3 17.5742 16.7283 17.8735 18.6795 17.5463 17.2203 18.2451 
PE 36:4 17.4308 16.8135 17.8103 18.5451 17.5292 17.0577 18.0334 
PE 36:5 14.4340 13.6647 13.9454 14.6638 14.7029 14.3617 14.8203 
PE 37:4 13.8993 13.3056 13.4834 14.0169 13.7440 13.3892 14.1248 
PE 38:3 16.2157 15.9145 16.2604 16.5139 16.1517 15.8069 16.7005 
PE 38:4 19.0604 18.9268 18.9758 19.2196 19.0497 18.6685 19.2469 
PE 38:5 16.5626 16.2480 16.4864 16.9148 16.4735 16.0970 17.0794 
PE 38:6 18.7076 18.5742 18.2734 19.3071 18.9921 18.1975 19.4603 
PE 38:7 13.3707 13.0755 12.9838 13.5922 13.2760 12.8280 13.6043 
PE 40:4 14.4294 13.4170 14.3971 14.1322 14.2704 13.6147 14.5411 
PE 40:5 15.8583 15.6772 15.8470 15.8092 15.8368 15.5354 16.1064 
PE 40:6 17.4233 17.6117 17.4031 17.4261 17.6006 16.9984 17.8487 
PE 40:7 15.4588 15.2942 15.3873 16.0047 15.6588 14.7349 16.1210 
PE 40:8 12.9873 12.4892 12.7850 13.4454 13.2164 12.6088 13.5135 
PG 33:0 13.3135 13.5331 12.8362 12.6606 12.9543 12.9606 13.1116 
PG 34:2 10.9755 10.7386 10.6666 10.8269 11.0090 10.9844 11.4843 
PG 36:0 14.5892 14.6343 14.8676 14.8048 14.3413 14.9466 14.5516 
PG 36:2 14.3803 13.8687 14.5287 14.4931 14.0964 14.0577 14.4499 
PG 36:3 11.9232 11.3894 11.9983 11.7926 11.8956 11.7077 11.8414 
PI 34:2 13.9076 13.2592 14.4324 13.7322 14.1889 14.2223 14.1939 
PI 36:1 13.6703 12.8066 13.4245 13.1456 13.0289 13.4491 12.9364 
PI 36:2 16.2933 15.9370 16.7696 16.4002 16.3665 16.4866 16.4937 
PI 36:4 14.1448 13.1857 14.3311 14.1416 14.3362 14.1884 14.2186 
PI 38:3 16.5387 16.3245 16.6265 16.1685 16.3293 16.4035 16.5780 
PI 38:4 18.0354 17.8465 18.1267 17.6990 17.9750 18.0775 17.9667 
PI 38:5 14.1903 13.7616 14.4494 13.6285 14.3479 14.4474 14.1124 
PI 38:6 11.7690 11.3217 12.1479 11.5485 12.0632 12.1808 11.9877 
PI 40:6 13.1300 13.2039 13.2130 13.0270 13.4493 13.4521 13.0399 
PlsCho 24:0 12.0666 11.7540 12.2381 12.5878 12.1016 12.0534 12.1822 
PlsCho 32:0 16.4487 16.6831 16.3627 16.3337 16.2229 16.5648 16.0613 
PlsCho 32:1 13.8642 13.6128 13.7962 13.9399 13.8892 14.0162 13.5472 
PlsCho 33:0 12.4738 12.0374 12.1296 11.8894 11.9404 12.1182 12.4112 
PlsCho 34:0 18.1060 17.7092 17.8023 18.3219 17.8431 17.6957 18.0899 
PlsCho 34:1 18.4815 17.9769 18.4490 18.8229 18.2400 18.3266 18.5745 
PlsCho 34:2 19.1738 18.6438 18.9259 19.7451 19.1347 19.0185 19.3184 
PlsCho 34:3 14.9020 14.5169 14.4094 14.7487 14.5821 14.6429 14.4630 
PlsCho 35:1 12.5706 12.0630 12.7079 12.1886 12.5602 12.2495 12.3995 
PlsCho 35:2 14.9639 14.4113 14.9347 15.1617 14.9797 14.7301 15.1039 
PlsCho 35:3 14.5569 14.0105 13.7197 13.8089 14.1293 14.1525 13.8906 
PlsCho 36:0 16.6471 16.2286 16.2919 16.4486 16.4226 16.3593 16.4258 
PlsCho 36:2 17.0771 16.5518 16.4639 17.3355 16.7539 16.6369 16.9814 
80 
 
Table S2.2F: PUFA/CHO study significant differences for within and between diet comparisons for 
all lipids (Plasmenyl-phosphatidylcholine 36:3 to Plasmenyl-phosphatidylethanolamine 37:5) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
PlsCho 36:3 20.2453 19.7406 20.0767 20.1130 19.9130 19.7907 20.0048 
PlsCho 36:4 19.5773 18.9890 19.4649 19.5626 19.3946 19.2970 19.3406 
PlsCho 36:5 15.5974 15.0886 15.7359 15.5570 15.1480 15.6385 15.2004 
PlsCho 36:6 13.6808 13.1595 13.4268 13.4427 13.6136 13.3565 13.5197 
PlsCho 37:1 13.1938 12.7648 13.2506 12.6342 13.0606 13.0474 13.0539 
PlsCho 37:3 13.1608 12.8984 13.1095 13.0217 13.1072 12.8191 13.0770 
PlsCho 37:4 15.8494 15.3344 15.6252 15.6549 15.5603 15.4312 15.6136 
PlsCho 37:6 16.0650 15.4429 15.8811 15.6679 15.7478 15.9157 15.7136 
PlsCho 38:1 16.8456 15.7698 16.6851 16.7810 17.1158 17.0451 17.0240 
PlsCho 38:3 19.0183 18.5950 18.6628 18.6833 18.6926 18.4382 18.7937 
PlsCho 38:4 19.7708 19.5584 19.6557 19.7523 19.5485 19.4022 19.6903 
PlsCho 38:5 18.7283 18.3614 18.6145 18.5776 18.4831 18.4613 18.5397 
PlsCho 38:6 17.2212 16.9251 17.0826 17.2121 17.0808 17.1354 16.8406 
PlsCho 39:3 17.9364 17.3284 17.9877 17.6734 18.0081 17.4323 18.3912 
PlsCho 39:4 16.2464 16.1425 16.2302 15.9396 16.1675 16.0376 16.1739 
PlsCho 39:5 16.1977 16.0579 16.3632 16.1288 16.3317 16.0984 16.2263 
PlsCho 39:6 13.6140 13.3718 13.2382 13.3281 13.4440 13.4878 13.1922 
PlsCho 40:1 15.2388 15.2467 15.0778 15.4230 15.2362 15.0616 15.3115 
PlsCho 40:3 17.3781 17.1230 17.0740 17.0019 17.1508 16.9293 17.2408 
PlsCho 40:4 17.6534 17.5872 17.5187 17.4183 17.4090 17.1823 17.6579 
PlsCho 40:5 17.1854 16.7036 17.2613 17.1207 16.7593 16.7346 17.0939 
PlsCho 40:6 15.6519 15.3487 15.3220 15.5187 15.4635 15.3243 15.3486 
PlsCho 42:0 11.9878 11.4197 11.7576 11.9948 11.7769 11.7230 11.8621 
PlsCho 42:1 14.3341 13.9316 14.0684 14.0980 13.8206 13.8148 14.3255 
PlsCho 42:2 15.3402 15.1221 15.1814 15.6898 15.1469 14.9932 15.7174 
PlsCho 42:3 15.9316 15.5640 15.8030 16.2813 15.7007 15.4842 16.0324 
PlsCho 42:4 16.9337 16.8455 16.6396 16.8338 16.5855 16.2264 17.0823 
PlsCho 42:5 16.4319 16.7297 16.4670 16.8589 16.4845 16.3177 16.8131 
PlsCho 42:6 15.3379 15.4166 15.1900 15.2969 15.0091 14.9246 15.6197 
PlsCho 44:3 15.0916 14.7861 14.6494 15.1561 14.6842 14.6138 15.4849 
PlsCho 44:4 17.2295 16.9592 16.9202 17.3994 16.9314 16.5278 17.6169 
PlsCho 44:5 16.5547 16.8942 16.7010 17.2216 16.7361 16.4554 17.3611 
PlsCho 44:6 15.3078 15.5688 15.1739 15.6946 15.3183 15.1268 15.6096 
PlsCho 46:4 14.0412 13.6771 13.7053 14.2964 13.6748 13.4551 14.4824 
PlsEth 32:1 13.1766 12.7113 13.1408 12.6920 12.9933 12.9504 12.9126 
PlsEth 32:2 11.5391 11.2461 11.4324 11.4435 11.1139 11.2643 11.3170 
PlsEth 33:2 11.0422 9.5308 10.6512 10.8091 10.3739 10.8782 10.6121 
PlsEth 34:0 14.8482 14.7825 14.6896 14.7254 14.6811 14.5230 14.6938 
PlsEth 34:1 16.5972 16.0940 16.8055 16.4272 16.4336 16.2942 16.4697 
PlsEth 34:2 15.8393 14.8727 15.8288 15.9019 15.5304 15.7731 15.6190 
PlsEth 34:3 13.1197 11.9910 12.8190 12.6893 12.6379 12.9921 12.0840 
PlsEth 34:4 12.5721 11.5223 12.2298 11.9401 11.4208 12.1683 12.0591 
PlsEth 35:1 12.9272 12.2471 12.9493 12.8424 12.6491 12.6234 12.8891 
PlsEth 35:2 14.6399 13.4892 14.3632 14.3347 13.9670 14.4070 13.9306 
PlsEth 35:4 13.2204 11.6327 12.9932 12.6534 12.6990 12.5350 12.2173 
PlsEth 36:1 16.7399 15.6038 16.2538 15.9743 16.0702 16.1593 16.1898 
PlsEth 36:2 16.7944 15.8905 16.6713 16.6967 16.3813 16.6284 16.3911 
PlsEth 36:3 18.7162 17.9725 18.8506 18.8223 18.3160 18.6349 18.4689 
PlsEth 36:4 17.5677 16.8956 17.8471 17.4149 17.2695 17.5590 17.1770 
PlsEth 36:5 16.2122 14.9447 16.1766 15.3007 15.3557 15.8901 15.4151 
PlsEth 36:6 11.8885 11.4956 11.6856 11.6313 11.7749 11.7927 11.7901 
PlsEth 37:1 13.5265 12.6576 13.7665 14.1641 13.2965 13.3584 14.1144 
PlsEth 37:2 12.6468 12.2144 13.1334 13.7537 12.5888 12.4256 13.4140 
PlsEth 37:4 14.0456 13.0911 13.7696 13.4978 13.5072 13.7110 13.3994 
PlsEth 37:5 14.2763 13.4684 13.7109 13.1294 13.4443 13.8067 13.4117 
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Table S2.2FG: PUFA/CHO study significant differences for within and between diet comparisons for 
all lipids (Plasmenyl-phosphatidylethanolamine 37:6 to Sphingomyelin 42:1) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
PlsEth 37:6 13.1881 12.1807 13.1534 12.7880 12.9597 13.1243 12.7014 
PlsEth 38:1 14.0967 13.2178 14.2878 13.7179 13.8287 13.7299 13.9064 
PlsEth 38:2 15.5743 15.1773 15.7746 15.5307 15.4134 15.4277 15.4479 
PlsEth 38:3 17.7422 16.7313 17.4204 17.3180 17.0359 17.2730 17.2356 
PlsEth 38:4 17.7781 17.0074 17.6313 17.4630 17.4991 17.6013 17.2082 
PlsEth 38:5 17.8328 17.3381 17.7850 17.6486 17.4723 17.6476 17.3798 
PlsEth 38:6 19.1827 18.5392 19.0856 19.0735 18.9183 18.9596 18.7195 
PlsEth 39:4 14.0723 13.1818 14.0724 13.6624 13.7829 13.6791 13.6038 
PlsEth 39:5 14.5032 14.1661 14.4418 14.2659 14.2318 14.3745 14.1006 
PlsEth 39:6 15.3597 14.9053 15.1371 14.8086 14.9051 15.0589 14.8710 
PlsEth 40:2 14.1009 13.8954 14.6024 13.9010 13.8277 14.0056 14.1125 
PlsEth 40:4 14.9277 14.4970 15.1201 14.7338 14.4603 14.7565 14.7530 
PlsEth 40:5 17.6031 16.8756 17.2113 16.9761 17.0203 17.1285 16.8149 
PlsEth 40:6 16.0911 15.4491 15.8867 15.6680 15.7266 15.8811 15.6787 
PlsEth 42:4 15.1971 15.1078 15.5684 14.7354 14.7188 15.0996 14.9478 
PlsEth 42:5 14.9426 14.7483 15.3316 14.7980 14.7072 14.7872 14.8554 
PlsEth 42:6 15.0700 14.6947 15.5484 14.5162 14.6981 14.7429 14.8624 
PlsEth 44:6 11.7030 11.8243 12.4832 11.9515 11.8704 12.0116 11.7090 
SM 30:0 11.0131 9.9937 10.7141 9.5203 10.4744 10.1075 10.6125 
SM 30:1 14.8914 14.0543 14.3571 14.1689 14.5078 14.4753 14.6195 
SM 30:2 11.5081 11.2261 10.8863 11.3239 11.4988 11.3246 11.4523 
SM 31:1 14.7240 13.9380 14.3707 14.2615 14.5664 14.5051 14.4706 
SM 32:0 15.1041 14.5626 15.1483 14.9033 14.8653 15.0289 14.9619 
SM 32:1 18.9678 18.2867 18.8468 18.6794 18.7307 18.6855 18.7009 
SM 32:2 16.0826 15.7948 15.7747 15.4883 15.8134 15.7766 15.9955 
SM 33:1 18.0823 17.6460 17.9322 17.8489 17.9765 17.8468 17.8326 
SM 33:2 14.0265 13.7211 14.0795 13.9925 14.0275 13.8170 14.0191 
SM 34:0 17.5612 17.2737 17.2759 17.2289 17.3019 17.3378 17.4507 
SM 34:1 20.7700 20.6682 20.7351 20.7052 20.7938 20.7081 20.6980 
SM 34:2 19.5272 19.3837 19.4669 19.2914 19.3638 19.2558 19.3760 
SM 34:3 14.0225 14.0356 14.1806 13.4667 14.1089 13.9517 14.0553 
SM 35:2 14.7368 14.6551 14.4481 14.1050 14.5171 14.5571 14.2783 
SM 36:1 18.0794 18.3635 17.8514 17.6163 18.1088 17.9135 17.9291 
SM 36:2 17.7240 18.1395 17.6057 17.2388 17.4984 17.4940 17.4954 
SM 36:3 16.6273 16.9353 16.6286 16.3777 16.6160 16.4961 16.7328 
SM 36:4 13.9274 14.0785 14.1344 14.0743 14.1062 13.9273 13.9782 
SM 37:1 14.8950 14.9730 14.4332 14.7045 14.7762 14.5557 14.6689 
SM 37:2 15.2173 15.3517 14.9353 15.3256 15.1563 14.9118 15.2332 
SM 38:0 11.2788 11.1924 11.4441 11.3856 11.1176 11.1512 11.4483 
SM 38:1 18.3329 18.1650 18.1603 18.2157 18.3979 18.2026 18.1439 
SM 38:2 16.0684 16.4716 15.9909 16.0255 16.1661 15.9838 16.1718 
SM 38:3 14.7749 15.1508 14.6558 14.5270 14.8167 14.6922 15.0877 
SM 38:4 13.1438 13.1942 12.9087 13.2008 13.2910 13.0770 13.3515 
SM 39:1 17.9034 17.4011 17.6213 17.4608 17.8117 17.6807 17.5603 
SM 39:2 15.5877 15.6780 15.3200 15.4001 15.5577 15.4155 15.5656 
SM 39:3 15.0865 14.6493 14.9469 15.0801 14.8322 14.5876 14.8424 
SM 40:1 20.0581 19.7345 19.9304 19.7374 19.9437 19.8388 19.7426 
SM 40:2 20.1827 19.9827 20.0044 20.0313 20.1120 20.0067 20.0823 
SM 40:3 17.0189 17.2343 17.0649 16.9916 17.1461 17.0228 17.3466 
SM 40:5 12.9681 12.3566 12.7753 12.6320 13.0082 12.4609 13.1547 
SM 41:1 19.7889 19.4738 19.6103 19.5814 19.8328 19.7630 19.5850 
SM 41:2 18.8977 18.8268 18.6672 18.8580 18.9203 18.7594 18.7518 
SM 41:4 14.7505 14.5550 14.7707 14.9135 14.6968 14.4985 14.8169 
SM 41:6 13.0777 12.8916 13.0255 12.8362 12.9416 12.6324 13.0044 
SM 42:1 20.5494 20.2232 20.3869 20.4661 20.5494 20.5914 20.3439 
82 
 
Table S2.2H: PUFA/CHO study significant differences for within and between diet comparisons for 
all lipids (Sphingomyelin 42:2 to Triacylglycerol 52:2) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
SM 42:2 21.2841 21.2420 21.2948 21.3989 21.3860 21.3683 21.4066 
SM 42:3 20.5116 20.6102 20.5286 20.6842 20.6487 20.5481 20.8150 
SM 42:4 17.1705 17.6487 17.0830 17.2804 17.3732 17.2533 17.6501 
SM 42:5 14.5143 14.5511 14.5690 14.4532 14.9004 14.4631 15.1043 
SM 42:6 13.8966 13.8295 13.9746 13.4948 14.0374 13.7640 14.3384 
SM 43:1 16.5805 16.1524 16.3285 16.2056 16.5970 16.3524 16.2063 
SM 43:2 16.9347 16.7924 16.9070 16.9117 17.1293 16.7950 16.8761 
SM 43:3 15.4008 15.4307 15.3972 15.2804 15.4116 15.2852 15.4946 
SM 43:6 12.6412 12.7272 12.6566 12.7804 12.5766 12.7499 12.9763 
SM 44:1 13.4704 13.1900 13.3197 13.2960 13.4926 13.5106 13.2698 
SM 44:2 14.8758 14.7738 14.8415 14.8012 15.0175 14.7369 14.7617 
SM 44:3 14.3227 14.6079 14.5527 14.6572 14.4767 14.5108 14.8251 
SM 44:4 13.8337 13.8811 13.2945 14.6799 14.0184 13.9697 14.2220 
SM 44:6 12.1872 11.6393 11.4725 12.7004 12.0153 12.1561 12.4723 
TG 38:0 15.5609 15.0369 15.3126 15.2460 15.3613 15.3801 15.4013 
TG 39:0 15.2288 14.9942 15.1395 15.1993 15.1644 15.1255 15.2778 
TG 40:0 14.2387 13.6842 13.9105 13.9672 14.0716 14.1003 14.1021 
TG 41:0 13.3587 12.8422 12.9934 12.9449 13.1087 13.3217 13.1333 
TG 42:0 14.6572 13.4796 14.0103 13.9571 14.2340 14.3375 14.3954 
TG 42:1 14.3256 12.8889 13.6709 13.5661 13.8681 13.9635 14.0894 
TG 43:1 12.9152 11.6642 12.2611 12.1585 12.6511 12.7354 12.6813 
TG 44:2 15.7173 14.2691 15.0987 14.8190 15.2362 15.3448 15.5043 
TG 45:0 13.6183 12.6973 12.9721 12.9392 13.2009 13.3229 13.1939 
TG 45:1 13.9146 12.6952 13.4486 13.1083 13.5757 13.6608 13.7088 
TG 45:2 13.6250 12.3889 12.9041 12.6824 13.3544 13.4116 13.3712 
TG 46:0 16.1034 14.6814 15.5996 15.3704 15.8235 15.8626 16.0007 
TG 46:1 17.6364 15.9666 16.8637 16.7101 17.1955 17.1658 17.4521 
TG 46:3 16.3579 15.2656 16.1049 15.5506 16.0165 16.0576 16.3837 
TG 47:0 13.6285 12.3395 12.9578 12.9203 13.3732 13.4082 13.3610 
TG 47:1 14.7674 13.3247 13.9900 13.4920 14.4192 14.5106 14.4143 
TG 47:2 14.9318 13.4107 14.2429 13.8818 14.6425 14.6422 14.7402 
TG 48:0 16.7938 15.5232 16.3043 16.1441 16.6452 16.6830 16.7923 
TG 48:1 19.4511 18.0246 18.9195 18.5066 19.1077 19.0244 19.3750 
TG 48:3 18.8112 17.6240 18.6335 18.1176 18.6675 18.4860 19.0039 
TG 48:4 17.4644 16.7535 17.6307 17.0399 17.3709 17.3278 17.7102 
TG 48:5 15.1455 14.6457 15.4684 14.9445 15.0977 15.1448 15.4752 
TG 49:0 13.7878 12.6736 13.3478 12.9536 13.6911 13.7124 13.7479 
TG 49:1 16.1831 14.7074 15.4293 15.0876 15.9089 15.8786 15.9370 
TG 49:2 16.5328 15.3107 16.0696 15.6031 16.4069 16.2856 16.4895 
TG 49:3 15.7347 14.8666 15.6442 15.1211 15.8318 15.6573 15.9039 
TG 50:0 17.0064 15.7024 16.7298 15.9966 16.9228 16.9375 17.1827 
TG 50:1 20.3004 19.3130 20.1418 19.7440 20.2939 20.1571 20.5827 
TG 50:2 21.2000 20.4757 21.2249 20.7485 21.3030 21.1154 21.5790 
TG 50:3 21.0190 20.2355 21.1518 20.6154 21.1187 20.9099 21.4036 
TG 50:4 20.0251 19.5473 20.4611 20.0206 20.2100 20.0147 20.4817 
TG 50:5 17.8423 17.5492 18.4983 17.8681 18.2543 18.0893 18.3668 
TG 50:6 15.6908 15.4371 16.3046 15.6185 15.9053 15.7989 16.0100 
TG 51:1 15.8792 14.7614 15.6448 14.9203 15.8568 15.9038 15.8988 
TG 51:2 17.9370 17.0533 17.8029 17.1705 17.9506 17.8229 17.9535 
TG 51:3 17.9646 17.3715 18.0784 17.7435 18.1904 18.0017 18.1256 
TG 51:4 17.1157 16.6778 17.4708 17.2308 17.3678 17.2733 17.2757 
TG 51:5 15.5675 15.3061 16.0139 15.6352 15.9133 15.8826 15.5671 
TG 52:0 16.8263 16.0775 16.8877 16.5115 16.7605 16.9460 16.8268 
TG 52:1 19.6156 18.6205 19.4146 18.6585 19.5177 19.6736 19.6450 
TG 52:2 21.9087 21.3302 22.0444 21.5598 22.0403 21.9131 22.0477 
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Table S2.2I: PUFA/CHO study significant differences for within and between diet comparisons for 
all lipids (Triacylglycerol 52:3 to Triacylglycerol 60:12) 
 Mean Log2 AUC Values For Each Lipid Species 
  PUFA Diet CHO Diet 
Lipid/Day Baseline P2 P7 P21 C2 C7  C21 
TG 52:3 22.7645 22.6627 23.0786 22.8410 23.0803 22.9409 23.0877 
TG 52:4 22.4518 22.4419 22.9904 22.8340 22.8793 22.6923 22.8984 
TG 52:5 17.4742 17.4432 17.5991 17.5236 17.7531 17.5291 17.6518 
TG 52:6 18.6709 18.7444 19.3183 19.1001 19.2491 19.0131 19.1958 
TG 52:7 16.0607 16.1877 16.6628 16.2649 16.6747 16.4863 16.4706 
TG 53:0 13.2553 12.6732 13.3400 13.1567 13.1946 13.3108 13.2502 
TG 53:1 14.5533 13.7783 13.8366 13.8446 14.5392 14.7025 14.6934 
TG 53:2 15.9839 16.0649 16.5204 15.9704 16.5587 16.6895 16.6671 
TG 53:3 17.8560 17.5413 18.1111 17.8048 18.1233 18.0782 17.9821 
TG 53:4 17.3970 17.3411 17.8264 17.7375 17.7265 17.7234 17.6238 
TG 53:5 16.3326 16.2360 16.7778 16.6680 16.7040 16.6849 16.4381 
TG 54:0 16.7251 16.1905 16.8869 16.8927 16.7732 16.8480 16.7125 
TG 54:1 17.0780 15.9120 16.9468 16.2524 16.8939 17.2195 16.8893 
TG 54:2 19.3927 18.7099 19.6604 18.8664 19.4684 19.7132 19.3820 
TG 54:3 20.2470 20.0231 20.8475 20.4337 20.5034 20.6334 20.4635 
TG 54:4 21.3399 21.3486 22.0504 21.8645 21.6601 21.8118 21.6802 
TG 54:5 21.3495 21.5192 22.1814 22.0959 21.7620 21.8849 21.7521 
TG 54:6 20.9255 21.2727 21.8545 21.8530 21.4188 21.4814 21.3273 
TG 54:7 19.1309 19.4139 19.8840 19.7360 19.6760 19.7531 19.4835 
TG 54:8 16.7989 17.0186 17.2857 17.1121 17.4210 17.3440 16.9255 
TG 55:0 11.8260 11.5373 11.6711 11.6741 11.8114 12.0514 11.8631 
TG 55:3 13.5836 13.1035 13.9515 13.7482 13.8527 13.8174 13.4256 
TG 55:4 14.5066 13.9814 14.4810 14.5506 13.5991 14.7356 14.4892 
TG 55:5 14.6868 14.3120 14.6339 14.5908 14.8159 14.8880 14.5650 
TG 56:0 12.6427 11.9887 12.7529 12.5447 12.5720 12.6424 12.5567 
TG 56:1 14.3772 13.0854 14.1235 13.6911 13.9831 14.4146 14.1344 
TG 56:2 15.7728 14.8201 15.9060 15.1931 15.5660 16.0173 15.6794 
TG 56:3 16.3864 15.8438 16.6962 16.4088 16.4494 16.7769 16.6697 
TG 56:4 16.6111 16.5511 16.9880 16.8696 16.7971 16.9507 16.9398 
TG 56:5 18.3591 18.3373 18.4916 18.6603 18.5635 18.5514 18.6569 
TG 56:6 19.0250 19.1710 19.1553 19.3305 19.3353 19.2649 19.2122 
TG 56:7 19.2233 19.4176 19.3555 19.4218 19.5686 19.4532 19.2834 
TG 56:8 18.7281 19.2148 19.0344 19.2304 19.3004 19.2149 18.9522 
TG 56:9 16.8880 17.5006 17.2100 17.4152 17.6482 17.6034 17.1442 
TG 58:10 16.5686 17.2266 16.7296 17.2168 17.1768 17.3286 16.7688 
TG 58:11 14.5134 15.4601 14.8423 15.1703 15.3565 15.5953 14.9073 
TG 58:2 14.2199 13.2070 14.2259 13.8306 13.9397 14.3833 14.2568 
TG 58:3 14.2984 13.6036 14.6781 14.1261 14.1488 14.5895 14.4163 
TG 58:6 15.2622 15.1692 15.3118 15.3556 15.4510 15.4131 15.5142 
TG 58:7 16.3364 16.2954 16.1942 16.3583 16.5411 16.5224 16.3785 
TG 58:8 16.8233 17.0023 16.8818 17.0961 17.1653 17.2411 16.9617 
TG 58:9 16.8179 17.3137 17.0137 17.3853 17.3563 17.4598 16.9500 
TG 60:11 14.2457 14.6512 13.9795 14.4610 14.7273 14.6618 14.3432 





Table S2.3A: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(16:0 Cholesterol ester to Ceramide [NP] 42:0) 
 Within Diet Comparisons 




















16:0 CE 0.9012 0.9883 0.9288 0.07667 0.5484 0.9008 0.4199 0.9532 0.8643 
16:1 CE 0.8499 0.8841 0.7603 0.0043 0.4059 0.9324 0.0160 0.0010 0.1248 
18:0 CE 0.9896 0.9106 0.8832 0.2365 0.7257 0.8314 0.1690 0.2871 0.8504 
18:1 CE 0.8325 0.5580 0.8832 0.2129 0.3169 0.5971 0.2233 0.0930 0.9327 
18:2 CE 0.0425 0.6154 0.9287 0.6709 0.9283 0.5971 0.7100 0.0224 0.1262 
18:3 CE 0.9598 0.3847 0.9291 0.1350 0.4059 0.7053 0.0318 0.1237 0.8093 
20:3 CE 0.2041 0.3847 0.1982 0.3518 0.3323 0.8886 0.0140 0.0010 0.6487 
20:4 CE 0.0227 0.8122 0.7954 0.0302 0.9109 0.9405 0.4524 0.0884 0.5093 
20:5 CE 0.8081 0.6632 0.7057 0.9628 0.3323 0.9910 0.0324 0.0185 0.9392 
22:4 CE 0.4889 0.9883 0.4055 0.8045 0.7450 0.9008 0.4521 0.3754 0.9022 
22:5 CE 0.0729 0.8122 0.7603 0.5149 0.5954 0.9790 0.5834 0.7348 0.9512 
22:6 CE 0.1937 0.9106 0.9287 0.0749 0.8884 0.8440 0.7200 0.6975 0.9468 
ACAR 10:0 0.9012 0.9883 0.7977 0.9771 0.8467 0.8371 0.4012 0.4087 0.1250 
ACAR 10:1 0.0350 0.9961 0.8159 0.0348 0.4750 0.7179 0.1575 0.0010 0.0274 
ACAR 12:0 0.9375 0.9961 0.9291 0.4789 0.9976 0.8825 0.4472 0.8050 0.3745 
ACAR 14:0 0.6625 0.9106 0.8171 0.6890 0.7560 0.8886 0.2507 0.9124 0.4093 
ACAR 14:1 0.6693 0.9883 0.8261 0.6560 0.8348 0.8886 0.5945 0.4847 0.3930 
ACAR 14:2 0.3028 0.9909 0.8102 0.2222 0.8406 0.8371 0.7200 0.0246 0.1248 
ACAR 16:0 0.1067 0.9338 0.9523 0.1416 0.7631 0.9253 0.0275 0.1608 0.6487 
ACAR 18:0 0.7139 0.9883 0.9848 0.9077 0.8066 0.9910 0.4170 0.7653 0.8018 
ACAR 18:1 0.7709 0.9612 0.9832 0.9845 0.8467 0.8371 0.6320 0.9124 0.8504 
ACAR 18:2 0.5181 0.9941 0.9887 0.2129 0.7433 0.8371 0.3730 0.0251 0.3601 
ACAR 24:0 0.8747 0.9106 0.9832 0.0369 0.9346 0.8371 0.8990 0.0053 0.0469 
ACAR 26:0 0.8355 0.9707 0.9523 0.3156 0.7560 0.9276 0.8407 0.5439 0.5724 
Cer[AS] 34:1 0.9979 0.9541 0.9832 0.7870 0.9342 0.9795 0.5925 0.9006 0.6487 
Cer[EODS] 
58:0 
0.6984 0.7039 0.8171 0.6381 0.8467 0.7579 0.9111 0.1924 0.3930 
Cer[NDS] 34:0 0.9990 0.9612 0.9848 0.5186 0.8884 0.7736 0.6488 0.8050 0.5954 
Cer[NDS] 36:0 0.7402 0.9883 0.9832 0.9292 0.6687 0.7579 0.4170 0.0701 0.4650 
Cer[NDS] 38:0 0.5374 0.9106 0.8102 0.9077 0.4775 0.9169 0.1151 0.2095 0.9327 
Cer[NDS] 40:0 0.8674 0.9106 0.9788 0.2660 0.7560 0.9276 0.4369 0.4655 0.3067 
Cer[NDS] 42:0 0.9484 0.8841 0.9709 0.8030 0.9346 0.8371 0.3804 0.5023 0.2835 
Cer[NDS] 42:1 0.8586 0.8660 0.7665 0.3411 0.9342 0.7991 0.0282 0.6909 0.1250 
Cer[NP] 34:0 0.7942 0.9883 0.9957 0.4116 0.5954 0.8661 0.7200 0.7148 0.5299 
Cer[NP] 42:0 0.8355 0.6632 0.9709 0.3074 0.5907 0.7991 0.0717 0.4898 0.1250 
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Table S2.3B: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Ceramide [NP] 42:1 to Diacylglycerol 35:3) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
Cer[NP] 42:1 0.1846 0.7970 0.9957 0.1753 0.5954 0.9389 0.8784 0.9903 0.9512 
Cer[NS] 32:1 0.9793 0.8122 0.9848 0.5236 0.3479 0.7736 0.1973 0.8034 0.4650 
Cer[NS] 33:1 0.9271 0.6632 0.7977 0.8587 0.9548 0.7736 0.9070 0.4898 0.6487 
Cer[NS] 34:1 0.6506 0.9298 0.9832 0.8070 0.8712 0.9910 0.7388 0.9021 0.6487 
Cer[NS] 34:2 0.8112 0.9106 0.9709 0.8856 0.7910 0.9253 0.4369 0.4350 0.9163 
Cer[NS] 35:1 0.9979 0.9961 0.9832 0.9077 0.8335 0.7579 0.8297 0.5095 0.8522 
Cer[NS] 36:1 0.7402 0.9106 0.9523 0.6709 0.4750 0.9910 0.1151 0.0292 0.6524 
Cer[NS] 36:2 0.9054 0.8846 0.9523 0.9479 0.5954 0.8886 0.6805 0.1215 0.5023 
Cer[NS] 37:1 0.9859 0.9298 0.9957 0.9115 0.7139 0.9795 0.5925 0.3315 0.8643 
Cer[NS] 38:1 0.8355 0.7395 0.9832 0.7649 0.5954 0.9925 0.0717 0.2304 0.5724 
Cer[NS] 38:2 0.9012 0.9298 0.8102 0.9979 0.5954 0.9577 0.0945 0.0297 0.9139 
Cer[NS] 39:1 0.6984 0.9883 0.9832 0.7179 0.4775 0.6005 0.4174 0.8492 0.5425 
Cer[NS] 40:1 0.6984 0.9106 0.8102 0.3072 0.8467 0.5971 0.0160 0.6285 0.0350 
Cer[NS] 40:2 0.9012 0.6154 0.9832 0.8917 0.5560 0.7824 0.0160 0.0712 0.3601 
Cer[NS] 40:3 0.7733 0.9916 0.9533 0.3671 0.9098 0.8371 0.2044 0.0224 0.6487 
Cer[NS] 41:1 0.7521 0.9106 0.7603 0.1933 0.8971 0.7991 0.0216 0.2587 0.1876 
Cer[NS] 41:2 0.9598 0.7393 0.9709 0.9292 0.5030 0.8371 0.0436 0.0585 0.6487 
Cer[NS] 42:1 0.9587 0.5039 0.9957 0.7574 0.6687 0.8830 0.0324 0.7363 0.1794 
Cer[NS] 42:2 0.9012 0.9106 0.7954 0.1795 0.8275 0.6676 0.0436 0.4063 0.3210 
Cer[NS] 42:3 0.9847 0.8122 0.9957 0.6829 0.6687 0.9601 0.0715 0.0081 0.6524 
Cer[NS] 43:1 0.8747 0.6632 0.9832 0.7140 0.4750 0.9405 0.0324 0.1215 0.5954 
Cer[NS] 43:2 0.8112 0.9483 0.7603 0.0402 0.8642 0.9925 0.0717 0.0240 0.9139 
DG 30:0 0.0227 0.9027 0.7603 0.0899 0.5100 0.8371 0.0555 0.1146 0.9477 
DG 30:1 0.1260 0.7464 0.9832 0.6437 0.4465 0.9778 0.2137 0.1350 0.8093 
DG 32:0 0.8844 0.9298 0.8171 0.4882 0.8275 0.7736 0.4813 0.9486 0.6375 
DG 32:1 0.0095 0.3847 0.8832 0.0043 0.7310 0.8452 0.0284 0.0167 0.7314 
DG 32:2 0.5258 0.7393 0.9523 0.0318 0.8467 0.8886 0.6195 0.0716 0.5165 
DG 33:0 0.8747 0.9883 0.9832 0.1509 0.8467 0.8371 0.4236 0.1827 0.7516 
DG 33:1 0.0658 0.5742 0.9291 0.1757 0.7560 0.9925 0.4630 0.0183 0.3930 
DG 34:0 0.9859 0.9298 0.8102 0.1795 0.6945 0.6769 0.6208 0.4702 0.4093 
DG 34:2 0.6733 0.9883 0.9523 0.1598 0.9152 0.9086 0.7633 0.2557 0.5724 
DG 34:3 0.9012 0.9106 0.9709 0.0437 0.8712 0.8371 0.7712 0.0854 0.3770 
DG 35:1 0.0615 0.6182 0.9533 0.0143 0.9026 0.8886 0.0845 0.0297 0.8093 
DG 35:2 0.0410 0.6632 0.9832 0.1507 0.5954 0.8371 0.3133 0.0397 0.5724 
DG 35:3 0.9012 0.9883 0.9523 0.0937 0.8884 0.7991 0.4552 0.3133 0.8504 
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Table S2.3C: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Diacylglycerol 36:0 to Glucoceramide [NS] 41:1) 
 Within Diet Comparisons 




















DG 36:0 0.9033 0.7395 0.7977 0.6287 0.8467 0.7728 0.9706 0.3554 0.5165 
DG 36:1 0.9979 0.9883 0.7603 0.0152 0.9159 0.7824 0.1192 0.2977 0.9731 
DG 36:2 0.2692 0.8122 0.9832 0.0120 0.9342 0.9178 0.5517 0.0137 0.3783 
DG 36:3 0.9012 0.9338 0.9523 0.3651 0.9283 0.8886 0.6347 0.6904 0.5054 
DG 36:4 0.2599 0.9186 0.9788 0.9875 0.8327 0.7991 0.2151 0.2557 0.9243 
DG 36:5 0.5181 0.8660 0.9287 0.6074 0.8763 0.7736 0.4170 0.8188 0.4093 
DG 38:1 0.9054 0.9048 0.9832 0.9147 0.4569 0.9581 0.4326 0.1455 0.6547 
DG 38:2 0.7457 0.9359 0.9607 0.0482 0.8348 0.8371 0.1692 0.0505 0.7314 
DG 38:3 0.8112 0.9961 0.9832 0.1005 0.9568 0.9324 0.7661 0.2444 0.5964 
DG 38:4 0.1778 0.9883 0.9533 0.0044 0.9494 0.9405 0.1718 0.0265 0.4650 
DG 38:5 0.6656 0.9298 0.9832 0.0097 0.8969 0.8371 0.4199 0.0444 0.4093 
DG 38:6 0.9012 0.9541 0.9957 0.1717 0.9342 0.8371 0.9643 0.8492 0.9022 
DG 40:6 0.2831 0.9883 0.9887 0.0352 0.9109 0.9423 0.1595 0.0400 0.6387 
DG 40:7 0.9896 0.9106 0.9832 0.0116 0.8434 0.9405 0.5871 0.0854 0.4946 
FFA(16:0) 0.9676 0.9298 0.9788 0.3988 0.6687 0.9778 0.8037 0.9533 0.8504 
FFA(18:0) 0.9012 0.9298 0.9533 0.4709 0.6345 0.8371 0.9785 0.8390 0.9022 
FFA(18:1) 0.8355 0.9961 0.9832 0.5784 0.9494 0.8886 0.4206 0.9124 0.5538 
FFA(18:2) 0.6625 0.9883 0.9957 0.0749 0.9342 0.9910 0.4206 0.1305 0.5054 
FFA(20:0) 0.9246 0.9883 0.9523 0.4092 0.6687 0.7991 0.5655 0.4350 0.9327 
FFA(20:1) 0.8355 0.9939 0.9788 0.8991 0.9875 0.9276 0.3703 0.9851 0.5638 
FFA(20:2) 0.9990 0.9961 0.9832 0.4347 0.9346 0.8886 0.7799 0.7887 0.6487 
FFA(20:4) 0.4942 0.9395 0.9788 0.0951 0.4775 0.8371 0.1192 0.9174 0.3828 
FFA(22:0) 0.9990 0.9883 0.9709 0.2129 0.6239 0.8886 0.6624 0.5545 0.9022 
FFA(22:1) 0.9182 0.8846 0.9533 0.2842 0.8577 0.8886 0.8407 0.8492 0.8093 
FFA(22:2) 0.8009 0.9883 0.9709 0.9133 0.9342 0.9925 0.1973 0.9872 0.3745 
FFA(22:3) 0.8112 0.8660 0.9832 0.9077 0.7433 0.8371 0.1151 0.1007 0.9512 
FFA(24:0) 0.9771 0.9883 0.9287 0.0152 0.9014 0.9276 0.4921 0.0068 0.1794 
FFA(24:1) 0.5662 0.7659 0.7977 0.0277 0.7560 0.8371 0.3282 0.1507 0.9139 
FFA(24:2) 0.9896 0.9106 0.8171 0.4530 0.9568 0.9276 0.7764 0.4791 0.7516 
FFA(24:3) 0.8206 0.9298 0.9291 0.4532 0.9283 0.9324 0.5120 0.6615 0.4093 
GlcCer[NS] 
34:1 
0.9054 0.8122 0.8102 0.4237 0.7310 0.8886 0.8651 0.7795 0.7286 
GlcCer[NS] 
34:2 
0.8747 0.9106 0.9523 0.8856 0.9342 0.8371 0.3727 0.4464 0.7998 
GlcCer[NS] 
40:1 
0.6984 0.8846 0.9832 0.7870 0.6945 0.7600 0.8033 0.0373 0.0274 
GlcCer[NS] 
41:1 
0.8947 0.8122 0.8289 0.9565 0.9109 0.9405 0.2731 0.9355 0.3783 
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Table S2.3D: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Glucoceramide [NS] 42:1 to Lysophosphatidylcholine 20:4) 
 Within Diet Comparisons 






















0.8324 0.9106 0.8832 0.9469 0.8577 0.7579 0.4170 0.6426 0.2546 
GlcCer[NS] 
42:2 
0.7525 0.9298 0.9832 0.9292 0.8563 0.9090 0.6805 0.9807 0.7998 
LysoPC 14:0 0.0121 0.9298 0.9832 0.0299 0.5560 0.8470 0.0160 0.0394 0.8038 
LysoPC 15:0 0.1937 0.9338 0.7812 0.6656 0.9026 0.9276 0.8861 0.6909 0.8504 
LysoPC 15:1 0.4367 0.9106 0.9832 0.9292 0.8092 0.6426 0.8480 0.5181 0.5299 
LysoPC 16:0 0.1762 0.9916 0.9709 0.1795 0.7433 0.7826 0.1328 0.4156 0.7516 
LysoPC 16:1 0.1919 0.9883 0.9832 0.0056 0.8288 0.7579 0.0811 0.0701 0.8938 
LysoPC 17:1 0.0727 0.9612 0.9832 0.0161 0.8719 0.7991 0.0160 0.0280 0.7121 
LysoPC 18:0 0.3883 0.9707 0.9709 0.9638 0.8092 0.6769 0.4326 0.5436 0.3424 
LysoPC 18:1 0.4022 0.9481 0.9788 0.8886 0.8642 0.7736 0.4206 0.8492 0.4274 
LysoPC 18:2 0.7942 0.9883 0.9848 0.5981 0.8712 0.7991 0.8528 0.1014 0.2546 
LysoPC 18:3 0.0209 0.9298 0.9832 0.0306 0.9875 0.7991 0.0403 0.3413 0.7314 
LysoPC 19:0 0.9761 0.9883 0.9832 0.7179 0.6687 0.5971 0.6856 0.8652 0.6487 
LysoPC 19:1 0.6500 0.9481 0.9788 0.9628 0.4059 0.5971 0.4170 0.8390 0.3831 
LysoPC 20:0 0.3493 0.9106 0.8289 0.2871 0.6687 0.7053 0.1695 0.0074 0.1262 
LysoPC 20:1 0.8324 0.8259 0.7977 0.8991 0.9109 0.6769 0.8014 0.1215 0.1248 
LysoPC 20:2 0.6904 0.9106 0.8761 0.9245 0.5954 0.7811 0.3145 0.0208 0.3745 
LysoPC 20:3 0.2599 0.9106 0.8832 0.0306 0.5954 0.8371 0.0207 0.0373 0.9888 
LysoPC 20:4 0.7942 0.7393 0.9287 0.7342 0.4775 0.8371 0.2866 0.7138 0.7308 
LysoPC 20:5 0.5773 0.9106 0.9832 0.6074 0.9892 0.7991 0.8407 0.1961 0.4274 
LysoPC 22:0 0.9054 0.9106 0.8247 0.2790 0.9391 0.5971 0.5914 0.0081 0.0813 
LysoPC 22:4 0.2692 0.9883 0.9887 0.1713 0.4775 0.9276 0.0501 0.0378 0.9327 
LysoPC 22:5 0.2279 0.9106 0.8102 0.2409 0.3598 0.9276 0.0140 0.0224 0.8093 
LysoPC 22:6 0.9012 0.8122 0.9832 0.9979 0.6239 0.8886 0.2328 0.4839 0.8504 
LysoPC 23:0 0.6984 0.8942 0.9832 0.2046 0.7560 0.8886 0.8424 0.3516 0.3745 
LysoPC 24:0 0.5544 0.9298 0.9832 0.9133 0.7560 0.5971 0.6665 0.0270 0.2221 
LysoPC 24:1 0.6904 0.9106 0.9887 0.7342 0.9875 0.7991 0.8431 0.8732 0.9856 
LysoPC 26:1 0.7942 0.9106 0.9832 0.8383 0.6657 0.5971 0.5693 0.7653 0.4533 
LysoPE 16:0 0.2984 0.9607 0.9832 0.0605 0.6687 0.8371 0.2119 0.0374 0.5724 
LysoPE 18:0 0.2094 0.9298 0.9523 0.1828 0.8046 0.7728 0.0664 0.3202 0.6487 
LysoPE 18:1 0.1100 0.9106 0.9832 0.9845 0.7560 0.6769 0.2295 0.4350 0.1248 
LysoPE 18:2 0.8324 0.9883 0.9533 0.7574 0.9922 0.6769 0.8209 0.2820 0.3601 
LysoPE 20:3 0.1364 0.9961 0.9957 0.1753 0.8188 0.8582 0.1002 0.1992 0.9337 
LysoPE 20:4 0.1398 0.9883 0.8442 0.0302 0.7546 0.8661 0.0238 0.0839 0.7308 
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Table S2.3E: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Lysophosphatidylcholine 20:5 to Phosphatidylcholine 36:4) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
LysoPE 20:5 0.0838 0.9546 0.9832 0.0386 0.6687 0.7991 0.0574 0.1118 0.9453 
LysoPE 22:4 0.6625 0.9298 0.9523 0.0614 0.9391 0.9405 0.0956 0.0402 0.9327 
LysoPE 22:5 0.1577 0.9298 0.7057 0.0389 0.4059 0.9778 0.0140 0.0029 0.8093 
LysoPE 22:6 0.6984 0.9106 0.8261 0.0248 0.6757 0.8886 0.0223 0.0224 0.9328 
PA 34:2 0.0705 0.4849 0.9887 0.2654 0.3341 0.8886 0.6805 0.6768 0.4653 
PC 26:0 0.0778 0.6154 0.9788 0.9746 0.3323 0.9276 0.2106 0.1635 0.8989 
PC 29:0 0.0227 0.9106 0.7977 0.0278 0.5696 0.9324 0.0207 0.0246 0.9477 
PC 30:0 0.0095 0.8122 0.7977 0.0411 0.4775 0.8886 0.0160 0.0020 0.6487 
PC 30:2 0.1022 0.9707 0.9832 0.2992 0.8467 0.8214 0.0973 0.1801 0.9022 
PC 31:0 0.0095 0.7311 0.7603 0.0217 0.4298 0.9008 0.0160 0.0027 0.7516 
PC 31:1 0.1778 0.7311 0.8171 0.0278 0.8884 0.9276 0.1973 0.0385 0.6487 
PC 32:0 0.5623 0.9883 0.7603 0.0535 0.5954 0.7991 0.0562 0.0374 0.9328 
PC 32:1 0.0778 0.9298 0.7954 0.0120 0.6687 0.9276 0.0294 0.0063 0.4567 
PC 32:2 0.5010 0.9961 0.9709 0.2337 0.9687 0.8470 0.1864 0.6187 0.6487 
PC 32:3 0.0218 0.8841 0.8107 0.0043 0.9342 0.8371 0.0216 0.0137 0.9453 
PC 33:0 0.0778 0.9338 0.7057 0.0265 0.5306 0.9090 0.0140 0.0021 0.8599 
PC 33:1 0.0095 0.8855 0.7603 0.0021 0.5701 0.8470 0.0140 0.0010 0.5093 
PC 33:2 0.8747 0.9961 0.9523 0.6675 0.8884 0.8886 0.4206 0.8876 0.4943 
PC 33:3 0.0548 0.8846 0.9533 0.0348 0.9873 0.9276 0.0612 0.0338 0.8093 
PC 34:1 0.0778 0.9106 0.7603 0.0001 0.8602 0.7991 0.0140 0.0010 0.6487 
PC 34:2 0.6984 0.7393 0.9523 0.5473 0.9159 0.8371 0.9639 0.2578 0.3745 
PC 34:3 0.9814 0.9106 0.9291 0.4702 0.9875 0.7991 0.9471 0.9826 0.9817 
PC 34:4 0.0567 0.9298 0.9523 0.6074 0.6687 0.8470 0.0948 0.4360 0.8093 
PC 34:5 0.9012 0.9298 0.9872 0.2849 0.6345 0.7736 0.6665 0.3621 0.9702 
PC 35:0 0.6904 0.3847 0.9533 0.3890 0.9875 0.6769 0.0753 0.0297 0.6691 
PC 35:1 0.4942 0.9909 0.7603 0.0358 0.3751 0.8886 0.0664 0.0035 0.6194 
PC 35:2 0.9967 0.9883 0.8102 0.6194 0.9152 0.6676 0.4115 0.4413 0.1518 
PC 35:3 0.6984 0.9106 0.9709 0.4247 0.9705 0.8249 0.5900 0.7863 0.8813 
PC 35:4 0.8054 0.9415 0.8102 0.0555 0.7325 0.8371 0.0811 0.0390 0.9969 
PC 35:5 0.0778 0.7427 0.9533 0.0240 0.9593 0.9405 0.0324 0.0185 0.7418 
PC 36:0 0.5087 0.9298 0.9287 0.9166 0.8467 0.5971 0.6856 0.4789 0.3783 
PC 36:1 0.0591 0.9106 0.9533 0.0075 0.4775 0.7736 0.0159 0.0068 0.9139 
PC 36:2 0.9484 0.9861 0.9287 0.9771 0.9976 0.5971 0.7200 0.1608 0.1262 
PC 36:3 0.9392 0.8122 0.9287 0.9316 0.6687 0.7736 0.5945 0.9650 0.6487 
PC 36:4 0.6984 0.5910 0.9848 0.4702 0.6345 0.9910 0.0690 0.0318 0.7120 
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Table S2.3F: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Phosphatidylcholine 36:5 to Phosphatidylcholine 42:2) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
PC 36:5 0.2929 0.9106 0.7603 0.0033 0.6757 0.7811 0.0166 0.0020 0.5538 
PC 36:6 0.2410 0.9883 0.9523 0.0152 0.8348 0.7826 0.0574 0.0738 0.9184 
PC 37:1 0.3652 0.9106 0.7603 0.3015 0.3728 0.7826 0.0466 0.0224 0.8938 
PC 37:2 0.9990 0.9707 0.9709 0.9077 0.9043 0.7991 0.6309 0.9282 0.6118 
PC 37:3 0.7942 0.9106 0.7603 0.0751 0.3341 0.5971 0.0445 0.0222 0.9731 
PC 37:4 0.6984 0.8346 0.7603 0.0229 0.6687 0.6769 0.0140 0.0229 0.5819 
PC 37:5 0.6984 0.9338 0.9287 0.0701 0.7560 0.7991 0.0980 0.0712 0.9512 
PC 37:6 0.6625 0.8846 0.7603 0.6074 0.6050 0.9336 0.2254 0.0394 0.6487 
PC 37:7 0.9484 0.9298 0.8895 0.4530 0.9312 0.8520 0.7894 0.5859 0.8504 
PC 38:1 0.9896 0.8122 0.9533 0.9945 0.8467 0.7991 0.6828 0.7363 0.6487 
PC 38:2 0.9896 0.9883 0.9523 0.1638 0.9494 0.7053 0.5727 0.9486 0.7516 
PC 38:3 0.6304 0.5910 0.8102 0.0222 0.4059 0.7579 0.0166 0.0205 0.9243 
PC 38:4 0.7525 0.9883 0.7954 0.1118 0.9152 0.8371 0.0680 0.1801 0.7314 
PC 38:5 0.6911 0.8122 0.7603 0.0060 0.4750 0.6769 0.0140 0.0053 0.7314 
PC 38:6 0.8184 0.9298 0.7603 0.1057 0.8467 0.8371 0.2631 0.0882 0.8599 
PC 38:7 0.8355 0.8802 0.9848 0.9077 0.8884 0.9276 0.7632 0.7564 0.6387 
PC 39:3 0.9182 0.9883 0.7954 0.4709 0.4356 0.7736 0.3387 0.2016 0.9139 
PC 39:4 0.8324 0.9106 0.7977 0.0437 0.3323 0.7991 0.0219 0.0297 0.9327 
PC 39:5 0.5376 0.9481 0.7603 0.1428 0.4059 0.8371 0.0207 0.0059 0.9849 
PC 39:6 0.6984 0.9106 0.6986 0.0116 0.4775 0.8452 0.0140 0.0068 0.8649 
PC 39:7 0.8355 0.9607 0.8895 0.3840 0.9875 0.9276 0.5945 0.3175 0.7516 
PC 40:1 0.9598 0.5580 0.7603 0.0639 0.9210 0.8371 0.7854 0.0854 0.2861 
PC 40:2 0.8009 0.9961 0.9832 0.6709 0.9342 0.7943 0.5824 0.1573 0.6487 
PC 40:3 0.9823 0.9338 0.9709 0.4268 0.5954 0.5971 0.4421 0.9761 0.5724 
PC 40:4 0.7942 0.9370 0.8482 0.2049 0.4812 0.9324 0.0680 0.0046 0.4274 
PC 40:5 0.9896 0.7393 0.7603 0.3015 0.3341 0.9795 0.0466 0.0020 0.4093 
PC 40:6 0.9859 0.9359 0.7057 0.0043 0.8066 0.8371 0.0294 0.0053 0.5724 
PC 40:7 0.6625 0.8259 0.9709 0.1713 0.9108 0.7579 0.6707 0.8781 0.6487 
PC 40:8 0.5181 0.8122 0.9832 0.7870 0.8763 0.7991 0.7764 0.4230 0.4946 
PC 40:9 0.3211 0.9298 0.9708 0.1920 0.9098 0.7991 0.0836 0.9187 0.5832 
PC 41:6 0.2823 0.9106 0.9832 0.1553 0.6945 0.8886 0.4676 0.8544 0.7516 
PC 41:7 0.1565 0.8122 0.9832 0.4220 0.8719 0.7579 0.2631 0.7777 0.5083 
PC 42:1 0.9905 0.9298 0.7603 0.3163 0.8884 0.8314 0.1604 0.9540 0.3601 
PC 42:10 0.6984 0.9883 0.7603 0.0599 0.9262 0.7600 0.0723 0.2095 0.4647 
PC 42:2 0.6984 0.9106 0.9832 0.9342 0.8719 0.7579 0.9471 0.2304 0.3067 
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Table S2.3G: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Phosphatidylcholine 42:3 to Phosphatidylethanolamine 40:6) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
PC 42:3 0.0492 0.9106 0.9859 0.9057 0.4750 0.9276 0.1575 0.2449 0.8504 
PC 42:4 0.8747 0.9961 0.9957 0.9133 0.9152 0.8371 0.6805 0.8845 0.8623 
PC 42:5 0.8324 0.9883 0.7977 0.4709 0.7325 0.8886 0.1156 0.3859 0.7516 
PC 42:6 0.9031 0.9106 0.9287 0.3618 0.4059 0.8371 0.2842 0.1761 0.8813 
PC 42:7 0.9012 0.9883 0.9887 0.9565 0.7658 0.9081 0.8990 0.4096 0.6487 
PC 42:8 0.6984 0.9883 0.9957 0.9479 0.9342 0.5971 0.6135 0.1528 0.5054 
PC 42:9 0.2599 0.9883 0.9848 0.9343 0.3341 0.5971 0.0477 0.9540 0.1250 
PC 44:4 0.9012 0.9607 0.7603 0.3489 0.8642 0.6426 0.5763 0.4898 0.3745 
PE 32:1 0.0336 0.3847 0.7977 0.0358 0.7631 0.8886 0.1192 0.0373 0.6070 
PE 32:2 0.9868 0.9106 0.8102 0.1529 0.8046 0.7991 0.1702 0.0977 0.8093 
PE 33:0 0.7112 0.9883 0.9832 0.4268 0.9109 0.8661 0.4779 0.2711 0.9337 
PE 33:1 0.9012 0.9883 0.9788 0.6329 0.7560 0.9276 0.7200 0.4105 0.8093 
PE 33:2 0.8355 0.9883 0.9523 0.2654 0.8467 0.8886 0.3313 0.3202 0.9337 
PE 34:0 0.9182 0.9961 0.9523 0.8988 0.9109 0.7914 0.7396 0.6509 0.9327 
PE 34:1 0.1229 0.7393 0.9287 0.0265 0.8951 0.9276 0.1575 0.0441 0.7047 
PE 34:2 0.7942 0.9106 0.9523 0.1434 0.9312 0.8886 0.6665 0.4663 0.8093 
PE 34:3 0.6739 0.8122 0.7603 0.0791 0.8719 0.9910 0.2197 0.0375 0.4093 
PE 35:1 0.9896 0.9106 0.9291 0.1123 0.9124 0.8825 0.9480 0.3175 0.6547 
PE 35:2 0.7879 0.9106 0.9709 0.3840 0.8348 0.8371 0.6805 0.3955 0.8038 
PE 35:4 0.9182 0.9707 0.8102 0.1847 0.9494 0.9276 0.4676 0.2820 0.8638 
PE 36:0 0.7942 0.9106 0.9832 0.9565 0.8763 0.8886 0.8674 0.9826 0.9328 
PE 36:1 0.4277 0.9298 0.9523 0.3840 0.9705 0.7600 0.8033 0.7863 0.6691 
PE 36:2 0.9868 0.9583 0.9895 0.8201 0.9875 0.7728 0.8162 0.4898 0.6959 
PE 36:3 0.9271 0.9941 0.9788 0.9565 0.9875 0.7826 0.5771 0.3724 0.7843 
PE 36:4 0.9990 0.9298 0.9957 0.9565 0.8719 0.8661 0.6537 0.9282 0.8504 
PE 36:5 0.7733 0.7393 0.7603 0.0239 0.8467 0.9276 0.0574 0.0161 0.4093 
PE 37:4 0.4535 0.9961 0.9523 0.3890 0.6345 0.8371 0.2515 0.1589 0.8599 
PE 38:3 0.9054 0.9338 0.9848 0.7256 0.7560 0.9531 0.5921 0.2095 0.5744 
PE 38:4 0.9033 0.9106 0.9887 0.7256 0.6732 0.8371 0.4851 0.3554 0.8504 
PE 38:5 0.8009 0.9883 0.9832 0.2842 0.9312 0.8371 0.5945 0.4704 0.9109 
PE 38:6 0.9831 0.9883 0.9709 0.5214 0.8467 0.9381 0.6347 0.2557 0.6487 
PE 38:7 0.9012 0.9298 0.9832 0.6074 0.7910 0.8371 0.5693 0.5604 0.9801 
PE 40:4 0.0834 0.8122 0.9709 0.3895 0.6687 0.7991 0.1973 0.4789 0.8813 
PE 40:5 0.8747 0.9298 0.8895 0.4220 0.5100 0.8371 0.1973 0.0441 0.5908 
PE 40:6 0.9990 0.9106 0.9832 0.5236 0.8467 0.8886 0.5925 0.2977 0.6691 
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Table S2.3H: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Phosphatidylethanolamine 40:7 to Plasmenyl-phosphatidylcholine 37:3) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
PE 40:7 0.8324 0.9106 0.9832 0.9628 0.9875 0.8371 0.8509 0.6509 0.8504 
PE 40:8 0.9012 0.9106 0.9709 0.9226 0.9109 0.8660 0.8810 0.6168 0.8504 
PG 33:0 0.9033 0.9106 0.9335 0.4805 0.6139 0.8371 0.5437 0.9006 0.6375 
PG 34:2 0.9054 0.8122 0.8102 0.7701 0.6687 0.8099 0.6105 0.5915 0.9953 
PG 36:0 0.9012 0.9106 0.9832 0.4358 0.8467 0.7179 0.2726 0.0854 0.5538 
PG 36:2 0.7002 0.8511 0.7603 0.6559 0.6565 0.7991 0.2647 0.2444 0.9856 
PG 36:3 0.9979 0.9106 0.9832 0.7045 0.8712 0.9778 0.6488 0.8210 0.8497 
PI 34:2 0.9648 0.9883 0.9832 0.2871 0.6945 0.8371 0.8861 0.4087 0.5908 
PI 36:1 0.2041 0.9883 0.9523 0.6031 0.9159 0.8886 0.0829 0.4180 0.2861 
PI 36:2 0.4022 0.9883 0.9788 0.3747 0.5954 0.8886 0.1575 0.0224 0.6487 
PI 36:4 0.5269 0.9883 0.9523 0.1416 0.9873 0.9925 0.3372 0.1089 0.5724 
PI 38:3 0.8947 0.9883 0.9533 0.9077 0.9210 0.8886 0.4464 0.2139 0.9832 
PI 38:4 0.9182 0.9918 0.9533 0.7256 0.8467 0.8314 0.5871 0.4096 0.9453 
PI 38:5 0.7942 0.9298 0.9848 0.2491 0.6687 0.8565 0.6488 0.4422 0.8043 
PI 38:6 0.9776 0.9883 0.8560 0.2337 0.9346 0.9405 0.5900 0.2711 0.6487 
PI 40:6 0.9033 0.9883 0.9887 0.6329 0.9494 0.7811 0.9609 0.0375 0.1250 
PlsCho 24:0 0.7525 0.9106 0.9887 0.6437 0.9705 0.7738 0.9653 0.8555 0.9327 
PlsCho 32:0 0.9472 0.9078 0.9291 0.7140 0.9109 0.7991 0.9950 0.9998 0.9961 
PlsCho 32:1 0.7237 0.9106 0.7057 0.2773 0.5954 0.8314 0.4095 0.9282 0.3067 
PlsCho 33:0 0.6625 0.9825 0.9832 0.6233 0.9159 0.8371 0.4421 0.9979 0.5908 
PlsCho 34:0 0.9012 0.9338 0.9832 0.9226 0.9494 0.7991 0.4245 0.5023 0.2546 
PlsCho 34:1 0.1953 0.9825 0.9832 0.0555 0.8642 0.6676 0.3387 0.0029 0.0274 
PlsCho 34:2 0.7942 0.9883 0.9832 0.7342 0.8884 0.7991 0.8417 0.1438 0.3783 
PlsCho 34:3 0.8445 0.9883 0.7603 0.4431 0.6687 0.9008 0.1250 0.8492 0.2546 
PlsCho 35:1 0.9979 0.7311 0.9333 0.5473 0.6345 0.8470 0.5900 0.5450 0.9512 
PlsCho 35:2 0.9012 0.9106 0.9848 0.9332 0.9391 0.7991 0.8674 0.3859 0.5819 
PlsCho 35:3 0.1778 0.9883 0.9788 0.5625 0.9875 0.9276 0.1690 0.6909 0.1794 
PlsCho 36:0 0.9884 0.8122 0.8159 0.6048 0.9109 0.8314 0.0403 0.1853 0.0274 
PlsCho 36:2 0.8324 0.9298 0.9832 0.8729 0.9875 0.9405 0.4236 0.8050 0.4274 
PlsCho 36:3 0.9054 0.9106 0.7603 0.4347 0.4059 0.6769 0.0664 0.4789 0.0274 
PlsCho 36:4 0.9979 0.9883 0.7603 0.6381 0.8467 0.7991 0.1973 0.4180 0.1250 
PlsCho 36:5 0.8355 0.9106 0.8107 0.4709 0.4059 0.6676 0.4977 0.6909 0.5724 
PlsCho 36:6 0.4942 0.9298 0.9523 0.9979 0.9465 0.7991 0.2497 0.4435 0.8590 
PlsCho 37:1 0.9859 0.9961 0.7977 0.1173 0.5152 0.9276 0.3387 0.3859 0.1258 
PlsCho 37:3 0.7942 0.9883 0.9832 0.7574 0.4569 0.7991 0.4813 0.8595 0.6487 
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Table S2.3I: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Plasmenyl-phosphatidylcholine 37:3 to Plasmenyl-phosphatidylethanolamine 34:3) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
PlsCho 37:4 0.9761 0.9883 0.7603 0.7574 0.8719 0.9778 0.1186 0.9190 0.2288 
PlsCho 37:6 0.9012 0.9106 0.9832 0.0617 0.5954 0.7736 0.2633 0.1215 0.0469 
PlsCho 38:1 0.9182 0.9106 0.7603 0.4688 0.9159 0.8371 0.4151 0.3136 0.8693 
PlsCho 38:3 0.6984 0.8122 0.7603 0.9565 0.5152 0.7991 0.0140 0.8032 0.0274 
PlsCho 38:4 0.7942 0.9106 0.9709 0.3784 0.7631 0.6769 0.6083 0.1215 0.0469 
PlsCho 38:5 0.9012 0.9298 0.7603 0.3586 0.6250 0.6769 0.2119 0.1904 0.0469 
PlsCho 38:6 0.9182 0.9481 0.9297 0.4530 0.8719 0.8371 0.4813 0.3859 0.2546 
PlsCho 39:3 0.8355 0.9106 0.9287 0.6437 0.8101 0.5971 0.6856 0.5859 0.5054 
PlsCho 39:4 0.7237 0.9961 0.7603 0.2129 0.4059 0.5971 0.0466 0.1086 0.6487 
PlsCho 39:5 0.7116 0.9392 0.6175 0.1205 0.4750 0.5971 0.1192 0.2738 0.5969 
PlsCho 39:6 0.8720 0.9106 0.9291 0.7140 0.9683 0.9405 0.4716 0.8555 0.5014 
PlsCho 40:1 0.8586 0.9106 0.9709 0.1378 0.8348 0.9405 0.6105 0.2747 0.7512 
PlsCho 40:3 0.8206 0.7311 0.9957 0.0736 0.7257 0.9090 0.4170 0.2292 0.1262 
PlsCho 40:4 0.9054 0.9481 0.7603 0.7870 0.7631 0.8371 0.1740 0.8150 0.1250 
PlsCho 40:5 0.9012 0.9106 0.9709 0.7574 0.8642 0.7991 0.2382 0.8555 0.3745 
PlsCho 40:6 0.9831 0.9106 0.7977 0.5236 0.7560 0.9910 0.1192 0.9285 0.1542 
PlsCho 42:0 0.9495 0.6987 0.9709 0.6074 0.9312 0.9499 0.3865 0.7067 0.5087 
PlsCho 42:1 0.9012 0.8122 0.7603 0.4823 0.9468 0.9910 0.1449 0.6103 0.4943 
PlsCho 42:2 0.6625 0.9106 0.9832 0.8201 0.8467 0.9324 0.9480 0.4096 0.5740 
PlsCho 42:3 0.6625 0.8841 0.9291 0.9511 0.6687 0.8371 0.6624 0.7863 0.5957 
PlsCho 42:4 0.9896 0.9106 0.8152 0.9565 0.6687 0.9910 0.1121 0.4898 0.5028 
PlsCho 42:5 0.8355 0.9961 0.9788 0.6709 0.9548 0.7179 0.4199 0.5023 0.9139 
PlsCho 42:6 0.9598 0.9106 0.9914 0.8587 0.9262 0.8371 0.5548 0.9254 0.6466 
PlsCho 44:3 0.8747 0.7427 0.7977 0.1988 0.9548 0.9324 0.1517 0.3175 0.7121 
PlsCho 44:4 0.9366 0.9106 0.8171 0.6559 0.8719 0.8886 0.1655 0.2709 0.8504 
PlsCho 44:5 0.6984 0.9481 0.7603 0.8150 0.7433 0.7579 0.0834 0.4898 0.4946 
PlsCho 44:6 0.8112 0.9939 0.9709 0.9077 0.5701 0.7736 0.9885 0.8613 0.8813 
PlsCho 46:4 0.9012 0.9883 0.9533 0.7574 0.9875 0.7943 0.4104 0.3175 0.9512 
PlsEth 32:1 0.1827 0.9541 0.9287 0.9292 0.4750 0.7579 0.2802 0.6237 0.7102 
PlsEth 32:2 0.8997 0.6154 0.9709 0.3015 0.8467 0.9675 0.6990 0.5238 0.4567 
PlsEth 33:2 0.8355 0.9106 0.9887 0.5124 0.6154 0.8825 0.4407 0.8634 0.5635 
PlsEth 34:0 0.9979 0.9338 0.9923 0.3266 0.9109 0.9276 0.6537 0.4941 0.3858 
PlsEth 34:1 0.9979 0.8660 0.9334 0.6048 0.9705 0.9910 0.6320 0.5575 0.4785 
PlsEth 34:2 0.6984 0.9298 0.9832 0.0565 0.9875 0.7991 0.8990 0.0224 0.0933 
PlsEth 34:3 0.9922 0.6506 0.9788 0.1267 0.4290 0.5971 0.2356 0.1007 0.1023 
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Table S2.3J: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Plasmenyl-phosphatidylethanolamine 34:4 to Sphingomyelin 30:2) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
PlsEth 34:4 0.6984 0.8122 0.9533 0.9077 0.9705 0.9276 0.1575 0.8163 0.2546 
PlsEth 35:1 0.6984 0.9106 0.9523 0.8186 0.4356 0.8886 0.4450 0.7067 0.8523 
PlsEth 35:2 0.7942 0.5580 0.9832 0.0535 0.4750 0.7179 0.4326 0.0839 0.0545 
PlsEth 35:4 0.2599 0.8122 0.9533 0.7140 0.5954 0.8314 0.0344 0.3935 0.3360 
PlsEth 36:1 0.6625 0.5039 0.9709 0.2694 0.4750 0.9276 0.0324 0.9540 0.1357 
PlsEth 36:2 0.9472 0.9298 0.9832 0.0120 0.6139 0.7579 0.7854 0.0161 0.0350 
PlsEth 36:3 0.6693 0.8846 0.9523 0.0073 0.5987 0.8371 0.6097 0.0315 0.2546 
PlsEth 36:4 0.7942 0.9106 0.9523 0.0598 0.5954 0.8371 0.8407 0.2556 0.3828 
PlsEth 36:5 0.9054 0.7039 0.7977 0.9077 0.3323 0.7736 0.0680 0.7824 0.3601 
PlsEth 36:6 0.9484 0.9106 0.9832 0.5236 0.8101 0.9577 0.7200 0.8781 0.7314 
PlsEth 37:1 0.9012 0.9027 0.9832 0.9022 0.9152 0.7811 0.7422 0.3737 0.6407 
PlsEth 37:2 0.9367 0.9106 0.9832 0.8238 0.6687 0.7579 0.2446 0.0971 0.6487 
PlsEth 37:4 0.6984 0.9106 0.9334 0.2337 0.4059 0.8371 0.0612 0.9826 0.2860 
PlsEth 37:5 0.6904 0.6182 0.7977 0.6010 0.7910 0.9698 0.0160 0.2304 0.3071 
PlsEth 37:6 0.8747 0.6154 0.7603 0.7870 0.4356 0.7736 0.1973 0.3988 0.6387 
PlsEth 38:1 0.8947 0.8122 0.9523 0.9327 0.9342 0.9265 0.2731 0.5736 0.6524 
PlsEth 38:2 0.7733 0.9106 0.9887 0.1655 0.6687 0.8371 0.9609 0.2578 0.5054 
PlsEth 38:3 0.7701 0.7393 0.9709 0.2654 0.3598 0.9048 0.0282 0.6122 0.3783 
PlsEth 38:4 0.8747 0.8885 0.8399 0.6010 0.5306 0.7991 0.0993 0.9533 0.1542 
PlsEth 38:5 0.9979 0.9298 0.7977 0.2670 0.4465 0.6769 0.1953 0.2977 0.1023 
PlsEth 38:6 0.6861 0.7393 0.9832 0.2222 0.8467 0.8371 0.7209 0.1924 0.1794 
PlsEth 39:4 0.9067 0.8846 0.7977 0.6675 0.8406 0.8886 0.1994 0.8050 0.3721 
PlsEth 39:5 0.9305 0.6154 0.9832 0.1416 0.3323 0.8886 0.1718 0.9190 0.4946 
PlsEth 39:6 0.8417 0.5580 0.9709 0.3618 0.6687 0.7826 0.0387 0.3692 0.1276 
PlsEth 40:2 0.7161 0.9546 0.9523 0.1998 0.5954 0.8565 0.9827 0.5345 0.7057 
PlsEth 40:4 0.8324 0.7393 0.9851 0.2660 0.6565 0.9276 0.5655 0.8032 0.5740 
PlsEth 40:5 0.9012 0.7311 0.9523 0.2735 0.4775 0.7991 0.0436 0.6509 0.1023 
PlsEth 40:6 0.7942 0.9142 0.9709 0.1432 0.6757 0.7736 0.1379 0.1215 0.0274 
PlsEth 42:4 0.9979 0.9106 0.9848 0.7574 0.9548 0.9157 0.6595 0.9646 0.8182 
PlsEth 42:5 0.6711 0.9106 0.9523 0.5473 0.5560 0.8371 0.6537 0.8576 0.6487 
PlsEth 42:6 0.6693 0.9106 0.9832 0.3747 0.9705 0.9531 0.6856 0.4108 0.3858 
PlsEth 44:6 0.6984 0.9961 0.9523 0.7477 0.9342 0.9324 0.8121 0.4789 0.5724 
SM 30:0 0.2907 0.9961 0.7603 0.6709 0.6687 0.7579 0.0235 0.0297 0.7335 
SM 30:1 0.5667 0.9106 0.6175 0.2435 0.4059 0.9276 0.0140 0.0429 0.3783 
SM 30:2 0.9896 0.8122 0.9923 0.7870 0.6345 0.8886 0.6805 0.6644 0.9034 
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Table S2.3K: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Sphingomyelin 31:1 to Sphingomyelin 42:2) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
SM 31:1 0.6984 0.9106 0.7603 0.6381 0.3323 0.9405 0.0160 0.0324 0.6487 
SM 32:0 0.7219 0.9923 0.9533 0.2402 0.4750 0.9276 0.6805 0.9282 0.7516 
SM 32:1 0.9012 0.8122 0.9832 0.6564 0.4775 0.8661 0.0680 0.4898 0.4093 
SM 32:2 0.7525 0.9106 0.6175 0.0800 0.4775 0.9531 0.0147 0.0102 0.5908 
SM 33:1 0.9990 0.8122 0.9957 0.6424 0.6687 0.9086 0.1250 0.8599 0.4093 
SM 33:2 0.8325 0.9106 0.8391 0.5825 0.9705 0.8371 0.2941 0.9028 0.4274 
SM 34:0 0.5623 0.9298 0.9333 0.5097 0.7560 0.7235 0.1745 0.2738 0.9328 
SM 34:1 0.5544 0.5580 0.9523 0.4092 0.6565 0.9796 0.7200 0.9799 0.8504 
SM 34:2 0.9495 0.7393 0.9635 0.3749 0.5954 0.9778 0.2303 0.8492 0.4946 
SM 34:3 0.9472 0.9883 0.8102 0.8469 0.8467 0.9276 0.6885 0.9540 0.8504 
SM 35:2 0.8355 0.9106 0.9709 0.9077 0.6687 0.8886 0.1250 0.8131 0.3858 
SM 36:1 0.9012 0.7039 0.9709 0.6437 0.8348 0.9276 0.5655 0.8919 0.8504 
SM 36:2 0.6984 0.6154 0.9957 0.7171 0.5907 0.9086 0.3282 0.6509 0.8182 
SM 36:3 0.5667 0.9298 0.9832 0.6424 0.8406 0.7991 0.6314 0.1215 0.4122 
SM 36:4 0.1240 0.9707 0.8071 0.9469 0.4059 0.7728 0.3366 0.0251 0.3093 
SM 37:1 0.9468 0.9883 0.9523 0.4702 0.9079 0.8371 0.5243 0.3202 0.3210 
SM 37:2 0.6495 0.9106 0.7603 0.2344 0.8348 0.7991 0.1433 0.5103 0.6020 
SM 38:0 0.9054 0.9298 0.9957 0.9417 0.6345 0.8371 0.8674 0.9190 0.9849 
SM 38:1 0.6984 0.7393 0.9523 0.2491 0.7631 0.7728 0.9921 0.0457 0.2546 
SM 38:2 0.0468 0.7658 0.9832 0.3793 0.7910 0.8371 0.4676 0.3621 0.8038 
SM 38:3 0.6693 0.9298 0.9832 0.9327 0.7560 0.9910 0.7200 0.6509 0.8813 
SM 38:4 0.9054 0.9883 0.9523 0.4347 0.9582 0.6769 0.3638 0.0292 0.3783 
SM 39:1 0.9761 0.9106 0.9788 0.2854 0.7560 0.7991 0.2905 0.2095 0.1250 
SM 39:2 0.7579 0.9186 0.6175 0.5124 0.8642 0.5971 0.1127 0.8652 0.1794 
SM 39:3 0.7525 0.9106 0.7977 0.8201 0.8712 0.7736 0.2690 0.4441 0.1023 
SM 40:1 0.8324 0.5580 0.9533 0.1927 0.7560 0.7579 0.3638 0.0240 0.0403 
SM 40:2 0.9033 0.9395 0.4083 0.6424 0.9079 0.5971 0.0831 0.0315 0.0274 
SM 40:3 0.7942 0.9298 0.7954 0.1598 0.7433 0.9276 0.9509 0.8188 0.8639 
SM 40:5 0.9990 0.9106 0.9832 0.9226 0.9346 0.7991 0.4703 0.6798 0.8813 
SM 41:1 0.7942 0.9106 0.7603 0.7574 0.9829 0.8371 0.1953 0.2825 0.1248 
SM 41:2 0.6500 0.7311 0.9533 0.7574 0.6687 0.8371 0.2119 0.8781 0.5623 
SM 41:4 0.5667 0.8784 0.9832 0.9628 0.9548 0.5971 0.9605 0.1065 0.2391 
SM 41:6 0.9587 0.9298 0.9291 0.9022 0.6345 0.7736 0.6707 0.8492 0.6487 
SM 42:1 0.6898 0.9106 0.7603 0.6010 0.9342 0.6769 0.3202 0.0297 0.0274 
SM 42:2 0.8355 0.9392 0.9832 0.8991 0.9312 0.9276 0.3703 0.4364 0.9781 
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Table S2.3L: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Sphingomyelin 42:3 to Triacylglycerol 48:5) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
SM 42:3 0.5667 0.9338 0.8107 0.5784 0.9283 0.8371 0.5921 0.8599 0.6466 
SM 42:4 0.9012 0.9106 0.8171 0.1280 0.9109 0.9276 0.9757 0.1608 0.2546 
SM 42:5 0.9472 0.9106 0.9287 0.8617 0.9342 0.9276 0.9640 0.5607 0.6487 
SM 42:6 0.8325 0.9883 0.8171 0.7534 0.8348 0.8470 0.7200 0.8050 0.9731 
SM 43:1 0.9054 0.9707 0.7603 0.8045 0.9079 0.8886 0.0690 0.9399 0.2411 
SM 43:2 0.8324 0.9106 0.7954 0.7045 0.9109 0.9795 0.3032 0.5181 0.9158 
SM 43:3 0.9979 0.9961 0.9287 0.7574 0.8467 0.9910 0.5605 0.4898 0.9139 
SM 43:6 0.8324 0.9961 0.9832 0.6437 0.9892 0.7991 0.7209 0.9190 0.7516 
SM 44:1 0.6861 0.9298 0.9555 0.8965 0.8884 0.8655 0.3202 0.9650 0.6487 
SM 44:2 0.9896 0.9941 0.9788 0.9416 0.9548 0.8886 0.7200 0.7765 0.6111 
SM 44:3 0.4210 0.9106 0.8102 0.7179 0.8763 0.8371 0.1575 0.3568 0.6487 
SM 44:4 0.9012 0.9106 0.9533 0.7202 0.7257 0.7991 0.5763 0.5009 0.8813 
SM 44:6 0.9979 0.9883 0.9709 0.5171 0.8467 0.8459 0.6037 0.9827 0.7255 
TG 38:0 0.0373 0.8660 0.7603 0.7123 0.9875 0.7600 0.2541 0.4087 0.1794 
TG 39:0 0.7521 0.9883 0.8102 0.0419 0.6687 0.7736 0.0948 0.0301 0.8759 
TG 40:0 0.0227 0.7311 0.0000 0.0749 0.0018 0.0630 0.6856 0.1656 0.3581 
TG 41:0 0.0470 0.8122 0.8102 0.6010 0.6687 0.5971 0.3387 0.4145 0.3018 
TG 42:0 0.0110 0.4063 0.7603 0.0856 0.4059 0.6769 0.0160 0.6168 0.2646 
TG 42:1 0.0138 0.5039 0.0455 0.1178 0.4059 0.7579 0.0207 0.5598 0.4093 
TG 43:1 0.0195 0.5064 0.9832 0.0386 0.5999 0.7991 0.0378 0.2095 0.6487 
TG 44:2 0.0095 0.3847 0.9832 0.0044 0.5611 0.7811 0.0153 0.1475 0.6278 
TG 45:0 0.0122 0.7464 0.6986 0.8988 0.3323 0.8886 0.0324 0.0292 0.8093 
TG 45:1 0.0195 0.5580 0.9523 0.1065 0.3968 0.8886 0.0649 0.0313 0.9817 
TG 45:2 0.0102 0.3847 0.8102 0.0075 0.5100 0.8822 0.0189 0.0094 0.9512 
TG 46:0 0.0110 0.3847 0.7977 0.0043 0.4059 0.8371 0.0141 0.0251 0.9856 
TG 46:1 0.0095 0.3847 0.9533 0.0080 0.4059 0.8371 0.0160 0.0163 0.9953 
TG 46:3 0.0095 0.3847 0.9533 0.0097 0.6345 0.7991 0.0318 0.0426 0.9832 
TG 47:0 0.0218 0.6154 0.9957 0.3175 0.4059 0.9920 0.0304 0.0324 0.9512 
TG 47:1 0.0095 0.3847 0.7977 0.0302 0.3341 0.8886 0.0180 0.0068 0.8813 
TG 47:2 0.0095 0.4849 0.9291 0.0047 0.6345 0.8371 0.0235 0.0139 0.9512 
TG 48:0 0.0128 0.3847 0.7603 0.0043 0.5954 0.8371 0.0160 0.0149 0.9022 
TG 48:1 0.0095 0.3847 0.8540 0.0043 0.4775 0.8371 0.0141 0.0034 0.8018 
TG 48:3 0.0111 0.5847 0.9333 0.0060 0.6687 0.8134 0.0294 0.0149 0.8093 
TG 48:4 0.1768 0.9298 0.9848 0.0240 0.7910 0.7736 0.1151 0.1475 0.9327 
TG 48:5 0.3211 0.9298 0.9887 0.0902 0.6945 0.8371 0.3202 0.0974 0.6487 
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Table S2.3M: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Triacylglycerol 49:0 to Triacylglycerol 54:4) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
TG 49:0 0.0347 0.5580 0.7977 0.0097 0.4775 0.8886 0.0301 0.0086 0.8504 
TG 49:1 0.0095 0.3847 0.8102 0.0120 0.3762 0.8886 0.0160 0.0037 0.7998 
TG 49:2 0.0095 0.4849 0.7977 0.0075 0.4356 0.8520 0.0207 0.0029 0.6487 
TG 49:3 0.0218 0.7393 0.8474 0.0045 0.6687 0.8655 0.0420 0.0035 0.4650 
TG 50:0 0.0138 0.3847 0.7603 0.0110 0.6139 0.8371 0.0284 0.0149 0.7121 
TG 50:1 0.0122 0.3863 0.7603 0.0043 0.6757 0.8371 0.0284 0.0048 0.4946 
TG 50:2 0.0314 0.8122 0.8159 0.0045 0.6687 0.8371 0.0436 0.0029 0.3067 
TG 50:3 0.0780 0.9298 0.9523 0.0060 0.8712 0.8371 0.0704 0.0076 0.4650 
TG 50:4 0.8355 0.9612 0.9887 0.0535 0.9312 0.7991 0.4332 0.1966 0.6524 
TG 50:5 0.9182 0.9961 0.9709 0.0358 0.9109 0.7991 0.5997 0.1215 0.4274 
TG 50:6 0.9776 0.9338 0.9533 0.0402 0.8719 0.7736 0.4332 0.3692 0.8038 
TG 51:1 0.0095 0.3847 0.7977 0.0060 0.5987 0.8371 0.0324 0.0053 0.5740 
TG 51:2 0.0095 0.7311 0.9287 0.0043 0.6687 0.8371 0.0284 0.0020 0.4653 
TG 51:3 0.1937 0.9298 0.9709 0.0120 0.9079 0.8371 0.1575 0.0086 0.4174 
TG 51:4 0.9896 0.9707 0.9832 0.0957 0.9109 0.7991 0.6734 0.4341 0.8093 
TG 51:5 0.9012 0.9298 0.9523 0.0749 0.9391 0.7736 0.5764 0.3621 0.8093 
TG 52:0 0.1057 0.6154 0.8560 0.0146 0.9109 0.7991 0.0973 0.2738 0.9454 
TG 52:1 0.0095 0.4849 0.7977 0.0043 0.6657 0.7736 0.0207 0.0053 0.6487 
TG 52:2 0.0208 0.8841 0.9533 0.0043 0.9159 0.7826 0.0496 0.0037 0.3071 
TG 52:3 0.9979 0.9607 0.7977 0.0096 0.9548 0.6769 0.4813 0.0712 0.3831 
TG 52:4 0.5202 0.9298 0.9832 0.2795 0.9548 0.7053 0.6512 0.9021 0.5832 
TG 52:5 0.9761 0.9338 0.9523 0.0043 0.9210 0.7991 0.4003 0.0377 0.3745 
TG 52:6 0.2961 0.8841 0.9832 0.1456 0.8467 0.7728 0.6068 0.9540 0.6387 
TG 52:7 0.2811 0.8122 0.9957 0.0461 0.9109 0.8314 0.8407 0.3841 0.3783 
TG 53:0 0.4461 0.9106 0.9832 0.1758 0.9875 0.8886 0.4236 0.4663 0.9856 
TG 53:1 0.0978 0.7393 0.9709 0.0190 0.6565 0.8459 0.0948 0.0029 0.4274 
TG 53:2 0.9012 0.8122 0.8171 0.0060 0.6945 0.7579 0.7824 0.0053 0.4943 
TG 53:3 0.7077 0.9883 0.9832 0.0138 0.8712 0.7738 0.4851 0.0657 0.5635 
TG 53:4 0.1953 0.9298 0.9709 0.3440 0.7257 0.5971 0.5618 0.4111 0.8504 
TG 53:5 0.3566 0.9106 0.9832 0.1828 0.8712 0.8371 0.8528 0.6909 0.5832 
TG 54:0 0.8325 0.9106 0.9832 0.5645 0.7560 0.8886 0.8861 0.6552 0.8599 
TG 54:1 0.0095 0.3847 0.8560 0.0543 0.6687 0.7736 0.1099 0.0851 0.9670 
TG 54:2 0.0350 0.7039 0.9790 0.0348 0.7557 0.7179 0.3037 0.0338 0.6387 
TG 54:3 0.9979 0.9106 0.9832 0.2486 0.8884 0.5971 0.5655 0.7611 0.8093 
TG 54:4 0.0717 0.9909 0.9832 0.9416 0.6345 0.5971 0.0973 0.0669 0.9953 
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Table S2.3N: PUFA/CHO study significant differences for within diet comparisons for all lipids 
(Triacylglycerol 54:5 to Triacylglycerol 60:12) 
 Within Diet Comparisons 
 FDR <0.1 = pink 
Lipid/Day B to P2 P2 to P7 P7 to P21 P21 to C2 C2 to C7 C7 to C21 B to P21 P21 to C21 B to C21 
TG 54:5 0.0121 0.9106 0.9872 0.7477 0.5100 0.5971 0.0703 0.0224 0.7516 
TG 54:6 0.0095 0.8122 0.9832 0.7574 0.5274 0.6769 0.0948 0.0222 0.5449 
TG 54:7 0.0851 0.8846 0.9832 0.4530 0.6687 0.7736 0.2507 0.3621 0.8599 
TG 54:8 0.6711 0.8336 0.9887 0.0152 0.8467 0.7738 0.9885 0.4789 0.6278 
TG 55:0 0.1229 0.5580 0.9291 0.2153 0.8406 0.9276 0.2866 0.0074 0.2835 
TG 55:3 0.8324 0.8122 0.9709 0.0565 0.9108 0.8371 0.4676 0.2488 0.6466 
TG 55:4 0.9979 0.8335 0.9709 0.4805 0.9346 0.6676 0.5834 0.8492 0.5740 
TG 55:5 0.4309 0.8122 0.9709 0.1290 0.8719 0.7728 0.4692 0.5859 0.8813 
TG 56:0 0.6625 0.9298 0.9887 0.1795 0.8658 0.7736 0.3727 0.8695 0.4567 
TG 56:1 0.0113 0.4849 0.9832 0.0290 0.8348 0.7579 0.0324 0.2774 0.5954 
TG 56:2 0.0314 0.7393 0.9291 0.0985 0.6687 0.7579 0.2608 0.3621 0.9512 
TG 56:3 0.5258 0.8846 0.9832 0.1927 0.8467 0.7053 0.8407 0.5436 0.8234 
TG 56:4 0.5834 0.9106 0.9957 0.2096 0.9875 0.7579 0.7854 0.8492 0.6691 
TG 56:5 0.6464 0.9106 0.9848 0.2747 0.8951 0.7736 0.8407 0.7653 0.6466 
TG 56:6 0.1229 0.8846 0.9709 0.2634 0.6945 0.7914 0.6195 0.9540 0.7125 
TG 56:7 0.3512 0.8378 0.8832 0.0551 0.7631 0.8371 0.9706 0.5023 0.6524 
TG 56:8 0.0218 0.7393 0.9287 0.2046 0.4812 0.8371 0.2850 0.4382 0.8093 
TG 56:9 0.0324 0.6632 0.9832 0.0348 0.5954 0.7991 0.3684 0.9124 0.4943 
TG 58:10 0.0314 0.8660 0.9832 0.6709 0.6687 0.8371 0.1685 0.2557 0.8504 
TG 58:11 0.1229 0.8122 0.9832 0.1298 0.8046 0.8371 0.2850 0.5103 0.3093 
TG 58:2 0.0567 0.7037 0.8102 0.3323 0.8642 0.6676 0.5834 0.6114 0.4650 
TG 58:3 0.6331 0.8660 0.9832 0.4882 0.9079 0.7991 0.8674 0.4829 0.6466 
TG 58:6 0.9012 0.9106 0.9957 0.1428 0.9875 0.8371 0.7633 0.3621 0.6487 
TG 58:7 0.8355 0.9106 0.8102 0.0302 0.8971 0.8371 0.2850 0.2319 0.9243 
TG 58:8 0.2806 0.9106 0.7977 0.0937 0.7560 0.8371 0.9785 0.6995 0.8093 
TG 58:9 0.0249 0.8841 0.7603 0.1632 0.5152 0.8491 0.4343 0.7079 0.8504 
TG 60:11 0.6904 0.9106 0.7603 0.0348 0.9391 0.8371 0.5834 0.0556 0.6194 





Table S2.4A: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (16:0 Cholesterol ester to Ceramide [NS] 43:1) 
 Between Diet Comparisons 
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
16:0 CE 0.4467 0.7765 0.9357 
16:1 CE 0.1855 0.0060 0.0009 
18:0 CE 0.7137 0.4118 0.2082 
18:1 CE 0.3514 0.0041 0.1098 
18:2 CE 0.0203 0.0997 0.0282 
18:3 CE 0.4007 0.0013 0.0144 
20:3 CE 0.0011 0.0567 0.0009 
20:4 CE 0.0002 0.0091 0.0329 
20:5 CE 0.0011 0.1789 0.0023 
22:4 CE 0.0270 0.0856 0.2803 
22:5 CE 0.0013 0.3461 0.5882 
22:6 CE 0.0048 0.0403 0.5826 
ACAR 10:0 0.0733 0.0521 0.2274 
ACAR 10:1 0.0127 0.0001 0.0023 
ACAR 12:0 0.1156 0.1215 0.7328 
ACAR 14:0 0.4779 0.2385 0.8534 
ACAR 14:1 0.0152 0.0210 0.3039 
ACAR 14:2 0.0286 0.0022 0.0214 
ACAR 16:0 0.2467 0.0955 0.0922 
ACAR 18:0 0.8331 0.5884 0.7113 
ACAR 18:1 0.7969 0.4393 0.8534 
ACAR 18:2 0.1600 0.0040 0.0178 
ACAR 24:0 0.0246 0.0161 0.0126 
ACAR 26:0 0.0087 0.1695 0.4286 
Cer[AS] 34:1 0.5986 0.8036 0.7943 
Cer[EODS] 58:0 0.4221 0.4317 0.1888 
Cer[NDS] 34:0 0.7750 0.8252 0.7165 
Cer[NDS] 36:0 0.6730 0.2570 0.0123 
Cer[NDS] 38:0 0.4862 0.9597 0.1098 
Cer[NDS] 40:0 0.1802 0.9488 0.0356 
Cer[NDS] 42:0 0.0403 0.5592 0.2975 
Cer[NDS] 42:1 0.2711 0.9080 0.3788 
Cer[NP] 34:0 0.3579 0.8876 0.7158 
Cer[NP] 42:0 0.1134 0.6820 0.2471 
Cer[NP] 42:1 0.0233 0.8876 0.9807 
Cer[NS] 32:1 0.0709 0.3276 0.7323 
Cer[NS] 33:1 0.5660 0.3887 0.3003 
Cer[NS] 34:1 0.6299 0.7835 0.8422 
Cer[NS] 34:2 0.2823 0.8694 0.1033 
Cer[NS] 35:1 0.9508 0.3248 0.3714 
Cer[NS] 36:1 0.6692 0.0425 0.0071 
Cer[NS] 36:2 0.7137 0.0142 0.0354 
Cer[NS] 37:1 0.6482 0.5235 0.2182 
Cer[NS] 38:1 0.1574 0.2986 0.0094 
Cer[NS] 38:2 0.3969 0.1938 0.0110 
Cer[NS] 39:1 0.7969 0.1338 0.7328 
Cer[NS] 40:1 0.3670 0.5862 0.2864 
Cer[NS] 40:2 0.1544 0.0603 0.0023 
Cer[NS] 40:3 0.6731 0.4090 0.0106 
Cer[NS] 41:1 0.4173 0.4417 0.0301 
Cer[NS] 41:2 0.0767 0.2997 0.0108 
Cer[NS] 42:1 0.0875 0.5399 0.4691 
Cer[NS] 42:2 0.5410 0.1375 0.2187 
Cer[NS] 42:3 0.6625 0.0599 0.0023 
Cer[NS] 43:1 0.1156 0.1978 0.0070 
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Table S2.4B: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Ceramide [NS] 43:2 to Lysophosphatidylcholine 16:1) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
Cer[NS] 43:2 0.8359 0.3335 0.0009 
DG 30:0 0.0283 0.0060 0.1131 
DG 30:1 0.1815 0.0246 0.1356 
DG 32:0 0.0586 0.0184 0.9046 
DG 32:1 0.0013 0.0041 0.0150 
DG 32:2 0.0029 0.0060 0.0350 
DG 33:0 0.3127 0.1204 0.1129 
DG 33:1 0.0203 0.0070 0.0090 
DG 34:0 0.3889 0.8254 0.4021 
DG 34:2 0.0066 0.0164 0.0088 
DG 34:3 0.0030 0.0010 0.0143 
DG 35:1 0.0122 0.0543 0.0150 
DG 35:2 0.0063 0.0048 0.0292 
DG 35:3 0.0673 0.0821 0.2079 
DG 36:0 0.4161 0.1933 0.2533 
DG 36:1 0.3051 0.1663 0.2270 
DG 36:2 0.0004 0.0015 0.0006 
DG 36:3 0.0048 0.0251 0.2132 
DG 36:4 0.7450 0.8496 0.0294 
DG 36:5 0.3051 0.0190 0.3767 
DG 38:1 0.2921 0.1565 0.1196 
DG 38:2 0.1464 0.0041 0.0085 
DG 38:3 0.0018 0.0195 0.0129 
DG 38:4 0.0018 0.0018 0.0040 
DG 38:5 0.0118 0.0063 0.0109 
DG 38:6 0.2290 0.2257 0.6988 
DG 40:6 0.0206 0.0017 0.0126 
DG 40:7 0.0031 0.0206 0.0184 
FFA(16:0) 0.3386 0.7474 0.9316 
FFA(18:0) 0.4910 0.5313 0.8160 
FFA(18:1) 0.3386 0.3400 0.8452 
FFA(18:2) 0.0979 0.0599 0.0515 
FFA(20:0) 0.7155 0.6038 0.4393 
FFA(20:1) 0.3902 0.4854 0.9744 
FFA(20:2) 0.2543 0.2392 0.6064 
FFA(20:4) 0.1549 0.9859 0.8534 
FFA(22:0) 0.4116 0.8442 0.5522 
FFA(22:1) 0.1475 0.9488 0.7489 
FFA(22:2) 0.6720 0.7191 0.9807 
FFA(22:3) 0.6000 0.2324 0.0524 
FFA(24:0) 0.0865 0.0787 0.0063 
FFA(24:1) 0.0665 0.9087 0.1261 
FFA(24:2) 0.5975 0.8471 0.2428 
FFA(24:3) 0.6692 0.9488 0.4362 
GlcCer[NS] 34:1 0.3898 0.2847 0.6048 
GlcCer[NS] 34:2 0.3902 0.6464 0.2411 
GlcCer[NS] 40:1 0.1172 0.0580 0.0227 
GlcCer[NS] 41:1 0.1156 0.2570 0.9046 
GlcCer[NS] 42:1 0.0895 0.6450 0.5403 
GlcCer[NS] 42:2 0.6068 0.5546 0.9556 
LysoPC 14:0 0.0142 0.0009 0.0224 
LysoPC 15:0 0.5336 0.3021 0.5933 
LysoPC 15:1 0.1549 0.3461 0.2638 
LysoPC 16:0 0.1464 0.0040 0.2055 
LysoPC 16:1 0.0233 0.0012 0.0239 
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Table S2.4C: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Lysophosphatidylcholine 17:1 to Phosphatidylcholine 35:3) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
LysoPC 17:1 0.1404 0.0060 0.0148 
LysoPC 18:0 0.7919 0.0158 0.1828 
LysoPC 18:1 0.6900 0.0578 0.6603 
LysoPC 18:2 0.1566 0.0578 0.0068 
LysoPC 18:3 0.0145 0.0029 0.1201 
LysoPC 19:0 0.8866 0.0543 0.7158 
LysoPC 19:1 0.9688 0.0153 0.7442 
LysoPC 20:0 0.2921 0.0063 0.0009 
LysoPC 20:1 0.9688 0.3274 0.0566 
LysoPC 20:2 0.9508 0.6358 0.0130 
LysoPC 20:3 0.2497 0.0027 0.0045 
LysoPC 20:4 0.3144 0.0473 0.3742 
LysoPC 20:5 0.0803 0.1695 0.0222 
LysoPC 22:0 0.2939 0.0801 0.0066 
LysoPC 22:4 0.2239 0.0060 0.0259 
LysoPC 22:5 0.4381 0.0185 0.0068 
LysoPC 22:6 0.2069 0.1983 0.2552 
LysoPC 23:0 0.3889 0.2967 0.2675 
LysoPC 24:0 0.4520 0.0974 0.0023 
LysoPC 24:1 0.8866 0.6450 0.7158 
LysoPC 26:1 0.9107 0.1179 0.7422 
LysoPE 16:0 0.0221 0.0123 0.0181 
LysoPE 18:0 0.1739 0.0869 0.1647 
LysoPE 18:1 0.4161 0.5142 0.1632 
LysoPE 18:2 0.7012 0.8876 0.0763 
LysoPE 20:3 0.2280 0.0169 0.1418 
LysoPE 20:4 0.2377 0.1701 0.1033 
LysoPE 20:5 0.0407 0.0195 0.1212 
LysoPE 22:4 0.1544 0.1725 0.0599 
LysoPE 22:5 0.4910 0.1376 0.0044 
LysoPE 22:6 0.7750 0.2091 0.0086 
PA 34:2 0.3902 0.8885 0.6064 
PC 26:0 0.1472 0.0084 0.1247 
PC 29:0 0.0100 0.0012 0.0114 
PC 30:0 0.0172 0.0012 0.0030 
PC 30:2 0.2341 0.9625 0.1385 
PC 31:0 0.0036 0.0030 0.0026 
PC 31:1 0.0011 0.0123 0.0122 
PC 32:0 0.0645 0.0041 0.0009 
PC 32:1 0.0183 0.0017 0.0058 
PC 32:2 0.0719 0.1338 0.3646 
PC 32:3 0.0029 0.0011 0.0225 
PC 33:0 0.2210 0.0016 0.0032 
PC 33:1 0.0005 0.0012 0.0015 
PC 33:2 0.9209 0.5295 0.6849 
PC 33:3 0.0048 0.2140 0.0153 
PC 34:1 0.0029 0.0012 0.0004 
PC 34:2 0.0980 0.9625 0.0040 
PC 34:3 0.2901 0.0556 0.9641 
PC 34:4 0.1903 0.0041 0.2132 
PC 34:5 0.4161 0.1338 0.2522 
PC 35:0 0.8255 0.0079 0.0169 
PC 35:1 0.2939 0.0012 0.0009 
PC 35:2 0.5778 0.2799 0.0928 
PC 35:3 0.2333 0.6160 0.7362 
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Table S2.4D: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Phosphatidylcholine 35:4 to Phosphatidylethanolamine 33:2) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
PC 35:4 0.4313 0.0298 0.0045 
PC 35:5 0.0729 0.0091 0.0181 
PC 36:0 0.6731 0.0182 0.4076 
PC 36:1 0.0572 0.0041 0.0023 
PC 36:2 0.4577 0.2201 0.0637 
PC 36:3 0.6625 0.0361 0.8469 
PC 36:4 0.7750 0.0071 0.0172 
PC 36:5 0.0087 0.0041 0.0043 
PC 36:6 0.0094 0.0182 0.0159 
PC 37:1 0.8331 0.0387 0.0099 
PC 37:2 0.5761 0.8496 0.8534 
PC 37:3 0.8056 0.0005 0.0023 
PC 37:4 0.6731 0.0033 0.0023 
PC 37:5 0.3857 0.0729 0.0230 
PC 37:6 0.2290 0.2748 0.0047 
PC 37:7 0.3945 0.6371 0.2009 
PC 38:1 0.4161 0.3644 0.6804 
PC 38:2 0.1131 0.1067 0.8556 
PC 38:3 0.3144 0.0015 0.0043 
PC 38:4 0.3776 0.1636 0.0437 
PC 38:5 0.6967 0.0030 0.0002 
PC 38:6 0.6629 0.4418 0.0220 
PC 38:7 0.4989 0.8314 0.6969 
PC 39:3 0.9703 0.1646 0.0644 
PC 39:4 0.9688 0.0176 0.0080 
PC 39:5 0.9688 0.0172 0.0043 
PC 39:6 0.7825 0.0165 0.0023 
PC 39:7 0.9325 0.8885 0.2822 
PC 40:1 0.0673 0.8072 0.0599 
PC 40:2 0.6247 0.4583 0.1033 
PC 40:3 0.7990 0.0250 0.9341 
PC 40:4 0.8340 0.0097 0.0026 
PC 40:5 0.1884 0.0043 0.0015 
PC 40:6 0.0719 0.0365 0.0004 
PC 40:7 0.9250 0.4565 0.8534 
PC 40:8 0.3537 0.8314 0.2471 
PC 40:9 0.2519 0.0773 0.8535 
PC 41:6 0.0759 0.9080 0.8481 
PC 41:7 0.5916 0.3502 0.6308 
PC 42:1 0.8056 0.7474 0.9192 
PC 42:10 0.3548 0.4331 0.1041 
PC 42:2 0.3079 0.3852 0.0727 
PC 42:3 0.4015 0.0070 0.1975 
PC 42:4 0.8837 0.7462 0.8361 
PC 42:5 0.4251 0.2601 0.0698 
PC 42:6 0.2921 0.2056 0.1033 
PC 42:7 0.7529 0.5294 0.0682 
PC 42:8 0.7634 0.9332 0.0233 
PC 42:9 0.7590 0.0041 0.9313 
PC 44:4 0.9722 0.5399 0.2829 
PE 32:1 0.0096 0.0060 0.0150 
PE 32:2 0.7390 0.8885 0.0364 
PE 33:0 0.4779 0.7091 0.1792 
PE 33:1 0.3893 0.4331 0.3646 
PE 33:2 0.2901 0.8036 0.1056 
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Table S2.4E: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Phosphatidylethanolamine 34:0 to Plasmenyl-phosphatidylcholine 36:6) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
PE 34:0 0.0497 0.2601 0.5912 
PE 34:1 0.0011 0.0091 0.0122 
PE 34:2 0.0040 0.1745 0.0071 
PE 34:3 0.0220 0.0153 0.0101 
PE 35:1 0.0673 0.0586 0.2533 
PE 35:2 0.1990 0.0161 0.2357 
PE 35:4 0.2319 0.1420 0.1417 
PE 36:0 0.5112 0.6988 0.9587 
PE 36:1 0.0206 0.0597 0.5942 
PE 36:2 0.3902 0.6820 0.0730 
PE 36:3 0.6251 0.7725 0.0122 
PE 36:4 0.6244 0.6820 0.7869 
PE 36:5 0.0731 0.0040 0.0118 
PE 37:4 0.3291 0.0125 0.0627 
PE 38:3 0.8613 0.0564 0.0171 
PE 38:4 0.9529 0.0070 0.0219 
PE 38:5 0.0473 0.0012 0.0219 
PE 38:6 0.5467 0.0091 0.0009 
PE 38:7 0.6237 0.8252 0.1975 
PE 40:4 0.1217 0.0599 0.2169 
PE 40:5 0.9289 0.0012 0.0033 
PE 40:6 0.6629 0.0091 0.0291 
PE 40:7 0.7450 0.4967 0.2278 
PE 40:8 0.9518 0.7555 0.4533 
PG 33:0 0.4387 0.2766 0.8509 
PG 34:2 0.9728 0.8294 0.5826 
PG 36:0 0.7783 0.8314 0.1261 
PG 36:2 0.8248 0.3373 0.2132 
PG 36:3 0.8340 0.8844 0.7731 
PI 34:2 0.3967 0.8876 0.3215 
PI 36:1 0.7595 0.9057 0.3651 
PI 36:2 0.3293 0.1563 0.0032 
PI 36:4 0.0614 0.0191 0.0555 
PI 38:3 0.9688 0.9488 0.2237 
PI 38:4 0.9508 0.6820 0.2533 
PI 38:5 0.3334 0.7555 0.2925 
PI 38:6 0.3902 0.9242 0.1913 
PI 40:6 0.4488 0.8380 0.0575 
PlsCho 24:0 0.9980 0.6032 0.6894 
PlsCho 32:0 0.5778 0.8496 0.9998 
PlsCho 32:1 0.5467 0.1123 0.9108 
PlsCho 33:0 0.6692 0.7877 0.9955 
PlsCho 34:0 0.1842 0.4974 0.0950 
PlsCho 34:1 0.0137 0.0060 0.0009 
PlsCho 34:2 0.0733 0.0955 0.0075 
PlsCho 34:3 0.1054 0.2681 0.8187 
PlsCho 35:1 0.1652 0.3476 0.4429 
PlsCho 35:2 0.3969 0.8866 0.1986 
PlsCho 35:3 0.7450 0.7791 0.6929 
PlsCho 36:0 0.0536 0.1864 0.0928 
PlsCho 36:2 0.3144 0.5399 0.5777 
PlsCho 36:3 0.0034 0.1663 0.2533 
PlsCho 36:4 0.0080 0.1016 0.2079 
PlsCho 36:5 0.1966 0.1380 0.6572 
PlsCho 36:6 0.9376 0.6186 0.3999 
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Table S2.4F: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Plasmenyl-phosphatidylcholine 37:1 to Plasmenyl-phosphatidylethanolamine 38:3) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
PlsCho 37:1 0.5315 0.3274 0.4286 
PlsCho 37:3 0.6629 0.5989 0.8176 
PlsCho 37:4 0.0403 0.2101 0.8835 
PlsCho 37:6 0.0187 0.3549 0.1201 
PlsCho 38:1 0.8631 0.4417 0.2889 
PlsCho 38:3 0.0086 0.6507 0.6070 
PlsCho 38:4 0.0214 0.2223 0.0575 
PlsCho 38:5 0.0029 0.0720 0.1301 
PlsCho 38:6 0.0198 0.1279 0.1791 
PlsCho 39:3 0.6702 0.6698 0.1041 
PlsCho 39:4 0.8695 0.1440 0.1032 
PlsCho 39:5 0.1600 0.4583 0.1879 
PlsCho 39:6 0.0384 0.1338 0.7574 
PlsCho 40:1 0.1662 0.2385 0.2767 
PlsCho 40:3 0.0011 0.2901 0.2298 
PlsCho 40:4 0.0100 0.0184 0.6953 
PlsCho 40:5 0.3579 0.7555 0.7682 
PlsCho 40:6 0.0092 0.1074 0.8534 
PlsCho 42:0 0.5977 0.8285 0.6048 
PlsCho 42:1 0.1156 0.3569 0.3974 
PlsCho 42:2 0.2031 0.1111 0.1208 
PlsCho 42:3 0.1399 0.0091 0.6969 
PlsCho 42:4 0.0048 0.6820 0.1815 
PlsCho 42:5 0.2889 0.2733 0.3559 
PlsCho 42:6 0.6900 0.6649 0.8847 
PlsCho 44:3 0.2820 0.7462 0.1360 
PlsCho 44:4 0.0080 0.7083 0.0293 
PlsCho 44:5 0.2733 0.0567 0.0126 
PlsCho 44:6 0.7434 0.2333 0.7158 
PlsCho 46:4 0.7453 0.8306 0.0299 
PlsEth 32:1 0.6566 0.0365 0.5851 
PlsEth 32:2 0.0240 0.7462 0.5299 
PlsEth 33:2 0.1156 0.8609 0.8201 
PlsEth 34:0 0.0895 0.6985 0.4463 
PlsEth 34:1 0.3924 0.9859 0.3695 
PlsEth 34:2 0.0043 0.0176 0.0023 
PlsEth 34:3 0.0390 0.7555 0.0873 
PlsEth 34:4 0.1966 0.6318 0.4286 
PlsEth 35:1 0.8518 0.7299 0.6804 
PlsEth 35:2 0.0034 0.3032 0.0386 
PlsEth 35:4 0.4932 0.1097 0.0873 
PlsEth 36:1 0.0228 0.6032 0.9108 
PlsEth 36:2 0.0005 0.0146 0.0065 
PlsEth 36:3 0.0059 0.3476 0.0053 
PlsEth 36:4 0.0010 0.0669 0.0729 
PlsEth 36:5 0.0151 0.3650 0.4362 
PlsEth 36:6 0.2204 0.9646 0.8534 
PlsEth 37:1 0.3276 0.8252 0.0575 
PlsEth 37:2 0.1208 0.8036 0.0287 
PlsEth 37:4 0.0499 0.9625 0.9744 
PlsEth 37:5 0.1880 0.7568 0.0752 
PlsEth 37:6 0.0203 0.7025 0.2796 
PlsEth 38:1 0.0198 0.8314 0.5217 
PlsEth 38:2 0.0250 0.4672 0.0752 
PlsEth 38:3 0.0203 0.6324 0.3651 
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Table S2.4G: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Phosphatidylethanolamine 38:4 to Sphingomyelin 42:5) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
PlsEth 38:4 0.0053 0.7690 0.9192 
PlsEth 38:5 0.0077 0.2733 0.1828 
PlsEth 38:6 0.0207 0.5735 0.0099 
PlsEth 39:4 0.0521 0.2766 0.7158 
PlsEth 39:5 0.0138 0.8314 0.8828 
PlsEth 39:6 0.0105 0.7725 0.3444 
PlsEth 40:2 0.0245 0.4756 0.3003 
PlsEth 40:4 0.0175 0.9778 0.7143 
PlsEth 40:5 0.0175 0.7835 0.3088 
PlsEth 40:6 0.0233 0.2970 0.1217 
PlsEth 42:4 0.3460 0.8668 0.9530 
PlsEth 42:5 0.0230 0.8668 0.7158 
PlsEth 42:6 0.0087 0.3650 0.2132 
PlsEth 44:6 0.7750 0.9859 0.3113 
SM 30:0 0.1852 0.8046 0.0301 
SM 30:1 0.1544 0.2066 0.0022 
SM 30:2 0.1100 0.3042 0.6253 
SM 31:1 0.0340 0.1535 0.0023 
SM 32:0 0.7662 0.6160 0.8954 
SM 32:1 0.1573 0.2901 0.0928 
SM 32:2 0.2559 0.0875 0.0006 
SM 33:1 0.1447 0.7474 0.6913 
SM 33:2 0.3902 0.8036 0.8847 
SM 34:0 0.3969 0.5870 0.1769 
SM 34:1 0.1123 0.5603 0.9587 
SM 34:2 0.1447 0.5546 0.7089 
SM 34:3 0.4673 0.1620 0.9357 
SM 35:2 0.1705 0.8559 0.5562 
SM 36:1 0.1870 0.7117 0.7071 
SM 36:2 0.0719 0.4014 0.3183 
SM 36:3 0.0787 0.0856 0.0763 
SM 36:4 0.3073 0.0310 0.0268 
SM 37:1 0.3036 0.4057 0.2265 
SM 37:2 0.1472 0.9488 0.4286 
SM 38:0 0.4932 0.5546 0.8954 
SM 38:1 0.0704 0.8285 0.0063 
SM 38:2 0.0657 0.5583 0.0729 
SM 38:3 0.4989 0.3723 0.4286 
SM 38:4 0.7969 0.8685 0.0288 
SM 39:1 0.1156 0.4331 0.0437 
SM 39:2 0.0206 0.4577 0.6988 
SM 39:3 0.0196 0.1434 0.3461 
SM 40:1 0.0353 0.6820 0.0085 
SM 40:2 0.0094 0.0060 0.0356 
SM 40:3 0.3514 0.6649 0.5888 
SM 40:5 0.3181 0.8876 0.4327 
SM 41:1 0.0048 0.0141 0.2009 
SM 41:2 0.1125 0.8876 0.7134 
SM 41:4 0.2467 0.9778 0.1212 
SM 41:6 0.2187 0.0486 0.7328 
SM 42:1 0.0138 0.0023 0.0222 
SM 42:2 0.9751 0.5235 0.3252 
SM 42:3 0.8528 0.9778 0.7096 
SM 42:4 0.0586 0.3335 0.0117 
SM 42:5 0.9270 0.6071 0.2246 
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Table S2.4H: PUFA/CHO study significant differences for between diet comparisons for all 
lipids (Sphingomyelin 42:6 to Triacylglycerol 52:6) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
SM 42:6 0.3386 0.0875 0.6378 
SM 43:1 0.0829 0.0597 0.9316 
SM 43:2 0.1023 0.6032 0.4060 
SM 43:3 0.8294 0.7453 0.2925 
SM 43:6 0.4673 0.6301 0.9046 
SM 44:1 0.8331 0.9254 0.9575 
SM 44:2 0.8331 0.7698 0.7377 
SM 44:3 0.8866 0.6988 0.2221 
SM 44:4 0.0207 0.4014 0.1647 
SM 44:6 0.7969 0.9859 0.9742 
TG 38:0 0.0343 0.0597 0.3654 
TG 39:0 0.3386 0.8046 0.0034 
TG 40:0 0.0338 0.0001 0.1761 
TG 41:0 0.0383 0.0571 0.3461 
TG 42:0 0.0207 0.0026 0.5888 
TG 42:1 0.0245 0.0021 0.5139 
TG 43:1 0.0206 0.0184 0.1986 
TG 44:2 0.0100 0.0052 0.1033 
TG 45:0 0.0746 0.0056 0.0729 
TG 45:1 0.0319 0.0066 0.0438 
TG 45:2 0.0123 0.0057 0.0150 
TG 46:0 0.0135 0.0046 0.0291 
TG 46:1 0.0105 0.0021 0.0202 
TG 46:3 0.0042 0.0015 0.0262 
TG 47:0 0.0572 0.0124 0.0233 
TG 47:1 0.0105 0.0019 0.0179 
TG 47:2 0.0037 0.0014 0.0121 
TG 48:0 0.0100 0.0015 0.0138 
TG 48:1 0.0018 0.0008 0.0059 
TG 48:3 0.0012 0.0008 0.0063 
TG 48:4 0.0110 0.0012 0.0259 
TG 48:5 0.0204 0.0176 0.0282 
TG 49:0 0.0206 0.0065 0.0219 
TG 49:1 0.0040 0.0012 0.0094 
TG 49:2 0.0006 0.0014 0.0043 
TG 49:3 0.0006 0.0012 0.0043 
TG 50:0 0.0070 0.0041 0.0068 
TG 50:1 0.0019 0.0016 0.0043 
TG 50:2 0.0004 0.0009 0.0026 
TG 50:3 0.0005 0.0009 0.0023 
TG 50:4 0.0101 0.0084 0.0152 
TG 50:5 0.0105 0.0043 0.0068 
TG 50:6 0.1320 0.0182 0.0468 
TG 51:1 0.0009 0.0017 0.0063 
TG 51:2 0.0001 0.0010 0.0023 
TG 51:3 0.0005 0.0012 0.0023 
TG 51:4 0.0036 0.0573 0.0641 
TG 51:5 0.1544 0.0590 0.0253 
TG 52:0 0.0145 0.0327 0.1136 
TG 52:1 0.0002 0.0013 0.0044 
TG 52:2 0.0001 0.0009 0.0013 
TG 52:3 0.0101 0.0285 0.0099 
TG 52:4 0.1652 0.1689 0.8399 
TG 52:5 0.0080 0.0170 0.0044 
TG 52:6 0.0979 0.0590 0.8835 
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Table S2.4I: PUFA/CHO study significant differences for between diet comparisons for all lipids 
(Triacylglycerol 52:7 to Triacylglycerol 60:12) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day Day 2 Day 7 Day 21 
TG 52:7 0.1174 0.0216 0.0391 
TG 53:0 0.1399 0.1695 0.2738 
TG 53:1 0.0239 0.0034 0.0033 
TG 53:2 0.0004 0.0015 0.0043 
TG 53:3 0.0001 0.0031 0.0063 
TG 53:4 0.7750 0.9950 0.2992 
TG 53:5 0.2703 0.4727 0.6205 
TG 54:0 0.3494 0.7758 0.5932 
TG 54:1 0.0016 0.0015 0.0152 
TG 54:2 0.0000 0.0003 0.0033 
TG 54:3 0.0011 0.0603 0.5983 
TG 54:4 0.9911 0.2570 0.0396 
TG 54:5 0.0829 0.0702 0.0184 
TG 54:6 0.0102 0.0702 0.0126 
TG 54:7 0.6900 0.8252 0.1208 
TG 54:8 0.0286 0.0383 0.0350 
TG 55:0 0.0466 0.2797 0.0134 
TG 55:3 0.0080 0.0043 0.1582 
TG 55:4 0.3902 0.0200 0.8176 
TG 55:5 0.0730 0.1779 0.3999 
TG 56:0 0.2226 0.3903 0.7808 
TG 56:1 0.0052 0.0043 0.0923 
TG 56:2 0.0019 0.0021 0.0368 
TG 56:3 0.0044 0.0048 0.1971 
TG 56:4 0.1174 0.0829 0.6988 
TG 56:5 0.2152 0.2697 0.5888 
TG 56:6 0.9688 0.9136 0.9518 
TG 56:7 0.4007 0.2901 0.4691 
TG 56:8 0.6438 0.3021 0.3654 
TG 56:9 0.4042 0.3644 0.7921 
TG 58:10 0.4649 0.4194 0.1869 
TG 58:11 0.4013 0.2896 0.1457 
TG 58:2 0.0105 0.0114 0.3935 
TG 58:3 0.0403 0.6036 0.2274 
TG 58:6 0.0496 0.1146 0.1129 
TG 58:7 0.2709 0.2896 0.1791 
TG 58:8 0.7634 0.8668 0.6849 
TG 58:9 0.6904 0.1737 0.6925 
TG 60:11 0.3514 0.2303 0.0108 





Table S2.5A: MEAL Study Mean Log2 Area under the Curve for Lipids (16:0 Cholesterol ester 
to Ceramide [NS] 35:1) 
 Mean Log2 AUC Values For Each Lipid Species 
 High Fat Diet 
 High Carbohydrate Diet 
Lipid/Day B S 2 7 14 21  B S 2 7 14 21 
16:0 CE 14.11 14.00 14.15 14.23 13.99 14.20  14.18 14.37 14.19 14.20 14.29 14.01 
16:1 CE 12.74 12.75 12.86 12.31 12.11 12.40  12.92 12.50 13.29 13.33 13.49 13.31 
18:0 CE 12.13 11.86 12.52 12.39 12.17 12.46  12.88 12.81 12.64 12.76 12.68 12.45 
18:1 CE 17.15 17.17 16.94 17.09 16.89 17.00  17.29 17.54 17.33 17.35 17.34 17.26 
18:2 CE 19.59 19.81 19.84 19.81 19.77 19.71  19.92 20.04 19.88 19.67 19.64 19.54 
18:3 CE 15.32 15.37 15.28 15.31 15.28 15.08  15.46 15.65 15.45 15.66 15.64 15.48 
20:3 CE 15.40 15.77 15.72 15.30 15.24 15.20  15.94 16.05 15.86 16.07 15.99 15.96 
20:4 CE 17.01 17.38 17.54 17.54 17.31 17.35  17.80 17.87 17.65 17.65 17.64 17.52 
20:5 CE 13.68 13.92 13.91 13.86 14.02 13.92  14.61 14.46 13.99 14.48 14.32 14.28 
22:4 CE 10.88 11.14 11.18 11.32 10.70 11.01  10.61 11.60 11.39 11.57 11.21 11.15 
22:5 CE 12.41 12.79 12.46 12.47 12.62 12.48  13.09 13.12 13.07 13.06 13.16 13.01 
22:6 CE 14.92 15.14 15.03 15.24 15.02 15.12  15.31 15.49 15.19 15.36 15.60 15.56 
ACAR 10:0 12.62 13.26 13.70 13.36 13.01 13.47  13.26 13.43 12.77 12.87 12.98 13.17 
ACAR 10:1 11.82 12.10 12.47 12.02 11.76 12.06  11.87 11.98 11.91 11.51 11.89 11.83 
ACAR 12:0 12.87 13.38 13.78 13.62 13.32 13.79  13.17 13.25 12.59 13.01 13.15 13.35 
ACAR 14:0 13.70 14.00 14.09 14.30 14.02 14.11  13.88 14.09 13.87 13.64 13.87 13.80 
ACAR 14:1 13.74 14.33 14.51 14.07 13.99 14.29  14.16 14.39 13.59 13.97 14.13 14.15 
ACAR 14:2 12.62 13.15 13.54 12.79 12.65 12.95  12.74 13.47 12.54 12.70 12.71 12.89 
ACAR 16:0 15.95 16.18 16.04 16.45 16.16 16.29  16.03 16.08 15.86 15.84 16.09 15.97 
ACAR 18:0 15.23 15.26 15.40 15.46 15.40 15.45  15.28 15.23 14.95 14.93 14.98 14.86 
ACAR 18:1 16.32 16.36 16.31 16.43 16.13 16.27  16.44 16.32 16.12 16.18 16.40 16.29 
ACAR 18:2 15.77 16.05 15.88 15.94 15.64 15.73  15.82 15.96 15.69 15.69 15.78 15.73 
ACAR 20:0 13.16 12.96 13.14 12.78 12.64 12.96  13.06 12.97 12.47 12.51 12.62 12.44 
ACAR 24:0 14.09 14.33 14.23 14.17 14.09 14.35  14.31 14.14 13.66 13.42 13.50 13.46 
ACAR 26:0 12.83 13.33 13.25 12.89 13.36 13.12  12.71 13.00 12.44 11.88 12.07 11.76 
Cer[AS] 34:1 11.95 11.85 12.02 12.06 11.74 12.39  12.41 12.14 12.23 11.96 12.15 12.07 
Cer[AS] 42:2 14.27 14.14 14.40 13.76 13.91 13.48  14.10 14.21 14.01 13.99 13.98 13.60 
Cer[EODS] 57:2 12.20 12.45 12.43 12.54 12.25 12.63  12.52 12.06 12.22 11.93 11.97 11.97 
Cer[EODS] 58:0 12.13 11.97 12.16 11.81 11.77 11.78  11.56 11.54 11.80 11.32 11.01 11.40 
Cer[EODS] 60:0 11.80 11.82 11.52 11.34 11.38 11.79  12.04 11.49 11.17 11.23 11.05 10.98 
Cer[NDS] 34:0 15.34 15.30 15.52 15.61 15.47 15.58  15.45 15.36 15.21 15.12 15.27 15.18 
Cer[NDS] 36:0 13.24 13.09 13.84 13.48 13.37 13.41  12.92 12.70 12.53 12.64 12.99 13.17 
Cer[NDS] 38:0 13.47 13.83 14.13 13.77 13.43 14.00  13.57 13.62 13.36 13.15 13.56 13.18 
Cer[NDS] 39:0 12.88 13.17 13.28 13.32 13.12 13.13  12.53 12.46 12.32 12.30 12.55 12.27 
Cer[NDS] 40:0 15.74 15.83 16.00 15.93 15.41 15.73  15.76 15.51 15.14 14.99 15.03 15.04 
Cer[NDS] 41:0 15.39 15.36 15.76 15.72 15.50 15.42  15.12 15.12 14.75 14.71 14.78 14.76 
Cer[NDS] 42:0 17.17 17.27 17.51 17.37 17.05 17.28  16.97 16.90 16.66 16.55 16.65 16.53 
Cer[NDS] 42:1 19.62 19.70 19.73 19.59 19.39 19.54  19.54 19.43 19.32 19.14 19.16 19.00 
Cer[NDS] 42:2 15.52 15.53 15.50 15.28 15.37 15.28  15.53 15.45 15.56 15.49 15.59 15.46 
Cer[NDS] 43:0 14.31 14.59 15.08 14.95 14.55 15.07  14.33 14.49 14.22 14.16 14.08 14.04 
Cer[NP] 34:0 11.75 12.31 12.12 12.65 12.44 12.02  12.51 12.39 12.00 12.01 11.88 11.73 
Cer[NP] 40:0 14.64 14.81 14.75 14.70 14.48 14.73  14.52 14.69 13.86 13.76 14.00 13.74 
Cer[NP] 41:0 15.55 15.50 15.62 15.63 15.41 15.64  15.70 15.85 15.36 15.36 15.39 15.13 
Cer[NP] 41:1 13.99 14.10 14.15 13.72 13.66 13.80  13.81 14.02 13.70 13.47 13.88 13.52 
Cer[NP] 42:0 16.13 16.18 16.00 16.06 15.76 16.05  16.31 16.34 15.97 15.82 15.71 15.76 
Cer[NP] 42:1 14.74 14.91 15.06 14.43 14.65 14.52  14.64 14.59 14.26 14.29 14.30 14.03 
Cer[NS] 32:1 14.42 14.62 14.60 14.50 14.26 14.65  14.94 14.79 14.62 14.64 14.72 14.44 
Cer[NS] 33:1 14.61 14.30 14.52 14.49 14.28 14.41  14.69 14.76 14.59 14.49 14.84 14.56 
Cer[NS] 33:4 11.70 11.27 10.91 11.15 10.83 10.72  10.82 10.99 10.40 10.48 9.99 11.00 
Cer[NS] 34:1 18.25 18.12 18.13 18.17 17.91 18.06  18.38 18.24 18.31 18.22 18.37 18.25 
Cer[NS] 34:2 14.00 14.08 14.16 13.98 13.90 13.84  14.17 14.45 13.85 13.94 14.31 14.05 
Cer[NS] 35:1 23.13 23.00 23.08 22.99 22.78 22.97  23.24 23.15 23.21 23.14 23.18 23.12 
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Table S2.5B: MEAL Study Mean Log2 Area under the Curve for Lipids (Ceramide [NS] 36:1 to 
Free Fatty Acid 18:1) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet   High Carbohydrate Diet  
Lipid/Day B S 2 7 14 21  B S 2 7 14 21 
Cer[NS] 36:1 16.17 16.36 16.51 16.45 16.15 16.56  16.45 16.46 16.48 16.35 16.50 16.43 
Cer[NS] 36:2 13.25 13.42 13.78 13.40 12.98 13.49  13.67 13.70 13.64 13.65 13.92 13.82 
Cer[NS] 37:1 13.87 13.79 13.98 13.83 13.66 13.78  13.44 13.47 13.50 13.33 13.56 13.34 
Cer[NS] 38:1 16.94 17.03 17.06 16.88 16.75 17.10  17.27 17.32 17.25 16.88 17.08 16.88 
Cer[NS] 38:2 14.17 14.28 14.33 14.02 13.85 14.03  14.46 14.54 14.47 14.20 14.30 14.33 
Cer[NS] 39:1 14.75 14.71 14.91 14.79 14.73 15.06  14.89 14.98 14.72 14.42 14.59 14.27 
Cer[NS] 40:1 19.57 19.54 19.56 19.36 19.32 19.52  19.80 19.70 19.49 19.31 19.33 19.19 
Cer[NS] 40:2 17.24 17.21 17.19 16.90 16.83 17.03  17.51 17.44 17.48 17.12 17.33 17.15 
Cer[NS] 40:3 11.65 11.72 12.15 12.09 11.84 12.03  11.48 11.45 11.34 11.60 11.44 11.86 
Cer[NS] 41:1 19.32 19.22 19.38 19.30 19.19 19.35  19.49 19.54 19.38 19.20 19.21 19.08 
Cer[NS] 41:2 17.43 17.34 17.39 17.27 17.02 17.29  17.71 17.63 17.73 17.50 17.61 17.45 
Cer[NS] 41:4 12.99 12.54 12.88 12.82 12.96 13.01  13.18 13.01 13.22 13.52 13.10 13.31 
Cer[NS] 42:1 21.28 21.20 21.16 20.94 20.90 21.03  21.37 21.36 21.24 20.92 20.98 20.85 
Cer[NS] 42:2 19.78 19.76 19.75 19.47 19.37 19.48  19.96 19.93 19.96 19.80 19.98 19.82 
Cer[NS] 42:3 15.46 15.62 15.47 15.41 15.18 15.36  15.55 15.65 15.53 15.60 15.81 15.68 
Cer[NS] 43:1 18.57 18.87 19.10 18.95 18.87 19.09  18.95 19.19 18.91 18.67 18.77 18.65 
Cer[NS] 43:2 14.90 15.11 15.26 15.00 14.78 14.94  14.98 15.02 14.87 14.72 14.90 14.86 
Cer[NS] 44:1 15.01 15.06 15.38 15.29 15.05 15.39  14.95 15.05 14.73 14.78 14.85 14.83 
Cer[NS] 44:2 13.80 14.06 14.15 13.97 13.76 14.00  13.83 13.66 13.57 13.76 13.95 14.03 
Cer[NS] 44:4 19.21 19.38 19.27 19.33 19.20 19.31  19.40 19.38 19.20 19.17 19.09 18.97 
Cer[NS] 45:1 11.83 12.31 12.59 12.53 12.04 12.57  12.25 12.50 11.88 11.84 12.13 11.93 
Cer[NS] 46:5 13.50 13.74 13.76 13.69 13.52 13.68  13.62 13.72 13.55 13.78 13.87 13.86 
DG 30:0 10.50 9.87 10.35 10.80 9.87 10.63  9.89 10.21 10.14 10.88 10.95 10.67 
DG 30:1 10.17 9.90 10.24 9.86 10.26 10.41  10.19 10.13 10.85 10.22 9.98 10.32 
DG 32:0 11.94 11.78 11.45 11.74 12.02 11.68  11.28 11.20 11.89 11.83 11.57 11.92 
DG 32:1 12.54 12.49 11.87 12.63 12.43 12.12  11.92 12.01 13.29 12.72 13.05 13.00 
DG 32:2 12.27 11.59 11.77 11.73 12.11 11.57  11.47 11.67 12.42 12.28 11.56 11.82 
DG 33:0 10.15 9.94 9.43 9.64 10.02 9.09  9.16 9.51 10.04 9.75 9.97 9.73 
DG 33:1 9.88 9.56 9.59 9.76 9.93 9.62  9.55 9.39 10.29 9.75 9.75 10.30 
DG 34:0 12.23 11.73 11.59 11.90 11.95 11.85  11.64 11.44 12.10 11.99 11.93 12.00 
DG 34:2 15.03 14.87 14.76 14.89 14.79 14.58  14.54 14.75 15.33 15.17 15.35 15.30 
DG 34:3 13.48 13.37 12.91 13.15 13.07 12.61  13.06 13.41 14.03 13.88 13.79 13.89 
DG 35:1 10.78 10.42 10.30 10.89 10.61 10.78  10.64 10.18 10.66 10.61 10.80 10.91 
DG 35:2 10.06 10.13 10.41 10.66 10.16 10.20  10.38 10.10 11.03 10.18 10.66 10.47 
DG 35:3 10.43 10.06 10.12 10.46 10.12 9.86  9.95 9.57 10.57 10.17 10.53 10.50 
DG 36:0 11.97 11.65 12.10 11.80 11.84 11.88  11.57 11.51 12.05 11.64 11.72 11.64 
DG 36:1 13.19 12.74 12.64 12.84 13.06 12.94  12.77 12.45 13.14 13.05 13.00 13.06 
DG 36:2 16.06 15.85 15.35 15.54 15.38 15.42  15.82 15.56 16.19 16.03 16.04 16.10 
DG 36:3 15.91 15.91 15.68 15.71 15.54 15.38  15.97 15.94 16.20 16.09 16.10 16.26 
DG 36:4 15.59 15.96 15.82 15.68 15.65 15.40  15.45 15.79 15.79 15.52 15.62 15.59 
DG 36:5 12.67 12.81 12.84 12.57 12.95 12.10  12.55 12.82 13.28 13.04 12.88 13.19 
DG 38:1 11.94 11.83 11.97 12.33 12.50 12.36  11.82 11.13 11.54 10.99 11.25 11.29 
DG 38:2 11.29 11.06 11.31 10.86 11.03 10.84  11.02 10.54 11.12 10.91 10.88 10.89 
DG 38:3 11.65 11.81 11.75 11.54 11.67 11.72  11.81 11.72 12.02 11.90 12.10 11.77 
DG 38:4 12.27 12.26 11.88 12.40 11.95 12.14  12.34 12.15 12.58 12.53 12.58 12.34 
DG 38:5 13.65 13.48 13.30 13.36 13.36 12.84  13.50 13.39 13.79 13.83 13.74 13.76 
DG 38:6 13.47 13.64 13.42 13.50 13.62 13.22  13.54 13.71 13.78 13.84 13.99 13.95 
DG 38:7 10.67 10.88 11.21 10.82 10.84 10.27  10.41 10.77 11.29 11.04 11.35 11.06 
DG 40:6 11.39 11.03 11.10 10.76 10.91 10.45  11.09 11.12 11.77 11.21 11.60 11.47 
DG 40:7 11.65 12.09 12.34 12.04 11.90 11.40  11.69 11.60 12.02 12.31 11.92 11.98 
FFA 16:0 25.40 25.40 25.47 25.35 25.24 25.23  25.44 25.43 25.30 25.37 25.44 25.37 
FFA 18:0 25.85 25.76 25.75 25.69 25.62 25.62  25.86 25.74 25.67 25.77 25.75 25.73 
FFA 18:1 24.52 24.80 24.79 24.57 24.41 24.40  24.61 24.97 24.71 24.65 25.04 24.67 
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Table S2.5C: MEAL Study Mean Log2 Area Under the Curve for Lipids (Ceramide [NS] 36:1 to 
Free Fatty Acid 18:2 to Lysophosphatidylethanolamine 20:2) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet   High Carbohydrate Diet  
Lipid/Day B S 2 7 14 21  B S 2 7 14 21 
FFA 18:2 23.63 24.10 24.24 23.86 23.75 23.75  23.71 24.24 23.82 23.78 24.19 23.79 
FFA 20:0 20.77 20.55 20.51 20.54 20.33 20.38  20.67 20.44 20.35 20.52 20.45 20.43 
FFA 20:1 19.03 19.07 18.98 18.77 18.55 18.61  18.99 19.19 18.95 18.90 19.21 18.84 
FFA 20:2 18.55 18.73 18.55 18.27 18.07 18.11  18.64 18.93 18.70 18.72 19.01 18.64 
FFA 20:4 20.06 20.43 20.29 20.01 19.81 20.04  20.42 20.61 20.46 20.51 20.65 20.40 
FFA 22:0 19.88 19.68 19.45 19.69 19.44 19.53  19.73 19.48 19.40 19.64 19.46 19.44 
FFA 22:1 16.81 16.56 16.94 16.61 16.26 16.39  16.76 16.60 16.34 16.59 16.88 16.47 
FFA 22:2 15.10 14.91 14.79 14.72 14.52 14.38  15.05 15.05 14.80 14.82 14.86 14.69 
FFA 22:3 15.21 15.13 14.87 14.88 14.80 14.74  15.23 15.30 15.38 15.02 15.27 15.01 
FFA 24:0 18.34 18.36 18.35 18.17 18.16 18.47  18.45 18.40 18.43 18.30 18.18 18.26 
FFA 24:1 17.73 17.63 17.54 17.48 17.37 17.20  17.63 17.63 17.40 17.35 17.56 17.42 
FFA 24:2 15.77 15.68 15.76 15.49 15.27 15.46  15.82 15.90 15.64 15.57 15.66 15.63 
FFA 24:3 13.16 12.85 13.10 12.96 12.56 12.68  13.14 12.91 13.11 12.59 12.75 12.59 
GlcCer[NS] 34:1 18.03 18.29 18.20 18.06 18.03 18.03  18.27 18.41 18.13 17.89 18.24 17.98 
GlcCer[NS] 34:2 12.03 12.41 12.70 12.38 12.46 12.23  11.88 12.21 11.91 11.56 11.67 11.85 
GlcCer[NS] 40:1 17.61 17.69 17.68 17.53 17.54 17.68  18.00 18.15 17.92 17.46 17.48 17.32 
GlcCer[NS] 41:1 12.45 12.69 12.61 12.67 12.62 12.58  12.42 12.45 12.65 12.28 12.24 12.22 
GlcCer[NS] 42:1 17.53 17.66 17.63 17.54 17.52 17.54  18.08 18.12 17.93 17.54 17.76 17.50 
GlcCer[NS] 42:2 17.41 17.55 17.49 17.33 17.20 17.34  17.79 17.95 17.85 17.70 17.91 17.83 
LysoPC 14:0 15.94 16.00 15.86 15.99 16.13 15.76  15.77 15.92 16.08 15.81 15.92 15.74 
LysoPC 15:0 15.71 15.98 15.99 15.96 15.96 15.82  15.77 15.94 15.87 15.68 15.74 15.64 
LysoPC 15:1 16.29 15.99 15.91 15.77 15.97 15.91  15.88 15.67 15.75 15.54 15.91 15.67 
LysoPC 16:0 21.93 21.96 21.77 21.60 21.57 21.58  21.90 22.05 22.01 21.89 22.03 21.90 
LysoPC 16:1 17.44 17.28 16.78 16.85 16.77 16.74  17.17 17.15 17.54 17.40 17.58 17.45 
LysoPC 17:1 14.69 14.66 14.43 14.61 14.66 14.56  14.61 14.64 14.85 14.79 14.83 14.68 
LysoPC 18:0 21.91 22.09 21.82 21.73 21.88 21.72  22.05 22.11 22.00 21.77 21.93 21.83 
LysoPC 18:1 21.23 21.09 20.87 20.73 20.77 20.70  21.08 20.95 20.95 20.94 21.04 20.99 
LysoPC 18:2 22.21 22.31 22.21 22.20 22.21 22.14  22.00 22.10 21.72 21.75 21.77 21.77 
LysoPC 18:3 16.03 15.78 15.55 15.62 15.70 15.34  15.66 15.55 15.61 15.64 15.66 15.65 
LysoPC 19:0 15.09 15.05 15.04 14.96 14.93 14.93  15.13 15.25 15.18 15.05 15.09 15.09 
LysoPC 19:1 13.65 13.67 13.61 13.67 13.51 13.61  13.47 13.64 13.52 13.63 13.60 13.53 
LysoPC 20:0 15.16 15.06 14.81 14.68 14.86 14.87  15.14 15.03 15.01 14.68 14.79 14.60 
LysoPC 20:1 15.57 15.50 15.04 14.93 14.97 15.02  15.53 15.44 15.44 15.23 15.49 15.33 
LysoPC 20:2 15.64 15.72 15.27 15.16 15.27 15.21  15.55 15.67 15.53 15.52 15.57 15.51 
LysoPC 20:3 18.14 18.30 17.86 17.80 17.69 17.79  18.14 18.13 18.18 18.24 18.22 18.20 
LysoPC 20:4 19.55 19.74 19.50 19.51 19.42 19.44  19.61 19.68 19.63 19.64 19.75 19.62 
LysoPC 20:5 20.35 20.34 20.15 20.32 20.38 20.32  20.25 19.81 20.00 20.13 20.03 20.03 
LysoPC 22:0 13.31 13.22 13.19 12.83 12.81 12.75  13.42 13.29 13.06 12.70 12.66 12.66 
LysoPC 22:4 14.56 14.60 14.37 14.19 14.27 14.43  14.58 14.61 14.70 14.85 14.88 14.72 
LysoPC 22:5 16.02 16.11 15.71 15.81 15.63 15.71  16.01 16.05 16.07 16.24 16.30 16.23 
LysoPC 22:6 17.40 17.62 17.28 17.23 17.29 17.25  17.53 17.50 17.52 17.53 18.00 17.92 
LysoPC 23:0 11.74 11.78 11.91 11.83 11.59 11.42  11.41 11.87 12.02 11.56 11.69 11.25 
LysoPC 24:0 14.12 14.15 13.85 13.68 13.54 13.66  14.22 14.13 14.02 13.73 13.89 13.69 
LysoPC 24:1 12.55 12.53 12.30 12.12 12.14 11.89  12.61 12.24 12.60 12.36 12.58 12.46 
LysoPC 26:1 11.95 11.67 11.32 10.63 10.97 10.89  11.71 11.78 11.79 11.59 12.25 11.73 
LysoPE 16:0 17.86 17.91 17.62 17.42 17.49 17.47  17.71 17.98 18.11 17.94 18.24 18.00 
LysoPE 16:1 11.46 11.15 10.53 11.13 11.18 10.45  10.71 11.10 11.57 11.64 11.78 11.34 
LysoPE 17:0 13.50 13.20 13.51 13.24 13.13 13.19  13.69 13.55 13.58 13.67 13.90 13.75 
LysoPE 18:0 18.11 18.16 18.01 17.74 17.87 17.98  18.29 18.44 18.29 18.09 18.31 18.07 
LysoPE 18:1 18.45 18.20 17.93 17.70 17.86 17.93  18.10 17.99 17.91 17.78 18.01 17.79 
LysoPE 18:2 19.28 19.32 19.41 19.08 19.27 19.16  18.81 19.07 18.62 18.52 18.80 18.55 
LysoPE 18:3 12.63 12.25 12.23 12.39 12.60 12.23  12.33 12.12 12.10 12.46 12.48 12.33 
LysoPE 20:2 13.04 13.07 12.71 12.37 12.67 12.64  12.93 12.98 12.89 12.72 12.95 12.69 
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Table S2.5D: MEAL Study Mean Log2 Area under the Curve for Lipids 
(Lysophosphatidylethanolamine 20:3 to Phosphatidylcholine 37:3) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet   High Carbohydrate Diet  
Lipid/Day B S 2 7 14 21  B S 2 7 14 21 
LysoPE 20:3 16.32 16.26 15.97 15.55 15.64 15.55  15.95 16.27 16.31 16.28 16.39 16.16 
LysoPE 20:4 18.68 18.78 18.70 18.48 18.44 18.56  18.65 18.81 18.59 18.56 18.79 18.49 
LysoPE 20:5 13.08 12.68 12.93 12.54 12.27 11.95  12.96 12.45 12.64 12.84 13.00 12.79 
LysoPE 22:4 14.20 14.00 13.75 13.60 13.49 13.49  13.84 14.07 14.18 14.40 14.39 14.24 
LysoPE 22:5 16.47 16.47 16.25 15.95 15.98 15.86  16.34 16.60 16.65 16.55 16.81 16.60 
LysoPE 22:6 18.07 18.13 17.99 17.71 17.82 17.80  17.87 18.08 17.86 17.92 18.31 17.98 
LysoPE 24:0 12.97 12.85 13.14 12.82 12.54 12.45  13.01 13.29 13.12 12.64 13.09 12.67 
PA 34:1 14.98 14.74 14.35 14.47 14.42 14.49  14.56 14.51 14.79 14.77 14.75 14.96 
PA 34:2 16.62 16.51 16.48 16.45 16.45 16.36  16.20 16.24 16.15 16.13 16.05 16.11 
PA 36:1 15.18 14.65 14.99 14.37 14.49 14.87  14.57 15.05 14.53 14.80 14.61 14.75 
PA 36:2 16.83 16.82 16.65 16.46 16.86 16.56  16.55 16.77 16.70 16.53 16.50 16.71 
PA 36:3 17.44 17.33 17.37 17.38 17.36 17.36  17.10 17.11 16.88 16.87 16.87 16.96 
PA 36:4 16.28 16.23 16.03 16.11 15.84 16.17  16.25 16.03 15.95 15.86 15.86 15.94 
PA 38:6 15.17 15.28 15.16 15.21 14.83 15.28  15.39 15.32 15.22 15.41 15.36 15.52 
PC 24:0 11.47 11.49 12.54 11.95 12.56 11.22  11.32 11.08 11.62 11.08 11.73 11.41 
PC 26:0 12.56 12.31 13.79 13.45 14.00 12.80  12.48 12.61 12.76 12.57 12.68 12.26 
PC 27:0 10.67 10.38 11.14 10.78 10.73 10.75  10.11 10.39 10.61 10.15 10.30 10.12 
PC 28:2 9.33 9.12 9.05 9.04 8.51 8.96  8.52 9.14 8.91 8.31 9.13 8.40 
PC 29:0 13.55 13.93 14.48 14.48 14.56 14.22  13.63 14.00 14.08 13.90 13.90 13.87 
PC 30:0 18.80 18.96 19.16 19.07 19.26 18.88  18.69 18.85 19.21 18.97 19.15 19.03 
PC 30:2 13.10 12.94 13.52 13.28 13.84 12.57  12.61 12.88 13.24 12.38 12.92 12.44 
PC 31:0 15.71 15.93 16.26 16.34 16.42 16.38  15.86 16.03 16.04 15.96 16.03 16.02 
PC 31:1 14.66 14.90 14.85 14.54 14.60 14.76  14.48 14.74 15.21 14.91 15.11 14.93 
PC 32:0 20.77 20.86 20.84 20.79 20.77 20.71  20.66 20.70 20.73 20.60 20.81 20.67 
PC 32:1 20.61 20.47 20.21 20.13 20.23 20.02  20.33 20.22 21.01 20.82 20.93 20.81 
PC 32:2 19.95 20.16 19.99 19.93 20.03 19.57  19.76 19.96 19.87 19.57 19.64 19.47 
PC 32:3 14.91 14.55 14.51 14.55 14.46 13.96  14.34 14.27 14.74 14.07 14.61 14.37 
PC 33:0 12.43 12.39 12.26 12.71 12.36 12.28  12.34 12.39 12.37 12.31 12.47 12.49 
PC 33:1 15.97 16.05 16.01 16.24 15.98 15.94  15.95 15.89 16.30 16.19 16.27 16.09 
PC 33:2 19.17 19.55 19.74 19.72 19.60 19.61  19.25 19.49 19.21 19.05 19.07 19.01 
PC 33:3 14.89 14.86 14.97 15.00 14.74 14.68  14.84 14.89 14.81 14.67 14.52 14.74 
PC 34:1 24.55 24.45 24.23 24.15 24.26 24.19  24.48 24.33 24.61 24.52 24.65 24.58 
PC 34:2 25.50 25.53 25.51 25.55 25.57 25.51  25.56 25.57 25.45 25.47 25.45 25.40 
PC 34:3 18.58 18.45 18.18 18.17 18.11 18.04  18.36 18.30 18.50 18.34 18.46 18.28 
PC 34:4 18.14 18.29 18.13 18.02 18.10 17.75  18.24 18.24 18.38 18.16 18.27 18.05 
PC 34:5 11.17 12.66 12.18 11.43 12.23 11.19  12.57 12.20 11.87 11.90 11.71 11.96 
PC 35:0 14.02 14.44 14.38 14.59 14.30 14.24  13.58 14.27 13.76 13.79 13.99 13.97 
PC 35:1 15.87 15.82 15.76 15.90 15.93 16.05  16.15 15.97 16.29 16.33 16.31 16.05 
PC 35:2 17.26 17.33 17.35 17.21 17.41 17.52  17.34 17.42 16.91 16.98 16.89 16.90 
PC 35:3 15.94 16.09 15.79 15.78 15.73 15.67  15.51 15.67 15.33 15.49 15.30 15.66 
PC 35:4 17.37 17.62 17.75 17.75 17.55 17.72  17.60 17.74 17.75 17.64 17.71 17.54 
PC 35:5 17.22 17.03 17.12 16.96 17.04 17.06  17.09 17.06 17.30 17.09 17.23 17.01 
PC 35:6 16.16 15.89 16.18 16.10 15.93 16.30  16.13 16.00 16.50 16.43 16.51 16.46 
PC 36:0 15.46 15.43 15.33 15.32 15.22 15.39  15.63 15.36 15.34 15.28 15.34 15.30 
PC 36:1 22.12 21.99 21.87 21.68 21.95 21.83  21.96 21.63 21.71 21.74 21.78 21.77 
PC 36:2 21.43 21.47 21.44 21.21 21.33 21.25  21.53 21.54 21.27 21.10 21.17 21.07 
PC 36:3 24.41 24.42 24.19 24.11 24.03 23.97  24.29 24.27 24.24 24.16 24.21 24.15 
PC 36:4 20.79 21.05 20.86 20.71 20.55 20.71  20.87 21.07 20.99 20.92 21.09 20.85 
PC 36:5 20.92 20.66 20.52 20.46 20.37 20.21  20.92 20.51 20.82 20.90 20.99 20.91 
PC 36:6 17.44 17.30 16.78 17.05 16.89 16.94  16.89 16.90 17.03 16.88 16.75 16.71 
PC 37:1 14.96 14.96 14.53 14.92 14.32 14.78  14.78 14.44 14.66 14.62 14.82 14.75 
PC 37:2 17.37 17.48 17.53 17.48 17.46 17.42  17.64 17.52 17.42 17.34 17.34 17.32 
PC 37:3 14.95 15.15 15.12 15.22 14.89 15.07  15.12 15.30 15.26 15.37 15.07 15.12 
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Table S2.5E: MEAL Study Mean Log2 Area under the Curve for Lipids (Phosphatidylcholine 
37:4 to Phosphatidylethanolamine 33:1) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet   High Carbohydrate Diet  
Lipid/Day B S 2 7 14 21  B S 2 7 14 21 
PC 37:4 15.74 16.08 16.06 15.87 15.90 15.93  16.15 16.10 16.14 16.18 16.21 15.95 
PC 37:5 16.63 16.59 16.61 16.58 16.42 16.48  16.80 16.62 16.87 16.81 16.87 16.89 
PC 37:6 16.05 16.18 16.21 16.34 15.91 16.26  16.14 16.28 16.25 16.16 16.38 16.32 
PC 37:7 14.73 14.67 14.67 14.52 14.37 14.42  14.77 14.36 14.61 14.37 14.75 14.43 
PC 38:1 15.85 15.71 15.46 15.23 15.35 15.49  15.78 15.58 15.56 15.52 15.65 15.60 
PC 38:2 16.87 16.86 16.69 16.30 16.41 16.53  16.88 16.83 16.60 16.52 16.65 16.55 
PC 38:3 22.03 22.08 21.77 21.46 21.55 21.39  22.33 22.22 22.40 22.24 22.37 22.26 
PC 38:4 23.05 23.19 23.14 23.15 23.02 23.06  23.34 23.35 23.43 23.38 23.45 23.37 
PC 38:5 22.23 22.15 22.01 22.00 21.92 21.92  22.36 22.27 22.42 22.38 22.54 22.35 
PC 38:6 23.02 23.14 22.96 22.98 22.94 22.89  23.18 23.14 23.31 23.28 23.49 23.36 
PC 38:7 17.97 17.79 17.60 17.57 17.50 17.43  17.92 17.69 17.94 17.86 17.99 17.91 
PC 39:3 14.48 14.69 14.45 14.52 14.58 14.58  14.90 14.84 14.70 14.81 14.73 14.77 
PC 39:4 16.09 16.06 16.10 16.29 16.09 15.99  16.39 16.37 16.40 16.34 16.39 16.26 
PC 39:6 16.77 16.82 16.83 16.87 16.94 16.97  17.05 17.03 17.22 17.12 17.28 17.26 
PC 39:7 13.64 13.52 13.65 13.33 13.51 13.52  13.67 13.49 14.13 14.05 14.10 13.73 
PC 39:8 13.58 13.45 13.59 13.59 13.53 13.57  13.47 13.50 13.62 13.73 13.70 13.49 
PC 40:0 11.55 11.52 11.05 11.17 10.81 11.35  12.00 11.79 11.63 11.67 11.45 11.41 
PC 40:1 13.22 13.10 12.95 12.87 12.57 12.98  13.07 13.07 12.95 12.94 12.85 12.91 
PC 40:2 14.44 14.16 13.75 13.91 13.81 13.82  14.06 13.90 13.84 13.68 13.87 13.67 
PC 40:4 16.12 16.05 16.00 15.84 15.62 15.85  16.26 16.18 16.24 16.25 16.40 16.25 
PC 40:5 16.70 16.70 16.49 16.44 16.22 16.35  16.91 16.85 17.06 16.95 17.19 17.29 
PC 40:6 20.42 20.55 20.44 20.39 20.41 20.35  20.62 20.58 20.89 20.74 21.03 20.98 
PC 40:7 15.88 15.90 15.74 15.48 15.47 15.53  16.12 15.87 16.16 15.83 16.04 15.96 
PC 40:8 17.28 17.42 17.82 17.19 16.63 17.03  17.99 17.78 18.49 17.62 17.69 17.59 
PC 41:3 13.16 13.25 13.16 13.28 13.26 13.02  13.19 13.04 13.29 13.23 13.03 13.01 
PC 41:4 13.48 13.10 13.33 13.33 13.27 13.27  13.10 13.20 13.17 13.25 13.34 12.97 
PC 41:5 13.16 13.33 13.49 13.51 13.54 13.32  13.51 13.57 13.65 13.53 13.79 13.66 
PC 41:6 13.22 13.26 13.14 13.42 13.52 13.54  13.27 13.71 13.92 13.85 14.02 13.93 
PC 41:7 11.96 11.69 12.03 11.82 11.91 11.99  12.38 11.90 12.13 12.16 12.00 12.33 
PC 42:1 13.10 13.01 12.66 12.38 12.25 12.40  13.25 13.05 13.14 12.69 12.94 12.97 
PC 42:10 15.39 15.21 15.26 15.00 15.01 15.13  15.25 15.15 15.38 15.20 15.49 15.38 
PC 42:2 14.01 13.86 13.47 13.33 13.21 13.12  13.85 13.65 13.60 13.41 13.40 13.30 
PC 42:3 13.30 13.51 12.87 13.08 13.04 12.63  13.28 13.10 13.26 13.23 13.26 13.06 
PC 42:4 14.03 13.61 13.57 13.44 13.53 13.47  13.82 13.91 13.82 13.95 13.97 13.77 
PC 42:5 14.98 14.58 14.59 14.68 14.30 14.39  14.97 14.93 14.85 14.97 14.97 14.93 
PC 42:6 14.90 14.89 14.85 14.45 14.13 14.34  15.25 14.82 15.25 15.26 15.28 15.29 
PC 42:7 14.79 14.64 14.28 14.54 14.02 14.53  14.76 14.86 15.01 14.63 14.87 14.78 
PC 42:8 14.30 14.24 14.09 13.86 13.84 13.69  14.40 14.40 14.56 14.55 14.65 14.43 
PC 42:9 14.93 14.84 14.74 14.65 14.62 14.76  15.17 14.71 15.33 15.17 15.29 15.40 
PC 44:12 12.15 11.79 11.85 11.65 12.06 11.83  12.46 11.90 12.27 12.05 12.34 12.19 
PC 44:2 12.72 12.88 12.17 12.03 12.10 12.12  12.50 11.99 12.26 12.19 12.57 12.35 
PC 44:3 11.89 11.71 11.53 11.55 11.22 10.86  11.68 11.97 12.07 11.67 11.64 11.98 
PC 44:4 13.05 12.69 12.68 12.35 12.52 12.51  12.98 12.97 13.14 12.90 12.82 12.84 
PC 44:5 12.45 12.40 11.92 12.25 12.02 11.99  12.45 12.29 12.76 12.35 12.65 12.72 
PC 44:6 12.16 12.02 11.62 11.87 11.70 11.43  12.14 11.90 11.75 11.97 11.77 11.60 
PC 44:8 11.69 12.04 11.98 11.82 12.00 12.18  11.53 11.65 11.74 11.29 11.91 11.36 
PC 46:4 11.96 11.91 11.62 10.84 11.36 11.10  12.26 11.40 12.10 12.10 12.04 11.69 
PE 30:0 12.29 12.39 13.03 12.49 13.20 12.15  12.01 11.99 12.31 12.03 12.46 12.23 
PE 32:0 15.18 15.27 15.46 15.51 15.34 15.22  14.86 14.98 15.45 15.15 15.31 15.13 
PE 32:1 15.33 14.79 14.68 14.86 14.59 14.79  14.76 14.70 15.65 15.41 15.58 15.29 
PE 32:2 12.66 13.12 12.25 12.94 13.50 12.98  12.67 12.06 12.44 12.15 12.32 12.44 
PE 33:0 13.35 13.43 13.61 13.66 13.34 13.44  13.56 13.46 13.61 13.63 13.59 13.52 
PE 33:1 13.32 13.16 12.93 13.13 13.40 12.81  13.76 13.28 13.82 13.30 13.57 13.83 
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Table S2.5F: MEAL Study Mean Log2 Area under the Curve for Lipids 
(Phosphatidylethanolamine 33:2 to Plasmenyl-phosphatidylcholine 34:0) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet  High Carb Diet 
Lipid/Day B S 2.00 7.00 14.00 21.00  B S 2.00 7.00 14.00 21.00 
PE 33:2 14.69 14.77 15.15 14.83 14.92 14.77  14.39 14.54 14.69 14.54 14.49 14.19 
PE 34:0 19.98 19.87 19.91 20.00 19.91 19.92  20.01 19.88 20.02 19.95 19.95 19.96 
PE 34:1 18.75 18.46 18.30 18.08 18.09 18.27  18.40 18.29 18.78 18.54 18.76 18.63 
PE 34:2 19.60 19.61 19.53 19.63 19.65 19.60  19.41 19.57 19.73 19.55 19.63 19.48 
PE 34:3 17.79 17.41 17.45 17.42 17.38 17.20  17.23 17.27 17.68 17.47 17.61 17.50 
PE 34:4 13.55 13.44 13.11 13.14 12.85 13.39  13.17 13.45 13.63 12.79 13.46 13.51 
PE 35:0 13.79 13.37 13.44 13.49 13.56 13.57  13.87 13.61 13.66 13.60 13.67 13.40 
PE 35:1 14.61 14.72 14.60 14.40 14.51 14.67  14.68 14.54 14.84 14.58 14.56 14.33 
PE 35:2 15.85 15.79 15.80 15.66 15.84 15.91  15.67 15.60 15.84 15.76 15.76 15.70 
PE 35:4 15.05 15.34 15.10 15.31 15.43 15.42  15.13 15.35 15.23 15.26 15.23 15.00 
PE 36:0 16.68 16.44 16.62 16.58 16.26 16.50  16.75 16.64 16.68 16.60 16.69 16.64 
PE 36:1 18.65 18.26 18.15 18.01 18.12 18.18  18.33 18.11 18.24 18.17 18.31 18.27 
PE 36:2 20.85 20.69 20.64 20.52 20.64 20.57  20.59 20.54 20.56 20.32 20.45 20.34 
PE 36:3 20.01 19.84 19.79 19.75 19.78 19.73  19.61 19.57 19.55 19.45 19.51 19.35 
PE 36:4 19.91 19.87 19.83 19.84 19.80 19.89  20.07 20.11 20.41 20.26 20.43 20.22 
PE 36:5 17.76 17.39 17.49 17.31 17.52 17.26  17.59 17.32 17.87 17.86 17.99 17.79 
PE 37:4 16.34 16.46 16.44 16.26 16.49 16.53  16.62 16.48 16.67 16.53 16.58 16.50 
PE 38:3 18.63 18.50 18.69 18.53 18.14 18.47  18.85 18.67 18.77 18.57 18.75 18.54 
PE 38:4 21.50 21.59 21.53 21.29 21.38 21.57  21.73 21.77 21.83 21.59 21.81 21.61 
PE 38:5 20.28 20.34 20.25 20.00 20.02 20.17  20.35 20.36 20.53 20.29 20.50 20.25 
PE 38:6 20.64 20.61 20.59 20.42 20.41 20.57  20.45 20.54 20.66 20.60 20.90 20.67 
PE 38:7 15.06 15.09 14.89 14.88 14.74 14.88  15.07 15.21 15.22 15.07 15.13 15.05 
PE 40:4 17.32 17.40 17.31 17.22 17.10 17.34  17.55 17.54 17.60 17.37 17.55 17.44 
PE 40:5 18.08 18.12 18.05 17.84 17.79 17.98  18.16 18.16 18.36 18.25 18.50 18.15 
PE 40:6 19.12 19.24 19.17 19.02 18.99 19.10  19.07 19.05 19.40 19.22 19.54 19.38 
PE 40:7 17.44 17.41 17.24 17.06 17.17 17.35  17.52 17.46 17.58 17.29 17.55 17.46 
PE 40:8 16.27 16.25 16.05 15.83 16.20 16.29  16.25 16.24 16.26 16.04 16.32 16.08 
PE 42:10 13.70 13.78 13.73 12.98 13.81 13.83  13.56 13.55 13.71 13.40 13.78 13.70 
PG 33:0 15.05 15.51 15.62 15.11 14.87 15.05  15.50 15.48 15.43 15.24 15.28 15.38 
PG 34:0 18.97 19.19 19.48 18.77 19.11 19.17  19.11 18.91 19.18 18.65 19.15 18.95 
PG 34:2 13.10 13.19 13.29 12.30 12.49 12.76  13.13 13.58 13.58 13.28 13.67 13.22 
PG 36:0 16.53 16.40 16.60 16.32 16.07 16.35  16.59 16.58 16.53 16.32 16.30 16.36 
PG 36:2 16.20 16.39 16.30 15.56 15.86 15.81  16.15 16.36 16.71 16.24 16.31 16.20 
PG 36:3 14.26 14.49 14.43 13.94 13.67 13.96  14.37 14.49 14.57 14.22 14.56 14.21 
PG 38:4 13.60 14.06 13.75 13.36 13.62 13.82  13.77 14.09 14.04 13.73 13.93 13.71 
PI 25:0 13.85 13.95 14.40 13.74 13.43 13.97  14.41 14.06 14.64 13.86 13.96 13.90 
PI 34:1 15.72 15.85 16.11 14.92 15.49 15.51  16.04 15.98 16.45 15.49 15.75 15.54 
PI 34:2 15.87 16.22 16.35 15.56 15.55 15.52  16.22 16.34 16.70 15.62 16.00 15.71 
PI 36:1 16.15 16.04 16.61 15.46 15.83 16.07  16.46 16.14 16.20 15.58 15.72 15.71 
PI 36:2 18.73 18.84 19.11 18.14 18.42 18.42  18.81 18.72 18.94 17.99 18.37 18.17 
PI 36:4 16.00 16.40 16.55 15.50 15.74 15.86  16.72 16.70 17.25 16.24 16.60 16.18 
PI 38:3 18.79 19.07 19.34 18.53 18.35 18.65  19.47 19.37 19.93 18.96 19.24 19.06 
PI 38:4 20.44 20.70 20.93 20.03 20.27 20.43  20.81 20.77 21.15 20.19 20.61 20.39 
PI 38:5 16.00 16.08 16.33 15.46 15.64 15.77  16.46 16.47 17.02 15.96 16.30 15.93 
PI 38:6 13.43 13.16 13.87 12.77 12.70 12.93  13.87 13.67 14.43 13.33 13.75 13.39 
PI 40:5 16.07 16.14 16.41 15.42 15.66 15.82  16.26 16.27 16.78 15.79 16.36 16.20 
PI 40:6 15.24 15.47 15.81 14.74 15.03 15.13  15.49 15.48 15.94 15.21 15.87 15.53 
PlsCho 24:0 12.55 12.53 12.30 12.12 12.14 11.89  12.61 12.24 12.60 12.36 12.58 12.46 
PlsCho 28:0 9.88 10.91 10.85 10.89 11.13 10.85  10.90 10.45 10.47 10.55 10.61 10.43 
PlsCho 32:0 16.46 16.79 16.58 16.67 15.81 16.47  16.35 16.10 16.38 16.41 15.64 16.02 
PlsCho 32:1 13.55 13.36 13.78 13.70 14.08 13.76  13.55 13.21 13.27 13.57 13.19 12.99 
PlsCho 33:0 13.23 13.86 14.10 14.35 14.13 14.20  14.35 14.15 13.94 14.05 14.17 13.96 
PlsCho 34:0 19.39 19.35 19.31 19.20 19.13 19.11  19.46 19.40 19.31 19.10 19.26 19.12 
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Table S2.5G: MEAL Study Mean Log2 Area under the Curve for Lipids (Plasmenyl-
phosphatidylcholine 34:1 to Plasmenyl-phosphatidylethanolamine 34:1) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet  High Carb Diet 
Lipid/Day B S 2.00 7.00 14.00 21.00  B S 2.00 7.00 14.00 21.00 
PlsCho 34:1 18.42 18.39 18.35 18.32 18.26 18.23  18.59 18.48 18.40 18.27 18.39 18.25 
PlsCho 34:2 20.07 20.08 20.09 20.04 20.15 20.17  20.24 20.09 19.93 19.84 19.86 19.68 
PlsCho 34:3 15.20 14.68 15.11 15.10 15.26 15.30  15.35 14.72 14.98 15.02 14.82 14.80 
PlsCho 35:0 14.53 14.66 14.86 15.06 14.65 14.84  13.95 13.78 13.83 14.34 14.51 13.71 
PlsCho 35:1 17.14 16.81 16.63 17.22 16.80 16.99  16.56 16.47 16.38 16.82 16.38 16.50 
PlsCho 35:2 13.32 13.11 13.19 13.34 13.36 13.49  13.42 13.43 13.23 13.26 13.09 13.21 
PlsCho 35:3 14.33 13.98 14.15 14.05 14.33 14.89  14.60 13.87 14.17 14.33 14.08 14.20 
PlsCho 35:4 14.77 14.64 15.32 14.66 14.97 15.23  15.00 14.58 14.97 14.32 14.97 14.76 
PlsCho 36:0 15.82 15.84 15.48 15.31 16.00 15.72  15.85 15.79 15.66 15.18 15.52 15.34 
PlsCho 36:2 18.34 18.10 18.34 18.29 18.30 18.36  18.61 18.55 18.31 18.25 18.28 18.24 
PlsCho 36:3 20.85 20.96 20.99 21.02 20.96 21.05  20.96 20.97 20.76 20.75 20.81 20.63 
PlsCho 36:4 20.17 20.22 20.21 20.21 20.22 20.33  20.55 20.41 20.31 20.26 20.30 20.09 
PlsCho 36:5 15.97 15.65 15.99 15.92 15.94 16.13  16.34 15.78 15.80 15.90 16.00 15.87 
PlsCho 36:6 13.81 13.78 14.20 14.19 14.21 14.21  14.22 14.09 13.91 13.77 14.12 14.19 
PlsCho 37:1 12.45 12.38 12.08 12.58 11.98 12.02  12.32 11.92 12.12 11.96 12.05 12.20 
PlsCho 37:2 12.85 12.85 13.06 12.65 12.79 12.81  12.59 12.81 12.45 12.85 12.38 12.54 
PlsCho 37:3 16.35 16.26 16.39 16.59 16.66 16.80  16.64 16.50 16.53 16.46 16.55 16.27 
PlsCho 37:4 16.06 15.95 16.17 16.48 16.53 16.75  16.78 16.32 16.28 16.37 16.57 16.01 
PlsCho 37:6 17.24 17.37 17.66 17.61 17.45 17.62  17.84 17.59 17.47 17.33 17.51 17.33 
PlsCho 38:0 13.54 13.71 13.87 13.55 13.60 13.72  13.59 13.66 13.77 13.25 13.77 13.62 
PlsCho 38:1 15.01 15.16 14.79 15.06 15.06 15.06  15.11 14.81 14.99 14.76 14.83 14.78 
PlsCho 38:3 20.02 20.13 20.14 20.21 20.29 20.27  20.22 20.19 20.10 19.95 20.00 19.83 
PlsCho 38:4 20.31 20.26 19.90 20.24 20.10 20.26  20.32 20.20 20.15 20.01 20.05 19.76 
PlsCho 38:5 19.19 19.13 19.21 19.20 19.12 19.31  19.32 19.20 19.06 19.12 19.19 19.04 
PlsCho 38:6 17.53 17.50 17.47 17.60 17.59 17.68  17.76 17.63 17.44 17.58 17.67 17.45 
PlsCho 39:3 17.20 16.81 16.92 17.14 16.98 17.07  16.98 16.73 16.80 16.63 16.59 16.87 
PlsCho 39:4 16.14 15.98 15.83 16.17 15.95 16.00  15.92 15.79 15.71 16.06 16.06 15.71 
PlsCho 39:5 16.62 16.37 16.22 16.72 16.49 16.50  16.09 16.01 15.92 16.32 15.92 16.07 
PlsCho 39:6 13.24 13.22 13.49 13.89 13.65 13.96  14.27 13.63 13.84 13.55 13.99 13.72 
PlsCho 40:0 14.37 14.51 14.34 14.25 13.97 14.09  14.46 14.59 14.47 14.42 14.40 14.14 
PlsCho 40:1 15.01 15.03 14.99 14.89 14.62 14.68  14.99 14.97 14.97 14.50 14.77 14.62 
PlsCho 40:3 17.52 17.62 17.61 17.63 17.74 17.78  17.55 17.60 17.55 17.26 17.36 17.31 
PlsCho 40:4 18.42 18.47 18.40 18.37 18.28 18.28  18.33 18.26 18.28 18.20 18.28 18.17 
PlsCho 40:5 17.67 17.59 17.82 17.99 17.87 17.95  17.89 17.81 17.75 17.57 17.62 17.72 
PlsCho 40:6 17.35 17.34 17.41 17.34 17.18 17.24  17.40 17.31 17.14 17.18 17.40 17.23 
PlsCho 42:1 15.38 15.31 15.40 15.19 15.17 14.99  15.63 15.57 15.50 15.17 15.41 15.25 
PlsCho 42:2 15.92 16.14 16.03 15.90 15.72 15.67  15.94 16.02 15.90 15.71 15.75 15.66 
PlsCho 42:3 16.72 16.98 16.79 16.65 16.74 16.64  16.69 16.70 16.78 16.17 16.56 16.44 
PlsCho 42:4 17.39 17.47 17.40 17.32 17.11 17.14  17.41 17.33 17.46 17.24 17.36 17.37 
PlsCho 42:5 16.76 16.82 16.80 16.93 16.34 16.59  16.48 16.69 16.54 16.41 16.59 16.51 
PlsCho 42:6 15.54 16.05 15.78 15.78 15.26 15.40  15.76 15.69 15.64 15.44 15.75 15.50 
PlsCho 44:3 15.53 15.59 15.52 15.72 15.51 15.30  15.90 15.90 16.03 15.97 15.96 15.79 
PlsCho 44:4 17.79 17.93 17.82 17.78 17.49 17.40  17.81 17.89 17.75 17.67 17.90 17.76 
PlsCho 44:5 16.94 16.90 16.70 16.90 16.09 16.54  17.21 17.19 16.97 16.69 17.28 17.12 
PlsCho 44:6 15.84 15.67 15.62 15.43 15.50 15.19  15.48 15.63 15.63 15.47 15.67 15.63 
PlsCho 46:4 15.05 15.11 14.98 15.04 14.66 14.41  15.18 15.18 15.26 15.15 15.38 15.21 
PlsEth 32:0 14.30 14.38 14.40 14.22 13.90 14.24  14.27 14.45 14.30 14.20 14.20 14.09 
PlsEth 32:1 14.36 14.49 14.63 14.62 14.67 14.46  14.57 14.61 14.21 14.31 14.35 14.14 
PlsEth 32:2 13.91 14.48 15.09 15.10 14.95 14.99  14.18 14.69 13.56 13.37 13.09 12.92 
PlsEth 33:1 13.29 13.03 13.96 13.99 13.93 13.91  13.71 13.72 13.29 12.84 12.86 12.96 
PlsEth 33:2 13.32 13.90 14.28 14.46 14.32 14.24  13.79 14.10 12.87 12.98 12.87 12.75 
PlsEth 34:0 16.56 16.32 16.29 16.19 15.91 16.01  16.41 16.24 15.95 15.99 15.98 15.89 
PlsEth 34:1 18.55 18.66 18.68 18.45 18.25 18.43  18.54 18.57 18.23 18.11 18.23 18.11 
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Table S2.5H: MEAL Study Mean Log2 Area under the Curve for Lipids (Plasmenyl-
phosphatidylethanolamine 34:2 to Sphingomyelin 35:2) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet  High Carb Diet 
Lipid/Day B S 2.00 7.00 14.00 21.00  B S 2.00 7.00 14.00 21.00 
PlsEth 34:2 19.72 19.97 20.01 19.87 19.81 19.80  19.83 19.94 19.51 19.32 19.35 19.31 
PlsEth 34:3 15.16 15.37 15.63 15.55 15.58 15.59  15.41 15.38 14.80 14.89 14.91 14.88 
PlsEth 34:4 15.18 15.45 16.04 15.99 16.05 16.30  15.93 15.83 15.05 15.07 14.99 15.08 
PlsEth 35:1 14.73 14.76 15.03 14.77 15.05 14.88  14.95 14.87 14.65 14.59 14.61 14.43 
PlsEth 35:2 12.87 12.51 13.26 13.51 13.41 13.45  13.46 13.16 12.28 12.49 12.53 12.54 
PlsEth 35:4 15.13 15.33 15.93 16.04 16.00 16.24  15.87 15.64 15.03 15.13 15.11 15.13 
PlsEth 36:0 15.70 15.54 15.64 15.45 15.28 15.34  15.61 15.51 15.59 15.56 15.31 15.35 
PlsEth 36:1 18.74 18.68 18.83 18.63 18.62 18.71  18.81 18.79 18.27 18.14 18.21 18.09 
PlsEth 36:2 20.24 20.35 20.50 20.33 20.36 20.36  20.33 20.34 19.73 19.63 19.56 19.53 
PlsEth 36:3 20.53 20.70 20.77 20.60 20.43 20.62  20.63 20.70 20.31 20.27 20.34 20.22 
PlsEth 36:4 21.91 22.26 22.10 21.95 21.85 22.06  22.14 22.29 22.03 21.86 22.14 21.98 
PlsEth 36:5 17.97 18.11 18.35 18.30 18.16 18.28  18.22 18.16 17.51 17.73 17.85 17.96 
PlsEth 36:6 14.49 14.69 15.08 15.13 15.06 15.17  15.00 14.96 14.50 14.71 14.63 14.48 
PlsEth 37:1 15.66 15.29 15.45 15.60 15.02 15.37  15.13 14.85 15.01 15.08 14.74 14.63 
PlsEth 37:2 14.40 14.33 14.38 14.12 14.41 14.50  14.61 14.72 14.14 13.98 14.22 13.88 
PlsEth 37:3 15.73 15.71 16.00 16.01 15.87 16.12  16.28 15.92 15.73 15.93 15.80 15.81 
PlsEth 37:4 18.21 18.36 18.58 18.51 18.62 18.88  18.98 18.77 18.44 18.50 18.62 18.43 
PlsEth 37:5 15.75 15.74 16.25 16.34 16.31 16.32  16.33 16.05 15.75 15.92 15.90 15.82 
PlsEth 37:6 15.51 15.62 16.09 16.12 16.13 16.24  15.77 15.79 15.34 15.32 15.22 15.23 
PlsEth 38:1 15.64 15.70 15.77 15.51 15.39 15.51  15.77 15.97 15.37 15.25 15.47 15.26 
PlsEth 38:2 17.67 17.85 17.90 17.63 17.55 17.56  17.88 17.93 17.53 17.44 17.40 17.38 
PlsEth 38:3 19.75 19.96 20.09 20.05 19.75 20.00  20.20 20.14 19.78 19.84 19.75 19.69 
PlsEth 38:4 22.16 22.37 22.37 22.27 22.27 22.46  22.63 22.56 22.32 22.24 22.35 22.15 
PlsEth 38:5 22.14 22.29 22.30 22.14 22.08 22.30  22.35 22.35 22.08 22.03 22.19 22.05 
PlsEth 38:6 21.18 21.35 21.39 21.30 21.16 21.32  21.44 21.45 21.18 21.09 21.26 21.16 
PlsEth 39:2 14.94 14.42 14.54 14.83 14.10 14.42  14.23 14.24 14.20 14.08 14.19 14.32 
PlsEth 39:4 16.42 16.43 16.55 16.42 16.63 16.75  16.90 16.86 16.57 16.57 16.70 16.43 
PlsEth 39:5 16.67 16.68 17.04 16.90 16.88 17.06  16.98 16.88 16.61 16.70 16.66 16.64 
PlsEth 39:6 17.08 16.93 17.10 17.13 17.12 17.32  17.41 17.11 17.08 17.03 17.14 17.12 
PlsEth 40:1 12.89 13.21 12.97 12.78 12.64 12.73  13.60 13.55 13.38 13.07 13.09 12.90 
PlsEth 40:2 15.56 15.67 15.58 15.60 15.08 15.24  15.74 15.92 15.49 15.12 15.41 15.20 
PlsEth 40:4 20.00 20.24 20.22 20.08 19.97 20.34  20.37 20.47 20.19 20.04 20.29 20.04 
PlsEth 40:5 19.85 20.05 20.05 19.99 19.85 20.11  20.11 20.09 19.87 19.67 19.84 19.73 
PlsEth 40:6 20.19 20.31 20.36 20.40 20.34 20.50  20.66 20.58 20.41 20.21 20.29 20.27 
PlsEth 41:4 13.89 13.81 13.93 13.88 13.81 14.14  14.38 14.23 14.27 14.10 14.34 13.97 
PlsEth 41:6 14.65 14.37 14.57 14.36 14.55 14.42  14.74 14.71 14.43 14.71 14.63 14.40 
PlsEth 42:4 16.94 16.92 17.12 16.56 16.72 16.76  17.37 17.38 16.94 16.90 17.26 16.72 
PlsEth 42:5 17.39 17.48 17.56 17.41 17.10 17.50  17.63 17.67 17.51 17.36 17.69 17.41 
PlsEth 42:6 12.68 13.23 13.03 12.95 13.14 13.30  13.15 13.12 13.15 13.25 13.42 12.97 
PlsEth 44:6 15.32 15.19 15.56 14.84 14.66 14.86  15.70 15.31 15.00 15.16 15.44 15.47 
PS 36:1 16.33 16.12 16.57 16.00 15.80 16.14  16.25 15.96 16.10 15.82 15.94 15.94 
PS 38:4 15.97 15.96 16.33 15.50 15.68 16.43  15.90 15.81 16.08 15.45 15.67 15.44 
SM 30:1 14.65 14.65 14.88 14.73 14.77 14.76  14.85 14.98 14.79 14.53 14.68 14.37 
SM 30:2 12.13 12.07 12.38 12.53 12.37 12.30  12.13 12.09 11.88 11.72 12.10 11.54 
SM 32:0 14.72 14.84 14.96 15.12 15.00 14.99  15.19 15.08 15.03 14.68 14.86 14.59 
SM 32:1 18.89 19.05 19.08 19.03 19.07 19.12  19.18 19.26 19.14 18.98 19.04 18.88 
SM 32:2 16.50 16.59 16.55 16.63 16.52 16.48  16.75 16.70 16.76 16.58 16.62 16.46 
SM 33:1 17.84 18.02 18.04 17.93 17.99 18.12  18.16 18.27 18.14 17.96 18.05 17.86 
SM 34:0 17.32 17.53 17.44 17.57 17.03 17.38  17.62 17.50 17.45 17.43 17.37 17.28 
SM 34:1 23.37 23.52 23.55 23.46 23.48 23.46  23.51 23.49 23.53 23.32 23.46 23.34 
SM 34:2 20.78 20.94 20.87 20.81 20.78 20.70  20.96 20.98 20.93 20.70 20.87 20.71 
SM 34:3 14.84 14.40 14.82 14.83 14.51 14.61  14.69 14.81 14.58 14.55 14.74 14.64 
SM 35:2 15.32 15.61 15.43 15.40 15.32 15.46  15.38 15.33 15.29 15.04 15.52 15.21 
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Table S2.5I: MEAL Study Mean Log2 Area under the Curve for Lipids (Sphingomyelin 36:1 to 
Triacylglycerol 43:1) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet  High Carb Diet 
Lipid/Day B S 2.00 7.00 14.00 21.00  B S 2.00 7.00 14.00 21.00 
SM 36:1 20.90 21.07 21.19 21.25 21.22 21.22  21.08 21.13 21.11 20.95 21.17 21.05 
SM 36:2 20.44 20.69 20.80 20.71 20.69 20.75  20.49 20.49 20.55 20.35 20.62 20.49 
SM 36:3 15.12 15.29 15.41 15.15 15.27 15.32  15.24 15.25 15.12 14.88 15.13 14.82 
SM 36:4 15.46 15.42 15.36 15.51 15.33 15.44  15.53 15.53 15.38 15.52 15.34 15.20 
SM 37:1 16.77 16.94 17.13 17.41 17.31 17.39  16.95 17.07 16.99 16.93 17.04 16.93 
SM 37:2 15.31 15.27 15.63 15.71 15.53 15.64  15.14 15.47 15.48 15.37 15.39 15.36 
SM 38:0 12.47 12.44 11.38 11.96 12.23 11.90  11.46 11.97 12.33 11.58 12.12 12.17 
SM 38:1 20.60 20.62 20.69 20.65 20.65 20.66  21.00 20.98 20.87 20.61 20.76 20.57 
SM 38:2 15.89 15.98 15.90 15.83 15.74 15.85  16.04 16.20 16.01 15.93 16.03 15.86 
SM 38:3 14.97 15.13 15.10 15.19 15.03 15.15  15.22 15.09 15.24 15.18 15.18 15.05 
SM 38:4 14.31 14.58 14.31 14.60 14.29 14.27  14.02 13.97 13.79 13.86 14.07 13.88 
SM 39:0 15.27 15.21 15.37 15.59 15.49 15.45  15.26 15.28 15.07 15.09 15.04 14.73 
SM 39:1 17.48 17.55 17.65 17.63 17.50 17.61  17.66 17.67 17.50 17.32 17.34 17.11 
SM 39:2 16.43 16.45 16.43 16.59 16.54 16.62  16.63 16.50 16.50 16.33 16.43 16.27 
SM 39:3 15.39 15.37 15.38 15.86 15.51 15.76  15.31 15.15 15.01 15.18 14.94 14.81 
SM 40:1 20.50 20.59 20.57 20.57 20.54 20.55  20.65 20.66 20.53 20.24 20.26 20.07 
SM 40:2 21.28 21.38 21.27 21.24 21.26 21.22  21.35 21.31 21.27 21.10 21.22 21.02 
SM 40:3 17.24 17.43 17.50 17.52 17.43 17.48  17.36 17.37 17.39 17.38 17.59 17.42 
SM 40:5 13.59 13.20 13.37 13.44 13.02 13.40  13.33 13.17 13.42 13.19 13.48 13.23 
SM 41:1 19.59 19.74 19.79 19.92 19.88 19.86  19.82 19.87 19.74 19.50 19.58 19.42 
SM 41:2 18.14 18.18 18.23 18.15 17.94 18.10  18.17 18.37 18.24 18.10 18.23 18.02 
SM 41:3 16.79 16.81 16.90 17.02 16.71 16.98  16.93 16.92 16.96 17.02 17.11 16.94 
SM 41:4 15.18 15.31 15.13 15.54 15.17 15.12  14.91 15.00 14.81 14.71 14.75 14.63 
SM 41:6 10.71 11.32 10.72 9.95 10.88 10.43  10.20 10.22 10.54 9.75 10.73 9.57 
SM 42:1 20.56 20.67 20.60 20.62 20.51 20.49  20.72 20.73 20.64 20.36 20.41 20.21 
SM 42:2 21.26 21.39 21.33 21.28 21.09 21.12  21.30 21.30 21.29 21.19 21.44 21.30 
SM 42:3 21.37 21.52 21.38 21.36 21.31 21.21  21.35 21.28 21.39 21.35 21.55 21.41 
SM 42:4 17.60 17.70 17.72 17.69 17.43 17.53  17.74 17.80 17.90 17.90 18.10 17.99 
SM 42:5 14.93 15.13 15.28 15.11 15.00 15.00  15.06 15.22 15.08 15.13 15.47 15.35 
SM 42:6 14.01 14.51 14.21 14.28 14.35 14.35  14.17 14.34 14.16 14.19 14.48 14.05 
SM 43:1 15.35 15.78 15.83 15.90 15.79 15.83  15.91 16.05 15.76 15.44 15.71 15.43 
SM 43:2 16.87 17.07 17.19 17.30 17.25 17.17  17.03 17.14 17.07 16.99 17.17 17.04 
SM 43:3 15.07 15.22 15.34 15.40 15.35 15.25  15.14 15.20 15.05 15.17 15.39 15.19 
SM 43:6 13.01 12.47 13.07 13.33 13.44 13.05  12.94 12.95 12.68 12.94 12.85 12.67 
SM 43:8 14.20 14.24 14.28 13.37 14.04 13.78  14.22 13.76 14.06 13.99 14.51 14.30 
SM 44:1 13.69 13.95 13.94 13.95 13.96 13.98  13.95 14.02 13.92 13.76 13.96 13.67 
SM 44:2 14.79 14.87 14.81 14.96 14.66 14.76  14.89 14.96 14.82 14.81 14.92 14.94 
SM 44:3 14.44 14.96 14.26 14.63 14.38 14.50  14.15 14.51 14.17 14.44 14.46 14.51 
SM 44:5 13.51 13.83 12.94 13.46 13.35 12.92  13.70 13.35 13.64 13.70 14.24 13.17 
SM 44:6 12.12 12.30 12.21 12.19 11.58 12.06  12.55 12.34 12.72 12.30 12.51 12.40 
SM 45:7 11.98 11.56 11.55 11.70 11.36 11.66  11.27 11.20 11.77 10.98 11.18 11.72 
TG 36:0 13.24 12.67 13.43 13.55 14.05 13.33  12.42 12.44 12.77 12.59 12.88 12.67 
TG 38:0 13.57 13.08 14.12 14.14 14.82 13.75  12.64 12.69 12.99 13.09 13.26 12.95 
TG 39:0 12.31 11.61 12.27 12.15 12.32 12.14  11.88 11.65 11.72 11.81 11.94 11.53 
TG 40:0 13.76 13.49 14.80 14.78 15.53 14.33  13.00 12.90 13.80 13.60 13.66 13.38 
TG 40:1 13.55 12.86 13.53 13.90 14.56 13.64  12.03 12.20 12.81 13.06 12.93 12.79 
TG 41:0 11.88 11.34 12.32 12.53 12.93 12.02  11.05 11.02 11.41 11.69 11.60 11.39 
TG 42:0 14.71 14.26 15.40 15.64 16.23 15.29  13.54 13.81 14.64 14.69 14.53 14.30 
TG 42:1 14.87 14.33 15.22 15.09 15.91 14.92  13.65 13.59 14.75 14.58 14.35 14.19 
TG 42:2 13.97 13.98 14.59 14.69 15.53 14.26  12.85 13.12 13.55 13.70 13.53 13.42 
TG 42:3 12.75 12.36 12.64 12.34 13.33 12.28  11.34 11.84 11.79 12.32 11.96 11.73 
TG 43:0 12.18 12.07 12.89 13.24 13.59 12.94  11.68 11.91 12.22 12.24 12.02 12.11 
TG 43:1 12.62 12.18 12.86 12.92 13.38 12.97  11.87 11.77 12.58 12.53 12.50 12.28 
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Table S2.5J: MEAL Study Mean Log2 Area under the Curve for Lipids (Triacylglycerol 43:2 to 
Triacylglycerol 53:5) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet  High Carb Diet 
Lipid/Day B S 2.00 7.00 14.00 21.00  B S 2.00 7.00 14.00 21.00 
TG 43:2 12.24 11.68 12.10 11.61 12.71 11.88  11.03 11.55 12.21 11.50 11.68 11.46 
TG 44:0 15.05 14.65 15.66 15.93 16.64 15.63  14.34 14.35 15.18 15.18 15.15 14.95 
TG 44:1 16.21 15.69 16.32 16.48 17.13 16.39  15.23 15.30 16.38 16.29 16.14 15.98 
TG 44:2 15.77 15.55 16.06 16.15 16.77 15.86  14.69 15.10 15.55 15.57 15.50 15.29 
TG 44:3 14.40 14.10 14.51 14.46 15.13 14.23  13.28 13.57 13.87 14.03 13.87 13.71 
TG 45:0 12.59 12.20 13.08 13.45 14.02 13.59  12.35 12.30 12.85 13.05 12.87 12.80 
TG 45:1 13.50 12.91 13.63 13.99 14.39 13.89  13.07 12.71 13.54 13.54 13.49 13.49 
TG 45:2 13.33 13.05 13.46 13.49 14.09 13.45  12.59 12.85 13.34 13.20 13.26 13.11 
TG 46:0 16.32 15.60 16.34 16.55 16.91 16.56  15.11 15.26 16.36 16.44 16.20 16.20 
TG 46:1 17.49 16.95 17.37 17.58 18.22 17.32  16.72 16.69 17.83 17.64 17.58 17.43 
TG 46:2 17.45 17.24 17.54 17.57 18.28 17.38  16.67 16.90 17.87 17.56 17.59 17.38 
TG 46:3 16.26 16.07 16.21 16.27 16.87 16.01  15.41 15.72 16.32 16.08 16.21 16.01 
TG 47:0 13.66 13.05 13.74 14.07 14.14 13.98  12.84 13.08 13.48 13.63 13.61 13.58 
TG 47:1 14.47 14.09 14.58 14.85 15.14 14.78  14.16 14.13 14.99 14.80 14.85 14.82 
TG 47:2 14.46 14.57 14.74 15.07 15.24 14.86  14.15 14.43 15.05 14.90 14.78 14.77 
TG 47:3 13.91 13.79 13.97 14.08 14.47 13.80  13.24 13.63 13.98 13.77 13.89 13.78 
TG 48:0 17.43 16.89 17.23 17.56 17.76 17.60  16.56 16.71 17.40 17.44 17.30 17.20 
TG 48:1 19.17 18.69 18.79 19.05 19.32 18.92  18.43 18.58 19.49 19.30 19.26 19.23 
TG 48:2 19.33 19.17 19.10 19.29 19.60 19.09  18.78 18.94 19.74 19.49 19.48 19.46 
TG 48:3 18.58 18.55 18.26 18.39 18.85 18.10  18.03 18.26 18.99 18.61 18.68 18.61 
TG 48:4 17.19 17.18 17.11 16.92 17.63 16.60  16.69 16.89 17.45 17.20 17.25 16.98 
TG 48:5 15.48 15.49 15.55 15.50 15.71 15.05  15.23 15.25 15.72 15.53 15.53 15.42 
TG 49:0 14.29 13.86 14.31 14.96 14.92 14.92  13.84 13.90 14.43 14.38 14.32 14.52 
TG 49:1 16.02 15.97 16.32 16.60 16.66 16.55  15.80 15.98 16.55 16.42 16.46 16.39 
TG 49:2 16.35 16.34 16.58 16.78 16.78 16.61  16.15 16.36 16.77 16.61 16.67 16.70 
TG 49:3 15.67 15.67 15.65 15.99 16.04 15.67  15.47 15.71 16.19 15.84 15.86 15.96 
TG 50:0 17.96 17.50 17.78 18.04 18.13 18.00  17.18 17.20 17.71 18.01 17.95 17.83 
TG 50:1 20.42 20.21 20.29 20.42 20.52 20.45  19.94 19.97 20.60 20.57 20.56 20.49 
TG 50:2 20.98 20.84 20.70 20.83 20.92 20.76  20.62 20.73 21.38 21.15 21.22 21.12 
TG 50:3 20.59 20.58 20.23 20.36 20.47 20.18  20.28 20.48 20.96 20.63 20.75 20.73 
TG 50:4 19.52 19.65 19.25 19.25 19.45 18.99  19.08 19.46 19.74 19.41 19.51 19.49 
TG 50:5 17.59 17.59 17.23 17.17 17.47 16.85  17.11 17.39 17.81 17.46 17.55 17.49 
TG 50:6 15.46 15.33 15.34 15.08 15.56 14.75  14.98 15.16 15.55 15.28 15.44 15.23 
TG 51:0 19.36 19.56 19.55 19.47 19.14 19.29  19.48 19.63 19.57 19.40 19.53 19.52 
TG 51:1 16.49 16.29 16.60 16.87 16.95 16.94  16.37 16.28 16.92 16.83 16.79 16.77 
TG 51:2 17.60 17.66 17.70 17.82 17.93 17.91  17.60 17.62 18.12 17.91 18.04 17.97 
TG 51:3 17.62 17.88 17.76 17.97 17.96 17.77  17.62 17.86 18.01 17.77 17.85 17.83 
TG 51:4 17.06 17.33 17.18 17.48 17.41 16.89  16.65 17.29 17.07 16.84 16.80 17.11 
TG 51:5 16.44 17.24 17.51 16.57 16.76 17.08  16.78 16.79 16.58 16.30 16.92 16.91 
TG 52:0 16.91 16.54 16.63 17.03 17.15 17.26  16.43 16.17 16.59 16.82 16.69 16.70 
TG 52:1 20.06 19.76 19.66 19.90 20.01 20.00  19.75 19.63 20.09 20.10 20.00 19.94 
TG 52:2 22.12 22.13 21.88 21.98 21.96 21.95  22.19 22.12 22.47 22.33 22.40 22.28 
TG 52:3 22.45 22.70 22.47 22.48 22.44 22.33  22.48 22.61 22.70 22.51 22.58 22.54 
TG 52:4 21.83 22.11 22.06 21.93 21.90 21.72  21.78 22.01 21.96 21.77 21.84 21.85 
TG 52:5 20.25 20.39 20.13 20.02 20.02 19.70  20.02 20.30 20.38 20.17 20.26 20.24 
TG 52:6 18.16 18.12 17.71 17.57 17.75 17.21  17.80 18.02 18.32 18.09 18.17 18.16 
TG 52:7 15.77 15.64 15.39 15.20 15.43 14.95  15.38 15.46 15.84 15.69 15.78 15.72 
TG 53:0 14.15 14.29 14.11 14.45 14.55 14.12  14.25 14.13 14.13 14.15 14.12 14.19 
TG 53:1 15.39 15.13 15.23 15.54 15.79 15.81  15.12 15.04 15.41 15.52 15.25 15.31 
TG 53:2 17.16 17.19 17.12 17.26 17.30 17.33  17.30 17.02 17.50 17.35 17.41 17.40 
TG 53:3 17.36 17.56 17.56 17.54 17.61 17.57  17.55 17.56 17.72 17.50 17.55 17.57 
TG 53:4 17.02 17.36 17.39 17.30 17.26 17.14  17.09 17.21 17.21 17.08 16.96 17.14 
TG 53:5 16.09 16.42 16.32 16.01 16.20 15.81  16.11 16.15 16.18 15.99 16.06 15.95 
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Table S2.5K: MEAL Study Mean Log2 Area under the Curve for Lipids (Triacylglycerol 54:0 to 
Triacylglycerol 62:12) 
 Mean Log2 AUC Values For Each Lipid Species  
 High Fat Diet High Carb Diet 
Lipid/Day B S 2.00 7.00 14.00 21.00  B S 2.00 7.00 14.00 21.00 
TG 54:0 14.68 14.55 14.52 14.92 15.32 14.84  13.66 13.96 14.20 14.39 14.26 14.02 
TG 54:1 17.73 17.21 17.14 17.48 17.72 17.80  17.23 16.86 17.10 17.21 16.96 17.14 
TG 54:2 19.77 19.46 19.13 19.26 19.48 19.47  19.57 19.18 19.41 19.45 19.37 19.37 
TG 54:3 20.83 20.74 20.28 20.36 20.43 20.42  20.76 20.46 20.58 20.52 20.54 20.48 
TG 54:4 21.00 21.10 20.62 20.62 20.73 20.52  20.92 20.82 20.82 20.73 20.72 20.73 
TG 54:5 20.85 20.93 20.57 20.49 20.52 20.29  20.68 20.73 20.66 20.57 20.61 20.59 
TG 54:6 20.15 20.27 20.05 19.82 19.89 19.62  19.92 20.08 19.95 19.90 19.93 19.91 
TG 54:7 18.79 18.76 18.54 18.16 18.36 17.88  18.39 18.58 18.50 18.47 18.54 18.54 
TG 54:8 16.45 16.44 16.11 15.85 16.12 15.46  16.14 16.22 16.42 16.29 16.34 16.33 
TG 55:0 10.31 10.71 10.91 10.39 11.18 10.81  10.25 8.85 9.76 10.78 10.51 10.35 
TG 55:2 14.21 14.03 14.20 13.69 14.18 14.33  14.07 13.79 13.92 14.03 13.73 13.93 
TG 55:3 14.75 15.01 14.83 14.67 14.86 14.89  14.58 14.65 14.76 14.50 14.60 14.41 
TG 55:4 14.67 15.08 14.99 14.88 14.73 14.82  14.53 14.65 14.62 14.61 14.73 14.60 
TG 55:5 14.55 14.62 15.02 15.18 14.79 14.88  14.72 14.63 14.89 14.76 14.84 14.79 
TG 56:0 11.85 10.98 11.27 11.79 12.08 11.93  11.08 10.97 10.63 11.07 10.92 10.91 
TG 56:1 14.44 14.23 13.99 14.10 14.73 14.94  13.95 13.71 13.82 13.79 13.52 13.73 
TG 56:10 14.10 13.97 14.09 13.55 13.74 13.16  13.87 13.77 14.00 14.00 13.94 13.90 
TG 56:2 16.14 15.82 15.54 15.68 15.80 16.06  15.62 15.24 15.39 15.55 15.39 15.45 
TG 56:3 16.72 16.75 16.11 16.18 16.32 16.29  16.39 16.20 16.33 16.42 16.34 16.34 
TG 56:4 17.28 17.41 17.00 16.92 16.95 16.86  17.14 17.09 17.20 17.20 17.17 17.19 
TG 56:5 18.18 18.46 18.18 18.05 18.07 18.01  18.34 18.27 18.33 18.33 18.36 18.32 
TG 56:6 18.84 19.01 18.83 18.72 18.65 18.59  18.93 18.90 18.91 18.93 18.95 18.89 
TG 56:7 18.93 19.05 19.04 18.87 18.82 18.68  18.93 18.92 18.92 18.95 19.02 18.96 
TG 56:8 18.27 18.38 18.50 18.19 18.22 18.10  18.15 18.22 18.14 18.20 18.22 18.19 
TG 56:9 16.59 16.54 16.54 16.19 16.28 15.94  16.37 16.41 16.40 16.41 16.51 16.42 
TG 57:2 15.00 15.04 14.72 14.80 14.82 14.75  14.99 14.98 15.31 15.14 14.98 15.06 
TG 57:4 14.65 15.10 14.72 14.85 14.63 14.35  14.64 15.07 14.68 14.57 14.97 14.77 
TG 58:1 12.78 12.69 12.19 12.30 12.54 12.79  12.31 11.51 11.82 12.29 11.45 12.07 
TG 58:10 16.09 16.13 16.26 15.95 16.04 15.83  15.92 15.98 15.82 15.96 15.99 15.90 
TG 58:11 14.44 14.38 14.61 14.11 14.39 13.96  14.25 14.11 14.11 14.22 14.40 14.22 
TG 58:2 14.12 13.87 13.54 12.97 13.79 13.54  13.56 12.62 13.29 13.51 13.57 13.17 
TG 58:3 14.26 14.31 13.40 13.64 13.80 13.62  13.53 13.13 12.91 13.61 13.52 13.54 
TG 58:4 14.07 14.40 13.88 13.76 13.71 13.73  13.71 13.34 13.62 13.93 13.98 13.83 
TG 58:5 14.96 14.96 14.72 14.44 14.58 14.49  14.66 14.71 14.78 14.79 14.99 14.74 
TG 58:6 15.72 15.79 15.69 15.53 15.49 15.48  15.73 15.76 15.72 15.74 15.87 15.81 
TG 58:7 16.43 16.39 16.29 16.12 16.21 16.13  16.44 16.29 16.38 16.43 16.45 16.35 
TG 58:8 16.64 16.75 16.74 16.49 16.49 16.40  16.70 16.59 16.60 16.75 16.76 16.72 
TG 58:9 16.56 16.70 16.73 16.44 16.50 16.35  16.60 16.50 16.39 16.52 16.62 16.43 
TG 60:10 14.06 14.12 14.39 13.98 13.92 14.03  14.14 13.95 14.17 14.31 14.32 14.16 
TG 60:11 14.01 14.10 14.40 14.11 14.23 14.05  14.03 13.91 13.84 14.15 14.23 14.00 
TG 60:12 13.57 13.44 13.89 13.39 13.71 13.57  13.34 13.30 13.19 13.42 13.60 13.52 





Table S2.6A: Significant difference within diet comparisons for all lipids (16:0 Cholesterol ester 
to Ceramide [NS] 36:1) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet   High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
16:0 CE 1.00 0.99 1.00 0.99 1.00 0.90 0.99 0.75   1.00 0.75 1.00 1.00 1.00 0.78 0.94 0.53 
16:1 CE 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.80   1.00 0.80 1.00 1.00 1.00 0.57 0.35 0.34 
18:0 CE 1.00 0.99 1.00 0.99 1.00 0.80 0.85 0.55   1.00 0.55 1.00 1.00 1.00 0.96 0.95 0.65 
18:1 CE 1.00 0.99 1.00 0.99 1.00 0.94 0.73 0.81   1.00 0.81 1.00 1.00 1.00 0.75 0.81 0.61 
18:2 CE 1.00 0.99 1.00 0.99 1.00 0.99 0.96 0.90   1.00 0.90 1.00 1.00 1.00 0.57 0.55 0.30 
18:3 CE 1.00 0.99 1.00 0.99 1.00 0.95 0.87 0.67   1.00 0.67 1.00 1.00 1.00 0.99 0.98 0.78 
20:3 CE 1.00 0.99 1.00 0.99 1.00 0.80 0.67 0.49   1.00 0.49 1.00 1.00 1.00 0.98 0.96 0.89 
20:4 CE 1.00 0.99 1.00 0.99 1.00 0.91 0.93 0.98   1.00 0.98 1.00 1.00 1.00 0.74 0.82 0.61 
20:5 CE 1.00 0.99 1.00 0.99 1.00 0.97 0.87 1.00   1.00 1.00 1.00 1.00 1.00 0.98 0.95 0.86 
22:4 CE 1.00 0.99 1.00 0.99 1.00 0.93 0.74 0.92   1.00 0.92 1.00 1.00 1.00 0.99 0.89 0.77 
22:5 CE 1.00 0.99 1.00 0.99 1.00 0.90 0.83 0.70   1.00 0.70 1.00 1.00 1.00 0.94 0.96 0.89 
22:6 CE 1.00 0.99 1.00 0.99 1.00 0.94 0.90 0.99   1.00 0.99 1.00 1.00 1.00 0.89 0.95 0.95 
ACAR 10:0 1.00 0.99 1.00 0.99 1.00 0.94 0.79 0.86   1.00 0.86 1.00 1.00 1.00 0.62 0.64 0.64 
ACAR 10:1 1.00 0.99 1.00 0.99 1.00 0.95 0.73 0.98   1.00 0.98 1.00 1.00 1.00 0.64 0.96 0.85 
ACAR 12:0 1.00 0.99 1.00 0.99 1.00 0.91 0.96 0.65   1.00 0.65 1.00 1.00 1.00 0.81 0.93 0.86 
ACAR 14:0 1.00 0.99 1.00 0.99 1.00 0.90 0.99 0.91   1.00 0.91 1.00 1.00 1.00 0.57 0.83 0.61 
ACAR 14:1 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.98   1.00 0.98 1.00 1.00 1.00 0.64 0.83 0.73 
ACAR 14:2 1.00 0.99 1.00 0.99 1.00 0.89 0.68 0.88   1.00 0.88 1.00 1.00 1.00 0.56 0.55 0.33 
ACAR 16:0 1.00 0.99 1.00 0.99 1.00 0.81 0.98 0.89   1.00 0.89 1.00 1.00 1.00 0.62 0.99 0.80 
ACAR 18:0 1.00 0.99 1.00 0.99 1.00 0.85 0.79 0.73   1.00 0.73 1.00 1.00 1.00 0.69 0.81 0.55 
ACAR 18:1 1.00 0.99 1.00 0.99 1.00 0.94 0.75 0.91   1.00 0.91 1.00 1.00 1.00 0.80 0.94 0.95 
ACAR 18:2 1.00 0.99 1.00 0.99 1.00 0.91 0.67 0.49   1.00 0.49 1.00 1.00 1.00 0.64 0.83 0.61 
ACAR 20:0 1.00 0.99 1.00 0.99 1.00 0.91 0.76 1.00   1.00 1.00 1.00 1.00 1.00 0.65 0.82 0.55 
ACAR 24:0 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.98   1.00 0.98 1.00 1.00 1.00 0.34 0.43 0.17 
ACAR 26:0 1.00 0.99 1.00 0.99 1.00 0.90 0.99 0.90   1.00 0.90 1.00 1.00 1.00 0.34 0.56 0.17 
Cer[AS] 34:1 1.00 0.99 1.00 0.99 1.00 0.94 0.96 0.78   1.00 0.78 1.00 1.00 1.00 0.89 0.99 0.95 
Cer[AS] 42:2 1.00 0.99 1.00 0.99 1.00 0.91 0.87 0.67   1.00 0.67 1.00 1.00 1.00 0.78 0.90 0.55 
Cer[EODS] 57:2 1.00 0.99 1.00 0.99 1.00 0.96 0.84 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.96 0.92 
Cer[EODS] 58:0 1.00 0.99 1.00 0.99 1.00 0.94 0.85 0.90   1.00 0.90 1.00 1.00 1.00 0.87 0.83 0.94 
Cer[EODS] 60:0 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.99   1.00 0.99 1.00 1.00 1.00 0.85 0.81 0.61 
Cer[NDS] 34:0 1.00 0.99 1.00 0.99 1.00 0.81 0.74 0.61   1.00 0.61 1.00 1.00 1.00 0.64 0.90 0.74 
Cer[NDS] 36:0 1.00 0.99 1.00 0.99 1.00 0.89 0.77 0.70   1.00 0.70 1.00 1.00 1.00 0.96 0.87 0.61 
Cer[NDS] 38:0 1.00 0.99 1.00 0.99 1.00 0.98 0.75 0.88   1.00 0.88 1.00 1.00 1.00 0.58 0.96 0.55 
Cer[NDS] 39:0 1.00 0.99 1.00 0.99 1.00 0.94 0.98 0.98   1.00 0.98 1.00 1.00 1.00 0.89 0.96 0.86 
Cer[NDS] 40:0 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.90   1.00 0.90 1.00 1.00 1.00 0.62 0.64 0.55 
Cer[NDS] 41:0 1.00 0.99 1.00 0.99 1.00 0.90 0.90 0.97   1.00 0.97 1.00 1.00 1.00 0.57 0.71 0.61 
Cer[NDS] 42:0 1.00 0.99 1.00 0.99 1.00 0.94 0.83 0.99   1.00 0.99 1.00 1.00 1.00 0.66 0.82 0.64 
Cer[NDS] 42:1 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.89   1.00 0.89 1.00 1.00 1.00 0.71 0.81 0.55 
Cer[NDS] 42:2 1.00 0.99 1.00 0.99 1.00 0.90 0.83 0.70   1.00 0.70 1.00 1.00 1.00 0.95 0.83 0.98 
Cer[NDS] 43:0 1.00 0.99 1.00 0.99 1.00 0.82 0.98 0.43   1.00 0.43 1.00 1.00 1.00 0.64 0.71 0.54 
Cer[NP] 34:0 1.00 0.99 1.00 0.99 1.00 0.90 0.90 0.84   1.00 0.84 1.00 1.00 1.00 0.76 0.71 0.55 
Cer[NP] 40:0 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.94   1.00 0.94 1.00 1.00 1.00 0.29 0.35 0.07 
Cer[NP] 41:0 1.00 0.99 1.00 0.99 1.00 0.94 0.96 0.90   1.00 0.90 1.00 1.00 1.00 0.57 0.57 0.17 
Cer[NP] 41:1 1.00 0.99 1.00 0.99 1.00 0.90 0.81 0.76   1.00 0.76 1.00 1.00 1.00 0.48 0.89 0.56 
Cer[NP] 42:0 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.90   1.00 0.90 1.00 1.00 1.00 0.57 0.42 0.28 
Cer[NP] 42:1 1.00 0.99 1.00 0.99 1.00 0.86 0.82 0.70   1.00 0.70 1.00 1.00 1.00 0.76 0.83 0.61 
Cer[NS] 32:1 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.98   1.00 0.98 1.00 1.00 1.00 0.85 0.95 0.55 
Cer[NS] 33:1 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.90   1.00 0.90 1.00 1.00 1.00 0.62 0.93 0.65 
Cer[NS] 33:4 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.59   1.00 0.59 1.00 1.00 1.00 0.69 0.55 0.99 
Cer[NS] 34:1 1.00 0.99 1.00 0.99 1.00 0.91 0.68 0.90   1.00 0.90 1.00 1.00 1.00 0.95 0.81 0.95 
Cer[NS] 34:2 1.00 0.99 1.00 0.99 1.00 0.92 0.78 0.70   1.00 0.70 1.00 1.00 1.00 0.48 0.89 0.55 
Cer[NS] 35:1 1.00 0.99 1.00 0.99 1.00 0.98 0.73 0.92   1.00 0.92 1.00 1.00 1.00 0.97 0.96 0.92 




Table S2.6B: MEAL Study significant difference within diet comparisons for all lipids (Ceramide 
[NS] 36:2 to Free Fatty Acid 20:0) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
Cer[NS] 36:2 1.00 0.99 1.00 0.99 1.00 0.99 0.68 0.96   1.00 0.96 1.00 1.00 1.00 0.95 0.81 0.86 
Cer[NS] 37:1 1.00 0.99 1.00 0.99 1.00 0.98 0.90 0.99   1.00 0.99 1.00 1.00 1.00 0.85 0.95 0.90 
Cer[NS] 38:1 1.00 0.99 1.00 0.99 1.00 0.91 0.79 0.92   1.00 0.92 1.00 1.00 1.00 0.56 0.81 0.53 
Cer[NS] 38:2 1.00 0.99 1.00 0.99 1.00 0.90 0.68 0.78   1.00 0.78 1.00 1.00 1.00 0.65 0.77 0.74 
Cer[NS] 39:1 1.00 0.99 1.00 0.99 1.00 0.97 0.99 0.70   1.00 0.70 1.00 1.00 1.00 0.54 0.64 0.25 
Cer[NS] 40:1 1.00 0.99 1.00 0.99 1.00 0.91 0.83 0.99   1.00 0.99 1.00 1.00 1.00 0.57 0.56 0.34 
Cer[NS] 40:2 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.88   1.00 0.88 1.00 1.00 1.00 0.65 0.89 0.63 
Cer[NS] 40:3 1.00 0.99 1.00 0.99 1.00 0.82 0.85 0.70   1.00 0.70 1.00 1.00 1.00 0.85 0.99 0.55 
Cer[NS] 41:1 1.00 0.99 1.00 0.99 1.00 0.96 0.98 0.90   1.00 0.90 1.00 1.00 1.00 0.65 0.66 0.43 
Cer[NS] 41:2 1.00 0.99 1.00 0.99 1.00 0.96 0.76 0.98   1.00 0.98 1.00 1.00 1.00 0.86 0.98 0.77 
Cer[NS] 41:4 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.67   1.00 0.67 1.00 1.00 1.00 0.57 0.96 0.73 
Cer[NS] 42:1 1.00 0.99 1.00 0.99 1.00 0.90 0.76 0.85   1.00 0.85 1.00 1.00 1.00 0.56 0.55 0.30 
Cer[NS] 42:2 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.75   1.00 0.75 1.00 1.00 1.00 0.85 0.96 0.86 
Cer[NS] 42:3 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.78   1.00 0.78 1.00 1.00 1.00 0.95 0.87 0.97 
Cer[NS] 43:1 1.00 0.99 1.00 0.99 1.00 0.95 1.00 0.75   1.00 0.75 1.00 1.00 1.00 0.45 0.55 0.33 
Cer[NS] 43:2 1.00 0.99 1.00 0.99 1.00 0.94 0.81 0.90   1.00 0.90 1.00 1.00 1.00 0.76 0.95 0.88 
Cer[NS] 44:1 1.00 0.99 1.00 0.99 1.00 0.90 0.99 0.67   1.00 0.67 1.00 1.00 1.00 0.73 0.83 0.77 
Cer[NS] 44:2 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.96   1.00 0.96 1.00 1.00 1.00 0.90 0.81 0.61 
Cer[NS] 44:4 1.00 0.99 1.00 0.99 1.00 0.97 0.80 0.91   1.00 0.91 1.00 1.00 1.00 0.72 0.64 0.34 
Cer[NS] 45:1 1.00 0.99 1.00 0.99 1.00 0.91 0.83 0.86   1.00 0.86 1.00 1.00 1.00 0.57 0.64 0.61 
Cer[NS] 46:5 1.00 0.99 1.00 0.99 1.00 0.97 0.76 0.95   1.00 0.95 1.00 1.00 1.00 0.94 0.90 0.86 
DG 30:0 1.00 0.99 1.00 0.99 1.00 0.81 1.00 0.70   1.00 0.70 1.00 1.00 1.00 0.62 0.55 0.77 
DG 30:1 1.00 0.99 1.00 0.99 1.00 0.99 0.82 0.70   1.00 0.70 1.00 1.00 1.00 0.97 0.96 0.89 
DG 32:0 1.00 0.99 1.00 0.99 1.00 0.99 0.83 0.94   1.00 0.94 1.00 1.00 1.00 0.65 0.86 0.55 
DG 32:1 1.00 0.99 1.00 0.99 1.00 0.95 0.98 0.85   1.00 0.85 1.00 1.00 1.00 0.71 0.56 0.55 
DG 32:2 1.00 0.99 1.00 0.99 1.00 0.96 0.76 0.99   1.00 0.99 1.00 1.00 1.00 0.73 0.96 0.95 
DG 33:0 1.00 0.99 1.00 0.99 1.00 0.91 0.96 0.53   1.00 0.53 1.00 1.00 1.00 0.87 0.81 0.89 
DG 33:1 1.00 0.99 1.00 0.99 1.00 0.94 0.83 0.98   1.00 0.98 1.00 1.00 1.00 0.81 0.88 0.54 
DG 34:0 1.00 0.99 1.00 0.99 1.00 0.94 0.83 0.91   1.00 0.91 1.00 1.00 1.00 0.58 0.64 0.61 
DG 34:2 1.00 0.99 1.00 0.99 1.00 0.99 0.96 0.84   1.00 0.84 1.00 1.00 1.00 0.65 0.55 0.55 
DG 34:3 1.00 0.99 1.00 0.99 1.00 0.91 0.82 0.65   1.00 0.65 1.00 1.00 1.00 0.65 0.81 0.64 
DG 35:1 1.00 0.99 1.00 0.99 1.00 0.90 0.85 0.70   1.00 0.70 1.00 1.00 1.00 0.73 0.56 0.53 
DG 35:2 1.00 0.99 1.00 0.99 1.00 0.90 0.99 0.98   1.00 0.98 1.00 1.00 1.00 0.97 0.71 0.82 
DG 35:3 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.91   1.00 0.91 1.00 1.00 1.00 0.73 0.55 0.55 
DG 36:0 1.00 0.99 1.00 0.99 1.00 0.94 0.87 0.89   1.00 0.89 1.00 1.00 1.00 0.89 0.85 0.91 
DG 36:1 1.00 0.99 1.00 0.99 1.00 0.97 0.80 0.90   1.00 0.90 1.00 1.00 1.00 0.57 0.64 0.61 
DG 36:2 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.70   1.00 0.70 1.00 1.00 1.00 0.57 0.64 0.48 
DG 36:3 1.00 0.99 1.00 0.99 1.00 0.92 0.76 0.67   1.00 0.67 1.00 1.00 1.00 0.86 0.90 0.68 
DG 36:4 1.00 0.99 1.00 0.99 1.00 0.91 0.78 0.61   1.00 0.61 1.00 1.00 1.00 0.73 0.90 0.80 
DG 36:5 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.49   1.00 0.49 1.00 1.00 1.00 0.83 0.96 0.61 
DG 38:1 1.00 0.99 1.00 0.99 1.00 0.90 0.68 0.70   1.00 0.70 1.00 1.00 1.00 0.89 0.95 0.88 
DG 38:2 1.00 0.99 1.00 0.99 1.00 0.94 0.99 0.91   1.00 0.91 1.00 1.00 1.00 0.72 0.83 0.71 
DG 38:3 1.00 0.99 1.00 0.99 1.00 0.91 0.87 0.92   1.00 0.92 1.00 1.00 1.00 0.88 0.81 0.95 
DG 38:4 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.91   1.00 0.91 1.00 1.00 1.00 0.71 0.71 0.86 
DG 38:5 1.00 0.99 1.00 1.00 1.00 0.94 0.90 0.59   1.00 0.59 1.00 1.00 1.00 0.64 0.81 0.65 
DG 38:6 1.00 0.99 1.00 0.99 1.00 0.94 0.99 0.75   1.00 0.75 1.00 1.00 1.00 0.89 0.83 0.77 
DG 38:7 1.00 0.99 1.00 1.00 1.00 0.98 0.99 0.67   1.00 0.67 1.00 1.00 1.00 0.85 0.77 0.85 
DG 40:6 1.00 0.99 1.00 0.99 1.00 0.91 0.93 0.72   1.00 0.72 1.00 1.00 1.00 0.95 0.81 0.82 
DG 40:7 1.00 0.99 1.00 0.99 1.00 0.98 0.88 0.67   1.00 0.67 1.00 1.00 1.00 0.62 0.89 0.80 
FFA 16:0 1.00 0.99 1.00 0.99 1.00 0.94 0.77 0.70   1.00 0.70 1.00 1.00 1.00 0.88 0.98 0.86 
FFA 18:0 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.70   1.00 0.70 1.00 1.00 1.00 0.89 0.96 0.99 
FFA 18:1 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.70   1.00 0.70 1.00 1.00 1.00 0.71 0.96 0.70 
FFA 18:2 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.70   1.00 0.70 1.00 1.00 1.00 0.62 0.96 0.55 
FFA 20:0 1.00 0.99 1.00 0.99 1.00 0.99 0.73 0.77   1.00 0.77 1.00 1.00 1.00 0.88 0.99 0.97 
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Table S2.6C: MEAL Study significant difference within diet comparisons for all lipids (Free 
Fatty Acid 20:1 to Lysophosphatidylethanolamine 20:5) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
FFA 20:1 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.70   1.00 0.70 1.00 1.00 1.00 0.75 0.99 0.68 
FFA 20:2 1.00 0.99 1.00 0.99 1.00 0.89 0.73 0.65   1.00 0.65 1.00 1.00 1.00 0.81 0.96 0.74 
FFA 20:4 1.00 0.99 1.00 0.99 1.00 0.86 0.68 0.70   1.00 0.70 1.00 1.00 1.00 0.89 0.96 0.75 
FFA 22:0 1.00 0.99 1.00 0.99 1.00 0.99 0.73 0.81   1.00 0.81 1.00 1.00 1.00 0.75 0.98 0.95 
FFA 22:1 1.00 0.99 1.00 0.99 1.00 0.98 0.76 0.88   1.00 0.88 1.00 1.00 1.00 0.99 0.83 0.88 
FFA 22:2 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.72 0.83 0.53 
FFA 22:3 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.59   1.00 0.59 1.00 1.00 1.00 0.73 0.98 0.74 
FFA 24:0 1.00 1.00 1.00 0.99 1.00 0.91 0.80 0.91   1.00 0.91 1.00 1.00 1.00 0.89 0.77 0.77 
FFA 24:1 1.00 0.99 1.00 0.99 1.00 0.91 0.75 0.50   1.00 0.50 1.00 1.00 1.00 0.69 0.96 0.74 
FFA 24:2 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.81   1.00 0.81 1.00 1.00 1.00 0.62 0.81 0.68 
FFA 24:3 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.88   1.00 0.88 1.00 1.00 1.00 0.76 0.93 0.77 
GlcCer[NS] 34:1 1.00 0.99 1.00 0.99 1.00 0.90 0.78 0.70   1.00 0.70 1.00 1.00 1.00 0.48 0.87 0.35 
GlcCer[NS] 34:2 1.00 0.99 1.00 0.99 1.00 0.99 0.97 0.90   1.00 0.90 1.00 1.00 1.00 0.57 0.56 0.61 
GlcCer[NS] 40:1 1.00 0.99 1.00 1.00 1.00 0.91 0.87 0.99   1.00 0.99 1.00 1.00 1.00 0.36 0.43 0.08 
GlcCer[NS] 41:1 1.00 0.99 1.00 0.99 1.00 0.99 0.92 0.86   1.00 0.86 1.00 1.00 1.00 0.85 0.84 0.77 
GlcCer[NS] 42:1 1.00 0.99 1.00 0.99 1.00 0.92 0.87 0.90   1.00 0.90 1.00 1.00 1.00 0.57 0.77 0.33 
GlcCer[NS] 42:2 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.81   1.00 0.81 1.00 1.00 1.00 0.75 0.96 0.86 
LysoPC 14:0 1.00 0.99 1.00 0.99 1.00 0.99 0.88 0.70   1.00 0.70 1.00 1.00 1.00 0.89 1.00 0.82 
LysoPC 15:0 1.00 0.99 1.00 1.00 1.00 0.99 0.98 0.73   1.00 0.73 1.00 1.00 1.00 0.71 0.83 0.61 
LysoPC 15:1 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.91   1.00 0.91 1.00 1.00 1.00 0.89 0.90 1.00 
LysoPC 16:0 1.00 0.99 1.00 0.99 1.00 0.80 0.68 0.41   1.00 0.41 1.00 1.00 1.00 0.83 0.99 0.77 
LysoPC 16:1 1.00 0.86 1.00 0.99 1.00 0.80 0.64 0.13   1.00 0.13 1.00 1.00 1.00 0.81 0.77 0.74 
LysoPC 17:1 1.00 0.99 1.00 0.99 1.00 0.97 1.00 0.90   1.00 0.90 1.00 1.00 1.00 0.88 0.90 0.95 
LysoPC 18:0 1.00 0.99 1.00 0.99 1.00 0.83 0.79 0.53   1.00 0.53 1.00 1.00 1.00 0.74 0.93 0.77 
LysoPC 18:1 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.99 0.96 0.96 
LysoPC 18:2 1.00 0.99 1.00 0.99 1.00 0.94 0.87 0.81   1.00 0.81 1.00 1.00 1.00 0.76 0.83 0.77 
LysoPC 18:3 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.49   1.00 0.49 1.00 1.00 1.00 0.95 0.96 0.94 
LysoPC 19:0 1.00 0.99 1.00 0.99 1.00 0.94 0.87 0.88   1.00 0.88 1.00 1.00 1.00 0.83 0.89 0.83 
LysoPC 19:1 1.00 0.99 1.00 0.99 1.00 0.99 0.81 0.91   1.00 0.91 1.00 1.00 1.00 0.99 0.98 0.92 
LysoPC 20:0 1.00 0.99 1.00 0.99 1.00 0.82 0.81 0.76   1.00 0.76 1.00 1.00 1.00 0.69 0.83 0.55 
LysoPC 20:1 1.00 0.99 1.00 0.99 1.00 0.70 0.67 0.49   1.00 0.49 1.00 1.00 1.00 0.84 0.96 0.90 
LysoPC 20:2 1.00 0.99 1.00 0.99 1.00 0.43 0.53 0.19   1.00 0.19 1.00 1.00 1.00 0.89 0.96 0.86 
LysoPC 20:3 1.00 0.99 1.00 0.99 1.00 0.59 0.45 0.16   1.00 0.16 1.00 1.00 1.00 0.94 0.96 0.95 
LysoPC 20:4 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.50   1.00 0.50 1.00 1.00 1.00 0.97 0.96 0.95 
LysoPC 20:5 1.00 0.99 1.00 0.99 1.00 0.98 0.93 0.98   1.00 0.98 1.00 1.00 1.00 0.88 0.96 0.92 
LysoPC 22:0 1.00 0.99 1.00 0.99 1.00 0.82 0.73 0.50   1.00 0.50 1.00 1.00 1.00 0.48 0.55 0.33 
LysoPC 22:4 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.78   1.00 0.78 1.00 1.00 1.00 0.85 0.89 0.92 
LysoPC 22:5 1.00 0.99 1.00 0.99 1.00 0.83 0.67 0.53   1.00 0.53 1.00 1.00 1.00 0.88 0.90 0.86 
LysoPC 22:6 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.67   1.00 0.67 1.00 1.00 1.00 0.98 0.77 0.70 
LysoPC 23:0 1.00 0.99 1.00 0.99 1.00 0.99 0.85 0.83   1.00 0.83 1.00 1.00 1.00 0.76 0.93 0.55 
LysoPC 24:0 1.00 0.99 1.00 0.99 1.00 0.81 0.67 0.49   1.00 0.49 1.00 1.00 1.00 0.66 0.83 0.57 
LysoPC 24:1 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.39   1.00 0.39 1.00 1.00 1.00 0.89 0.81 0.80 
LysoPC 26:1 1.00 0.99 1.00 0.99 1.00 0.53 0.73 0.42   1.00 0.42 1.00 1.00 1.00 0.87 0.73 0.96 
LysoPE 16:0 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.95 0.83 0.99 
LysoPE 16:1 1.00 0.99 1.00 0.99 1.00 0.99 0.98 0.56   1.00 0.56 1.00 1.00 1.00 0.65 0.71 0.82 
LysoPE 17:0 1.00 0.99 1.00 0.99 1.00 0.99 0.96 1.00   1.00 1.00 1.00 1.00 1.00 0.89 0.81 0.83 
LysoPE 18:0 1.00 0.99 1.00 0.99 1.00 0.81 0.76 0.81   1.00 0.81 1.00 1.00 1.00 0.65 0.94 0.55 
LysoPE 18:1 1.00 0.99 1.00 0.99 1.00 0.81 0.74 0.70   1.00 0.70 1.00 1.00 1.00 0.86 0.99 0.86 
LysoPE 18:2 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.89   1.00 0.89 1.00 1.00 1.00 0.66 0.90 0.61 
LysoPE 18:3 1.00 0.99 1.00 0.99 1.00 0.94 0.73 0.99   1.00 0.99 1.00 1.00 1.00 0.71 0.81 0.85 
LysoPE 20:2 1.00 0.99 1.00 0.99 1.00 0.80 0.74 0.67   1.00 0.67 1.00 1.00 1.00 0.85 0.99 0.80 
LysoPE 20:3 1.00 0.99 1.00 0.99 1.00 0.67 0.67 0.39   1.00 0.39 1.00 1.00 1.00 0.99 0.96 0.91 
LysoPE 20:4 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.75   1.00 0.75 1.00 1.00 1.00 0.85 0.99 0.74 
LysoPE 20:5 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.65   1.00 0.65 1.00 1.00 1.00 0.85 0.83 0.85 
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Table S2.6D: MEAL Study significant difference within diet comparisons for all lipids 
(Lysophosphatidylethanolamine 22:4 to Phosphatidylcholine 37:7) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
LysoPE 22:4 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.82 0.90 0.89 
LysoPE 22:5 1.00 0.99 1.00 0.99 1.00 0.80 0.71 0.41   1.00 0.41 1.00 1.00 1.00 0.95 0.90 0.99 
LysoPE 22:6 1.00 0.99 1.00 0.99 1.00 0.81 0.74 0.67   1.00 0.67 1.00 1.00 1.00 0.89 0.89 0.93 
LysoPE 24:0 1.00 0.99 1.00 0.99 1.00 0.99 0.85 0.78   1.00 0.78 1.00 1.00 1.00 0.57 0.92 0.54 
PA 34:1 1.00 0.99 1.00 0.99 1.00 0.81 0.67 0.69   1.00 0.69 1.00 1.00 1.00 0.72 0.77 0.33 
PA 34:2 1.00 0.99 1.00 0.99 1.00 0.91 0.81 0.70   1.00 0.70 1.00 1.00 1.00 0.86 0.83 0.86 
PA 36:1 1.00 0.99 1.00 0.99 1.00 0.91 0.93 0.90   1.00 0.90 1.00 1.00 1.00 0.73 0.71 0.66 
PA 36:2 1.00 0.99 1.00 0.81 1.00 0.43 0.91 0.50   1.00 0.50 1.00 1.00 1.00 0.65 0.77 0.91 
PA 36:3 1.00 0.99 1.00 0.99 1.00 0.93 0.95 0.98   1.00 0.98 1.00 1.00 1.00 0.72 0.77 0.82 
PA 36:4 1.00 0.99 1.00 0.99 1.00 0.91 0.68 0.91   1.00 0.91 1.00 1.00 1.00 0.83 0.89 0.89 
PA 38:6 1.00 0.99 1.00 0.99 1.00 0.94 0.67 1.00   1.00 1.00 1.00 1.00 1.00 0.89 0.97 0.77 
PC 24:0 1.00 0.36 1.00 0.99 0.59 0.87 0.45 0.70   1.00 0.70 1.00 1.00 1.00 1.00 0.71 0.77 
PC 26:0 1.00 0.10 1.00 0.99 1.00 0.43 0.42 0.54   1.00 0.54 1.00 1.00 1.00 0.97 0.96 0.71 
PC 27:0 1.00 0.99 1.00 0.99 1.00 0.93 0.83 0.75   1.00 0.75 1.00 1.00 1.00 0.86 0.96 0.82 
PC 28:2 1.00 0.99 1.00 0.99 1.00 0.98 0.76 0.91   1.00 0.91 1.00 1.00 1.00 0.62 0.99 0.62 
PC 29:0 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.80   1.00 0.80 1.00 1.00 1.00 0.91 0.96 0.90 
PC 30:0 1.00 0.99 1.00 0.99 1.00 0.92 0.73 0.90   1.00 0.90 1.00 1.00 1.00 0.85 0.71 0.77 
PC 30:2 1.00 0.99 1.00 0.99 1.00 0.87 0.45 0.72   1.00 0.72 0.79 1.00 1.00 0.65 0.98 0.64 
PC 31:0 1.00 0.99 1.00 0.99 1.00 0.53 0.45 0.41   1.00 0.41 1.00 1.00 1.00 0.86 1.00 0.99 
PC 31:1 1.00 0.99 1.00 0.99 1.00 0.89 0.77 0.90   1.00 0.90 1.00 1.00 1.00 0.86 0.77 0.80 
PC 32:0 1.00 0.99 1.00 0.99 1.00 0.91 0.84 0.69   1.00 0.69 1.00 1.00 1.00 0.85 0.88 0.95 
PC 32:1 1.00 0.99 1.00 0.99 1.00 0.80 0.75 0.41   1.00 0.41 1.00 1.00 1.00 0.48 0.35 0.37 
PC 32:2 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.50   1.00 0.50 1.00 1.00 1.00 0.64 0.81 0.51 
PC 32:3 1.00 0.99 1.00 0.99 1.00 0.99 0.95 0.65   1.00 0.65 0.79 1.00 1.00 0.85 0.77 0.91 
PC 33:0 1.00 0.99 1.00 0.99 1.00 0.67 0.96 0.75   1.00 0.75 1.00 1.00 1.00 0.89 0.96 0.90 
PC 33:1 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.88   1.00 0.88 1.00 1.00 1.00 0.69 0.64 0.77 
PC 33:2 1.00 0.99 1.00 0.99 1.00 0.89 0.90 0.90   1.00 0.90 1.00 1.00 1.00 0.12 0.20 0.07 
PC 33:3 1.00 0.99 1.00 0.99 1.00 0.91 0.85 0.72   1.00 0.72 1.00 1.00 1.00 0.73 0.66 0.80 
PC 34:1 1.00 0.99 1.00 0.99 1.00 0.71 0.74 0.53   1.00 0.53 1.00 1.00 1.00 0.73 0.55 0.59 
PC 34:2 1.00 0.99 1.00 0.99 1.00 0.97 0.90 0.98   1.00 0.98 1.00 1.00 1.00 0.73 0.73 0.55 
PC 34:3 1.00 0.99 1.00 0.99 1.00 0.84 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.95 0.83 0.95 
PC 34:4 1.00 0.99 1.00 0.99 1.00 0.91 0.86 0.64   1.00 0.64 1.00 1.00 1.00 0.94 0.98 0.82 
PC 34:5 1.00 0.99 1.00 0.99 1.00 0.53 0.73 0.59   1.00 0.59 1.00 1.00 1.00 0.88 0.84 0.88 
PC 35:0 1.00 0.99 1.00 0.99 1.00 0.91 0.85 0.81   1.00 0.81 1.00 1.00 1.00 0.45 0.71 0.59 
PC 35:1 1.00 0.99 1.00 0.99 1.00 0.94 0.85 0.70   1.00 0.70 1.00 1.00 1.00 0.48 0.56 0.86 
PC 35:2 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.67   1.00 0.67 1.00 1.00 1.00 0.48 0.31 0.13 
PC 35:3 1.00 0.99 1.00 0.99 1.00 0.83 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.85 0.77 0.99 
PC 35:4 1.00 0.99 1.00 0.99 1.00 0.91 0.91 0.91   1.00 0.91 1.00 1.00 1.00 0.86 0.96 0.61 
PC 35:5 1.00 0.99 1.00 0.99 1.00 0.94 0.99 0.98   1.00 0.98 1.00 1.00 1.00 0.95 0.83 0.94 
PC 35:6 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.70   1.00 0.70 1.00 1.00 1.00 0.65 0.69 0.55 
PC 36:0 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.93   1.00 0.93 1.00 1.00 1.00 0.89 0.96 0.91 
PC 36:1 1.00 0.99 1.00 0.99 1.00 0.80 0.95 0.72   1.00 0.72 1.00 1.00 1.00 0.89 0.92 0.86 
PC 36:2 1.00 0.99 1.00 0.99 1.00 0.82 0.83 0.70   1.00 0.70 1.00 1.00 1.00 0.45 0.55 0.17 
PC 36:3 1.00 0.99 1.00 0.99 1.00 0.80 0.67 0.39   1.00 0.39 1.00 1.00 1.00 0.85 0.95 0.80 
PC 36:4 1.00 0.99 1.00 0.99 1.00 0.87 0.68 0.70   1.00 0.70 1.00 1.00 1.00 0.85 0.99 0.74 
PC 36:5 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.49   1.00 0.49 1.00 1.00 1.00 0.65 0.64 0.55 
PC 36:6 1.00 0.99 1.00 0.99 1.00 0.80 0.68 0.49   1.00 0.49 1.00 1.00 1.00 0.99 0.90 0.82 
PC 37:1 1.00 0.99 1.00 0.99 1.00 0.98 0.73 0.88   1.00 0.88 1.00 1.00 1.00 0.85 0.77 0.74 
PC 37:2 1.00 0.99 1.00 0.99 1.00 0.99 0.98 0.91   1.00 0.91 1.00 1.00 1.00 0.78 0.83 0.77 
PC 37:3 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.81 0.74 
PC 37:4 1.00 0.99 1.00 0.99 1.00 0.91 0.83 0.89   1.00 0.89 1.00 1.00 1.00 0.89 0.93 0.77 
PC 37:5 1.00 0.99 1.00 0.99 1.00 0.99 0.74 0.89   1.00 0.89 1.00 1.00 1.00 0.73 0.77 0.55 
PC 37:6 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.92   1.00 0.92 1.00 1.00 1.00 0.85 0.90 0.95 




Table S2.6E: MEAL Study significant difference within diet comparisons for all lipids 
(Phosphatidylcholine 38:1 to Phosphatidylethanolamine 34:3) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
PC 38:1 1.00 0.99 1.00 0.99 1.00 0.71 0.73 0.70   1.00 0.70 1.00 1.00 1.00 0.93 0.95 0.97 
PC 38:2 1.00 0.99 1.00 0.99 1.00 0.45 0.68 0.64   1.00 0.64 1.00 1.00 1.00 0.62 0.81 0.54 
PC 38:3 1.00 0.99 1.00 0.99 1.00 0.79 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.98 0.92 0.95 
PC 38:4 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.78   1.00 0.78 1.00 1.00 1.00 0.95 0.92 0.97 
PC 38:5 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.53   1.00 0.53 1.00 1.00 1.00 0.84 0.64 0.85 
PC 38:6 1.00 0.99 1.00 0.99 1.00 0.91 0.80 0.76   1.00 0.76 1.00 1.00 1.00 0.85 0.66 0.74 
PC 38:7 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.70   1.00 0.70 1.00 1.00 1.00 0.85 0.77 0.75 
PC 39:3 1.00 0.99 1.00 0.99 1.00 0.91 0.88 0.90   1.00 0.90 1.00 1.00 1.00 0.95 0.94 0.92 
PC 39:4 1.00 0.99 1.00 0.99 1.00 0.83 0.98 0.91   1.00 0.91 1.00 1.00 1.00 0.95 0.98 0.82 
PC 39:6 1.00 0.99 1.00 0.99 1.00 0.96 0.83 0.83   1.00 0.83 1.00 1.00 1.00 0.88 0.77 0.74 
PC 39:7 1.00 0.99 1.00 0.99 1.00 0.93 0.99 1.00   1.00 1.00 1.00 1.00 1.00 0.48 0.32 0.74 
PC 39:8 1.00 0.99 1.00 0.99 1.00 0.91 0.93 0.90   1.00 0.90 1.00 1.00 1.00 0.65 0.77 0.98 
PC 40:0 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.91   1.00 0.91 1.00 1.00 1.00 0.92 0.83 0.77 
PC 40:1 1.00 0.99 1.00 0.99 1.00 0.91 0.67 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.86 0.86 
PC 40:2 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.67   1.00 0.67 1.00 1.00 1.00 0.76 0.98 0.74 
PC 40:4 1.00 0.99 1.00 0.99 1.00 0.90 0.68 0.75   1.00 0.75 1.00 1.00 1.00 0.89 0.77 0.89 
PC 40:5 1.00 0.99 1.00 0.99 1.00 0.85 0.67 0.64   1.00 0.64 1.00 1.00 1.00 0.85 0.66 0.33 
PC 40:6 1.00 0.99 1.00 0.99 1.00 0.91 0.84 0.80   1.00 0.80 1.00 1.00 1.00 0.81 0.55 0.53 
PC 40:7 1.00 0.99 1.00 0.99 1.00 0.81 0.68 0.65   1.00 0.65 1.00 1.00 1.00 0.95 0.83 0.86 
PC 40:8 1.00 0.99 1.00 0.99 1.00 0.91 0.67 0.84   1.00 0.84 1.00 1.00 1.00 0.89 0.96 0.86 
PC 41:3 1.00 0.99 1.00 0.99 1.00 0.98 0.99 0.67   1.00 0.67 1.00 1.00 1.00 0.76 0.99 0.95 
PC 41:4 1.00 0.99 1.00 0.99 1.00 0.90 0.81 0.86   1.00 0.86 1.00 1.00 1.00 0.95 0.93 0.86 
PC 41:5 1.00 0.99 1.00 0.99 1.00 0.91 0.80 0.99   1.00 0.99 1.00 1.00 1.00 0.95 0.83 0.89 
PC 41:6 1.00 0.99 1.00 0.99 1.00 0.92 0.76 0.78   1.00 0.78 1.00 1.00 1.00 0.86 0.69 0.68 
PC 41:7 1.00 0.99 1.00 0.99 1.00 0.94 0.83 0.86   1.00 0.86 1.00 1.00 1.00 0.81 0.96 0.68 
PC 42:1 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.65   1.00 0.65 1.00 1.00 1.00 0.73 0.95 0.95 
PC 42:10 1.00 0.99 1.00 1.00 1.00 0.91 0.80 0.92   1.00 0.92 1.00 1.00 1.00 0.95 0.77 0.77 
PC 42:2 1.00 0.99 1.00 0.99 1.00 0.81 0.68 0.49   1.00 0.49 1.00 1.00 1.00 0.78 0.83 0.62 
PC 42:3 1.00 0.99 1.00 0.99 1.00 0.81 0.71 0.13   1.00 0.13 1.00 1.00 1.00 0.89 0.90 0.96 
PC 42:4 1.00 0.99 1.00 0.99 1.00 0.91 0.93 0.90   1.00 0.90 1.00 1.00 1.00 0.95 0.96 0.86 
PC 42:5 1.00 0.99 1.00 0.99 1.00 0.94 0.81 0.90   1.00 0.90 1.00 1.00 1.00 0.95 0.96 1.00 
PC 42:6 1.00 0.99 1.00 0.99 1.00 0.81 0.45 0.49   1.00 0.49 1.00 1.00 1.00 0.62 0.64 0.37 
PC 42:7 1.00 0.99 1.00 0.99 1.00 0.94 0.67 0.91   1.00 0.91 1.00 1.00 1.00 0.81 0.99 0.91 
PC 42:8 1.00 0.99 1.00 0.99 1.00 0.88 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.83 0.81 0.96 
PC 42:9 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.90   1.00 0.90 1.00 1.00 1.00 0.74 0.77 0.55 
PC 44:12 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.98   1.00 0.98 1.00 1.00 1.00 0.89 0.75 0.77 
PC 44:2 1.00 0.99 1.00 0.99 1.00 0.45 0.67 0.41   1.00 0.41 1.00 1.00 1.00 0.90 0.82 0.85 
PC 44:3 1.00 0.99 1.00 0.99 1.00 0.94 0.81 0.70   1.00 0.70 1.00 1.00 1.00 0.87 0.90 0.99 
PC 44:4 1.00 0.99 1.00 0.99 1.00 0.90 0.87 0.90   1.00 0.90 1.00 1.00 1.00 0.95 0.94 0.89 
PC 44:5 1.00 0.99 1.00 0.99 1.00 0.92 0.73 0.54   1.00 0.54 0.92 1.00 1.00 0.94 0.71 0.55 
PC 44:6 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.41   1.00 0.41 1.00 1.00 1.00 0.92 0.93 0.65 
PC 44:8 1.00 0.99 1.00 0.99 1.00 0.91 0.96 0.89   1.00 0.89 1.00 1.00 1.00 0.78 0.88 0.82 
PC 46:4 1.00 0.99 1.00 0.99 1.00 0.64 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.66 0.81 0.86 
PE 30:0 1.00 0.99 1.00 0.99 1.00 0.95 0.67 0.86   1.00 0.86 1.00 1.00 1.00 0.96 0.82 0.82 
PE 32:0 1.00 0.99 1.00 0.99 1.00 0.90 0.95 0.96   1.00 0.96 1.00 1.00 1.00 0.85 0.77 0.86 
PE 32:1 1.00 0.99 1.00 0.99 1.00 0.97 0.85 1.00   1.00 1.00 1.00 1.00 1.00 0.61 0.55 0.62 
PE 32:2 1.00 0.99 1.00 0.99 1.00 0.93 0.74 0.91   1.00 0.91 1.00 1.00 1.00 0.95 0.94 0.83 
PE 33:0 1.00 0.99 1.00 0.99 1.00 0.89 0.90 0.99   1.00 0.99 1.00 1.00 1.00 0.85 0.90 0.92 
PE 33:1 1.00 0.99 1.00 0.99 1.00 0.99 0.76 0.90   1.00 0.90 1.00 1.00 1.00 0.98 0.83 0.54 
PE 33:2 1.00 0.99 1.00 0.99 1.00 0.98 0.83 1.00   1.00 1.00 1.00 1.00 1.00 1.00 0.96 0.64 
PE 34:0 1.00 0.99 1.00 0.99 1.00 0.85 0.94 0.90   1.00 0.90 1.00 1.00 1.00 0.81 0.85 0.80 
PE 34:1 1.00 0.99 1.00 1.00 1.00 0.82 0.73 0.84   1.00 0.84 1.00 1.00 1.00 0.76 0.63 0.62 
PE 34:2 1.00 0.99 1.00 0.99 1.00 0.99 0.98 0.99   1.00 0.99 1.00 1.00 1.00 0.98 0.96 0.91 




Table S2.6F: MEAL Study significant difference within diet comparisons for all lipids 
(Phosphatidylethanolamine 34:4 to Plasmenyl-phosphatidylcholine 35:3) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
PE 34:4 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.98   1.00 0.98 1.00 1.00 1.00 0.66 1.00 0.95 
PE 35:0 1.00 0.99 1.00 0.99 1.00 0.93 0.83 0.89   1.00 0.89 1.00 1.00 1.00 0.99 0.96 0.77 
PE 35:1 1.00 0.99 1.00 0.99 1.00 0.90 0.80 0.98   1.00 0.98 1.00 1.00 1.00 0.95 0.99 0.84 
PE 35:2 1.00 0.99 1.00 0.99 1.00 0.91 0.96 0.90   1.00 0.90 1.00 1.00 1.00 0.85 0.87 0.88 
PE 35:4 1.00 0.99 1.00 0.99 1.00 0.99 0.93 0.92   1.00 0.92 1.00 1.00 1.00 0.89 0.94 0.57 
PE 36:0 1.00 0.99 1.00 0.99 1.00 0.90 0.79 0.91   1.00 0.91 1.00 1.00 1.00 0.89 0.94 0.98 
PE 36:1 1.00 0.99 1.00 0.99 1.00 0.90 0.87 0.91   1.00 0.91 1.00 1.00 1.00 0.94 0.83 0.82 
PE 36:2 1.00 0.99 1.00 0.99 1.00 0.91 0.96 0.89   1.00 0.89 1.00 1.00 1.00 0.72 0.93 0.70 
PE 36:3 1.00 0.99 1.00 0.99 1.00 0.94 0.96 0.90   1.00 0.90 1.00 1.00 1.00 0.88 0.96 0.74 
PE 36:4 1.00 0.99 1.00 0.99 1.00 0.99 0.96 0.99   1.00 0.99 1.00 1.00 1.00 0.88 0.81 0.89 
PE 36:5 1.00 0.99 1.00 0.99 1.00 0.97 0.90 0.91   1.00 0.91 1.00 1.00 1.00 0.65 0.64 0.64 
PE 37:4 1.00 0.99 1.00 0.99 1.00 0.90 0.97 0.91   1.00 0.91 1.00 1.00 1.00 0.94 0.93 0.97 
PE 38:3 1.00 0.99 1.00 0.99 1.00 0.98 0.73 0.97   1.00 0.97 1.00 1.00 1.00 0.88 0.95 0.86 
PE 38:4 1.00 0.99 1.00 0.99 1.00 0.80 0.77 0.99   1.00 0.99 1.00 1.00 1.00 0.74 0.96 0.71 
PE 38:5 1.00 0.99 1.00 0.99 1.00 0.85 0.73 0.86   1.00 0.86 1.00 1.00 1.00 0.92 0.93 0.86 
PE 38:6 1.00 0.99 1.00 1.00 1.00 0.91 0.85 0.99   1.00 0.99 1.00 1.00 1.00 0.95 0.81 0.90 
PE 38:7 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.89   1.00 0.89 1.00 1.00 1.00 0.89 0.96 0.86 
PE 40:4 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.94   1.00 0.94 1.00 1.00 1.00 0.76 0.99 0.86 
PE 40:5 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.90   1.00 0.90 1.00 1.00 1.00 0.90 0.71 0.99 
PE 40:6 1.00 0.99 1.00 0.99 1.00 0.91 0.83 0.91   1.00 0.91 1.00 1.00 1.00 0.88 0.66 0.71 
PE 40:7 1.00 0.99 1.00 0.99 1.00 0.90 0.83 0.98   1.00 0.98 1.00 1.00 1.00 0.85 0.96 0.99 
PE 40:8 1.00 0.99 1.00 0.99 1.00 0.81 0.96 0.98   1.00 0.98 1.00 1.00 1.00 0.77 0.95 0.78 
PE 42:10 1.00 0.99 1.00 0.99 1.00 0.59 0.98 0.98   1.00 0.98 1.00 1.00 1.00 0.89 0.81 0.85 
PG 33:0 1.00 0.99 1.00 0.99 1.00 0.80 0.42 0.49   1.00 0.49 1.00 1.00 1.00 0.73 0.83 0.89 
PG 34:0 1.00 0.99 1.00 0.99 1.00 0.49 0.85 0.98   1.00 0.98 0.79 1.00 1.00 0.65 0.77 0.95 
PG 34:2 1.00 0.99 1.00 0.99 1.00 0.43 0.68 0.67   1.00 0.67 1.00 1.00 1.00 0.81 0.96 0.70 
PG 36:0 1.00 0.99 1.00 0.99 1.00 0.94 0.73 0.94   1.00 0.94 1.00 1.00 1.00 0.65 0.64 0.68 
PG 36:2 1.00 0.99 1.00 0.99 1.00 0.44 0.67 0.49   1.00 0.49 0.79 1.00 1.00 0.88 0.96 0.84 
PG 36:3 1.00 0.99 1.00 0.99 1.00 0.80 0.67 0.67   1.00 0.67 1.00 1.00 1.00 0.85 0.96 0.79 
PG 38:4 1.00 0.99 1.00 0.99 1.00 0.53 0.67 0.81   1.00 0.81 1.00 1.00 1.00 0.73 0.87 0.58 
PI 25:0 1.00 0.99 1.00 0.99 1.00 0.90 0.68 0.99   1.00 0.99 1.00 1.00 1.00 0.86 0.96 0.89 
PI 34:1 1.00 0.99 1.00 0.99 1.00 0.76 0.76 0.88   1.00 0.88 1.00 1.00 1.00 0.69 0.90 0.74 
PI 34:2 1.00 0.99 1.00 1.00 1.00 0.79 0.67 0.67   1.00 0.67 0.79 1.00 1.00 0.57 0.81 0.55 
PI 36:1 1.00 0.99 1.00 0.99 1.00 0.81 0.81 0.99   1.00 0.99 1.00 1.00 1.00 0.44 0.64 0.54 
PI 36:2 1.00 0.99 1.00 0.99 1.00 0.59 0.68 0.70   1.00 0.70 0.44 1.00 1.00 0.34 0.70 0.53 
PI 36:4 1.00 0.99 1.00 0.99 1.00 0.70 0.67 0.70   1.00 0.70 1.00 1.00 1.00 0.73 0.96 0.70 
PI 38:3 1.00 0.99 1.00 0.99 1.00 0.80 0.63 0.78   1.00 0.78 0.79 1.00 1.00 0.70 0.95 0.77 
PI 38:4 1.00 0.99 1.00 0.99 1.00 0.45 0.67 0.78   1.00 0.78 0.44 1.00 1.00 0.48 0.87 0.61 
PI 38:5 1.00 0.99 1.00 0.99 1.00 0.81 0.74 0.88   1.00 0.88 0.79 1.00 1.00 0.69 0.93 0.63 
PI 38:6 1.00 0.99 1.00 0.99 1.00 0.91 0.82 0.91   1.00 0.91 0.79 1.00 1.00 0.85 0.96 0.86 
PI 40:5 1.00 0.99 1.00 0.99 1.00 0.64 0.67 0.75   1.00 0.75 0.51 1.00 1.00 0.62 0.95 0.95 
PI 40:6 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.84   1.00 0.84 1.00 1.00 1.00 0.81 0.74 0.97 
PlsCho 24:0 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.39   1.00 0.39 1.00 1.00 1.00 0.89 0.81 0.80 
PlsCho 28:0 1.00 0.99 1.00 0.99 1.00 0.99 0.87 0.98   1.00 0.98 1.00 1.00 1.00 0.95 0.95 0.99 
PlsCho 32:0 1.00 0.99 1.00 0.99 1.00 0.94 0.42 0.79   1.00 0.79 1.00 1.00 1.00 0.83 0.81 0.95 
PlsCho 32:1 1.00 0.99 1.00 0.99 1.00 0.90 0.50 0.67   1.00 0.67 1.00 1.00 1.00 0.71 0.99 0.82 
PlsCho 33:0 1.00 0.99 1.00 0.99 1.00 0.78 0.78 0.65   1.00 0.65 1.00 1.00 1.00 0.91 0.98 0.82 
PlsCho 34:0 1.00 0.99 1.00 0.99 1.00 0.91 0.79 0.73   1.00 0.73 1.00 1.00 1.00 0.62 0.89 0.57 
PlsCho 34:1 1.00 0.99 1.00 0.99 1.00 0.94 0.85 0.86   1.00 0.86 1.00 1.00 1.00 0.76 0.95 0.74 
PlsCho 34:2 1.00 0.99 1.00 0.99 1.00 0.94 0.87 0.90   1.00 0.90 1.00 1.00 1.00 0.73 0.83 0.55 
PlsCho 34:3 1.00 0.99 1.00 0.99 1.00 0.43 0.45 0.08   1.00 0.08 1.00 1.00 1.00 0.80 0.95 0.93 
PlsCho 35:0 1.00 0.99 1.00 0.99 1.00 0.94 1.00 0.98   1.00 0.98 1.00 1.00 1.00 0.75 0.77 0.97 
PlsCho 35:1 1.00 0.99 1.00 0.99 1.00 0.81 0.99 0.90   1.00 0.90 1.00 1.00 1.00 0.73 0.96 0.97 
PlsCho 35:2 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.64   1.00 0.64 1.00 1.00 1.00 0.86 0.81 0.77 
PlsCho 35:3 1.00 0.99 1.00 0.99 1.00 0.95 0.73 0.12   1.00 0.12 1.00 1.00 1.00 0.61 0.88 0.61 
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Table S2.6G: MEAL Study significant difference within diet comparisons for all lipids 
(Plasmenyl-phosphatidylcholine 35:4 to Plasmenyl-phosphatidylethanolamine 36:2) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
PlsCho 35:4 1.00 0.99 1.00 0.99 1.00 0.99 0.80 0.67   1.00 0.67 1.00 1.00 1.00 0.83 0.66 0.80 
PlsCho 36:0 1.00 0.99 1.00 0.99 1.00 0.82 0.86 0.86   1.00 0.86 0.79 1.00 1.00 0.48 0.87 0.55 
PlsCho 36:2 1.00 0.99 1.00 1.00 1.00 0.91 0.81 0.78   1.00 0.78 1.00 1.00 1.00 0.71 0.77 0.61 
PlsCho 36:3 1.00 0.99 1.00 0.99 1.00 0.92 0.99 0.78   1.00 0.78 1.00 1.00 1.00 0.72 0.87 0.54 
PlsCho 36:4 1.00 0.99 1.00 0.99 1.00 0.99 0.99 0.70   1.00 0.70 1.00 1.00 1.00 0.85 0.95 0.61 
PlsCho 36:5 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.89 0.83 0.92 
PlsCho 36:6 1.00 0.99 1.00 0.99 1.00 0.43 0.42 0.49   1.00 0.49 1.00 1.00 1.00 0.71 0.98 0.89 
PlsCho 37:1 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.68   1.00 0.68 1.00 1.00 1.00 0.96 0.94 0.68 
PlsCho 37:2 1.00 0.99 1.00 0.99 1.00 0.91 0.97 0.98   1.00 0.98 1.00 1.00 1.00 0.95 0.66 0.73 
PlsCho 37:3 1.00 0.99 1.00 0.99 1.00 0.26 0.45 0.00   1.00 0.00 1.00 1.00 1.00 0.96 0.96 0.74 
PlsCho 37:4 1.00 0.99 1.00 0.99 1.00 0.43 0.42 0.02   1.00 0.02 1.00 1.00 1.00 0.95 0.81 0.71 
PlsCho 37:6 1.00 0.99 1.00 0.99 1.00 0.90 0.92 0.70   1.00 0.70 1.00 1.00 1.00 0.80 0.96 0.79 
PlsCho 38:0 1.00 0.99 1.00 0.99 1.00 0.91 0.85 0.99   1.00 0.99 0.79 1.00 1.00 0.64 0.95 0.96 
PlsCho 38:1 1.00 0.99 1.00 1.00 1.00 0.92 0.90 0.90   1.00 0.90 1.00 1.00 1.00 0.96 0.99 0.97 
PlsCho 38:3 1.00 0.99 1.00 0.99 1.00 0.93 0.80 0.81   1.00 0.81 1.00 1.00 1.00 0.73 0.83 0.55 
PlsCho 38:4 1.00 0.99 1.00 0.99 1.00 0.98 0.80 0.99   1.00 0.99 1.00 1.00 1.00 0.72 0.86 0.53 
PlsCho 38:5 1.00 0.99 1.00 0.99 1.00 0.93 0.98 0.65   1.00 0.65 1.00 1.00 1.00 0.89 0.99 0.77 
PlsCho 38:6 1.00 0.99 1.00 0.99 1.00 0.91 0.81 0.67   1.00 0.67 1.00 1.00 1.00 0.95 0.96 0.81 
PlsCho 39:3 1.00 0.99 1.00 0.99 1.00 0.81 0.82 0.75   1.00 0.75 1.00 1.00 1.00 0.93 0.96 0.86 
PlsCho 39:4 1.00 0.99 1.00 0.99 1.00 0.92 0.99 0.99   1.00 0.99 1.00 1.00 1.00 0.76 0.83 0.95 
PlsCho 39:5 1.00 0.99 1.00 0.99 1.00 0.90 0.91 0.92   1.00 0.92 1.00 1.00 1.00 0.71 0.96 0.95 
PlsCho 39:6 1.00 0.99 1.00 0.99 1.00 0.59 0.67 0.15   1.00 0.15 1.00 1.00 1.00 0.94 0.71 0.89 
PlsCho 40:0 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.70   1.00 0.70 1.00 1.00 1.00 0.87 0.92 0.77 
PlsCho 40:1 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.65   1.00 0.65 1.00 1.00 1.00 0.64 0.90 0.70 
PlsCho 40:3 1.00 0.99 1.00 0.99 1.00 0.99 0.80 0.72   1.00 0.72 1.00 1.00 1.00 0.64 0.83 0.63 
PlsCho 40:4 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.68   1.00 0.68 1.00 1.00 1.00 0.94 0.98 0.89 
PlsCho 40:5 1.00 0.99 1.00 0.99 1.00 0.80 0.74 0.53   1.00 0.53 1.00 1.00 1.00 0.73 0.83 0.89 
PlsCho 40:6 1.00 0.99 1.00 0.99 1.00 1.00 0.79 0.88   1.00 0.88 1.00 1.00 1.00 0.82 0.93 0.86 
PlsCho 42:1 1.00 0.99 1.00 0.99 1.00 0.94 0.91 0.80   1.00 0.80 1.00 1.00 1.00 0.65 0.93 0.70 
PlsCho 42:2 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.54   1.00 0.54 1.00 1.00 1.00 0.73 0.83 0.64 
PlsCho 42:3 1.00 0.99 1.00 0.99 1.00 0.79 0.73 0.49   1.00 0.49 0.79 1.00 1.00 0.57 0.94 0.75 
PlsCho 42:4 1.00 0.99 1.00 0.99 1.00 0.91 0.68 0.49   1.00 0.49 1.00 1.00 1.00 0.89 0.98 0.95 
PlsCho 42:5 1.00 0.99 1.00 0.99 1.00 0.91 0.67 0.69   1.00 0.69 1.00 1.00 1.00 0.73 0.95 0.80 
PlsCho 42:6 1.00 0.99 1.00 0.99 1.00 0.80 0.45 0.13   1.00 0.13 1.00 1.00 1.00 0.76 0.96 0.80 
PlsCho 44:3 1.00 0.99 1.00 0.99 1.00 0.94 0.96 0.86   1.00 0.86 1.00 1.00 1.00 0.95 0.96 0.91 
PlsCho 44:4 1.00 0.99 1.00 0.99 1.00 0.91 0.71 0.42   1.00 0.42 1.00 1.00 1.00 0.85 0.99 0.89 
PlsCho 44:5 1.00 0.99 1.00 0.99 1.00 0.99 0.68 0.70   1.00 0.70 1.00 1.00 1.00 0.64 0.95 0.93 
PlsCho 44:6 1.00 0.99 1.00 0.99 1.00 0.90 0.78 0.46   1.00 0.46 1.00 1.00 1.00 0.77 0.96 1.00 
PlsCho 46:4 1.00 0.99 1.00 0.99 1.00 0.96 0.74 0.49   1.00 0.49 1.00 1.00 1.00 0.98 0.93 0.97 
PlsEth 32:0 1.00 0.99 1.00 0.99 1.00 0.91 0.71 0.88   1.00 0.88 1.00 1.00 1.00 0.76 0.83 0.61 
PlsEth 32:1 1.00 0.99 1.00 0.99 1.00 0.91 0.81 0.98   1.00 0.98 1.00 1.00 1.00 0.65 0.81 0.38 
PlsEth 32:2 1.00 0.99 1.00 0.99 1.00 0.59 0.68 0.49   1.00 0.49 1.00 1.00 1.00 0.10 0.05 0.07 
PlsEth 33:1 1.00 0.78 1.00 0.99 1.00 0.35 0.45 0.18   1.00 0.18 1.00 1.00 1.00 0.44 0.32 0.17 
PlsEth 33:2 1.00 0.99 1.00 0.99 1.00 0.64 0.72 0.70   1.00 0.70 1.00 1.00 1.00 0.29 0.10 0.07 
PlsEth 34:0 1.00 0.99 1.00 0.99 1.00 0.91 0.68 0.63   1.00 0.63 1.00 1.00 1.00 0.62 0.71 0.51 
PlsEth 34:1 1.00 0.99 1.00 0.99 1.00 0.90 0.67 0.65   1.00 0.65 1.00 1.00 1.00 0.44 0.64 0.24 
PlsEth 34:2 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.73   1.00 0.73 1.00 1.00 1.00 0.40 0.35 0.17 
PlsEth 34:3 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.70   1.00 0.70 1.00 1.00 1.00 0.62 0.64 0.53 
PlsEth 34:4 1.00 0.99 1.00 0.99 1.00 0.59 0.50 0.13   1.00 0.13 1.00 1.00 1.00 0.39 0.20 0.12 
PlsEth 35:1 1.00 0.99 1.00 0.99 1.00 0.99 0.71 0.86   1.00 0.86 1.00 1.00 1.00 0.72 0.77 0.53 
PlsEth 35:2 1.00 0.99 1.00 0.99 1.00 0.43 0.45 0.39   1.00 0.39 1.00 1.00 1.00 0.62 0.71 0.55 
PlsEth 35:4 1.00 0.78 1.00 0.99 1.00 0.26 0.42 0.07   1.00 0.07 1.00 1.00 1.00 0.58 0.55 0.33 
PlsEth 36:0 1.00 0.99 1.00 0.99 1.00 0.92 0.73 0.67   1.00 0.67 1.00 1.00 1.00 0.92 0.81 0.70 
PlsEth 36:1 1.00 0.99 1.00 1.00 1.00 0.94 0.93 0.98   1.00 0.98 1.00 1.00 1.00 0.34 0.35 0.08 
PlsEth 36:2 1.00 0.99 1.00 0.99 1.00 0.98 0.99 0.99   1.00 0.99 1.00 1.00 1.00 0.34 0.20 0.07 
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Table S2.6H: MEAL Study significant difference within diet comparisons for all lipids 
(Plasmenyl-phosphatidylethanolamine 36:3 to Sphingomyelin 38:4) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
PlsEth 36:3 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.90   1.00 0.90 1.00 1.00 1.00 0.48 0.56 0.22 
PlsEth 36:4 1.00 0.99 1.00 0.99 1.00 0.70 0.67 0.65   1.00 0.65 1.00 1.00 1.00 0.45 0.83 0.55 
PlsEth 36:5 1.00 0.99 1.00 0.99 1.00 0.90 0.92 0.86   1.00 0.86 1.00 1.00 1.00 0.66 0.83 0.86 
PlsEth 36:6 1.00 0.99 1.00 0.99 1.00 0.79 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.85 0.81 0.61 
PlsEth 37:1 1.00 0.99 1.00 0.99 1.00 0.90 0.76 0.91   1.00 0.91 1.00 1.00 1.00 0.81 0.95 0.85 
PlsEth 37:2 1.00 0.99 1.00 0.99 1.00 0.92 0.95 0.88   1.00 0.88 1.00 1.00 1.00 0.62 0.55 0.17 
PlsEth 37:3 1.00 0.99 1.00 0.99 1.00 0.81 0.78 0.49   1.00 0.49 1.00 1.00 1.00 0.99 0.93 0.86 
PlsEth 37:4 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.18   1.00 0.18 1.00 1.00 1.00 0.73 0.91 0.55 
PlsEth 37:5 1.00 0.51 1.00 0.99 1.00 0.18 0.42 0.18   1.00 0.18 1.00 1.00 1.00 0.89 0.93 0.80 
PlsEth 37:6 1.00 0.86 1.00 0.99 1.00 0.45 0.50 0.15   1.00 0.15 1.00 1.00 1.00 0.58 0.55 0.34 
PlsEth 38:1 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.86   1.00 0.86 1.00 1.00 1.00 0.34 0.57 0.13 
PlsEth 38:2 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.65   1.00 0.65 1.00 1.00 1.00 0.57 0.55 0.34 
PlsEth 38:3 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.97   1.00 0.97 1.00 1.00 1.00 0.62 0.55 0.17 
PlsEth 38:4 1.00 0.99 1.00 1.00 1.00 0.91 0.88 0.90   1.00 0.90 1.00 1.00 1.00 0.62 0.81 0.33 
PlsEth 38:5 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.99   1.00 0.99 1.00 1.00 1.00 0.62 0.83 0.54 
PlsEth 38:6 1.00 0.99 1.00 0.99 1.00 0.96 0.78 0.98   1.00 0.98 1.00 1.00 1.00 0.62 0.83 0.61 
PlsEth 39:2 1.00 0.99 1.00 0.99 1.00 0.71 0.73 0.99   1.00 0.99 1.00 1.00 1.00 0.89 0.97 0.95 
PlsEth 39:4 1.00 0.99 1.00 0.99 1.00 0.99 0.77 0.61   1.00 0.61 1.00 1.00 1.00 0.72 0.89 0.55 
PlsEth 39:5 1.00 0.99 1.00 0.99 1.00 0.81 0.74 0.41   1.00 0.41 1.00 1.00 1.00 0.80 0.81 0.61 
PlsEth 39:6 1.00 0.99 1.00 0.99 1.00 0.90 0.78 0.49   1.00 0.49 1.00 1.00 1.00 0.91 0.98 0.99 
PlsEth 40:1 1.00 0.99 1.00 0.99 1.00 0.90 0.74 0.81   1.00 0.81 1.00 1.00 1.00 0.74 0.81 0.55 
PlsEth 40:2 1.00 0.99 1.00 0.99 1.00 0.95 0.68 0.65   1.00 0.65 1.00 1.00 1.00 0.44 0.66 0.34 
PlsEth 40:4 1.00 0.99 1.00 0.99 1.00 0.91 0.78 0.91   1.00 0.91 1.00 1.00 1.00 0.45 0.83 0.28 
PlsEth 40:5 1.00 0.99 1.00 0.99 1.00 0.94 0.78 0.91   1.00 0.91 1.00 1.00 1.00 0.44 0.71 0.33 
PlsEth 40:6 1.00 0.99 1.00 0.99 1.00 0.94 0.98 0.80   1.00 0.80 1.00 1.00 1.00 0.65 0.81 0.70 
PlsEth 41:4 1.00 0.99 1.00 0.99 1.00 0.98 1.00 0.84   1.00 0.84 1.00 1.00 1.00 0.89 0.96 0.82 
PlsEth 41:6 1.00 0.99 1.00 0.99 1.00 0.99 0.83 0.98   1.00 0.98 1.00 1.00 1.00 1.00 0.96 0.73 
PlsEth 42:4 1.00 0.99 1.00 0.99 1.00 0.90 0.83 0.89   1.00 0.89 1.00 1.00 1.00 0.57 0.93 0.46 
PlsEth 42:5 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.99   1.00 0.99 1.00 1.00 1.00 0.57 0.98 0.55 
PlsEth 42:6 1.00 0.99 1.00 0.99 1.00 0.90 0.93 0.97   1.00 0.97 1.00 1.00 1.00 0.92 0.89 0.92 
PlsEth 44:6 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.86   1.00 0.86 1.00 1.00 1.00 0.89 0.95 0.85 
PS 36:1 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.99   1.00 0.99 1.00 1.00 1.00 0.87 0.98 0.98 
PS 38:4 1.00 0.99 1.00 0.99 1.00 0.79 0.74 0.54   1.00 0.54 1.00 1.00 1.00 0.75 0.95 0.74 
SM 30:1 1.00 0.99 1.00 0.99 1.00 0.94 0.90 0.91   1.00 0.91 1.00 1.00 1.00 0.45 0.65 0.13 
SM 30:2 1.00 0.99 1.00 0.99 1.00 0.81 0.76 0.84   1.00 0.84 1.00 1.00 1.00 0.65 0.99 0.13 
SM 32:0 1.00 0.99 1.00 0.99 1.00 0.90 0.87 0.90   1.00 0.90 1.00 1.00 1.00 0.65 0.88 0.55 
SM 32:1 1.00 0.99 1.00 0.99 1.00 0.99 0.99 0.92   1.00 0.92 1.00 1.00 1.00 0.64 0.77 0.40 
SM 32:2 1.00 0.99 1.00 0.99 1.00 0.98 0.95 0.91   1.00 0.91 1.00 1.00 1.00 0.88 0.96 0.74 
SM 33:1 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.88   1.00 0.88 1.00 1.00 1.00 0.62 0.76 0.30 
SM 34:0 1.00 0.99 1.00 0.99 1.00 0.97 0.67 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.93 0.77 
SM 34:1 1.00 0.99 1.00 0.99 1.00 0.91 0.93 0.89   1.00 0.89 1.00 1.00 1.00 0.75 0.96 0.77 
SM 34:2 1.00 0.99 1.00 0.99 1.00 0.91 0.85 0.75   1.00 0.75 1.00 1.00 1.00 0.72 0.95 0.70 
SM 34:3 1.00 0.99 1.00 0.99 1.00 0.81 0.93 0.85   1.00 0.85 1.00 1.00 1.00 0.73 0.95 0.77 
SM 35:2 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.83   1.00 0.83 1.00 1.00 1.00 0.73 0.90 0.89 
SM 36:1 1.00 0.99 1.00 0.99 1.00 0.89 0.78 0.78   1.00 0.78 1.00 1.00 1.00 0.75 0.96 0.89 
SM 36:2 1.00 0.99 1.00 0.99 1.00 0.99 1.00 0.91   1.00 0.91 1.00 1.00 1.00 0.85 0.92 0.99 
SM 36:3 1.00 0.99 1.00 0.99 1.00 0.91 0.98 0.98   1.00 0.98 1.00 1.00 1.00 0.57 0.91 0.35 
SM 36:4 1.00 0.99 1.00 0.99 1.00 0.91 0.81 0.98   1.00 0.98 1.00 1.00 1.00 0.97 0.81 0.34 
SM 37:1 1.00 0.99 1.00 0.99 1.00 0.18 0.45 0.12   1.00 0.12 1.00 1.00 1.00 0.75 0.96 0.74 
SM 37:2 1.00 0.99 1.00 0.99 1.00 0.80 0.74 0.59   1.00 0.59 1.00 1.00 1.00 0.89 0.96 0.86 
SM 38:0 1.00 0.99 1.00 0.99 1.00 0.81 0.86 0.67   1.00 0.67 1.00 1.00 1.00 0.86 0.93 0.82 
SM 38:1 1.00 0.99 1.00 1.00 1.00 0.99 0.99 0.98   1.00 0.98 1.00 1.00 1.00 0.64 0.81 0.53 
SM 38:2 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.90   1.00 0.90 1.00 1.00 1.00 0.64 0.81 0.52 
SM 38:3 1.00 0.99 1.00 0.99 1.00 0.94 0.85 0.99   1.00 0.99 1.00 1.00 1.00 0.88 0.93 0.95 
SM 38:4 1.00 0.99 1.00 0.99 1.00 0.99 0.74 0.73   1.00 0.73 1.00 1.00 1.00 0.89 0.95 0.92 
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Table S2.6I: MEAL Study significant difference within diet comparisons for all lipids 
(Sphingomyelin 39:0 to Triacylglycerol 47:0) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
SM 39:0 1.00 0.99 1.00 0.99 1.00 0.80 0.74 0.70   1.00 0.70 1.00 1.00 1.00 0.80 0.82 0.34 
SM 39:1 1.00 0.99 1.00 0.99 1.00 0.92 0.95 0.91   1.00 0.91 1.00 1.00 1.00 0.44 0.35 0.07 
SM 39:2 1.00 0.99 1.00 0.99 1.00 0.91 0.87 0.71   1.00 0.71 1.00 1.00 1.00 0.81 0.96 0.70 
SM 39:3 1.00 0.99 1.00 0.99 1.00 0.80 0.87 0.67   1.00 0.67 1.00 1.00 1.00 0.97 0.90 0.71 
SM 40:1 1.00 0.99 1.00 0.99 1.00 0.99 0.95 0.93   1.00 0.93 0.79 1.00 1.00 0.44 0.43 0.08 
SM 40:2 1.00 0.99 1.00 0.99 1.00 0.90 0.83 0.75   1.00 0.75 1.00 1.00 1.00 0.71 0.92 0.55 
SM 40:3 1.00 0.99 1.00 0.99 1.00 0.91 1.00 0.92   1.00 0.92 1.00 1.00 1.00 0.97 0.77 0.91 
SM 40:5 1.00 0.99 1.00 0.99 1.00 0.90 0.86 0.88   1.00 0.88 1.00 1.00 1.00 0.97 0.83 0.95 
SM 41:1 1.00 0.99 1.00 0.99 1.00 0.90 0.83 0.88   1.00 0.88 1.00 1.00 1.00 0.58 0.75 0.34 
SM 41:2 1.00 0.99 1.00 0.99 1.00 0.98 0.74 0.90   1.00 0.90 1.00 1.00 1.00 0.60 0.83 0.33 
SM 41:3 1.00 0.99 1.00 0.99 1.00 0.90 0.91 0.83   1.00 0.83 1.00 1.00 1.00 0.86 0.82 0.97 
SM 41:4 1.00 0.99 1.00 0.99 1.00 0.91 0.85 0.84   1.00 0.84 1.00 1.00 1.00 0.75 0.83 0.69 
SM 41:6 1.00 0.99 1.00 0.99 1.00 0.79 0.82 0.66   1.00 0.66 1.00 1.00 1.00 0.85 0.83 0.80 
SM 42:1 1.00 0.99 1.00 0.99 1.00 0.95 0.83 0.78   1.00 0.78 1.00 1.00 1.00 0.62 0.77 0.34 
SM 42:2 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.65   1.00 0.65 1.00 1.00 1.00 0.86 0.90 1.00 
SM 42:3 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.50   1.00 0.50 1.00 1.00 1.00 0.90 0.81 0.85 
SM 42:4 1.00 0.99 1.00 0.99 1.00 0.99 0.73 0.75   1.00 0.75 1.00 1.00 1.00 0.85 0.56 0.61 
SM 42:5 1.00 0.99 1.00 0.99 1.00 0.99 0.88 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.81 0.86 
SM 42:6 1.00 0.99 1.00 0.99 1.00 0.91 0.86 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.93 0.75 
SM 43:1 1.00 0.99 1.00 0.99 1.00 0.93 0.99 0.95   1.00 0.95 1.00 1.00 1.00 0.10 0.64 0.07 
SM 43:2 1.00 0.99 1.00 0.99 1.00 0.90 0.80 0.90   1.00 0.90 1.00 1.00 1.00 0.85 0.98 0.89 
SM 43:3 1.00 0.99 1.00 0.99 1.00 0.90 0.84 0.98   1.00 0.98 1.00 1.00 1.00 0.97 0.89 0.99 
SM 43:6 1.00 0.99 1.00 0.99 1.00 0.43 0.45 0.65   1.00 0.65 1.00 1.00 1.00 0.99 0.95 0.77 
SM 43:8 1.00 0.99 1.00 0.99 1.00 0.35 0.81 0.65   1.00 0.65 1.00 1.00 1.00 0.85 0.36 0.53 
SM 44:1 1.00 0.99 1.00 0.99 1.00 0.99 1.00 0.99   1.00 0.99 1.00 1.00 1.00 0.78 0.96 0.71 
SM 44:2 1.00 0.99 1.00 0.99 1.00 0.94 0.76 0.89   1.00 0.89 1.00 1.00 1.00 0.85 0.96 0.97 
SM 44:3 1.00 0.78 1.00 0.99 1.00 0.90 0.67 0.70   1.00 0.70 1.00 1.00 1.00 0.95 0.96 1.00 
SM 44:5 1.00 0.99 1.00 0.99 1.00 0.81 0.67 0.42   1.00 0.42 1.00 1.00 1.00 0.85 0.66 0.92 
SM 44:6 1.00 0.99 1.00 0.99 1.00 0.95 0.73 0.89   1.00 0.89 1.00 1.00 1.00 0.95 0.94 0.95 
SM 45:7 1.00 0.99 1.00 0.99 1.00 0.96 0.90 0.98   1.00 0.98 1.00 1.00 1.00 0.88 0.99 0.55 
TG 36:0 1.00 0.99 1.00 0.99 1.00 0.71 0.45 0.59   1.00 0.59 1.00 1.00 1.00 0.85 0.77 0.80 
TG 38:0 1.00 0.99 1.00 0.99 1.00 0.79 0.45 0.70   1.00 0.70 1.00 1.00 1.00 0.72 0.77 0.85 
TG 39:0 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.78   1.00 0.78 1.00 1.00 1.00 0.89 0.92 0.95 
TG 40:0 1.00 0.99 1.00 0.99 1.00 0.80 0.49 0.70   1.00 0.70 1.00 1.00 1.00 0.66 0.81 0.79 
TG 40:1 1.00 0.99 1.00 0.99 1.00 0.83 0.67 0.75   1.00 0.75 1.00 1.00 1.00 0.65 0.81 0.79 
TG 41:0 1.00 0.99 1.00 0.99 1.00 0.80 0.67 0.75   1.00 0.75 1.00 1.00 1.00 0.69 0.82 0.83 
TG 42:0 1.00 0.99 1.00 0.99 1.00 0.79 0.53 0.67   1.00 0.67 1.00 1.00 1.00 0.62 0.82 0.80 
TG 42:1 1.00 0.99 1.00 0.99 1.00 0.90 0.67 0.78   1.00 0.78 1.00 1.00 1.00 0.62 0.82 0.78 
TG 42:2 1.00 0.99 1.00 0.99 1.00 0.90 0.67 0.91   1.00 0.91 1.00 1.00 1.00 0.79 0.92 0.89 
TG 42:3 1.00 0.99 1.00 0.99 1.00 0.99 0.73 0.98   1.00 0.98 1.00 1.00 1.00 0.71 0.96 0.95 
TG 43:0 1.00 0.99 1.00 0.99 1.00 0.78 0.53 0.64   1.00 0.64 1.00 1.00 1.00 0.85 0.96 0.89 
TG 43:1 1.00 0.99 1.00 0.99 1.00 0.90 0.68 0.67   1.00 0.67 1.00 1.00 1.00 0.64 0.77 0.78 
TG 43:2 1.00 0.99 1.00 0.99 1.00 0.99 0.72 0.91   1.00 0.91 1.00 1.00 1.00 0.97 0.96 0.95 
TG 44:0 1.00 0.99 1.00 0.99 1.00 0.79 0.45 0.65   1.00 0.65 1.00 1.00 1.00 0.64 0.81 0.75 
TG 44:1 1.00 0.99 1.00 0.99 1.00 0.87 0.67 0.70   1.00 0.70 1.00 1.00 1.00 0.57 0.77 0.73 
TG 44:2 1.00 0.99 1.00 0.99 1.00 0.90 0.71 0.90   1.00 0.90 1.00 1.00 1.00 0.79 0.89 0.92 
TG 44:3 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.96   1.00 0.96 1.00 1.00 1.00 0.76 0.90 0.95 
TG 45:0 1.00 0.99 1.00 0.99 1.00 0.79 0.42 0.43   1.00 0.43 1.00 1.00 1.00 0.57 0.81 0.75 
TG 45:1 1.00 0.99 1.00 0.99 1.00 0.71 0.45 0.49   1.00 0.49 1.00 1.00 1.00 0.65 0.77 0.68 
TG 45:2 1.00 0.99 1.00 0.99 1.00 0.91 0.68 0.85   1.00 0.85 1.00 1.00 1.00 0.82 0.83 0.86 
TG 46:0 1.00 0.99 1.00 0.99 1.00 0.81 0.67 0.64   1.00 0.64 1.00 1.00 1.00 0.48 0.71 0.55 
TG 46:1 1.00 0.99 1.00 0.99 1.00 0.85 0.62 0.82   1.00 0.82 1.00 1.00 1.00 0.57 0.71 0.62 
TG 46:2 1.00 0.99 1.00 0.99 1.00 0.91 0.68 0.93   1.00 0.93 1.00 1.00 1.00 0.65 0.77 0.75 
TG 46:3 1.00 0.99 1.00 0.99 1.00 0.94 0.73 0.98   1.00 0.98 1.00 1.00 1.00 0.83 0.81 0.84 
TG 47:0 1.00 0.99 1.00 0.99 1.00 0.80 0.68 0.49   1.00 0.49 1.00 1.00 1.00 0.71 0.81 0.74 
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Table S2.6J: MEAL Study significant difference within diet comparisons for all lipids 
(Triacylglycerol 47:1 to Triacylglycerol 56:0) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
TG 47:1 1.00 0.99 1.00 0.99 1.00 0.81 0.67 0.65   1.00 0.65 1.00 1.00 1.00 0.64 0.71 0.60 
TG 47:2 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.86   1.00 0.86 1.00 1.00 1.00 0.71 0.83 0.79 
TG 47:3 1.00 0.99 1.00 0.99 1.00 0.91 0.73 1.00   1.00 1.00 1.00 1.00 1.00 0.89 0.83 0.89 
TG 48:0 1.00 0.99 1.00 0.99 1.00 0.81 0.68 0.65   1.00 0.65 1.00 1.00 1.00 0.62 0.77 0.70 
TG 48:1 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.88   1.00 0.88 1.00 1.00 1.00 0.62 0.71 0.61 
TG 48:2 1.00 0.99 1.00 0.99 1.00 0.94 0.74 0.96   1.00 0.96 1.00 1.00 1.00 0.65 0.77 0.64 
TG 48:3 1.00 0.99 1.00 0.99 1.00 0.94 0.82 0.67   1.00 0.67 1.00 1.00 1.00 0.78 0.81 0.77 
TG 48:4 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.64   1.00 0.64 1.00 1.00 1.00 0.80 0.81 0.94 
TG 48:5 1.00 0.99 1.00 0.99 1.00 0.99 0.87 0.67   1.00 0.67 1.00 1.00 1.00 0.72 0.81 0.86 
TG 49:0 1.00 0.99 1.00 0.99 1.00 0.70 0.67 0.49   1.00 0.49 1.00 1.00 1.00 0.73 0.83 0.61 
TG 49:1 1.00 0.99 1.00 0.99 1.00 0.82 0.71 0.65   1.00 0.65 1.00 1.00 1.00 0.71 0.77 0.74 
TG 49:2 1.00 0.99 1.00 1.00 1.00 0.90 0.74 0.84   1.00 0.84 1.00 1.00 1.00 0.85 0.81 0.74 
TG 49:3 1.00 0.99 1.00 0.99 1.00 0.91 0.76 1.00   1.00 1.00 1.00 1.00 1.00 0.89 0.93 0.79 
TG 50:0 1.00 0.99 1.00 0.99 1.00 0.82 0.71 0.70   1.00 0.70 1.00 1.00 1.00 0.45 0.55 0.55 
TG 50:1 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.84   1.00 0.84 1.00 1.00 1.00 0.57 0.55 0.55 
TG 50:2 1.00 0.99 1.00 0.99 1.00 0.99 0.95 0.92   1.00 0.92 1.00 1.00 1.00 0.65 0.56 0.61 
TG 50:3 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.65   1.00 0.65 1.00 1.00 1.00 0.87 0.81 0.74 
TG 50:4 1.00 0.99 1.00 0.99 1.00 0.89 0.85 0.49   1.00 0.49 1.00 1.00 1.00 0.96 0.96 0.97 
TG 50:5 1.00 0.99 1.00 0.99 1.00 0.90 0.93 0.43   1.00 0.43 1.00 1.00 1.00 0.95 0.93 0.93 
TG 50:6 1.00 0.99 1.00 0.99 1.00 0.91 0.85 0.61   1.00 0.61 1.00 1.00 1.00 0.91 0.82 0.95 
TG 51:0 1.00 0.99 1.00 0.99 1.00 0.93 0.68 0.70   1.00 0.70 1.00 1.00 1.00 0.79 0.95 0.89 
TG 51:1 1.00 0.99 1.00 0.99 1.00 0.81 0.68 0.64   1.00 0.64 1.00 1.00 1.00 0.62 0.66 0.61 
TG 51:2 1.00 0.99 1.00 0.99 1.00 0.91 0.78 0.78   1.00 0.78 1.00 1.00 1.00 0.75 0.64 0.62 
TG 51:3 1.00 0.99 1.00 1.00 1.00 0.94 0.92 0.90   1.00 0.90 1.00 1.00 1.00 0.89 0.99 0.95 
TG 51:4 1.00 0.99 1.00 0.99 1.00 0.91 0.92 0.49   1.00 0.49 1.00 1.00 1.00 0.62 0.55 0.77 
TG 51:5 1.00 0.99 1.00 0.99 1.00 0.80 0.74 0.88   1.00 0.88 1.00 1.00 1.00 0.71 0.95 0.90 
TG 52:0 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.65   1.00 0.65 1.00 1.00 1.00 0.57 0.75 0.61 
TG 52:1 1.00 0.99 1.00 0.99 1.00 0.93 0.81 0.83   1.00 0.83 1.00 1.00 1.00 0.61 0.71 0.74 
TG 52:2 1.00 0.99 1.00 0.99 1.00 0.91 0.83 0.86   1.00 0.86 1.00 1.00 1.00 0.73 0.58 0.77 
TG 52:3 1.00 0.99 1.00 0.99 1.00 0.90 0.76 0.64   1.00 0.64 1.00 1.00 1.00 0.86 0.96 0.89 
TG 52:4 1.00 0.99 1.00 0.99 1.00 0.91 0.81 0.55   1.00 0.55 1.00 1.00 1.00 0.71 0.87 0.77 
TG 52:5 1.00 0.99 1.00 1.00 1.00 0.81 0.73 0.18   1.00 0.18 1.00 1.00 1.00 0.86 0.96 0.94 
TG 52:6 1.00 0.99 1.00 0.99 1.00 0.80 0.74 0.15   1.00 0.15 1.00 1.00 1.00 0.94 0.93 0.86 
TG 52:7 1.00 0.99 1.00 0.99 1.00 0.85 0.85 0.49   1.00 0.49 1.00 1.00 1.00 0.85 0.82 0.79 
TG 53:0 1.00 0.99 1.00 0.99 1.00 0.93 0.81 0.91   1.00 0.91 1.00 1.00 1.00 0.98 0.99 0.95 
TG 53:1 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.64   1.00 0.64 1.00 1.00 1.00 0.62 0.87 0.78 
TG 53:2 1.00 0.99 1.00 0.99 1.00 0.96 0.90 0.90   1.00 0.90 1.00 1.00 1.00 0.68 0.64 0.55 
TG 53:3 1.00 0.99 1.00 0.99 1.00 0.99 0.96 0.99   1.00 0.99 1.00 1.00 1.00 0.91 0.98 0.99 
TG 53:4 1.00 0.99 1.00 0.99 1.00 0.96 0.88 0.70   1.00 0.70 1.00 1.00 1.00 0.85 0.81 0.90 
TG 53:5 1.00 0.99 1.00 0.99 1.00 0.85 0.84 0.49   1.00 0.49 1.00 1.00 1.00 0.88 0.95 0.80 
TG 54:0 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.92   1.00 0.92 1.00 1.00 1.00 0.62 0.83 0.95 
TG 54:1 1.00 0.99 1.00 0.99 1.00 0.91 0.74 0.67   1.00 0.67 1.00 1.00 1.00 0.69 0.96 0.77 
TG 54:2 1.00 0.99 1.00 0.99 1.00 0.91 0.99 0.99   1.00 0.99 1.00 1.00 1.00 0.65 0.81 0.77 
TG 54:3 1.00 0.99 1.00 0.99 1.00 0.82 0.74 0.70   1.00 0.70 1.00 1.00 1.00 0.89 0.93 0.95 
TG 54:4 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.88 0.93 0.86 
TG 54:5 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.30   1.00 0.30 1.00 1.00 1.00 0.81 0.92 0.78 
TG 54:6 1.00 0.99 1.00 0.99 1.00 0.80 0.73 0.24   1.00 0.24 1.00 1.00 1.00 0.81 0.89 0.77 
TG 54:7 1.00 0.99 1.00 0.99 1.00 0.79 0.73 0.12   1.00 0.12 1.00 1.00 1.00 0.89 0.96 0.95 
TG 54:8 1.00 0.99 1.00 0.99 1.00 0.80 0.76 0.13   1.00 0.13 1.00 1.00 1.00 0.95 0.95 0.90 
TG 55:0 1.00 0.99 1.00 0.99 1.00 0.93 0.78 0.98   1.00 0.98 1.00 1.00 1.00 0.10 0.35 0.33 
TG 55:2 1.00 0.99 1.00 0.99 1.00 0.91 0.92 0.80   1.00 0.80 1.00 1.00 1.00 0.78 0.96 0.86 
TG 55:3 1.00 0.99 1.00 0.99 1.00 0.90 0.88 0.90   1.00 0.90 1.00 1.00 1.00 0.88 0.96 0.74 
TG 55:4 1.00 0.99 1.00 0.99 1.00 0.91 0.73 0.75   1.00 0.75 1.00 1.00 1.00 0.95 0.95 0.95 
TG 55:5 1.00 0.99 1.00 0.99 1.00 0.79 0.84 0.80   1.00 0.80 1.00 1.00 1.00 0.85 0.81 0.77 
TG 56:0 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.76   1.00 0.76 1.00 1.00 1.00 0.97 0.98 0.97 
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Table S2.6K: MEAL Study significant difference within diet comparisons for all lipids 
(Triacylglycerol 56:1 to Triacylglycerol 62:12) 
 Within Diet Comparisons (FDR <0.1) 
 High Fat Diet  High Carbohydrate Diet 
Lipid/Day B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21   B to S S to 2 2 to 7 7 to 14 14 to 21 S to 7 S to 14 S to 21 
TG 56:1 1.00 0.99 1.00 0.99 1.00 0.97 0.79 0.70   1.00 0.70 1.00 1.00 1.00 0.94 0.93 0.99 
TG 56:10 1.00 0.99 1.00 0.99 1.00 0.82 0.79 0.18   1.00 0.18 1.00 1.00 1.00 0.86 0.94 0.89 
TG 56:2 1.00 0.99 1.00 0.99 1.00 0.94 0.99 0.90   1.00 0.90 1.00 1.00 1.00 0.71 0.93 0.82 
TG 56:3 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.67   1.00 0.67 1.00 1.00 1.00 0.71 0.90 0.83 
TG 56:4 1.00 0.99 1.00 0.99 1.00 0.80 0.71 0.49   1.00 0.49 1.00 1.00 1.00 0.87 0.96 0.86 
TG 56:5 1.00 0.99 1.00 0.99 1.00 0.80 0.68 0.49   1.00 0.49 1.00 1.00 1.00 0.91 0.94 0.92 
TG 56:6 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.49   1.00 0.49 1.00 1.00 1.00 0.97 0.96 0.98 
TG 56:7 1.00 0.99 1.00 0.99 1.00 0.91 0.76 0.64   1.00 0.64 1.00 1.00 1.00 0.97 0.94 0.95 
TG 56:8 1.00 0.99 1.00 0.99 1.00 0.91 0.84 0.70   1.00 0.70 1.00 1.00 1.00 0.98 0.99 0.96 
TG 56:9 1.00 0.99 1.00 0.99 1.00 0.86 0.76 0.41   1.00 0.41 1.00 1.00 1.00 1.00 0.95 0.99 
TG 57:2 1.00 0.99 1.00 0.99 1.00 0.90 0.73 0.61   1.00 0.61 1.00 1.00 1.00 0.73 1.00 0.87 
TG 57:4 1.00 0.99 1.00 0.99 1.00 0.90 0.72 0.39   1.00 0.39 1.00 1.00 1.00 0.48 0.95 0.68 
TG 58:1 1.00 0.99 1.00 0.99 1.00 0.91 0.95 0.98   1.00 0.98 1.00 1.00 1.00 0.45 0.99 0.62 
TG 58:10 1.00 0.99 1.00 0.99 1.00 0.91 0.90 0.67   1.00 0.67 1.00 1.00 1.00 0.99 0.99 0.94 
TG 58:11 1.00 0.99 1.00 0.99 1.00 0.90 0.99 0.63   1.00 0.63 1.00 1.00 1.00 0.94 0.87 0.92 
TG 58:2 1.00 0.99 1.00 0.99 1.00 0.86 0.98 0.90   1.00 0.90 1.00 1.00 1.00 0.65 0.71 0.77 
TG 58:3 1.00 0.99 1.00 0.99 1.00 0.90 0.79 0.70   1.00 0.70 1.00 1.00 1.00 0.71 0.83 0.73 
TG 58:4 1.00 0.99 1.00 0.99 1.00 0.81 0.73 0.65   1.00 0.65 1.00 1.00 1.00 0.62 0.64 0.61 
TG 58:5 1.00 0.99 1.00 0.99 1.00 0.79 0.73 0.53   1.00 0.53 1.00 1.00 1.00 0.92 0.81 0.97 
TG 58:6 1.00 0.99 1.00 0.99 1.00 0.90 0.76 0.70   1.00 0.70 1.00 1.00 1.00 0.99 0.93 0.95 
TG 58:7 1.00 0.99 1.00 0.99 1.00 0.90 0.81 0.75   1.00 0.75 1.00 1.00 1.00 0.85 0.89 0.93 
TG 58:8 1.00 0.99 1.00 1.00 1.00 0.90 0.76 0.67   1.00 0.67 1.00 1.00 1.00 0.85 0.90 0.85 
TG 58:9 1.00 0.99 1.00 0.99 1.00 0.90 0.78 0.65   1.00 0.65 1.00 1.00 1.00 0.98 0.95 0.94 
TG 60:10 1.00 0.99 1.00 0.99 1.00 0.92 0.80 0.91   1.00 0.91 1.00 1.00 1.00 0.73 0.81 0.82 
TG 60:11 1.00 0.99 1.00 0.99 1.00 0.99 0.86 0.98   1.00 0.98 1.00 1.00 1.00 0.85 0.83 0.93 
TG 60:12 1.00 0.99 1.00 0.99 1.00 0.98 0.80 0.91   1.00 0.91 1.00 1.00 1.00 0.94 0.90 0.86 





Table S2.7A: MEAL Study significant differences for between diet comparisons for all lipids 
(16:0 Cholesterol ester to Ceramide [NS] 36:2) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2v2 7v7 14v14 21v21 
16:0 CE 0.961 0.994 0.941 0.957 0.365 0.570 
16:1 CE 0.923 0.994 0.538 0.308 0.031 0.073 
18:0 CE 0.781 0.994 0.872 0.732 0.673 0.983 
18:1 CE 0.899 0.994 0.224 0.644 0.078 0.426 
18:2 CE 0.781 0.994 0.881 0.797 0.694 0.596 
18:3 CE 0.909 0.994 0.766 0.496 0.222 0.243 
20:3 CE 0.781 0.994 0.829 0.127 0.043 0.039 
20:4 CE 0.781 0.994 0.868 0.855 0.375 0.702 
20:5 CE 0.781 0.994 0.884 0.440 0.622 0.434 
22:4 CE 0.956 0.994 0.872 0.847 0.564 0.874 
22:5 CE 0.781 0.994 0.297 0.406 0.211 0.175 
22:6 CE 0.818 0.994 0.870 0.918 0.258 0.282 
ACAR 10:0 0.781 0.994 0.235 0.661 0.962 0.527 
ACAR 10:1 0.981 0.994 0.566 0.642 0.886 0.733 
ACAR 12:0 0.899 0.994 0.224 0.459 0.731 0.187 
ACAR 14:0 0.909 0.994 0.722 0.218 0.796 0.418 
ACAR 14:1 0.800 0.994 0.071 0.934 0.880 0.753 
ACAR 14:2 0.937 0.994 0.064 0.939 0.942 0.906 
ACAR 16:0 0.917 0.994 0.691 0.005 0.883 0.108 
ACAR 18:0 0.967 0.994 0.277 0.203 0.258 0.084 
ACAR 18:1 0.909 0.994 0.740 0.644 0.563 0.961 
ACAR 18:2 0.963 0.994 0.620 0.644 0.821 0.986 
ACAR 20:0 0.950 0.994 0.214 0.769 0.989 0.243 
ACAR 24:0 0.804 0.994 0.110 0.127 0.245 0.009 
ACAR 26:0 0.951 0.994 0.410 0.362 0.211 0.094 
Cer[AS] 34:1 0.781 0.994 0.878 0.948 0.643 0.701 
Cer[AS] 42:2 0.909 0.994 0.654 0.871 0.954 0.912 
Cer[EODS] 57:2 0.899 0.994 0.741 0.526 0.795 0.213 
Cer[EODS] 58:0 0.781 0.994 0.566 0.642 0.471 0.669 
Cer[EODS] 60:0 0.910 0.994 0.842 0.939 0.699 0.099 
Cer[NDS] 34:0 0.909 0.994 0.397 0.320 0.457 0.201 
Cer[NDS] 36:0 0.818 0.994 0.140 0.398 0.583 0.588 
Cer[NDS] 38:0 0.956 0.994 0.055 0.459 0.883 0.059 
Cer[NDS] 39:0 0.891 0.994 0.314 0.306 0.375 0.175 
Cer[NDS] 40:0 0.987 0.994 0.038 0.235 0.586 0.109 
Cer[NDS] 41:0 0.899 0.994 0.038 0.127 0.258 0.175 
Cer[NDS] 42:0 0.909 0.994 0.051 0.218 0.480 0.072 
Cer[NDS] 42:1 0.961 0.994 0.277 0.588 0.698 0.295 
Cer[NDS] 42:2 0.987 0.994 0.880 0.756 0.585 0.646 
Cer[NDS] 43:0 0.989 0.994 0.055 0.141 0.457 0.009 
Cer[NP] 34:0 0.781 0.994 0.884 0.418 0.268 0.682 
Cer[NP] 40:0 0.944 0.994 0.055 0.238 0.354 0.010 
Cer[NP] 41:0 0.909 0.994 0.736 0.795 0.981 0.248 
Cer[NP] 41:1 0.923 0.994 0.271 0.847 0.883 0.669 
Cer[NP] 42:0 0.909 0.994 0.953 0.847 0.951 0.527 
Cer[NP] 42:1 0.961 0.994 0.172 0.892 0.628 0.527 
Cer[NS] 32:1 0.781 0.994 0.947 0.852 0.314 0.588 
Cer[NS] 33:1 0.909 0.994 0.881 0.994 0.142 0.642 
Cer[NS] 33:4 0.804 0.994 0.566 0.541 0.338 0.740 
Cer[NS] 34:1 0.818 0.994 0.102 0.852 0.078 0.371 
Cer[NS] 34:2 0.899 0.994 0.466 0.957 0.330 0.667 
Cer[NS] 35:1 0.834 0.994 0.581 0.666 0.211 0.511 
Cer[NS] 36:1 0.800 0.994 0.957 0.891 0.454 0.753 
Cer[NS] 36:2 0.800 0.994 0.867 0.769 0.029 0.548 
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Table S2.7B: MEAL Study significant differences for between diet comparisons for all lipids 
(Ceramide [NS] 37:1 to Free Fatty Acid 20:1) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2v2 7v7 14v14 21v21 
Cer[NS] 37:1 0.781 0.994 0.171 0.398 0.883 0.527 
Cer[NS] 38:1 0.799 0.994 0.725 0.992 0.620 0.640 
Cer[NS] 38:2 0.818 0.994 0.842 0.847 0.295 0.578 
Cer[NS] 39:1 0.909 0.994 0.741 0.756 0.883 0.109 
Cer[NS] 40:1 0.818 0.994 0.884 0.958 0.996 0.491 
Cer[NS] 40:2 0.818 0.994 0.566 0.847 0.338 0.843 
Cer[NS] 40:3 0.923 0.994 0.073 0.387 0.400 0.680 
Cer[NS] 41:1 0.899 0.994 0.988 0.930 0.977 0.585 
Cer[NS] 41:2 0.818 0.994 0.495 0.839 0.280 0.770 
Cer[NS] 41:4 0.899 0.994 0.738 0.298 0.883 0.642 
Cer[NS] 42:1 0.910 0.994 0.881 0.979 0.907 0.667 
Cer[NS] 42:2 0.899 0.994 0.706 0.706 0.258 0.505 
Cer[NS] 42:3 0.961 0.994 0.907 0.847 0.136 0.527 
Cer[NS] 43:1 0.781 0.994 0.738 0.756 0.891 0.294 
Cer[NS] 43:2 0.961 0.994 0.501 0.813 0.898 0.926 
Cer[NS] 44:1 0.961 0.994 0.184 0.459 0.810 0.213 
Cer[NS] 44:2 0.987 0.994 0.135 0.847 0.796 0.961 
Cer[NS] 44:4 0.781 0.998 0.842 0.812 0.788 0.213 
Cer[NS] 45:1 0.818 0.994 0.055 0.524 0.899 0.449 
Cer[NS] 46:5 0.909 0.994 0.566 0.890 0.353 0.616 
DG 30:0 0.899 0.994 0.908 0.957 0.381 0.982 
DG 30:1 0.991 0.994 0.657 0.906 0.891 0.940 
DG 32:0 0.818 0.994 0.725 0.957 0.696 0.819 
DG 32:1 0.852 0.994 0.198 0.959 0.583 0.456 
DG 32:2 0.800 0.994 0.654 0.847 0.754 0.873 
DG 33:0 0.781 0.994 0.606 0.939 0.962 0.566 
DG 33:1 0.909 0.994 0.561 0.992 0.894 0.527 
DG 34:0 0.818 0.994 0.566 0.955 0.989 0.874 
DG 34:2 0.818 0.994 0.448 0.847 0.442 0.398 
DG 34:3 0.818 0.994 0.109 0.459 0.375 0.179 
DG 35:1 0.961 0.994 0.761 0.852 0.858 0.885 
DG 35:2 0.909 0.994 0.583 0.847 0.701 0.823 
DG 35:3 0.899 0.994 0.799 0.866 0.699 0.471 
DG 36:0 0.818 0.994 0.941 0.918 0.890 0.771 
DG 36:1 0.907 0.994 0.566 0.891 0.951 0.912 
DG 36:2 0.909 0.994 0.198 0.644 0.338 0.349 
DG 36:3 0.981 0.994 0.434 0.756 0.408 0.198 
DG 36:4 0.944 0.994 0.978 0.883 0.975 0.761 
DG 36:5 0.961 0.994 0.691 0.691 0.937 0.050 
DG 38:1 0.956 0.994 0.590 0.140 0.031 0.119 
DG 38:2 0.909 0.994 0.867 0.971 0.891 0.968 
DG 38:3 0.937 0.994 0.706 0.797 0.530 0.952 
DG 38:4 0.975 0.994 0.237 0.923 0.286 0.804 
DG 38:5 0.951 0.994 0.566 0.706 0.641 0.185 
DG 38:6 0.981 0.994 0.706 0.830 0.671 0.248 
DG 38:7 0.934 0.994 0.941 0.855 0.636 0.393 
DG 40:6 0.907 0.994 0.417 0.758 0.454 0.393 
DG 40:7 0.987 0.994 0.763 0.847 0.986 0.612 
FFA 16:0 0.909 0.994 0.566 0.957 0.509 0.540 
FFA 18:0 0.981 0.994 0.782 0.830 0.530 0.616 
FFA 18:1 0.956 0.994 0.909 0.936 0.338 0.646 
FFA 18:2 0.963 0.994 0.566 0.940 0.505 0.952 
FFA 20:0 0.899 0.994 0.691 0.964 0.699 0.901 
FFA 20:1 0.981 0.994 0.978 0.892 0.375 0.718 
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Table S2.7C: MEAL Study significant differences for between diet comparisons for all lipids 
(Fatty Acid 20:2 to Lysophosphatidylethanolamine 22:4) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2v2 7v7 14v14 21v21 
FFA 20:2 0.961 0.994 0.870 0.630 0.211 0.455 
FFA 20:4 0.781 0.994 0.820 0.444 0.226 0.451 
FFA 22:0 0.865 0.994 0.875 0.923 0.951 0.819 
FFA 22:1 0.975 0.994 0.109 0.983 0.391 0.897 
FFA 22:2 0.967 0.994 0.988 0.892 0.539 0.527 
FFA 22:3 0.987 0.994 0.208 0.871 0.469 0.642 
FFA 24:0 0.909 0.994 0.871 0.852 0.959 0.566 
FFA 24:1 0.909 0.994 0.784 0.852 0.731 0.534 
FFA 24:2 0.975 0.994 0.871 0.892 0.498 0.646 
FFA 24:3 0.987 0.994 0.988 0.746 0.813 0.901 
GlcCer[NS] 34:1 0.818 0.994 0.881 0.811 0.721 0.874 
GlcCer[NS] 34:2 0.931 0.994 0.313 0.322 0.154 0.526 
GlcCer[NS] 40:1 0.781 0.994 0.706 0.934 0.938 0.371 
GlcCer[NS] 41:1 0.981 0.994 0.941 0.418 0.371 0.213 
GlcCer[NS] 42:1 0.781 0.994 0.563 0.992 0.698 0.952 
GlcCer[NS] 42:2 0.800 0.994 0.561 0.589 0.233 0.172 
LysoPC 14:0 0.909 0.994 0.761 0.847 0.788 0.964 
LysoPC 15:0 0.951 0.994 0.842 0.648 0.671 0.527 
LysoPC 15:1 0.818 0.994 0.867 0.844 0.938 0.592 
LysoPC 16:0 0.981 0.994 0.606 0.692 0.290 0.212 
LysoPC 16:1 0.818 0.994 0.071 0.460 0.163 0.041 
LysoPC 17:1 0.956 0.994 0.389 0.847 0.798 0.785 
LysoPC 18:0 0.909 0.994 0.784 0.957 0.938 0.701 
LysoPC 18:1 0.909 0.994 0.884 0.847 0.652 0.431 
LysoPC 18:2 0.907 0.994 0.492 0.621 0.408 0.425 
LysoPC 18:3 0.818 0.994 0.943 0.982 0.962 0.560 
LysoPC 19:0 0.967 0.994 0.754 0.892 0.746 0.591 
LysoPC 19:1 0.909 0.994 0.884 0.958 0.890 0.871 
LysoPC 20:0 0.989 0.994 0.672 0.998 0.915 0.359 
LysoPC 20:1 0.981 0.994 0.276 0.706 0.338 0.425 
LysoPC 20:2 0.951 0.994 0.644 0.644 0.529 0.451 
LysoPC 20:3 0.992 0.994 0.593 0.617 0.375 0.278 
LysoPC 20:4 0.961 0.994 0.875 0.891 0.598 0.596 
LysoPC 20:5 0.917 0.994 0.820 0.812 0.338 0.349 
LysoPC 22:0 0.925 0.994 0.875 0.852 0.823 0.789 
LysoPC 22:4 0.989 0.998 0.657 0.325 0.314 0.526 
LysoPC 22:5 0.996 0.994 0.606 0.643 0.326 0.282 
LysoPC 22:6 0.917 0.994 0.784 0.784 0.245 0.200 
LysoPC 23:0 0.899 0.994 0.881 0.847 0.891 0.874 
LysoPC 24:0 0.950 0.994 0.784 0.954 0.480 0.930 
LysoPC 24:1 0.961 0.994 0.566 0.715 0.457 0.109 
LysoPC 26:1 0.899 0.994 0.496 0.322 0.163 0.110 
LysoPE 16:0 0.902 0.994 0.419 0.588 0.245 0.213 
LysoPE 16:1 0.781 0.994 0.169 0.617 0.454 0.231 
LysoPE 17:0 0.899 0.994 0.909 0.715 0.190 0.418 
LysoPE 18:0 0.899 0.994 0.673 0.706 0.526 0.871 
LysoPE 18:1 0.834 0.994 0.988 0.944 0.883 0.791 
LysoPE 18:2 0.818 0.994 0.357 0.644 0.529 0.243 
LysoPE 18:3 0.818 0.994 0.893 0.936 0.880 0.899 
LysoPE 20:2 0.961 0.994 0.831 0.769 0.747 0.940 
LysoPE 20:3 0.818 0.994 0.654 0.396 0.338 0.248 
LysoPE 20:4 0.981 0.994 0.884 0.947 0.651 0.874 
LysoPE 20:5 0.951 0.994 0.843 0.847 0.466 0.425 
LysoPE 22:4 0.818 0.994 0.620 0.415 0.338 0.088 
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Table S2.7D: MEAL Study significant differences for between diet comparisons for all lipids 
(Lysophosphatidylethanolamine 22:5 to Phosphatidylcholine 38:1) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
LysoPE 22:5 0.909 0.994 0.566 0.412 0.239 0.089 
LysoPE 22:6 0.899 0.994 0.875 0.847 0.457 0.739 
LysoPE 24:0 0.981 0.994 0.987 0.854 0.583 0.734 
PA 34:1 0.781 0.994 0.263 0.644 0.258 0.152 
PA 34:2 0.781 0.994 0.456 0.325 0.277 0.527 
PA 36:1 0.781 0.994 0.240 0.459 0.891 0.776 
PA 36:2 0.781 0.994 0.881 0.847 0.277 0.548 
PA 36:3 0.781 0.994 0.128 0.235 0.078 0.248 
PA 36:4 0.975 0.994 0.876 0.661 0.975 0.503 
PA 38:6 0.899 0.994 0.881 0.661 0.245 0.425 
PC 24:0 0.937 0.994 0.038 0.398 0.314 0.725 
PC 26:0 0.975 0.994 0.095 0.351 0.211 0.285 
PC 27:0 0.818 0.994 0.656 0.847 0.731 0.321 
PC 28:2 0.818 0.994 0.916 0.614 0.671 0.581 
PC 29:0 0.977 0.994 0.566 0.453 0.363 0.585 
PC 30:0 0.929 0.994 0.941 0.871 0.880 0.739 
PC 30:2 0.818 0.994 0.768 0.238 0.268 0.871 
PC 31:0 0.909 0.994 0.593 0.235 0.273 0.255 
PC 31:1 0.917 0.994 0.566 0.706 0.457 0.753 
PC 32:0 0.818 0.994 0.768 0.469 0.898 0.891 
PC 32:1 0.818 0.994 0.062 0.298 0.226 0.093 
PC 32:2 0.909 0.994 0.867 0.644 0.535 0.871 
PC 32:3 0.799 0.994 0.796 0.588 0.843 0.527 
PC 33:0 0.909 0.994 0.844 0.398 0.843 0.566 
PC 33:1 0.981 0.994 0.566 0.940 0.339 0.636 
PC 33:2 0.907 0.994 0.020 0.008 0.044 0.007 
PC 33:3 0.967 0.994 0.784 0.541 0.669 0.872 
PC 34:1 0.909 0.994 0.098 0.322 0.226 0.136 
PC 34:2 0.909 0.994 0.855 0.814 0.496 0.581 
PC 34:3 0.818 0.994 0.277 0.814 0.413 0.501 
PC 34:4 0.961 0.994 0.763 0.892 0.858 0.616 
PC 34:5 0.818 0.994 0.875 0.847 0.690 0.646 
PC 35:0 0.904 0.994 0.208 0.127 0.462 0.541 
PC 35:1 0.818 0.994 0.315 0.406 0.344 0.986 
PC 35:2 0.909 0.994 0.098 0.692 0.226 0.010 
PC 35:3 0.781 0.994 0.341 0.644 0.340 0.986 
PC 35:4 0.818 0.994 0.988 0.852 0.713 0.616 
PC 35:5 0.909 0.994 0.784 0.854 0.714 0.929 
PC 35:6 0.987 0.994 0.691 0.744 0.286 0.739 
PC 36:0 0.818 0.994 0.988 0.942 0.701 0.776 
PC 36:1 0.899 0.994 0.774 0.935 0.723 0.884 
PC 36:2 0.909 0.994 0.583 0.847 0.723 0.511 
PC 36:3 0.859 0.994 0.878 0.923 0.592 0.526 
PC 36:4 0.961 0.994 0.855 0.813 0.340 0.753 
PC 36:5 0.996 0.994 0.553 0.617 0.245 0.078 
PC 36:6 0.478 0.994 0.782 0.847 0.830 0.615 
PC 37:1 0.899 0.994 0.864 0.715 0.564 0.968 
PC 37:2 0.781 0.994 0.741 0.847 0.813 0.789 
PC 37:3 0.899 0.994 0.838 0.847 0.788 0.901 
PC 37:4 0.781 0.994 0.875 0.643 0.556 0.968 
PC 37:5 0.899 0.994 0.436 0.691 0.226 0.221 
PC 37:6 0.945 0.994 0.941 0.847 0.277 0.874 
PC 37:7 0.981 0.994 0.941 0.852 0.344 0.986 
PC 38:1 0.961 0.994 0.829 0.654 0.415 0.680 
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Table S2.7E: MEAL Study significant differences for between diet comparisons for all lipids 
(Phosphatidylcholine 38:2 to Phosphatidylethanolamine 34:4) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
PC 38:2 0.984 0.994 0.774 0.758 0.622 0.952 
PC 38:3 0.800 0.994 0.064 0.263 0.174 0.046 
PC 38:4 0.781 0.994 0.467 0.592 0.258 0.213 
PC 38:5 0.825 0.994 0.172 0.263 0.043 0.046 
PC 38:6 0.899 0.998 0.331 0.644 0.205 0.235 
PC 38:7 0.967 0.994 0.357 0.706 0.277 0.221 
PC 39:3 0.781 0.994 0.761 0.617 0.820 0.652 
PC 39:4 0.781 0.994 0.467 0.934 0.526 0.431 
PC 39:6 0.818 0.994 0.320 0.666 0.338 0.448 
PC 39:7 0.981 0.994 0.389 0.459 0.245 0.669 
PC 39:8 0.910 0.994 0.941 0.847 0.775 0.874 
PC 40:0 0.902 0.994 0.466 0.644 0.526 0.952 
PC 40:1 0.909 0.994 0.996 0.934 0.526 0.885 
PC 40:2 0.781 0.994 0.867 0.756 0.907 0.642 
PC 40:4 0.899 0.994 0.566 0.415 0.084 0.212 
PC 40:5 0.818 0.994 0.055 0.140 0.040 0.009 
PC 40:6 0.899 0.994 0.171 0.478 0.120 0.092 
PC 40:7 0.818 0.994 0.389 0.644 0.210 0.243 
PC 40:8 0.781 0.994 0.581 0.644 0.120 0.566 
PC 41:3 0.981 0.994 0.725 0.934 0.496 0.982 
PC 41:4 0.818 0.994 0.838 0.930 0.891 0.702 
PC 41:5 0.818 0.994 0.761 0.964 0.599 0.272 
PC 41:6 0.981 0.994 0.071 0.617 0.154 0.330 
PC 41:7 0.836 0.994 0.916 0.813 0.928 0.680 
PC 42:1 0.917 0.994 0.466 0.812 0.391 0.319 
PC 42:10 0.903 0.994 0.868 0.847 0.268 0.589 
PC 42:2 0.909 0.994 0.875 0.934 0.816 0.701 
PC 42:3 0.981 0.994 0.397 0.847 0.626 0.131 
PC 42:4 0.899 0.994 0.754 0.459 0.353 0.573 
PC 42:5 0.992 0.994 0.595 0.541 0.258 0.174 
PC 42:6 0.781 0.994 0.271 0.235 0.027 0.015 
PC 42:7 0.981 0.994 0.268 0.934 0.070 0.667 
PC 42:8 0.909 0.994 0.309 0.298 0.108 0.064 
PC 42:9 0.818 0.994 0.055 0.398 0.070 0.029 
PC 44:12 0.834 0.994 0.620 0.756 0.525 0.592 
PC 44:2 0.894 0.994 0.941 0.852 0.496 0.669 
PC 44:3 0.956 0.994 0.586 0.944 0.796 0.291 
PC 44:4 0.961 0.994 0.394 0.322 0.574 0.451 
PC 44:5 0.996 0.994 0.020 0.918 0.226 0.066 
PC 44:6 0.981 0.994 0.867 0.892 0.891 0.669 
PC 44:8 0.951 0.994 0.864 0.532 0.886 0.125 
PC 46:4 0.818 0.994 0.389 0.235 0.403 0.411 
PE 30:0 0.909 0.994 0.512 0.642 0.462 0.928 
PE 32:0 0.844 0.994 0.988 0.617 0.962 0.869 
PE 32:1 0.818 0.994 0.111 0.645 0.237 0.559 
PE 32:2 0.996 0.994 0.884 0.450 0.226 0.566 
PE 33:0 0.899 0.994 0.997 0.974 0.586 0.871 
PE 33:1 0.818 0.994 0.271 0.906 0.858 0.425 
PE 33:2 0.874 0.994 0.405 0.814 0.404 0.179 
PE 34:0 0.917 0.994 0.665 0.854 0.886 0.874 
PE 34:1 0.828 0.994 0.373 0.617 0.245 0.512 
PE 34:2 0.909 0.994 0.784 0.938 0.962 0.819 
PE 34:3 0.818 0.994 0.829 0.958 0.783 0.645 
PE 34:4 0.818 0.994 0.566 0.847 0.432 0.843 
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Table S2.7F: MEAL Study significant differences for between diet comparisons for all lipids 
(Phosphatidylethanolamine 35:0 to Plasmenyl-phosphatidylcholine 35:3) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
PE 35:0 0.961 0.994 0.606 0.871 0.886 0.776 
PE 35:1 0.975 0.994 0.750 0.847 0.943 0.636 
PE 35:2 0.909 0.994 0.941 0.919 0.891 0.646 
PE 35:4 0.961 0.994 0.871 0.957 0.795 0.372 
PE 36:0 0.909 0.994 0.817 0.958 0.239 0.611 
PE 36:1 0.896 0.994 0.881 0.849 0.788 0.871 
PE 36:2 0.884 0.994 0.878 0.811 0.707 0.527 
PE 36:3 0.818 0.994 0.716 0.706 0.591 0.252 
PE 36:4 0.924 0.994 0.277 0.644 0.287 0.527 
PE 36:5 0.950 0.994 0.606 0.661 0.526 0.443 
PE 37:4 0.818 0.994 0.691 0.706 0.883 0.945 
PE 38:3 0.899 0.994 0.878 0.957 0.245 0.884 
PE 38:4 0.818 0.994 0.412 0.614 0.344 0.926 
PE 38:5 0.961 0.994 0.566 0.706 0.353 0.867 
PE 38:6 0.922 0.994 0.941 0.871 0.457 0.901 
PE 38:7 0.996 0.994 0.699 0.847 0.589 0.799 
PE 40:4 0.818 0.994 0.538 0.847 0.375 0.834 
PE 40:5 0.951 0.994 0.561 0.643 0.211 0.760 
PE 40:6 0.981 0.994 0.820 0.852 0.375 0.669 
PE 40:7 0.961 0.994 0.561 0.847 0.526 0.871 
PE 40:8 0.981 0.994 0.686 0.841 0.873 0.635 
PE 42:10 0.937 0.994 0.988 0.715 0.945 0.871 
PG 33:0 0.478 0.994 0.784 0.852 0.315 0.426 
PG 34:0 0.907 0.994 0.639 0.847 0.921 0.255 
PG 34:2 0.983 0.994 0.761 0.322 0.136 0.526 
PG 36:0 0.951 0.994 0.884 0.992 0.452 0.982 
PG 36:2 0.975 0.994 0.496 0.325 0.375 0.526 
PG 36:3 0.951 0.998 0.855 0.811 0.142 0.666 
PG 38:4 0.909 0.994 0.741 0.753 0.375 0.874 
PI 25:0 0.781 0.994 0.868 0.847 0.314 0.940 
PI 34:1 0.899 0.994 0.844 0.661 0.731 0.982 
PI 34:2 0.818 0.994 0.829 0.957 0.457 0.874 
PI 36:1 0.899 0.994 0.737 0.918 0.883 0.610 
PI 36:2 0.961 0.994 0.875 0.852 0.919 0.739 
PI 36:4 0.781 0.994 0.566 0.588 0.163 0.761 
PI 38:3 0.781 0.994 0.621 0.648 0.094 0.642 
PI 38:4 0.800 0.994 0.839 0.847 0.330 0.956 
PI 38:5 0.818 0.994 0.566 0.706 0.297 0.885 
PI 38:6 0.818 0.994 0.691 0.692 0.338 0.703 
PI 40:5 0.899 0.994 0.741 0.706 0.136 0.630 
PI 40:6 0.899 0.994 0.900 0.692 0.070 0.668 
PlsCho 24:0 0.961 0.994 0.566 0.715 0.457 0.109 
PlsCho 28:0 0.781 0.994 0.763 0.760 0.454 0.635 
PlsCho 32:0 0.951 0.994 0.868 0.852 0.883 0.592 
PlsCho 32:1 0.996 0.994 0.419 0.921 0.136 0.165 
PlsCho 33:0 0.781 0.994 0.784 0.644 0.943 0.404 
PlsCho 34:0 0.909 0.994 0.998 0.847 0.807 0.952 
PlsCho 34:1 0.818 0.994 0.884 0.930 0.818 0.952 
PlsCho 34:2 0.818 0.998 0.706 0.652 0.375 0.109 
PlsCho 34:3 0.909 0.994 0.803 0.934 0.338 0.175 
PlsCho 35:0 0.899 0.994 0.535 0.769 0.928 0.393 
PlsCho 35:1 0.781 0.994 0.620 0.644 0.492 0.425 
PlsCho 35:2 0.937 0.994 0.947 0.930 0.564 0.529 
PlsCho 35:3 0.825 0.994 0.957 0.756 0.699 0.073 
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Table S2.7G: MEAL Study significant differences for between diet comparisons for all lipids 
(Plasmenyl-phosphatidylcholine 35:4 to Plasmenyl-phosphatidylethanolamine 36:1) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
PlsCho 35:4 0.899 0.994 0.691 0.847 0.996 0.201 
PlsCho 36:0 0.981 0.994 0.878 0.921 0.526 0.237 
PlsCho 36:2 0.818 0.994 0.947 0.957 0.975 0.791 
PlsCho 36:3 0.909 0.994 0.563 0.398 0.699 0.012 
PlsCho 36:4 0.781 0.994 0.844 0.934 0.890 0.296 
PlsCho 36:5 0.818 0.994 0.784 0.974 0.907 0.611 
PlsCho 36:6 0.781 0.994 0.561 0.398 0.832 0.982 
PlsCho 37:1 0.910 0.994 0.953 0.342 0.920 0.667 
PlsCho 37:2 0.895 0.994 0.140 0.821 0.457 0.573 
PlsCho 37:3 0.818 0.994 0.761 0.814 0.831 0.009 
PlsCho 37:4 0.478 0.994 0.845 0.871 0.891 0.030 
PlsCho 37:6 0.781 0.994 0.741 0.715 0.928 0.559 
PlsCho 38:0 0.961 0.994 0.880 0.617 0.713 0.871 
PlsCho 38:1 0.917 0.994 0.836 0.459 0.629 0.291 
PlsCho 38:3 0.818 0.994 0.941 0.546 0.466 0.034 
PlsCho 38:4 0.987 0.994 0.761 0.422 0.907 0.185 
PlsCho 38:5 0.899 0.994 0.706 0.847 0.858 0.136 
PlsCho 38:6 0.834 0.994 0.948 0.958 0.858 0.512 
PlsCho 39:3 0.899 0.994 0.855 0.644 0.699 0.666 
PlsCho 39:4 0.909 0.994 0.881 0.930 0.899 0.716 
PlsCho 39:5 0.799 0.994 0.689 0.644 0.338 0.534 
PlsCho 39:6 0.781 0.994 0.606 0.756 0.480 0.581 
PlsCho 40:0 0.956 0.994 0.784 0.852 0.530 0.961 
PlsCho 40:1 0.987 0.994 0.978 0.592 0.880 0.888 
PlsCho 40:3 0.981 0.994 0.908 0.398 0.338 0.066 
PlsCho 40:4 0.910 0.994 0.774 0.746 0.996 0.635 
PlsCho 40:5 0.874 0.994 0.884 0.459 0.598 0.527 
PlsCho 40:6 0.961 0.994 0.475 0.715 0.526 0.952 
PlsCho 42:1 0.874 0.994 0.872 0.971 0.775 0.602 
PlsCho 42:2 0.984 0.994 0.820 0.812 0.956 0.986 
PlsCho 42:3 0.975 0.994 0.993 0.238 0.722 0.490 
PlsCho 42:4 0.981 0.994 0.881 0.892 0.598 0.243 
PlsCho 42:5 0.781 0.994 0.741 0.298 0.570 0.725 
PlsCho 42:6 0.818 0.994 0.818 0.440 0.338 0.791 
PlsCho 44:3 0.818 0.994 0.208 0.847 0.567 0.425 
PlsCho 44:4 0.981 0.994 0.884 0.890 0.442 0.213 
PlsCho 44:5 0.818 0.994 0.741 0.847 0.136 0.248 
PlsCho 44:6 0.781 0.994 0.988 0.957 0.593 0.213 
PlsCho 46:4 0.917 0.994 0.654 0.891 0.295 0.099 
PlsEth 32:0 0.981 0.994 0.849 0.971 0.615 0.691 
PlsEth 32:1 0.899 0.994 0.277 0.552 0.375 0.434 
PlsEth 32:2 0.907 0.994 0.001 0.003 0.007 0.002 
PlsEth 33:1 0.818 0.994 0.140 0.127 0.043 0.010 
PlsEth 33:2 0.818 0.994 0.055 0.029 0.019 0.021 
PlsEth 34:0 0.909 0.994 0.190 0.706 0.891 0.703 
PlsEth 34:1 0.989 0.994 0.140 0.459 0.981 0.189 
PlsEth 34:2 0.917 0.994 0.178 0.238 0.222 0.099 
PlsEth 34:3 0.909 0.994 0.038 0.308 0.116 0.072 
PlsEth 34:4 0.781 0.994 0.038 0.127 0.019 0.002 
PlsEth 35:1 0.874 0.994 0.277 0.847 0.222 0.248 
PlsEth 35:2 0.818 0.994 0.132 0.218 0.188 0.105 
PlsEth 35:4 0.781 0.994 0.020 0.127 0.031 0.002 
PlsEth 36:0 0.909 0.994 0.881 0.847 0.938 0.983 
PlsEth 36:1 0.961 0.994 0.051 0.308 0.330 0.014 
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Table S2.7H: MEAL Study significant differences for between diet comparisons for all lipids 
(Plasmenyl-phosphatidylethanolamine 36:2 to Sphingomyelin 38:2) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
PlsEth 36:2 0.950 0.994 0.038 0.141 0.031 0.007 
PlsEth 36:3 0.929 0.994 0.095 0.459 0.843 0.084 
PlsEth 36:4 0.818 0.994 0.872 0.847 0.375 0.761 
PlsEth 36:5 0.909 0.994 0.055 0.398 0.592 0.612 
PlsEth 36:6 0.818 0.994 0.135 0.706 0.425 0.174 
PlsEth 37:1 0.818 0.994 0.492 0.459 0.526 0.131 
PlsEth 37:2 0.899 0.994 0.706 0.939 0.788 0.243 
PlsEth 37:3 0.781 0.994 0.566 0.918 0.891 0.418 
PlsEth 37:4 0.781 0.994 0.761 0.982 0.996 0.109 
PlsEth 37:5 0.781 0.994 0.055 0.642 0.349 0.295 
PlsEth 37:6 0.852 0.994 0.020 0.127 0.040 0.009 
PlsEth 38:1 0.909 0.994 0.311 0.706 0.913 0.566 
PlsEth 38:2 0.874 0.994 0.237 0.812 0.843 0.667 
PlsEth 38:3 0.781 0.994 0.297 0.706 0.995 0.213 
PlsEth 38:4 0.781 0.994 0.881 0.957 0.891 0.243 
PlsEth 38:5 0.818 0.994 0.396 0.847 0.821 0.242 
PlsEth 38:6 0.818 0.994 0.563 0.706 0.858 0.612 
PlsEth 39:2 0.781 0.994 0.592 0.398 0.905 0.901 
PlsEth 39:4 0.781 0.994 0.978 0.847 0.906 0.380 
PlsEth 39:5 0.800 0.994 0.095 0.732 0.526 0.059 
PlsEth 39:6 0.781 0.994 0.960 0.866 0.962 0.529 
PlsEth 40:1 0.818 0.994 0.701 0.847 0.652 0.874 
PlsEth 40:2 0.909 0.994 0.881 0.617 0.671 0.961 
PlsEth 40:4 0.818 0.994 0.941 0.934 0.583 0.426 
PlsEth 40:5 0.818 0.994 0.566 0.398 0.981 0.107 
PlsEth 40:6 0.781 0.994 0.934 0.814 0.928 0.573 
PlsEth 41:4 0.799 0.994 0.644 0.847 0.526 0.823 
PlsEth 41:6 0.951 0.994 0.866 0.502 0.898 0.982 
PlsEth 42:4 0.781 0.994 0.836 0.706 0.349 0.952 
PlsEth 42:5 0.818 0.994 0.881 0.920 0.314 0.753 
PlsEth 42:6 0.818 0.994 0.900 0.617 0.583 0.553 
PlsEth 44:6 0.818 0.994 0.271 0.847 0.396 0.310 
PS 36:1 0.950 0.994 0.563 0.847 0.823 0.704 
PS 38:4 0.968 0.994 0.820 0.957 0.994 0.064 
SM 30:1 0.909 0.994 0.829 0.789 0.891 0.425 
SM 30:2 0.996 0.994 0.218 0.238 0.639 0.024 
SM 32:0 0.781 0.994 0.882 0.614 0.883 0.471 
SM 32:1 0.781 0.994 0.878 0.934 0.944 0.491 
SM 32:2 0.825 0.994 0.566 0.934 0.858 0.982 
SM 33:1 0.781 0.994 0.796 0.957 0.905 0.283 
SM 34:0 0.818 0.994 0.988 0.847 0.481 0.874 
SM 34:1 0.799 0.994 0.941 0.617 0.938 0.527 
SM 34:2 0.818 0.994 0.881 0.847 0.883 0.982 
SM 34:3 0.909 0.994 0.566 0.692 0.698 0.945 
SM 35:2 0.967 0.994 0.868 0.553 0.699 0.534 
SM 36:1 0.818 0.994 0.855 0.271 0.886 0.527 
SM 36:2 0.967 0.994 0.706 0.416 0.880 0.435 
SM 36:3 0.909 0.994 0.566 0.644 0.821 0.107 
SM 36:4 0.917 0.994 0.951 0.969 0.981 0.172 
SM 37:1 0.818 0.994 0.656 0.082 0.363 0.032 
SM 37:2 0.899 0.994 0.820 0.617 0.788 0.311 
SM 38:0 0.781 0.994 0.319 0.854 0.910 0.749 
SM 38:1 0.781 0.994 0.706 0.959 0.882 0.871 
SM 38:2 0.899 0.994 0.833 0.847 0.425 0.982 
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Table S2.7I: MEAL Study significant differences for between diet comparisons for all lipids 
(Sphingomyelin 38:3 to Triacylglycerol 46:1) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
SM 38:3 0.818 0.994 0.784 0.981 0.702 0.791 
SM 38:4 0.818 0.994 0.315 0.308 0.723 0.534 
SM 39:0 0.987 0.994 0.561 0.238 0.312 0.046 
SM 39:1 0.818 0.994 0.761 0.418 0.678 0.089 
SM 39:2 0.781 0.994 0.875 0.493 0.788 0.100 
SM 39:3 0.967 0.994 0.410 0.325 0.375 0.059 
SM 40:1 0.800 0.994 0.881 0.263 0.365 0.021 
SM 40:2 0.907 0.994 0.988 0.680 0.891 0.359 
SM 40:3 0.874 0.994 0.845 0.672 0.622 0.843 
SM 40:5 0.818 0.994 0.941 0.706 0.545 0.786 
SM 41:1 0.781 0.994 0.881 0.203 0.373 0.050 
SM 41:2 0.981 0.994 0.988 0.892 0.391 0.760 
SM 41:3 0.899 0.994 0.892 0.992 0.363 0.885 
SM 41:4 0.899 0.994 0.592 0.243 0.457 0.411 
SM 41:6 0.818 0.994 0.881 0.934 0.906 0.591 
SM 42:1 0.818 0.994 0.916 0.546 0.880 0.285 
SM 42:2 0.967 0.994 0.916 0.844 0.314 0.425 
SM 42:3 0.981 0.994 0.988 0.974 0.375 0.426 
SM 42:4 0.899 0.994 0.620 0.589 0.019 0.029 
SM 42:5 0.909 0.994 0.820 0.982 0.375 0.434 
SM 42:6 0.912 0.994 0.957 0.937 0.880 0.610 
SM 43:1 0.781 0.994 0.880 0.398 0.891 0.175 
SM 43:2 0.899 0.994 0.829 0.406 0.883 0.667 
SM 43:3 0.955 0.994 0.574 0.459 0.935 0.873 
SM 43:6 0.967 0.994 0.592 0.706 0.365 0.635 
SM 43:8 0.987 0.994 0.900 0.398 0.363 0.358 
SM 44:1 0.818 0.994 0.987 0.812 0.996 0.527 
SM 44:2 0.909 0.994 0.988 0.769 0.526 0.544 
SM 44:3 0.818 0.994 0.867 0.852 0.891 0.986 
SM 44:5 0.884 0.994 0.566 0.773 0.070 0.776 
SM 44:6 0.781 0.994 0.561 0.921 0.375 0.636 
SM 45:7 0.781 0.994 0.871 0.614 0.927 0.926 
TG 36:0 0.781 0.994 0.348 0.238 0.239 0.385 
TG 38:0 0.799 0.994 0.239 0.398 0.239 0.471 
TG 39:0 0.850 0.994 0.740 0.852 0.843 0.680 
TG 40:0 0.839 0.994 0.496 0.459 0.256 0.503 
TG 40:1 0.781 0.994 0.763 0.706 0.338 0.619 
TG 41:0 0.818 0.994 0.533 0.666 0.363 0.636 
TG 42:0 0.818 0.994 0.706 0.642 0.338 0.526 
TG 42:1 0.818 0.994 0.820 0.847 0.375 0.642 
TG 42:2 0.818 0.994 0.596 0.617 0.238 0.573 
TG 42:3 0.781 0.994 0.621 0.989 0.338 0.701 
TG 43:0 0.909 0.994 0.691 0.580 0.268 0.491 
TG 43:1 0.818 0.994 0.872 0.847 0.529 0.619 
TG 43:2 0.802 0.994 0.941 0.958 0.408 0.776 
TG 44:0 0.899 0.994 0.829 0.706 0.363 0.635 
TG 44:1 0.818 0.994 0.978 0.934 0.540 0.776 
TG 44:2 0.818 0.994 0.812 0.789 0.375 0.667 
TG 44:3 0.799 0.994 0.706 0.839 0.338 0.680 
TG 45:0 0.956 0.994 0.881 0.847 0.349 0.527 
TG 45:1 0.909 0.994 0.951 0.823 0.480 0.740 
TG 45:2 0.818 0.994 0.934 0.871 0.496 0.782 
TG 46:0 0.818 0.994 0.988 0.957 0.670 0.776 
TG 46:1 0.818 0.994 0.784 0.971 0.674 0.945 
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Table S2.7J: MEAL Study significant differences for between diet comparisons for all lipids 
(Triacylglycerol 46:2 to Triacylglycerol 55:2) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
TG 46:2 0.818 0.994 0.849 0.992 0.585 0.997 
TG 46:3 0.818 0.994 0.941 0.930 0.570 0.998 
TG 47:0 0.818 0.994 0.867 0.847 0.722 0.725 
TG 47:1 0.919 0.994 0.782 0.976 0.858 0.982 
TG 47:2 0.910 0.994 0.833 0.930 0.692 0.940 
TG 47:3 0.818 0.994 0.988 0.847 0.506 0.986 
TG 48:0 0.818 0.994 0.884 0.938 0.710 0.701 
TG 48:1 0.818 0.994 0.561 0.870 0.962 0.753 
TG 48:2 0.818 0.994 0.561 0.892 0.912 0.669 
TG 48:3 0.818 0.994 0.496 0.876 0.891 0.560 
TG 48:4 0.818 0.994 0.784 0.847 0.711 0.635 
TG 48:5 0.909 0.994 0.870 0.971 0.883 0.581 
TG 49:0 0.899 0.994 0.941 0.706 0.586 0.690 
TG 49:1 0.937 0.994 0.844 0.918 0.880 0.874 
TG 49:2 0.923 0.994 0.867 0.899 0.907 0.924 
TG 49:3 0.917 0.994 0.535 0.927 0.871 0.680 
TG 50:0 0.818 0.994 0.948 0.981 0.883 0.874 
TG 50:1 0.818 0.994 0.741 0.892 0.959 0.961 
TG 50:2 0.818 0.994 0.198 0.784 0.661 0.566 
TG 50:3 0.836 0.994 0.140 0.838 0.682 0.313 
TG 50:4 0.818 0.994 0.563 0.892 0.944 0.425 
TG 50:5 0.818 0.994 0.563 0.847 0.931 0.321 
TG 50:6 0.818 0.994 0.855 0.871 0.891 0.527 
TG 51:0 0.956 0.994 0.981 0.934 0.462 0.699 
TG 51:1 0.967 0.994 0.770 0.971 0.886 0.871 
TG 51:2 0.996 0.994 0.563 0.940 0.891 0.929 
TG 51:3 0.996 0.994 0.691 0.847 0.880 0.923 
TG 51:4 0.818 0.994 0.878 0.418 0.230 0.572 
TG 51:5 0.899 0.994 0.184 0.852 0.891 0.791 
TG 52:0 0.899 0.994 0.980 0.882 0.633 0.570 
TG 52:1 0.899 0.994 0.586 0.852 0.994 0.945 
TG 52:2 0.961 0.994 0.135 0.661 0.344 0.540 
TG 52:3 0.981 0.994 0.566 0.958 0.795 0.616 
TG 52:4 0.967 0.994 0.869 0.847 0.931 0.739 
TG 52:5 0.899 0.994 0.691 0.852 0.723 0.177 
TG 52:6 0.818 0.994 0.315 0.617 0.532 0.059 
TG 52:7 0.818 0.994 0.592 0.644 0.652 0.175 
TG 53:0 0.975 0.994 0.988 0.814 0.583 0.952 
TG 53:1 0.925 0.994 0.871 0.985 0.526 0.559 
TG 53:2 0.961 0.994 0.566 0.934 0.890 0.928 
TG 53:3 0.911 0.998 0.820 0.957 0.907 0.986 
TG 53:4 0.975 0.994 0.741 0.789 0.530 0.986 
TG 53:5 0.987 0.994 0.878 0.982 0.883 0.810 
TG 54:0 0.825 0.994 0.833 0.706 0.258 0.632 
TG 54:1 0.899 0.994 0.978 0.847 0.371 0.391 
TG 54:2 0.925 0.994 0.725 0.847 0.890 0.874 
TG 54:3 0.975 0.994 0.566 0.847 0.873 0.891 
TG 54:4 0.967 0.994 0.725 0.871 0.996 0.595 
TG 54:5 0.909 0.994 0.878 0.930 0.891 0.385 
TG 54:6 0.899 0.994 0.878 0.930 0.951 0.426 
TG 54:7 0.818 0.994 0.957 0.769 0.831 0.091 
TG 54:8 0.899 0.994 0.737 0.706 0.795 0.069 
TG 55:0 0.987 0.994 0.401 0.847 0.564 0.739 
TG 55:2 0.961 0.994 0.761 0.852 0.633 0.534 
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Table S2.7K: MEAL Study significant differences for between diet comparisons for all lipids 
(Triacylglycerol 55:3 to Triacylglycerol 62:12) 
 Between Diet Comparisons  
 FDR <0.1 
Lipid/Day B v B S v S 2 v 2 7 v 7 14 v 14 21 v 21 
TG 55:3 0.956 0.994 0.916 0.892 0.699 0.385 
TG 55:4 0.950 0.994 0.397 0.756 0.996 0.652 
TG 55:5 0.909 0.994 0.829 0.614 0.937 0.874 
TG 56:0 0.818 0.998 0.761 0.811 0.230 0.534 
TG 56:1 0.899 0.994 0.909 0.852 0.226 0.179 
TG 56:10 0.909 0.994 0.882 0.706 0.816 0.099 
TG 56:2 0.818 0.994 0.875 0.911 0.603 0.391 
TG 56:3 0.899 0.994 0.774 0.821 0.981 0.952 
TG 56:4 0.917 0.994 0.761 0.715 0.731 0.488 
TG 56:5 0.909 0.994 0.784 0.692 0.564 0.421 
TG 56:6 0.923 0.994 0.875 0.784 0.563 0.371 
TG 56:7 0.996 0.994 0.829 0.934 0.723 0.527 
TG 56:8 0.923 0.994 0.496 0.982 0.996 0.871 
TG 56:9 0.899 0.994 0.864 0.847 0.739 0.278 
TG 57:2 0.992 0.994 0.071 0.630 0.643 0.425 
TG 57:4 0.987 0.994 0.941 0.662 0.526 0.418 
TG 58:1 0.899 0.994 0.833 0.992 0.639 0.566 
TG 58:10 0.909 0.994 0.410 0.983 0.948 0.896 
TG 58:11 0.923 0.994 0.401 0.934 0.994 0.630 
TG 58:2 0.895 0.994 0.868 0.746 0.880 0.770 
TG 58:3 0.818 0.994 0.829 0.982 0.832 0.940 
TG 58:4 0.899 0.994 0.819 0.891 0.788 0.912 
TG 58:5 0.865 0.994 0.941 0.720 0.535 0.662 
TG 58:6 0.992 0.994 0.943 0.828 0.526 0.534 
TG 58:7 0.992 0.994 0.876 0.706 0.690 0.669 
TG 58:8 0.967 0.994 0.829 0.797 0.674 0.527 
TG 58:9 0.981 0.994 0.566 0.934 0.890 0.874 
TG 60:10 0.967 0.994 0.741 0.789 0.526 0.843 
TG 60:11 0.987 0.994 0.271 0.969 0.996 0.952 
TG 60:12 0.917 0.994 0.271 0.982 0.910 0.952 
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Chapter 3: A Comparison of Actual and Reported Energy and 
Macronutrient Intake in a Well-Controlled Human Feeding Study 
Abstract 
Objectives: Dietary guidelines are largely based on epidemiological studies that rely on memory-
based dietary assessments (MBDA) such as 24-hour recalls (24HR). Well-controlled feeding 
studies are often used to help confirm these larger epidemiological studies findings and help 
draw associations between diet and disease (1). Few studies have compared actual and reported 
dietary intake in well-controlled feeding studies. This study sought to directly compare 
discrepancies between dietary intake from experimental diets and reported 24HR intake in free-
living participants.  
Methods: Eucaloric diets were provided to 24 participants (50% female, mean age 24.4(3.4); 
mean BMI 23.1(SD 2.9) for 24 days. Participants were provided a standard diet (15% protein 
(PRO): 35% fat: 50% carbohydrate (CHO)) for 3 days and then randomly assigned to either a 21-
day high fat (60% fat, HF) or a high CHO (75% CHO, HC). PRO% was held constant at 15%. 
Percent difference from provided food was calculated as (g reported/g actual)*100. Dietitians 
prepared diets with macronutrient compositions adjusted to achieve targeted percentages, either 
overtly (added sugary drinks) or covertly (added coconut oil). Total provided energy intake (EI) 
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was adjusted to maintain weight (±1 kg) over the course of the study. Trained staff at the 
Michigan Nutrition Obesity Research Center administered four 24HR; one after                          
completing the 3-day standard diet, then once a week during the 21-day experimental diets. 
Participants were instructed to return uneaten food and beverages for accurate calculation of 
dietary intake. Actual and reported energy intake (EI) and macronutrient intakes were estimated 
using the Nutrition Data System for Research software (NDSR) and compared within group via 
paired Student’s t-tests (α=0.05).  
Results:  
No difference was observed between actual EI and reported EI during the standard or 
experimental diet for HF or HC groups. PRO intake was over-reported by all participants during 
the standard diet by 27.4% (11.3) and during the HC by 15.6% (7.2) and HF by 16.1% (5.6). 
Differences in protein intake between actual and reported was due to over-reporting of animal 
protein in foods. During the experimental diet, HC participants over-reported CHO by 66.4% 
(11.4) and under-reported fat by 6.3% (4.7) while HF participants under-reported CHO by 10.8% 
(6.5) and over-reported fat by 19.8% (6.7). (p<0.05).  
Conclusion:  
In this well-controlled feeding study in free-living participants, EI was accurately reported. 
Participants over-reported animal protein intake. When given extreme diets, participants tended 
to underreport the experimental macronutrient (HF or HC). These results suggest that while EI 
can be estimated from feeding studies, estimates of macronutrients should be determined directly 






Measuring food and nutrient intake is challenging for nutrition researchers and health 
practitioners. To do this, most researchers rely on MBDA such as food frequency questionnaires 
(FFQ) and 24-hour recalls (24HR) (2, 3). Despite their widespread use, under-reporting of EI is a 
well-known problem with MBDAs (4-10) and established methods to adjust for known over and 
under-reporting are widely used (11-14). Examples of errors include respondent systematic over-
reporting or under-reporting of a certain foods consumed as well as respondent random memory 
lapses resulting in unintentionally omitting or adding foods during the recall (15). 
Misrepresentation or misreporting of portion size is also an important factor associated with 
misreporting of EI and macronutrient intake (15).   Influences on this misreporting include a 
social desirability trait (6, 16-18) which has been associated with bias in dietary recall and/or 
changing dietary intake as a reaction to the act of completing the MBDA (reactivity) (19). For 
example, it has been reported that in feeding studies women will eat less perceived unhealthy 
foods when they know that they are being overtly observed but not when covertly observed (20, 
21).  
Accurate quantification of dietary intake has important implications for determining 
individual and population-wide trends relating food intake with disease (22-28). 
Recommendations about energy and macronutrient intake are based on large cross-sectional 
studies, such as What We Eat in America (WWEIA), which is based on the National Health and 
Nutrition Examination Survey (NHANES) (29). These surveys rely on memory-based dietary 
assessments (MBDA) such as food frequency questionnaires (FFQs) and 24-hour dietary recalls 
(24HR) (2, 3). For health practitioners and researchers to make effective recommendations, 
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accurate caloric and macronutrient intake must be known. (24, 28). One major problem 
associated with the under-reporting of macronutrients is that this leads to misrepresentation of 
the health effects from reliance on self-reported macronutrients (22-26). Equations have been 
developed which attempt to adjust for known over- and underreporting of energy intake (11-14). 
Additionally, recovery biomarkers exist for EI (doubly labeled water) and for protein intake (24 
hour urinary nitrogen).  However, these biomarkers are expensive, difficult to use in large 
populations, and are not yet available for carbohydrate and fat intake (2, 9). For these reasons, it 
is necessary to further classify the accuracy of MBDAs on actual energy intake and 
macronutrient intake, potentially elucidating types of foods contributing to over- and under-
reporting. 
Despite the challenges with self-report methods of diet assessment, 24HR are still 
considered the least biased of MBDAs to estimate EI (9) and remain the most important source 
of information on dietary intake of large populations in surveys such as NHANES (29, 30). The 
limitations of 24HR are well known and can be controlled for statistically in large studies (11-
14). However, do the limitations of 24HR carry over into feeding studies? Well-controlled 
feeding studies are often used to help confirm these larger epidemiological studies findings and 
help draw associations between diet and disease (1). But the use of 24HR in controlled feeding 
studies is not well understood, with only a few studies comparing actual intake to reported intake 
with 24HR with some balanced and some under-reporting of fats and carbohydrates (21, 26, 31, 
32).  
The aim of this analysis is to analyze discrepancies in EI and macronutrient intake between 
actual dietary intake from experimental diets and reported 24HR intake in free-living 
participants. To conduct this aim, we will use a well-controlled feeding trial and will provide 
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participants with all their meals as previous studies report strong adherence to meals provided 
(33). Our hypothesis is that energy and macronutrient intake in our controlled feeding study will 
be under-reported by 24HR compared to actual intake, but to a lesser extent than that reported in 
the literature (6, 10, 17, 19, 22-24, 34). 
Materials/Subjects and Methods 
Subjects:  
Our study design is shown in Figure 1. 12 men and 12 women participated in this study. 
Inclusion criteria were age between 19-45 years, no history of metabolic disorders, body mass 
index (BMI) between 18.5 and 27, not currently taking metabolism altering drugs and weight 
stable +/- 2kg for the last 6 months. Prospective participants were recruited through 
umclinicalresearch.org and asked to visit the Michigan Clinical Research Unit at the University 
of Michigan.  
Recruitment and Ethics:  
All procedures involved in this study were approved by the University of Michigan 
Institutional Review Board, HUM#000110543. Written and signed informed consent forms were 
obtained from all participants before beginning any portion of the study. 
Study design summary and randomization scheme:  
Participants completed baseline assessments, consumed a ‘standard’ diet for 3 days, and 
were then randomly assigned to one of two experimental diet groups for the following 21 days 
(figure 1). Randomization was based upon date of consent and sex was balanced between groups. 




Body composition and anthropometry:  
Height using a wall-mounted stadiometer (Easy-Glide Bearing Stadiometer, Perspective 
Enterprises, Portage, MI) was measured in duplicate to the nearest 0.5 cm. Baseline fasted 
weight was measured in light clothing using a calibrated scale (Scale-Tronix Model 6002, White 
Plains, NY) to the nearest 0.1 kg. Body composition was measured by trained technicians using 
dual x-ray absorptiometry (Lunar DPX DEXA Scanner, Madison, WI, USA). Weight was 
measured during the study during picked-up. If body weight fluctuated more than 1kg, the total 
kJ provided were adjusted to maintain baseline body weight.  
Blood collection:  
Fasted blood samples were collected in EDTA treated vacutainers on days -3, 0, 2, 7, 14 
and 21. Samples were immediately inverted 7x and placed on ice. Plasma was frozen at -800C for 
later LC/MS analysis.  
Diets: 
Subjects’ target kJ for eucaloric diets was determined using the Institutes of Medicine 
(IOM) formulas based upon height, weight, age, and reported physical activity levels (35). For 
men ages 19 years and older, estimated energy requirement (EER) = 4.184*(662 – (9.53 x age 
[yrs.]) + Physical activity (PA) x (15.91 x weight [kg] + 539.2 x height [m])) where PA was 
assumed to be 1.25 for active men (35). For women ages 19 years and older, EER = 4.184*(354 
– (9.91 x age) + PA x (9.36 x weight + 726 x height)) where PA was assumed to be 1.27 for 
active women (35). Diets were designed by registered dietitians and prepared by the Michigan 
Nutrition and Obesity Research Center metabolic kitchen staff. All foodstuffs except 
commercially available prepackaged foods (i.e. granola bars, cans of soda) were weighed to the 
gram. All diets comprised “every day” foods which were designed to be palatable for a wide 
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variety of individuals (Table 3.3). For three days, participants were provided a eucaloric diet 
meant to match the average  macronutrient intake reported in NHANES (Standard) and to 
provide a brief habitual diet ‘wash-out’ period for all participants (36, 37). All participants 
consumed the same foods during this period, with quantities determined by estimated caloric 
requirements.  Standard diet macronutrient proportions approximated usual intake among adults 
in the United States at 15% protein, 35% fat (50% saturated/50% unsaturated), and 50% 
carbohydrate (28). During the experimental diet phase (21 days total), participants were provided 
with HC (15% protein/10% fat (50% saturated/50% unsaturated)/75% carbohydrate) diets or HF 
(15% protein/60% fat (50% saturated/50% unsaturated)/25% carbohydrate) diets. Subjects were 
instructed to eat and drink everything provided and return uneaten food to the metabolic kitchen 
on their subsequent visit to be weighed and recorded. Subjects were permitted as many non-
caloric beverages as they wished. If subjects requested cream or sugar to add to their coffee or 
tea this was provided by the metabolic kitchen and accounted for in the foods provided.  
24-hour dietary calls (24HR) and food frequency questionnaires (FFQ): 
24-hour recalls were collected using standard protocols (2) during the standard diet (1 
recall) and during the 3-week experimental diet (3 recalls; 1 per week). Recalls were 
unannounced, conducted during times when the participant stated they were usually available 
and occurred on any day of the week. All recalls were administered by trained bionutrition staff 
from the University of Michigan Nutrition and Obesity Research Core (MNORC) staff at the 
MCRU. Most recalls were conducted via phone unless this was unfeasible, then they were 
administered in person by study dietitians during a food pick up. The Nutrition Data System for 
Research (NDSR) software, version 2016, developed by the Nutrition Coordinating Center 
(NCC), University of Minnesota, Minneapolis, MN (38), was utilized to administer the recall and 
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determine the energy, macronutrient and micronutrient content of the diet (Reported). Each 
subject’s actual diet (Actual) was also entered into NDSR to determine EI and macronutrient 
content. NDSR provided amounts and sources of kilojoules, macronutrients, and micronutrients. 
These amounts included sources and amounts of vegetable animal proteins. Uneaten foodstuffs 
was weighed and subtracted from provided. For each subject this produced 4 time points for 
comparison: during the 3-day standard diet and then during week 1, week 2, and week 3 of the 
experimental diet. In order to assess usual intake, subjects also completed the Harvard 
University2007 validated FFQ during the baseline visit. 
(https://regepi.bwh.harvard.edu/health/FFQ/files/2007%20BOOKLET%20FFQ.pdf) (39, 40). 
Statistical Analysis: 
NDSR summary data for each subject’s individual diets from individual days were used 
to estimate EI and macronutrient intake. The EI and % macronutrients provided in the Actual 
diet was determined using NDSR and was compared for all participants to identify differences in 
EI and macronutrients between and within diet groups. These comparisons were conducted at the 
standard diet and for each week of the experimental diet. Mean EI and % macronutrients were 
also compared between and within the HF and HC groups during the experimental diet. 
Descriptive statistics (age, weight, caloric intake, BMI and DEXA measurements) were found to 
be normally distributed using Shapiro-Wilks tests (p>0.5) and computed and compared between 
groups (HC vs. HF) using Student’s T-tests (p<0.05) to confirm randomization was successful. 
Week 1 through 3 values for EI and macronutrients for each individual were compared with one-
way repeated measures ANOVA with random intercept (α=0.05) and were not found to be 
significantly different for EI, %FAT, %PRO, and %CHO.  Bland-Altman plots comparing the 
difference in actual and reported intake with the average between these two measures were used 
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to evaluate the agreement between the two methods of dietary assessment; 24HR and actual 
intake. Over/under-reporting was calculated using the following formula (reported nutrient/actual 
nutrient * 100) with a score of 100% representing perfect agreement between recall and actual 
intake (Figure 3.1A). All statistical analysis was done using SAS software version 9.4 TS Level 
1M3 of the SAS System for Windows (SAS Institute Inc., Cary, NC; copyright 2002-2012). FFQ 
data measuring usual intake for EI, %PRO, %FAT, and %CHO was compared to baseline 24HR 
using Student’s T-tests. Pearson’s correlations between FFQ data and baseline 24HR were also 
compared for kJ, %PRO, %FAT, and %CHO. 
Results 
Baseline anthropometric data did not differ significantly between HC and HF groups 
(Table 3.1). Furthermore, subject weight change over the course of the experiment did not differ 
significantly between HC and HF groups (p=0.38).  
Actual vs Reported intake 
The estimates of EI in kJ/day did not significantly differ between actual intake and 24HR 
during the standard diet (102.5((25.1)), in the HC diet (101.7 (40.5)), nor in the HF diet (103.7 
(25.0)) (Figure 3.1). However, protein was over reported during all diet conditions (Standard diet 
127.4 (42.3), HC diet 115.6 (42.4), and HF 116.1 (31.4). Fat was over-reported (166 (67.7)) and 
carbohydrate was under-reported (89.2 (36.3)) in the HC diet. Conversely in the HF diet, fat was 
under-reported (93.7 (25.9)) and carbohydrate was over-reported (119.8 (37.5)), (Figure 3.1) 
Next, we compared actual diet and reported diet when macronutrients are taken as a percentage 
of total kilojoules reported or consumed (3.1). Percent protein reporting was significantly higher 
in all diets with standard diet at 14.4% actual vs 17.8% reported (p<0.0001), participants on the 
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HC diet at 14.8% actual vs. 17.1% reported (p=0.0006), and in HF participants at 15.0% in actual 
vs 17.1% reported (p=0.027). Percent fat did not differ between participants during the standard 
diet; 35.8% actual vs 33.5% reported (p=0.0678), but HC participants reported 17.2% fat vs. 
10.4% actual fat (p<0.0001) and HF participants reported 53.7% fat vs. 60.1% actual (p=0.0002). 
Similarly, percent carbohydrates did not differ during the standard diet; 49.8% actual vs. 48.8% 
reported (p=0.5828), but HC participants reported 65.8% carbohydrates vs. 74.8% actual intake 
(p<0.0001) and HF participants reported 29.2% carbs vs. 24.8% actual intake (p=0.015) (Figure 
1). 
The relationship between Reported diet and Actual diet was also plotted as Bland-Altman 
diagrams for EI, %PRO, %FAT, and %CHO for the experimental diets (figure 3.2) and for the 
standard diet (figure 3.4). In the Standard diet (figure 3.4), it can be seen that reported means 
(dark blue line) are very similar to actual means (light grey line). There does appear to be a slight 
proportional bias shown in a slight positive slope of all data, which is indicative of an increase in 
error with higher caloric intake (41). For the experimental diets, EI and %PRO show similar 
proportional bias as the standard diet (figure 3.2). EI shows similar reporting between recall and 
actual diet regardless of study group (figure 3.1). Protein is over-reported by both groups with 
proportional bias shown as a positive slope in Bland-Altman plots (figure 3). This is indicative of 
an increase in recall error with an increase in EI Figures 3.1 and 3.2 show %FAT is over-
reported by HC and underreported by HF while %CHO is over-reported by HF and 
underreported by HC. Animal protein was over-reported compared to vegetable protein by all 
participants at each time point while vegetable protein was well reported (Table 3.2 & Figure 
3.3). During the standard diet, subjects reported 84.2g (34.4) animal protein compared to 62.1g 
(14.3) of actual intake (p<0.02) in contrast to 36.5g (9.2) reported vegetable protein vs. 32.7g 
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(5.9) actual intake, a difference that was not statistically significant. The tendency to in over-
report animal protein but not vegetable protein was also seen in the HC diet and the HF diets 
(table 3.2 & figure 3.2). 
FFQ estimates of  usual intake of  EI, %PRO, %FAT, and %CHO of subjects was compared to 
baseline 24HR recalls and were not found to be significantly different between groups with 
FFQ’s reporting 9769.2 kJ (4748.8), 16.4%PRO, 34.1%FAT, and 48.2%CHO while baseline 
24HR showed 9683.4 kJ (3474.4), 16.7%PRO, 32.1%FAT, and 48.4%CHO. Pearson’s 
correlation between EI and macronutrients was also good with r for kJ = 0.44, %PRO = 0.32, 
%FAT =0.52, %CHO = 0.82. 
Discussion 
In this study, our objective was to compare 24HR estimated nutrient intake vs. actual 
intake in the standard and experimental diets, as we hypothesized that, consistent with literature, 
there would be significant under-reporting of energy, CHO, and fats. However, in this study, we 
found no difference in actual EI vs reported in any of the diet conditions. We provided all 
foodstuffs for this study for participants which was consumed during the study period and used 
24HR recalls to establish dietary intake. We found that, in the feeding study setting, our 
participants reported EI accurately. For macronutrient intake, we found that animal protein was 
over reported in both the standard diet and during the experimental diet. During the standardized 
diet, fat and carbohydrate were accurately reported by study participants, but during the 
experimental diet, participants on the high fat diet under-reported fat and over-reported 
carbohydrate intake while participants on the high carbohydrate diet under-reported carbohydrate 
and over-reported fat intake.  
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The use of dietary recall in feeding studies is sparse, with just a few studies identified 
(21, 31, 32, 42). Unlike our study, each of these studies provided food ad libitum and determined 
actual food intake using a covert design using video recordings of subject food choices (20, 21, 
31) or were cross-sectional (42). Our study, in contrast, was a eucaloric feeding study in which 
participants were free-living and took prepared food home. Because well-controlled feeding 
studies are used to confirm the science of larger epidemiological studies (1), we believe it is 
important to understand how 24HR perform in these types of studies and what proportion of 
macronutrients are being consumed.  Furthermore, the systematic under-reporting of EI or any 
one macronutrient could diminish the accuracy of associations between disease and diet (22).  
Overall, the participants in this study were very consistent reporters. The agreement 
between their FFQ and the baseline 24HR recall was very good with no statistically significant 
difference between kJ, %PRO, %FAT, or %CHO. While one 24HR recall is not a good measure 
of habitual intake, the baseline 24HR recall did compare favorably with the FFQ.  
The under-reporting of EI by MBDA such as the 24HR is well documented (4, 6-9, 43, 44). 
Under-reporting of EI is especially associated with women, obese status, and the desire to lose 
weight. Furthermore, other studies find under-reporting when comparing laboratory settings with 
dietary recalls (21, 31, 32). In contrast to the literature, we found accurate EI reporting by 24HR 
between actual and reported intake, similar to one study which looked at 24HR vs actual at one 
day (42). Our study population was small (n=24), and largely comprised of conscientious 
graduate students who were weight stable and not overweight. Our reports are also not in 
accordance the findings of Hebert et al. (45) who demonstrated that women who are highly 
educated report more downward desirability bias (under-reporting) in 24HR than women who 
are less educated. Most of our subjects were graduate students and, regardless of sex, under-
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reported carbohydrates on the high carbohydrate diet and under-reported fat on the high fat diet. 
Higher education level has been found to be associated with less bias in the 24HR recall, which 
could explain the accurate recall of our population which was highly educated (4). Perhaps the 
accuracy and reliability of response for our subjects was increased due to their level of education, 
conscientious natures, and investment in science as graduate students. Secondly, our diets were 
provided on a cycle of 4 possible meals for breakfast, lunch, and dinner, so it is possible that our 
participants were able to recall their meals better. 
While our participants were not aware of when they would receive recalls, they did know 
that they were coming and perhaps were better at recalling than true free-living individuals. This 
is similar to an observational cross-sectional study that found that when comparing actual 
observed diet to the USDA five-step multi-pass method for dietary recall that men (ages 21-65) 
reported EI, protein, fat, and carbohydrate very well (42). One possibility is that the mere act of 
subjects knowing they are being observed increased the accuracy of their response as in this 
study and the Stubbs studies (20, 21, 42). 
Although carbohydrates and fats are underreported in the literature, we found that if 
participants were given a high carbohydrate diet which was necessarily low fat, they tended to 
under-report carbohydrates and over-report fats. Consistent with the literature, we found that 
macronutrients are differentially misreported (46). Specifically, participants on a high fat diet 
tended to under-report fat and over-report carbohydrates. In other feeding studies, energy intake 
was under-reported by both men and women at all levels of intake (17, 20, 21, 31, 47). This 
seems to be associated with under-reporting of high carbohydrate and high fat foods (17, 48). 
While the participants in our study were not told the diet to which they were randomized, it was 
impossible to hide the true nature of the food they were eating from them. Perhaps, in this case, 
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participants were under-reporting the macronutrients in the very high fat or very high 
carbohydrate diets because of social desirability, but this seems unlikely. More likely, subjects 
are under-reporting fats or carbohydrates because these diets are so very high in these 
macronutrients. 
The nature of the eucaloric, targeted macronutrient diet may have contributed to this 
pattern we observed, with subjects on HC diets under-reporting carbohydrates and subjects on 
the HF diet under-reporting fat. Diets were prepared from real food to reach particular 
macronutrient percentages. Often, excess fats and excess carbohydrates were “hidden” in foods 
by adding foods such as butter and coconut oil for fat and soda or candy for high carbohydrates. 
Because participants did not prepare their own foods, they did not necessarily know how much 
of these balancing foods were added to their foods. Although, one might assume that if “hidden” 
foods were under-reported, EI would be under-reported as well, but rather EI was not 
differentially reported from actual intake.  
We found that protein was over-reported by all participants during the standard diet as 
well as in HC and HF diets. In the literature, misreporting of protein is not consistent, with some 
studies reporting no misreporting (6), some under reporting (24), and some over-reporting (22, 
23, 34, 49). This finding is in accordance with research which compares observed intake with 
24HR which shows that protein is often well reported (20). This was also found in a large 
epidemiological study which showed high correlation between urinary nitrogen, a biomarker of 
protein intake, and dietary recall (50). 
While our participants reported EI equal to their intake but over-reporting of protein, both 
(or either) carbohydrates and fats must be under-reported to conserve caloric balance. Our results 
suggest that the over-reporting of protein is due to over-reporting of animal proteins. This is 
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perhaps due to the sources of meat in these particular diets as many animal protein sources were 
in the form of ground beef in foods such as lasagna and meat loaf. While this is a small study, it 
is important to understand that animal protein may be over estimated by 24HR as animal protein 
intake has been associated with obesity (51). 
Strengths/Limitations 
The strengths of this study include the experimental design and the direct comparison 
between 24HR and provided diet. This study was well-controlled in that our subjects were 
provided with all food that they consumed. The generalizability to a “real world” setting of this 
study, given the free-living subjects is better than studies with participants kept in a hospital 
setting during the study. Limitations of this study are the heterogeneity of the population and 
small population size (n=23). The subjects in this study were, for the most part, undergraduate 
student and graduate students at the University of Michigan, which could diminish the 
generalizability of this study to a larger population. This population was also composed of 
young, metabolically healthy and non-overweight individuals, which is not reflective of the 
general population of the United States. Finally, we used weight change as a metric for 
compliance to the diet. It may be naïve to assume that the participants in this study were 100% 
compliant to the diet for the entire study.  
Conclusion 
This study is unique in that it shows that, in a well-controlled feeding study amongst free-
living healthy individuals, 24HR recall may adequately estimate EI. As these studies are used to 
confirm large epidemiological studies, it is important to know that the over-reporting seen in 
MBDAs may not co-vary with these sorts of studies. Energy intake, while highly variable 
between participants, does seem to be accurate in the laboratory feeding study setting. This leads 
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to our conclusion that 24HR accurately estimate EI in controlled feeding studies. However, in 
studies such as this one, which looked at very high macronutrient intakes, tested macronutrients 
may be under/over-reported when assessed by 24HR. In this study, participants on very high fat 
diets under reported fat and over reported carbohydrates and participants on very high 
carbohydrate diets under-reported carbohydrates and over-reported fat. We would further 
conclude that in studies which use over-feeding/under-feeding of carbohydrates and fats, 24HR 
does not accurately assess macronutrient intake as seen in our studies. Finally, from this study, it 
appears that the 24HR may overestimate animal protein in the context of an experimental feeding 
trial. 
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Tables and Figures: 
 
Table 3.1 Baseline participant data of the HC and HF study groups.  
  
HC (n=13 - 7♂,6♀) HF (n=11 - 5♂,6♀) 
 
Age (yrs.) 24.85 (4.04) 23.91 (2.63) 
 
Weight Change (Δkg) -0.05 (1.02) 0.3 (0.85) 
 
Caloric Intake (kJ) 11819.8 (2181.6) 11466.0 (2101.4) 













Total Mass (kg) 70.52 (7.8) 68.08 (7.64) 
Tissue (kg) 67.67 (7.45) 65.48 (7.31) 
Fat (kg) 15.32 (5.49) 16.88 (7.36) 
Lean (kg) 52.36 (10.31) 48.6 (8.34) 
BMC (kg) 2.86 (0.46) 2.69 (0.58) 
FFM (kg) 53.65 (13.88) 51.29 (8.85) 
Android %FAT 21.98 (10.96) 23.22 (11.1) 
Gynoid %FAT 25.62 (10.78) 29.42 (13.03) 
A/G Ratio 0.85 (0.21) 0.8 (0.19) 
BF% 23.06 (8.97) 25.54 (10.44) 
BMD 1.28 (0.12) 1.24 (0.14) 
BMR (J) 6279.2 (884.0) 5983.9 (706.2) 
Data presented as mean (SD). No data reached the threshold for significance  
(α=0.05) within these data when compared using Student’s paired t-tests. FFM = fat free 








Table 3.2: A comparison of reported and actual animal and vegetable protein during the 
Standard diet and during the HC and HF experimental diets  
 
Diet  Standard Diet (n=23) High Carbohydrate Diet (n=13) High Fat Diet (n=10) 




































Data represent grams of reported or actual protein (SD). * represents a p-value <0.05 for 






















































































(A) The proportion of over and under-reported energy in kJ and macronutrients with 24-hour 
recall compared to actually consumed during the standard diet (both groups combined) and the 
average intake of weeks 1 through 3 for HC and HF experimental diet eaters expressed as a 
ratio (reported nutrient/actual nutrient). Above 100 represent over-reporting of 
energy/nutrients while values below 100 represent under-reporting. (B) Comparison of the 
percentage of actual provided macronutrients with the percentage of reported macronutrients 
for HC and HF diets during experimental weeks. * = p<0.5 for paired Student’s T-tests 





Figure 3.2. Bland-Altman plots of differences in Experimental diets for (A) EI, (B) %PRO, (C) %FAT, and (D) %CHO (mean 










Means for all participants and study groups are at the bottom of the plots and are presented as mean (SD). The black solid line is the mean 
difference for all participants, grey line represents a mean difference of 0.  For C and D, gray dot-dashed lines represent mean difference for HF 





Figure 3.3. Comparison of sources of protein (animal or plant) during the Standard diet and 
during the experimental diet (HC and HF). 
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Figure 3.4. Bland-Altman plots of differences in Standard diets for (A) EI, (B) %PRO, (C) %FAT, and (D) %CHO (mean reported 









Means for all participants and study groups are at the bottom of the plots and are represented as mean (SD). The black line is the 
mean difference for all participants; the grey line represents a mean difference of 0. 
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Table 3.3 Sample menus based on a 2000 kcal diet for the standard diet (A-C), high 
carbohydrate diet (D-G), and high fat diet (H-K). Summary data includes actual calculated grams 
and kcal of macronutrients as well as target grams and kcal of macronutrients in diets. 
A) Sample Standard Diet #1 





Rice Chex 1 bowl 70 1 0 0 16 
2% milk 240 ml 113 7.6 4.4 2.7 11 
Strawberry 
yogurt 
6 oz. carton 160 5 1.5 0 33 





1 unit 381 19.1 14.1 7.5 42 
Applesauce 1 container 51 0.2 0.1 0 13 




325 g 346 29.4 8.5 3.3 38 
Butter in 
Primavera 




168 g 137 4.8 7.3 2.3 14 
Butter in 
soup 
10 g 72 0 8 5.2 0 
Chocolate 
chip cookie 




1963 78.3 g 78.5 g 34.7 g 245 g 
Percent of 
kCal 
  16.0% 36.0% 15.9% 49.9% 
Goal  2000 76 g 78 g 39 g 250 g 
Percent of 
kCal 
  15%  35% 17.5% 50% 






B) Sample Standard Diet #2 






1 251 19.6 7.9 4.5 25 
Orange juice 2 122 0 0 0 28 
Clementine 1 50 0.7 0.2 
 
13 
Raisins 30 g 94 0.8 0 0 25 
Lunch 






50 0 5 0 0 
Tomato slice 3 
slices 
12 0.5 0.2 0 3 
Potato chips 1 bag 160 2 11 3 15 
String cheese 2 
sticks 
160 12 12 7 0 
White bread 1 
slice 












5 g 36 0 4 2.6 0 
Garden medley 
vegetables 
112 g 42 1.7 0 0 8 
Macaroni and 
cheese 
120 g 231 10 13.8 7.75 16 
BBQ chicken 
breast 
60 g 75 10 2.1 0.2 4 




2042 77.6 77.9 33.45 255 
Percent of kCal   15.2% 34.3% 14.7% 50.0% 
Goal 
 
2000  76 g 78 g 39 g 250 g 
Percent of kCal   15%  35% 17.5% 50% 




C) Sample Standard Diet #3 









120 0 0 0 30 
Putter for 
pancakes 
10 g 72 0 8 5.2 0  
Orange juice 1 61 













180 5.1 9.5 1 21 
White bun 1 
whole 






50 0 5 0  0 
Cheddar 
Cheese 
23 g 84 5.3 7.3 4.6 0 
Potato chips 1 bag 160 2 11 3 15 
Banana mediu
m 




157 g 233 27.6 7.7 1.9 13 
Penne 98 g 159 5.3 0.8 0 32 
Marinara 
sauce 
56 g 24 1 0.4 0 4 
White roll 28 g 80 2.5 1 0.5 15 
Butter for roll 5 g 36 
 









2014 76 80.9 27.5 252 
Percent of 
kCal 
  15.1% 36.2% 12.3% 50.0% 
Goal   2000 76 g 78 g 39 g 250 g 
Percent of 
kCal 
  15%  35% 17.5% 50% 




D) Sample High Carbohydrate Diet #1 
 










Frosted Flakes "Bowl" 110 1 0 0 26 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Fat free strawberry 
yogurt 
170 g carton 90 6 0 0 17 
Apple Juice 4 oz. carton 61 0 0 0 15 
Coffee 1 cup 4 0.4 0 0 0 
Lunch 
Chicken noodle canned 206 g 50 3 0 0.5 8 
Fresh cut vegetables 96 g 21 0.7 0.3 0 5 
Ranch dressing  30 g 44 0.8 3.4 1 2.8 
Grilled chicken breast 67 g 85 15.5 2.4 0.2 0 
Lettuce leaf 15 g 4 0 0 0 0.4 
Wheat bun 1 145 7 1 0 28 
Butter on bun 5 g 36 0 4 2.6 0 
Vernor’s ginger ale 8 oz. can 96 0 0 0 26 
Banana small 6-6.8" 90 1.1 0.3 0.1 23 
Dinner 
Lasagna half serving 78 g 118 9 5.4 3 7 
Grape juice 2 cartons 122 0 0 0 30 
Tossed greens 116 g 16 1.2 0.2 0 3 
Raisins in salad 32 g 90 0.9 0.1 0 24 
Fat free Italian dressing 22 g 10 0 0 0 2 
Garden vegetable medley 113 g 42 1.7 0 0 8 
Lemon ice 23 g carton 80 0 0 0 20 
Sliced peaches 140 g 66 0 0 0 14.9 
Snacks 
Banana, honey, coconut, 
juice,  
protein, yogurt Smoothie 
240 g 243 9.6 5.1 3.6 43 
US crackers 2 package 50 2 0 0 10 
Grape jelly 3 packets 105 0 0 0 27 
Skim milk to mix with: 236 g carton 79 7.7 0.4 0.3 11 




2006 80.3 23 11.6 374.1 
Percent of Kcal 
  
16.1% 11% 5.2% 75% 
GOALS   2000 77 22 11 375 
Percent of Kcal   15 10 5 75 




E) Sample High Carbohydrate Diet #2 





Orange juice 1 carton g 61 0 0 0 14 
Oatmeal 142 g 92 2.7 1.8 0 17 
Raisins 35 g 110 1 0.2 0 27 
Brown sugar 18 g 68 0 0 0 17.7 
Skim milk 8 oz. carton 79 7.7 0.4 0.3 11 
Coffee 1 cup 4 0.3 0 0 1 
Lunch 
Tuna salad 68 g 88 13 3.5 0.4 1.7 
Wheat bread 2 Slices 146 8 0.6 0 28 
Pretzels 28 g package 110 2 1 0 23 
Clementine one  (~ 113 g) 50 0.7 0.2 0 13 
Lemon ice carton 80 0 0 0 20 
Soft drink 8 oz. can 90 0 0 0 24 
Dinner 
Chili 160 g 137 8.5 3.8 1.5 16 
Baked potato 250 g 247 5.2 0.2 0.1 57 
Butter on potato 4 g 29 0 3.3 2.1 0 
Sour cream 1/3 packet 20 0.3 1.7 1 0.7 
Rasp sherbet carton 120 0 1.5 1 27 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Snacks 
Banana, honey, coconut, 
juice, protein, yogurt 
Smoothie 
~ 240 g 243 9.6 5.1 3.6 43 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 




2002 79.4 24.1 10.6 375.1 





GOALS  2000 77 22 11 375 
Percent of Kcal   15% 10% 5% 75% 





F) Sample High Carbohydrate Diet #3 




Raisin Bran 1 bowl 126 3 1 0 27 
Extra raisins in 
cereal 
32 g 90 0.9 0.1 0 24 
Honey   2 packets 60 0 0 0 16 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Clementine one  (~ 113 g) 50 0.7 0.2 0 13 
Coffee 1 cup 4 0.4 0 0 0 
Grape juice carton 61 0 0 0 15 
Lunch 
White bread bun one 114 3 2 0 21 
Sliced ham 57 g 50 9 1.5 0.5 1 
Sliced turkey 33 g 40 9.7 0 0 0 
Leaf lettuce 15 g 4 0 0 0 0.4 
American cheese 17 g 51 2.6 4.3 2.6 0.9 
Hellman’s light 
mayonnaise 
6 g 13 0 1.4 0 0.2 
Pretzels 28 g 
package 
110 2 1 0 23 
Fresh grapes 120 g 83 0.9 0.2 0 21 
Raspberry sherbet 1 carton 120 0 1.5 1 27 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Dinner 
Penne pasta 99 g 160 5.3 0.8 0 32 
Marinara sauce 113 g 48 2 0.8 0 8 
Parmesan cheese 1 packet 15 1.3 1 0.6 0 
Green beans 90 g 25 1.4 0.2 0 6 
Tossed greens 116 g 16 1.2 0.2 0 3 
Fat free Italian 
dressing 
22 g 10 0 0 0 2 
Orange jello 1 carton 73 1.5 0 0 17 
Soft drink 1 can 95 0 0 0 24 
Banana and coconut small 6-6.8" 90 1.1 0.3 0.1 23 
Unsweetened 
coconut 
5 g 33 0.3 3.2 2.9 1.2 
Snacks 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Vanilla CIB no 
sugar 
20 g packet 70 5 0 0 12 




1976 77.4 22.9 10.1 374.7 
Percent of Kcal 
  
15.7% 10.4% 4.6% 75.9% 
GOALS   2000 77 22 11 375 
   15% 10% 5% 75% 





G) Sample High Carbohydrate Diet #4 




Omelet half serving 120 g 50 4.4 3.4 1.1 0.4 
Pancakes reduced 
sugar  
1 serving (2) 126 2.8 1.1 0.4 26 
Pancake syrup 1 package 120 0 0 0 30 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Coffee 1 cup 4 0.4 0 0 0 
Orange juice carton 1 carton 60 0 0 0 14 
Lunch 
Cream of tomato soup 170 g bowl 113 4.6 3 1.8 17 
White bread  1 slice 83 2.5 0.5 0 16 
Sliced ham 22 g 19 3.5 0.6 0.2 0.4 
Swiss cheese 15 g 56 3.6 4.6 3.1 0 
Pretzels  28 g package 110 2 1 0 23 
Apple juice two 4-oz 
carton 
122 0 0 0 30 
Yogurt Greek 
strawberry 
140 g 121 11 0 0 20.5 
Unsweetened coconut 5 g 33 0.3 3.2 2.9 1.2 
Dinner 
BBQ sauce packet 2 packets 30 0 0 0 8 
Grilled chicken breast 85 g 108 19.6 3 0.3 0 
Wild rice half 50 g 48 1.1 0.8 0.1 9 
White rice 55 g 63 1.3 0.2 0 18.5 
Garden vegetable 
medley 
113 g 40 1.7 0 0 8 
Strawberry jello 116 g 71 1 0 0 17 
Vernor’s ginger ale 8 oz. can 100 0 0 0 26 
Raisins 20 g 60 0.6 0 0 15 
Snacks 
Skim milk 236 g carton 79 7.7 0.4 0.3 11 
Rice Chex 1 bowl 70 1 0 0 16 
Sugar for cereal 2 packets 22 0 0 0 6 
Banana small 6-6.8" 90 1.1 0.3 0.1 23 
Unsalted crackers 2 package 50 2 0 0 10 




1997 79.9 22.5 10.6 375 
Percent of kCal 
  
16.0% 10.1% 4.8% 75.1% 
GOALS   2000 77 22 11 375 
Percent of kCal   15% 10% 5% 75% 




H) Sample High Fat Diet #1 





Egg omelet with cheese 99 g 180 10 13 5 4 
Sausage link 2 each 146 6 13.2 5.3 1 
Wheat bread for toast 1 slice 73 4 0.3 0 14 
Butter for bread 10 g 72 0 8 5.1 0 
Coffee provided by 
participant 
1 cup 4 0.4 0 0 0 
Half and half 2 tubs (30 g) 39 0.9 3.5 2.2 1.3 
Lunch 
Grilled ham and cheese 138 g (less 
than one) 
344 20.6 17.8 10 28 
Potato chips 1 package  28-
29 g 
160 2 11 3 15 
Dinner 
Meatloaf 125 g 213 15.8 11.2 4.3 12.3 
Macaroni and cheese 95 g 180 7.8 10.8 6 12.5 




30 g 216 0.2 24.4 15.4 0 
Snacks 




1943 73.8 133.1 68.8 120.1 
Percent of Kcal 
  
15.2% 61.7% 31.9% 24.7% 
GOALS   2000 76 133 66.5 125 
   15% 60% 30% 25% 





I) Sample High Fat Diet #2 










     
  
Half and half 2 tubs (30 g) 39 0.9 3.5 2.2 1.3 
Oatmeal 195 g 123 3.6 2.4 0 23 
Coconut oil in oatmeal 11 g 95 0 11 9.5 0 
Butter in oatmeal 10 g 72 0 8.1 5.1 0 
no calorie sweetener 1 packet 0 0 0 0 0  
Vanilla Greek yogurt 125 g 91 10.8 0 0 12.5 
Lunch 
Caesar salad one 100 g 49 5.1 2.9 1.8 2 
Caesar dressing one packet 233 1 25 4 1 
Grilled chicken breast 75 g 95 17.2 2.6 0.3 0 
Corn 45 g 36 1.2 0.2 0.05 8.5 
Butter in corn and on 
chicken 
10 g 72 0 8 5.2 0 
Dinner 
Potato crusted cod 85 g 151 15.8 6 2.3 7.5 
Tartar sauce 12 g packet 40 0 4 0 2 
Baked potato (half) 112 g 113 2.3 0.1 0 26.1 
Sour cream 1 packet 60 1 5 3 2 
Broccoli 85 g 21 2.3 0.1 0 4 
Shredded cheddar on 
vegetables 
29 g 113 7.1 9.1 5.1 1 
Butter on broccoli 10 g 72 0 8.1 5.1 0 
Butter in potato 14 g 100 0.1 11.4 7.2 0 
Almond joy 45 g 220 2 13 8 26 
String cheese 28-29 g stick 80 6 6 3.5 0 




2035 78.4 137.5 65.35 131.9 
 Percent of kCals 
  
15.4% 60.8% 28.9% 25.9% 
GOALS   2000 76 133 66.5 125 
   15% 60% 30% 25% 





J) Sample High Fat Diet #3 








Breakfast Wrap one (~ 125 g) 328 16.6 16 6 29 
Coffee provided by 
participant 
1 cup 4 0.4 0 0 0 
Half and half 2 tubs (30 g) 39 0.9 3.5 2.2 1.3 
Lunch 
Grilled cheese 1 sandwich 343 16.3 19.2 11.1 28 
potato chips 1 bag 160 2 11 3 15 
Dinner 
Grilled chicken breast  72 g 91 16.7 2.6 0.3 0 
Broccoli 82 g 23 2.5 0.1 0 4 
Butter on broccoli 15 g (1 T) 108 0.1 12.2 7.7 0 
Garden vegetable 
medley 
57 g 21 0.9 0 0 4 
Butter in macaroni 
and cheese 
15 g (1 T) 108 0.1 12.2 7.7 0 
Macaroni & cheese 196 g 375 16.2 22.4 12.6 26 
Butter in vegetable 15 g (1 T) 108 0.1 12.2 7.7 0 
Salt and pepper 
     
  
Vegetable oil in 
macaroni and cheese 
10 g 91  0 10 0   0 
Snacks 




1994 75.9 134.6 66.7 124.3 
Percent of Kcal 
  
15.2% 60.8% 30.1% 24.9% 
GOALS   2000 76 133 66.5 125 
   15% 60% 30% 25% 





K) Sample High Fat Diet #4 








Egg omelet with cheese 99 g 180 10 13 5 4 
Sausage link 2 links 146 6 13.2 5.3 1 
Coffee participant to 
provide 
1 cup 4 0.3 0 0 1 
Half and half 2 tubs 
(30 g) 
39 0.9 3.5 2.2 1.3 
Lunch 
Cheesy potato bisque 1 
serving 
(170 g) 
180 6.5 10.4 6.5 15 
Butter in soup 10 g 72 0 8 5.1 0 
Beef brisket sandwich 
made of:  
     
  
Roast beef 81 g 110 10.3 4.9 1.9 4.5 
 Cheddar cheese 23 g 84 5.3 7.3 4.6 0 
 Wheat roll 1 (35 g) 81 3.1 0.8 0 15 
 Butter on roll 10 g 72 0 8 5.1 0 
 Mustard packet  one 3 0.2 0.2 0 0.3 
Dinner 
Meat sauce 113.5 g 113 7.7 5.3 0 9 
Penne plain 99 g 159 5.3 0.8 
 
32 
Butter in penne 20 g 144 0 16 10.2 0 
Broccoli 82 g 23 2.5 0.1 0 0 
Cheddar cheese on 
broccoli 
23 g 84 5.5 7.3 4.6 0 
Butter in broccoli 7 g 50 0 5.6 3.6 0 
Snacks 




2009 76.6 135.1 66 118.1 
Percent of Kcal 
  
15.3% 60.5% 29.6% 23.5% 
GOALS   2000 76 133 66.5 125 
   15% 60% 30% 25% 
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Chapter 4: Dynamic Response of the Metabolome During the 
Hyperinsulinemic-Euglycemic Clamp in Healthy Obese Individuals 
 
Abstract 
Although the vast majority of obese adults are insulin resistant (IR), some obese individuals 
remain relatively insulin sensitive (IS), though the underlying mechanisms for this difference are 
unclear. The hyperinsulinemic-euglycemic clamp (HEIC) is the gold standard test for insulin 
sensitivity. However, it is not clear if the differences in insulin-mediated changes in glucose 
metabolism between IS and IR obese individuals extend to other key metabolites.  
In this study, we monitored the dynamics of 62 metabolites in obese-IR, obese-IS, and 
lean controls during a HEIC. From an original screening of 28 obese adults, twelve non-diabetic 
subjects, matched for age, sex, BMI, fat mass and fat-free mass were divided into the 6 most IS 
and 6 most IR women based on glucose infusion rate during a HEIC. 6 lean controls were also 
measured as a negative control. After initial groups as obese-IR, obese,-IS, and lean it was 
apparent that the lean controls clustered with the obese subjects by glucose infusion rate (GIR) 
rather than by obesity. All subjects were then recharacterized as either low GIR or high GIR with 
9 subjects (6 obese and 3 lean) falling into both groups.  
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Fasting insulin was 16.4(7.9) and 9.4(2.0) between low GIR and high GIR groups 
respectively (p<0.05). Serum metabolite levels were measured at 8 time points during the clamp 
using liquid chromatography-mass spectrometry (LC-MS): 2 samples at baseline, immediately 
prior to insulin infusion, every 20 minutes during the insulin infusion (4 samples), and 2 samples 
at steady state (SS) glucose levels (after ~2h of insulin infusion). We quantitated metabolite 
levels by peak area, with stable-isotope internal standards used to allow absolute quantitation of 
select metabolites. Statistical differences between IS and IR groups were assessed using paired 
Student’s t-tests and ANOVA with Tukey’s post-hoc analysis. 
Regardless of adiposity, branched chain amino acids (BCAA) and free fatty acids (FFA) 
were higher in the low GIR group throughout the clamp (p<0.05). Acylcarnitines (ACAR) were 
significantly higher (p<0.05) in low GIR subjects from ACAR 2:0 through ACAR 14:1 and 
again at ACAR 18:1. However, this pattern was not evident in the longer chain ACAR except for 
18:0 and 18:1. The suppression of lipolysis is seen in all FFA and in most acylcarnitines. 
However, while FFA is reduced to near zero, their longer chain cognate acylcarnitines do not see 
a similar and expected reduction. 
These findings indicate that obese adults, who are seemingly “protected” against a 
decline in insulin-mediated glucose uptake, also demonstrate improved response of insulin to 
lower BCAA and other amino acids, as well as short and medium-chain acylcarnitines which 
have been associated with an increased risk of development of type 2 diabetes. These results 
suggest that insulin resistance and not obesity per se drive changes in the plasma level of 
metabolites associated with risk of type 2 diabetes. Furthermore, the differential suppression of 
acylcarnitines with short and medium chain acylcarnitines are reduced but long chain 
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Obesity is a growing global public health problem (1) and is associated with metabolic 
disorders such as insulin resistance and type 2 diabetes mellitus (T2DM) which lead to an 
increased risk for cardiovascular disease (2-4). While the connection between obesity and insulin 
resistance is well established (5), not all obese individuals become insulin resistant (6-8).  These 
metabolically healthy obese people exhibit excess adiposity yet have favorable lipid, cytokine, 
and inflammatory profiles not seen in their metabolically unhealthy obese counterparts (6, 7, 9-
11). Metabolically healthy, obese individuals have been found to have less risk for cancer 
mortality (12), T2DM (13, 14), coronary heart disease, and other cardiovascular diseases when 
compared to their metabolically unhealthy counter parts (13, 15). Metabolically healthy subjects 
also have a similar response in insulin sensitivity and adaptation to caloric challenge (high 
caloric meal) as metabolically, lean individuals when compared to unhealthy subjects (16).  
Recently, the use of high-throughput profiling of metabolic status or metabolomics has 
shown the ability to elucidate differences between insulin resistant and insulin sensitive 
individuals including differences in levels of amino acids, TCA cycle intermediates, and fatty 
acids (17, 18). Using metabolomics, circulating branched chain amino acids (BCAA) are shown 
to be negatively correlated with insulin sensitivity and obesity induced T2DM (19). Elevated 
plasma BCAAs and aromatic amino acids appear to be potential predictors of future diabetes in 
healthy individuals identified using metabolomics (20-22). This finding highlights the use of 
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emerging technologies of metabolomics to enhance our knowledge and understanding of 
metabolic disorders like insulin resistance and T2DM and their causes (9, 18, 23, 24).  
Currently, the HIEC is considered the gold standard for assessing in vivo insulin 
sensitivity (25, 26). Studies using metabolomic profiling have shown blunted responses in key 
metabolites related to proteolysis (19, 27), lipolysis (27-29), and glycolysis (30). Researchers 
have conducted metabolomic studies using glucose challenges such as oral glucose tests (20, 27-
30) but not using the HIEC.  
In this study, we sought to compare the metabolic response in metabolically healthy 
obese individuals with lean healthy controls during the HEIC.  
Research Design and Methods 
Study Sample   
We recruited a cohort of 28 metabolically healthy obese individuals for an initial study of 
fat cell metabolism (31). From this group we chose to further assess the plasma metabolomics 
profiles on the 6 most sensitive (Obese-IS) and 6 least sensitive (Obese-IR) individuals as 
determined by HIEC as well as 6 lean individuals (Lean) which were chosen as a negative 
control group (Table 4.1). Written, informed consent was obtained from all subjects before 
beginning any testing. The University of Michigan Institutional Review Board approved all 
study procedures. All obese subjects were female, but LEAN was comprised of 2 males and 4 
females. When grouped with LEAN and with Low GIR/High GIR the men did not significantly 
differ in metabolites from their female counterparts (p > 0.05) so were retained in the study. 
Exclusion criteria included coronary heart disease, T2DM, hypertension, clinically 
significant hypertriacylglycerolemia, or taking regular medications known to affect metabolic 
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processes. Inclusion criteria included BMI > 30 for obese subjects BMI <27 for lean subjects, 
ages between 21-45, and no history of metabolic disorder for either group.  All subjects were 
nonsmokers, weight stable (±2 kg) for the past 6 months, and no participation in regular exercise 
for the prior 6 months.  
 
Clinical Assessment 
Subjects arrived and were admitted to the Michigan Clinical Research Unit (MCRU) 
following an overnight fast on the morning of the study. The clamp was preceded by 2 hours 
with subcutaneous adipose tissue collection and 13C-palmitate infusion to measure resting fatty 
acid rate of appearance in the plasma. The clamp was performed using a primed 2 hour insulin 
infusion at a rate of 100µM/m2/min. This rate was selected to inhibit hepatic glucose production, 
even in insulin resistant subjects (32). Glucose was infused at a variable rate to maintain plasma 
concentrations. Insulin sensitivity was determined using samples collected in the final 20 
minutes of the HIEC. Blood samples were taken at 9 time points during the clamp and 
immediately processed to extract plasma (figure 4.1). Samples were taken before beginning of 
the HEIC to establish a background measurement, twice for baseline values before insulin and 
glucose infusion, 5 times every 20 minutes during the infusion until a SS glucose level was 
reached, and twice during SS 5 minutes apart (figure 4.1). Average plasma glucose 
concentrations during the final 20 minutes of the clamp was 98 ± 5% of baseline fasting glucose 
concentration values. Insulin sensitivity level is defined as the GIR during the last 20 minutes of 
the HIEC/fat-free mass. The entire procedures are further described in a prior paper by this study 
group (31). Plasma samples were frozen in liquid nitrogen as soon as possible after extraction 





Metabolites were extracted and analyzed by LC-MS-based metabolomics using methods 
similar to those previously described elsewhere (33). Briefly, extraction solvent was prepared by 
adding stable-isotope labeled internal standards at the concentration specified in Table 1 to a 
1:1:1 mixture of methanol:acetonitrile:acetone. Plasma samples were thawed at 4°C and a 50 µL 
aliquot was extracted by addition of 200 µL of extraction solvent followed by vortexing. After 
incubating on ice 5 minutes, samples were centrifuged at 15,000 x g for 10 minutes. The 
supernatant was transferred to autosampler vials for analysis. Polar metabolites (Amino acids, 
TCA cycle metabolites, etc.) were analyzed by hydrophilic interaction chromatography-
electrospray time-of-flight mass spectrometry (HILIC-ESI-TOF-MS) (34) on an Agilent 6220 
TOF-MS. The column used was a Phenomenex Luna NH2, 3µ particle diameter, 150 mm x 1 mm 
i.d. Mobile phase A was 5 mM ammonium acetate in water, adjusted to pH 9.9 with ammonium 
hydroxide; mobile phase B was acetonitrile. The gradient consisted of a 10 minute linear ramp 
from 80% to 0% B, a 5 minute hold at 0%B, and a 12 minute re-equilibration at 80%B. The 
injection volume was 10 µL and the flow rate was 0.07 mL/min. MS parameters were as follows: 
drying gas temp 350°C, drying gas flow rate 10 L/min, nebulizer 20 psig, capillary voltage 3500 
V, negative ion mode. ACAR were analyzed using reversed phase liquid chromatography- 
electrospray ionization-tandem quadrupole mass spectrometry (RPLC-ESI-QQQ-MS) (35, 36) 
on an Agilent 6410 LC-MS. The column used was a Waters HSS T3, 1.8µ particle diameter, 100 
mm x 2.1 mm i.d. Mobile phase A was 0.1% formic acid in water; mobile phase B was 0.1% 
formic acid in acetonitrile. The gradient consisted of a 7 minute linear ramp from 0 to 99% B, a 3 
minute hold at 99%B, and a 5 minute re-equilibration at 0%B. The injection volume was 5 µL 
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and the flow rate was 0.20 mL/min. MS parameters were as follows: drying gas temp 320°C, 
drying gas flow rate 10 L/min, nebulizer 40 psig, capillary voltage 4000 V, positive ion mode. 
MRM transitions for acylcarnitines (ACAR) were the same as those specified previously (33). 
Targeted metabolites were identified based on retention time and accurate mass (for HILIC-TOF 
data) or MRM transition (for RPLC-QQQ data) determined by previous analysis of authentic 
standards (table 4.2). We performed relative quantitation by measuring peak area using Agilent 
Masshunter Quantitative Analysis Software version B.07.00 (Santa Clara, CA).  
Subject Grouping  
Initially, we performed metabolomic profiling on 28 obese subjects recruited to the study. 
They were then separated into the 6 most glucose sensitive (Obese-IS) and 6 most glucose 
resistant (Obese-IR). These 6 were compared to the metabolomic profiles of 6 LEAN subjects 
that also went through the screening and HEIC. This grouping into three groups was called 
Obese-IR/Obese-IS/Lean and will be called grouping by adiposity from this point forward. 
When it was noted that the metabolic profile of the LEAN group tended to fall in between the 
Obese-IR and Obese-IS instead of grouping with the Obese-IS group as expected, subjects were 
regrouped into two groups based upon their glucose infusion rate (GIR) (High GIR vs Low GIR). 
This grouping is referred to as grouping by GIR from this point forward. 
Statistical analysis 
Baseline data grouped by adiposity was compared using One-Way Analysis of Variance 
(ANOVA) with a Fisher’s Least Significant Difference (LSD) post-hoc test with a cutoff of 
p<0.05 using Prism 7.04 (www.graphpad.com) (table 4.2). Grouping by GIR was compared 
using Students T-tests with a cutoff of p<0.05 using Excel 2016 (table 4.2). Metabolite peak 
areas were corrected for minor instrument peak area drift. This correction was performed using 
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locally estimated scatterplot smoothing (LOESS) performed in MetaboDrift software operating 
in Microsoft Excel 2016 (37). Metabolite data was normalized using Metaboanalyst using drift 
corrected peak intensity data files. Missing values were replaced with small values by default. 
Data was filtered using the interquartile range (IQR) and data was normalized by log 
transformation and autoscaling (mean/SD).  Metabolite areas under the curve (AUC) and internal 
standard ratios were compared using either ANOVA with a Fisher’s LSD post-hoc test or 
Student’s t-tests using Metaboanalyst with p<0.05 with a false discovery rate (FDR) cutoff of 
0.1. (www.metaboanalyst.ca) (38, 39). Fold-change was calculated using Microsoft Excel 2016 
using a negative ratio of baseline value to clamp value for a decrease over the clamp and a 
positive ratio of baseline value to clamp value for an increase over the clamp.  
Results 
Subject characteristics 
There were no differences in age between adiposity or GIR groupings. As expected, the 
lean subjects had a significantly lower body mass, BMI, and body fat percentage when compared 
with obese groups (Table 4.1). Subjects were well matched for BMI and body composition 
between obese-IR and obese-IS differing only in fat mass and BMI between both obese groups 
and lean (Table 4.2). When stratified into GIR groups, there were no differences in physical 
characteristics between subjects (Table 4.2). Groups only differed in mass and BMI between 
obese groups and lean groups. GIR expressed in mg/kg FFM/min was significantly different 
between Obese-IR and Obese-IS, between Obese-IS and lean, but not between Obese-IR and 
lean (p<0.05). GIR was also significantly higher in Obese-IR and Obese-IS when sorted by GIR 
(p<0.05) (Table 4.2 & Fig. 4.2). Assayed glucose was not different between any groups whether 
sorted by adiposity or GIR at neither the beginning of the clamp nor SS (Table 4.2). 
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Differences between groups when comparing grouping by adiposity 
Subjects were initially divided into Obese-IR, Obese-IS, and LEAN. Only glutamate was 
found to be different at any time point (20 minutes and at Clamp) (Figure 4). In general, it was 
found that the LEAN subjects average metabolite values mediated Obese-IR and Obese-IS, 
falling in between Obese-IR and Obese-IS. A representative sample of these values are found in 
Figure 4.5. While abundance of lipids was not significantly different between groups, the rate of 
decrease for fatty acids, specifically oleic, palmitic, stearic, and linoleic acids, was greater in 
Obese-IR than in Obese-IS and LEAN during the clamp (figure 4.5). This was not found in 
phospholipid species (figure 4.7b). Fold change was also computed for metabolite levels and 
only ACAR 16:0 showed a statistical difference between groups with the Obese-IS group 
reporting a larger fold change decrease compared to the lean group and no difference between 
Obese-IR and lean (figure 4.4 & figure 4.8c). LEAN subjects followed a mediating pattern 
between the Obese-IR and Obese-IS groups (figures 4.5 – 4.10). This led us to choose to separate 
subjects by a measure of insulin resistance, glucose infusion rate (GIR).  
Difference between groups when sorted by grouping by GIR 
The differences in metabolite changes were more profound when sorted into relatively 
Low GIR and High GIR than when these differences were mediated by the LEAN subjects being 
separated out. For all metabolites, no groups differed at baseline (figures 4.5 – 4.10). However, 
for amino acids, the branched chained amino acids (BCAAs) were higher for Low GIR subjects 
throughout the time course for isoleucine/leucine and at the end of the time course (time 80 min 
and clamp) for valine (figures 4.4 - 4.6). Similarly, glutamate was higher throughout the time 
course for Low GIR, but was only significant at time 20 and at the clamp (figures 4.4 – 4.6). 
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Lipid patterns were similar, if even more profound, when grouped as High GIR vs Low 
GIR (figure 4.5). Low GIR subjects had higher abundance of fatty acids during all time points of 
the clamp for oleic, stearic, and palmitic acid and linoleic acid followed the same pattern but did 
not reach significance at 60 or 80 minutes. Like the earlier grouping, the less insulin sensitive 
group had a steeper slope than the more insulin sensitive group early in the clamp (figure 4.5). 
As with the earlier grouping, fatty acids were the only type of lipids that reached significance 
during the clamp. Fold change did not differ between groups for any lipid species.  
Short and mid-chain acylcarnitines were significantly higher in Low GIR subjects than in 
High GIR subjects toward the end of the clamp, 80 minutes and at SS (figures 4.4 & 4.5). This 
pattern was found in ACAR 2:0 through ACAR 14:1 carnitines and again in ACAR 18:1 
carnitine (figures 4.8a – 4.8c). This pattern was evident in other acylcarnitines, but did not reach 
the threshold for significance. The slope of acylcarnitines were not significantly different 
between groups except for in ACAR 6:0, ACAR 8:0, and ACAR 10:0 all seeing the Obese-IS 
group having a steeper slope between the 20 minute and 40 minute of the clamp.  Finally, when 
comparing the fold change in acylcarnitines the IS group showed greater fold change decrease in 
many of the acylcarnitine species. Specifically ACAR 6:0, ACAR 8:0, ACAR 10:0, ACAR 12:1, 
ACAR 12:0, ACAR 16:1, ACAR 14:1, ACAR 16:0, and ACAR 18:0 (figure 4.4). Fold changes 
were also computed for other metabolites but they were not found to be statistically different 
between Low GIR and High GIR groups (figure 4.4). 
Discussion 
General Summary 
Using a simple, yet systematic approach, we have demonstrated differences between 
obese, yet metabolically healthy individuals based on insulin sensitivity expressed at GIR and 
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established during the HIEC. Further, we have shown that these differences appear to be 
primarily due to insulin resistance rather than excess adiposity. Before grouping by GIR, it was 
expected that LEAN subjects would cluster nicely with the “healthier” Obese-IS group. Instead, 
most LEAN metabolites tended to mediate between Obese-IR and Obese-IS subjects. Lastly, we 
have identified differences in metabolite responses in lean, Obese-IR, and Obese-IS subjects 
during the HIEC which may be used to indicate metabolic phenotypes for future studies.  
To the best of our knowledge, this is the first study to describe physiological changes in 
metabolites during the HIEC. Specifically, in healthy, yet obese individuals and their lean 
counterparts. Several studies have reported changes during caloric challenges (16) and oral 
glucose tolerance tests (OGTT) (20, 28-30, 40), but few have been done during the HIEC. In an 
HIEC, subjects are given insulin appropriate to their body volume while glucose is infused to 
maintain blood glucose levels (26, 31), while in an OGTT, a glucose bolus is ingested and 
insulin response is measured (41). Due to these differences in assessment method, we have 
shown metabolite differences due to insulin action as opposed to response to glucose. While 
subtle, this may be important for drawing physiological conclusions.  
Amino Acids  
All amino acids, except for alanine, dropped significantly from their baseline levels 
independent of grouping figure 4.6. This drastic drop in amino acid levels is a clear indication of 
a downregulation of proteolysis, probably due to an increase in insulin (42). However, it was 
only when grouped by GIR that we see significant differences between groups. 
Leucine/Isoleucine (20, 40, 60, 80, SS), Valine (80, SS), and Glutamate (20, SS) were higher in 
the Low GIR group compared to the High GIR group. At the time points indicated in parenthesis. 
There is ample evidence that insulin resistance and obesity have an effect on branched chain 
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amino acid differences between obese, insulin resistant subjects and lean subjects (30, 43-45). 
However, in this instance, the lean subjects did not differ from either obese-IR or obese-IS 
subjects, but rather these differences were revealed when taking insulin resistance (GIR) into 
account. In this population, this is evidence that insulin resistance, rather than obesity alone is the 
cause of these differences in amino acid differences. Our results suggest that disordered BCAA 
short chain acylcarnitine metabolism could be due to decreased insulin sensitivity (45, 46) 
independent of obesity. 
Lipids 
All fatty acids, both saturated (stearic acid – 18:0, palmitic acid – 16:0) and unsaturated 
(oleic acid – 18:1, linoleic acid – 18:2) showed a significant and drastic suppression of lipid 
abundance during the clamp (figures 4.5 & 4.7). The levels of circulating free fatty acids (FFA) 
are dependent upon the rates of lipolysis within adipose tissues (47). The decrease seen in our 
study is likely due to the effects of both insulin and glucose inhibiting lipolysis (47-49). 
However, there was a slight yet significant dampening of this decrease in lipolysis in all of these 
fatty acids with the abundance levels of all four being higher in low GIR subjects compared to 
high GIR subjects throughout the clamp and at baseline (figures 4.5 & 4.7). Impaired fatty acid 
oxidation may be indicative of increased insulin resistance (50), and may be implicated in the 
differences we see in Low GIR and High GIR subjects. Increased accumulations of fatty acids 
could also lead to alterations in the insulin signaling pathway which we may be seeing in a 
decrease insulin sensitivity in Low GIR subjects here (51).  
Acylcarnitines 
Like amino acids and fatty acids, there were no significant differences throughout the 
course of the clamp. However, when subjects were sorted by GIR, a very interesting result 
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emerged. There were few differences between GIR groups at the beginning of the clamp, but the 
short and medium chain acylcarnitines (C2:0 – C14:1, but not C8:1) were significantly lower in 
High GIR subjects than Low GIR subjects at SS (C2:0 –C14:1, but not C8:1) and also at 80 
minutes (C5:6, C6:0, C10:0, C12:0, C12:1, and C16:1) (figures 4.4 & 4.5). This leads to two 
important insights.  
First, GIR differences rather than obesity are playing a part in these differences as we do 
not see these differences between groups when sorted by obesity (figure 4.5). While none of 
these subjects have diabetes, some are able to infuse glucose better to other due to the action of 
insulin and are thus slightly more insulin sensitive (High GIR) than the others (Low GIR). These 
differences must be due to these slight differences in insulin resistance, and not due to obesity. 
Acylcarnitines have been established as being associated with insulin resistance in many studies 
(28, 52-55). In particular, C10:0 and C12:0 are suppressed less in insulin resistant individuals 
(28), this is mirrored in our data. Short chain acylcarnitines have also been associated in insulin 
resistance, as in our data (56). Incomplete fatty acid oxidation may be implicated in this 
phenomenon and could be associated with insulin resistance (52-54).  
Secondly, acylcarnitines are indicative of fatty acid metabolism and as such would be 
expected to decrease in concert with fatty acids This should be especially true of the longer chain 
acylcarnitines which are direct metabolites of their fatty acid cognates (i.e. Oleic acid – 18:1  
C18:1). Levels of oleate (18:1) and palmitate (16:0) are significantly decreased during the course 
of the HEIC while their cognate acylcarnitines, C18:1 and C16:0 respectively, are not (figures 
4.4 & 4.5).  
One potential reason for this is that acylcarnitines are cleared from the blood by the 
kidneys (57). Kalim et al. found that carnitines are preferentially cleared from the blood 
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according to carbon chain length (58). Our data support this by showing that short and medium 
chain acylcarnitines are decreasing significantly through the clamp while longer chain 
acylcarnitines are not. This pattern is also found in other studies (28, 59, 60). This leads us to 
wonder if other studies that find major clearance of medium but not longer chain acylcarnitines 
could potentially be due to a lack of clearance rather than just action of the medium chain 
acylcarnitines. Our lab is currently analyzing urine acylcarnitine levels during HEIC which 
should provide evidence to help determine differential renal clearance of acylcarnitines. 
Another potential reason for this discrepancy in the clearance of acylcarnitine by carbon 
chain length could be due to the action of glucose on the acylcarnitine enzymes. Carnitine 
palmitoyltransferase I (CPT1) is a mitochondrial enzyme that acts to produce long chain 
acylcarnitines from long chain fatty acyl-CoA through the replacement of a carnitine for a CoA 
(57). Malonyl-CoA inhibits the action of CPT1 that produced in the presence of excess glucose 
such as during the HEIC (57). This promotes glycolysis and lipogenesis while inhibiting lipolysis 
in the presence of excess glucose (57). However, medium chain acylcarnitines are produced by a 
proxosomal enzyme called peroxisomal carnitine O-octanolytransferace (CrOT) which is not 
inhibited by malonyl-CoA (61). It is possible that medium chain acylcarnitines are produced and 
undergo lipolytic metabolism under the presence of excess glucose while stalling this process for 
longer chain acylcarnitines.   
Strengths/Limitations 
 This particular study uses metabolically healthy individuals that could potentially provide 
insight into the etiology of diseases such as T2DM. The use of healthy obese participants as well 
as lean negative controls leads to strong conclusions concerning the role of GIR in metabolomic 
difference instead of adiposity. The inclusion of lean negative controls with obese-IR and obese-
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IS highlights the control of metabolomic difference is from GIR rather than adiposity. Further, 
the use internal standards and targeted metabolomics lends confidence to our results. The use of 
the HEIC is particular useful in illuminating dynamic changes in metabolomic profiles due to 
acute glucose and insulin infusions.  
 This particular study was small (n=18) with 6 obese-IR, 6 obese-IS, and 6 lean subjects 
and a further study involving a larger population is warranted to validate these results. This is 
also a cross-sectional study so obesity histories are unknown for these subjects. As such, it is 
difficult to understand long-term repercussions of obesity to the metabolomic profiles of these 
participants. As such, a longitudinal study involving obese-healthy and lean subjects could be 
used to follow-up this study. 
Conclusion 
While this was a small, cross-sectional study, it does raise important findings concerning 
the metabolomic dynamics during the HEIC. First, differences in suppression of levels of fatty 
acids, amino acids, and short to medium-chain acylcarnitines appear to be due to differences in 
innate insulin sensitivity of participants rather than due to adiposity. However, this is a small 
study and is cross-sectional so warrants a larger, longitudinal study using more metabolically 
healthy lean and obese participants. Secondly, we saw clearance of short and medium chain 
acylcarnitines but not long chain acylcarnitines. Concurrently, reciprocal long chain fatty acids 
that should mirror these unchanging long chain acylcarnitines are highly suppressed. This 
discrepancy is perhaps due to a differential clearance of acylcarnitines, which decreases with 
increasing carbon length (58). Further metabolomic analysis of differential clearance of urine 
acylcarnitines will help elucidate whether the differences we see in clearance is due to metabolic 
processes or renal clearance differences. Alternatively, medium chain acylcarnitine production is 
202 
 
not inhibited by high glucose induced production of malonyl-CoA at peroxisomal CrOT while 
long chain acylcarnitine production is inhibited at CPT1.  




Table 4.1: Hyperinsulinemic-euglycemic Clamp Subject characteristics 
 Grouped by Obese-IR, Obese-IS, & Lean 
(A) 
Grouped by GIR (B) 
Obese-IR(a) Obese-IS(b) Lean(c) LOW 
GIR 
High GIR 
Sex (m/f) (0/6) (0/6) (2/4) (1/8) (1/8) 
Age (years) 32.8(7.0) 33.3(10.1) 28.8(9.2) 30.2(7.9) 33.1(9.9) 
Mass (kg) 101.7(11.9) 94.3(8.1) 70.8(6.3) * 92(17.3) 85.9(13.9) 
BMI (kg/m2) 37.7(3.8) 35.4(3.2) 23.2(1.2) * 33.1(7.3) 31.1(6.6) 
Body Fat (%) 47.6(11.6) 52.0(3.1) 29.5(8.0) * 41.6(12.2) 44.5(12.4) 
Fat Mass (kg) 48.8(11.6) 49.2(6.3) 20.5(4.4) * 39.5(17.5) 39.5(15.7) 
Fat Free Mass 
(kg) 




83.7(3.6) 83.6(16.4) 80.7(6.4) 82.2(5.0) 83.8(15.0) 
Assayed Glucose 
(SS) (mg/dL)† 
81.0(2.7) 83.6(14.5) 80.3(5.6) 80.2(3.6) 
 
83.9(13.3) 
Fasting Glucose 4.8(0.8) 4.7(0.5) 4.7(0.2) 4.8(0.7) 4.7(0.4) 
Fasting insulin 
[µU/mL] 











17.5(4.2) 7.6(2.5)* n/a n/a n/a 
M3 
(mg/kgFFM/min) 
7.4(1.0) 15.6(2.1)* n/a n/a n/a 
TG (mg/dL) 77.2(42.1) 47.4(19.5) 95.3(29.8)* 83.5(44.0) 63.1(29.8) 
Total cholesterol 157.5(12.1) 166.7(40.3) 141.8(29.0) 7.6(1.2) 14.9(2.1) 
Data are presented as Mean (SD) unless otherwise noted. * = p < 0.05 using ANOVA with 
Tukey’s post-hoc test for the grouping by adiposity and p < 0.05 using student’s t-test for 
grouping by GIR. Lean measurements for fasting insulin, fatty acid rate of appearance (FA 
RA), M3, triglyceride, and cholesterol were not available do they are not included in the 
analysis. †Two lean subject glucose assays were unavailable, so for glucose assay n=16. 
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Small samples (3 ml) were taken throughout the clamp to monitor glucose levels throughout 
the HIEC. Large vials (10 ml) were taken at the time points indicated above. Baseline 
measurements were taken as an average of Baseline #1 and Baseline #2 and Steady State (SS) 













Table 4.2: Authentic C-13 labeled internal standards added to LC/MS plasma 
samples for comparison/identification of targeted metabolites. 
Amino Acids Acylcarnitines 
Leucine/Isoleucine L-carnitine  ACAR 8:0  ACAR 16:2 
Phenylalanine  ACAR 3:0  ACAR 10:1  ACAR 14:0 
Valine  ACAR 2:0  ACAR 10:0  ACAR 16:1 
Methionine  ACAR 4:0  ACAR 12:1 ACAR 18:2 
Alanine  ACAR 5:0  ACAR 14:2 ACAR 16:0 
Tyrosine  ACAR 6:0  ACAR 12:0 ACAR 18:1 
Threonine  ACAR 8:1  ACAR 14:1 ACAR 18:0 
Histidine  Lipids Glucose Metabolites 
Serine  Oleic acid  Hexose Succinate  
Aspartate  Palmitic acid  Lactate Malate  





Figure 4.2:  GIR Infusion rates of individual subjects grouped as either Obese-IR/Obese-


























(A ) G lu c o s e  In fu s io n  R a te  o f  In d iv id u a l S u b je c ts
G ro u p in g  b y  O b e s e -IR /O b e s e -IS /L e a n







































(B )  G lu c o s e  In fu s io n  R a te  o f In d iv id u a l S u b je c ts
S o r te d  b y  G IR
G ro u p in g  b y  O b e s e -IR /O b e s e -IS /L e a n























One-way ANOVA with Tukey’s post-hoc test was run for data in A with * representing 
p<0.05 showing GIR was statistically higher than both Obese-IR and Lean. Students T-tests 
were run to compare GIR between Low GIR and High GIR with * signifying p<0.05. Subject 
symbols and colors remain constant from grouping A to grouping B to show where lean 




Figure 4.4: Heat map representing z-scored changes abundance in 62 targeted metabolites 
between High GIR and Low GIR subjects.  
 
* = FDR < 0.1 comparing Students T-tests between groups at each time point. Time points are 
at Baseline, 20 minutes, 40 minutes, 60 minutes, 80 minutes, and at the average of two clamp 
(C) time points. The range goes from Bright Red (0.98 STD above the mean) to Bright Green 





Figure 4.5: Changes in representative significantly different metabolite abundance over the 


















































































































































































































































































































































































































































































































































































































































Representative Significantly Different Metabolites
 
Data is presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 
area under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with 
Tukey’s post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low 
GIR. The color of the * represents the group identified as different using Tukey’s post hoc. 
































































































































































































































































































































































































































































































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or area 
under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with Tukey’s 
post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low GIR. The color 
of the * represents the group identified as different using Tukey’s post hoc. †† = FDR <0.1 using 
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Palmitic Acid (16:0) IR/IS/Lean






























































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or area 
under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with Tukey’s 
post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low GIR. The color 
of the * represents the group identified as different using Tukey’s post hoc. †† = FDR <0.1 using 

































































































































































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 
area under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with 
Tukey’s post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low 
GIR. The color of the * represents the group identified as different using Tukey’s post hoc. †† 







Figure 4.8a: Changes in short chain acylcarnitine (L-carnitine to ACAR 5:0) abundance over 























































































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 
area under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with 
Tukey’s post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low 
GIR. The color of the * represents the group identified as different using Tukey’s post hoc. †† 










Figure 4.8b: Changes in medium chain acylcarnitine (ACAR 8:0 to ACAR 12:1) abundance 















































































































































































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 
area under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with 
Tukey’s post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low 
GIR. The color of the * represents the group identified as different using Tukey’s post hoc. †† 









Figure 4.8c: Changes in long chain acylcarnitine (ACAR 14:0 – ACAR 18:2) abundance over 





























































































































































































































































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 
area under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with 
Tukey’s post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low 
GIR. The color of the * represents the group identified as different using Tukey’s post hoc. †† 







Figure 4.9: Changes in glucose metabolism related metabolite abundance over the course of 












































































































































































































































































































































Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 
area under the curve (AUC). Slope differences are represented as * = p<0.05 ANOVA with 
Tukey’s post hoc for Obese-IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low 
GIR. The color of the * represents the group identified as different using Tukey’s post hoc. †† 






Figure 4.10: Changes in other unrelated metabolite abundance over the course of the clamp.  
Data are presented as a ratio of AUC/AUC of authentic internal standard +/- SD (AUC IS) or 





















































































































































































































































































































Slope differences are represented as * = p<0.05 ANOVA with Tukey’s post hoc for Obese-
IR/Obese-IS/LEAN or Student’s T-test for High GIR vs Low GIR. The color of the * 
represents the group identified as different using Tukey’s post hoc. †† = FDR <0.1 using 






1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and 
projections to 2030. Int J Obes (Lond). 2008;32(9):1431-7. Epub 2008/07/09. doi: 
10.1038/ijo.2008.102. PubMed PMID: 18607383. 
2. Center for Disease Control and Prevention. Diabetes at a Glance 2016. In: Promotion 
NCfCDPaH, editor. Atlanta, GA: National Center for Chronic Disease Preventation and Health 
Promotion; 2016. 
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. 
Atlanta, GA: U.S. Department of Health and Humans Services; 2017. 
4. Centers for Disease Control and Prevention. Diabetes Report Card 2017. Atlanta, GA: 
US Department of Health and Human Services; 2018. 
5. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of 
co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC 
Public Health. 2009;9:88. Epub 2009/03/27. doi: 10.1186/1471-2458-9-88. PubMed PMID: 
19320986; PMCID: PMC2667420. 
6. Chen DL, Liess C, Poljak A, Xu A, Zhang J, Thoma C, Trenell M, Milner B, Jenkins AB, 
Chisholm DJ, Samocha-Bonet D, Greenfield JR. Phenotypic Characterization of Insulin-
Resistant and Insulin-Sensitive Obesity. J Clin Endocrinol Metab. 2015;100(11):4082-91. Epub 
2015/09/18. doi: 10.1210/jc.2015-2712. PubMed PMID: 26378474. 
7. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. 
What are the physical characteristics associated with a normal metabolic profile despite a high 
level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86(3):1020-5. Epub 
2001/03/10. doi: 10.1210/jcem.86.3.7365. PubMed PMID: 11238480. 
8. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers 
MR. The obese without cardiometabolic risk factor clustering and the normal weight with 
cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US 
population (NHANES 1999-2004). Arch Intern Med. 2008;168(15):1617-24. Epub 2008/08/13. 
doi: 10.1001/archinte.168.15.1617. PubMed PMID: 18695075. 
9. Hivert MF, Perng W, Watkins SM, Newgard CS, Kenny LC, Kristal BS, Patti ME, 
Isganaitis E, DeMeo DL, Oken E, Gillman MW. Metabolomics in the developmental origins of 
obesity and its cardiometabolic consequences. J Dev Orig Health Dis. 2015;6(2):65-78. doi: 
10.1017/S204017441500001X. PubMed PMID: 25631626; PMCID: PMC4406410. 
217 
 
10. Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008;372(9646):1281-
3. Epub 2008/10/22. doi: 10.1016/S0140-6736(08)61531-7. PubMed PMID: 18929889. 
11. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud'homme D, Rabasa-
Lhoret R. The metabolically healthy but obese individual presents a favorable inflammation 
profile. J Clin Endocrinol Metab. 2005;90(7):4145-50. Epub 2005/04/28. doi: 10.1210/jc.2005-
0482. PubMed PMID: 15855252. 
12. Akinyemiju T, Moore JX, Pisu M, Judd SE, Goodman M, Shikany JM, Howard VJ, 
Safford M, Gilchrist SC. A Prospective Study of Obesity, Metabolic Health, and Cancer 
Mortality. Obesity (Silver Spring). 2017. Epub 2017/11/28. doi: 10.1002/oby.22067. PubMed 
PMID: 29178569. 
13. Hinnouho GM, Czernichow S, Dugravot A, Nabi H, Brunner EJ, Kivimaki M, Singh-
Manoux A. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 
diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36(9):551-9. Epub 2014/03/29. doi: 
10.1093/eurheartj/ehu123. PubMed PMID: 24670711; PMCID: PMC4344958. 
14. Bagheri M, Farzadfar F, Qi L, Yekaninejad MS, Chamari M, Zeleznik OA, Kalantar Z, 
Ebrahimi Z, Sheidaie A, Koletzko B, Uhl O, Djazayery A. Obesity-Related Metabolomic 
Profiles and Discrimination of Metabolically Unhealthy Obesity. J Proteome Res. 
2018;17(4):1452-62. Epub 2018/03/02. doi: 10.1021/acs.jproteome.7b00802. PubMed PMID: 
29493238. 
15. Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, 
Nirantharakumar K. Metabolically Healthy Obese and Incident Cardiovascular Disease Events 
Among 3.5 Million Men and Women. J Am Coll Cardiol. 2017;70(12):1429-37. Epub 
2017/09/16. doi: 10.1016/j.jacc.2017.07.763. PubMed PMID: 28911506. 
16. Badoud F, Lam KP, Perreault M, Zulyniak MA, Britz-McKibbin P, Mutch DM. 
Metabolomics Reveals Metabolically Healthy and Unhealthy Obese Individuals Differ in their 
Response to a Caloric Challenge. PLoS One. 2015;10(8):e0134613. Epub 2015/08/15. doi: 
10.1371/journal.pone.0134613. PubMed PMID: 26274804; PMCID: PMC4537251. 
17. Abu Bakar MH, Sarmidi MR, Cheng KK, Ali Khan A, Suan CL, Zaman Huri H, Yaakob 
H. Metabolomics - the complementary field in systems biology: a review on obesity and type 2 
diabetes. Mol Biosyst. 2015;11(7):1742-74. doi: 10.1039/c5mb00158g. PubMed PMID: 
25919044. 
18. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 
2017;25(1):43-56. doi: 10.1016/j.cmet.2016.09.018. PubMed PMID: 28094011; PMCID: 
PMC5245686. 
19. Goffredo M, Santoro N, Trico D, Giannini C, D'Adamo E, Zhao H, Peng G, Yu X, Lam 
TT, Pierpont B, Caprio S, Herzog RI. A Branched-Chain Amino Acid-Related Metabolic 
218 
 
Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. Nutrients. 
2017;9(7). Epub 2017/06/24. doi: 10.3390/nu9070642. PubMed PMID: 28640216; PMCID: 
PMC5537762. 
20. Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, Florez JC, Clish CB, 
Gerszten RE, Wang TJ. Metabolite profiles during oral glucose challenge. Diabetes. 
2013;62(8):2689-98. doi: 10.2337/db12-0754. PubMed PMID: 23382451; PMCID: 
PMC3717862. 
21. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, 
Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, 
Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med. 
2011;17(4):448-53. Epub 2011/03/23. doi: 10.1038/nm.2307. PubMed PMID: 21423183; 
PMCID: PMC3126616. 
22. Albu JB, Heilbronn LK, Kelley DE, Smith SR, Azuma K, Berk ES, Pi-Sunyer FX, 
Ravussin E, Look AARG. Metabolic changes following a 1-year diet and exercise intervention in 
patients with type 2 diabetes. Diabetes. 2010;59(3):627-33. Epub 2009/12/24. doi: 
10.2337/db09-1239. PubMed PMID: 20028945; PMCID: PMC2828653. 
23. Griffin JL, Nicholls AW. Metabolomics as a functional genomic tool for understanding 
lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics. 2006;7(7):1095-
107. doi: 10.2217/14622416.7.7.1095. PubMed PMID: 17054419. 
24. Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The Emerging Role of Metabolomics in 
the Diagnosis and Prognosis of Cardiovascular Disease. J Am Coll Cardiol. 2016;68(25):2850-
70. doi: 10.1016/j.jacc.2016.09.972. PubMed PMID: 28007146. 
25. De Souza AL, Batista GA, Alegre SM. Assessment of insulin sensitivity by the 
hyperinsulinemic euglycemic clamp: Comparison with the spectral analysis of 
photoplethysmography. J Diabetes Complications. 2017;31(1):128-33. Epub 2016/11/15. doi: 
10.1016/j.jdiacomp.2016.10.018. PubMed PMID: 27839921. 
26. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying 
insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-23. Epub 1979/09/01. PubMed 
PMID: 382871. 
27. Glynn EL, Piner LW, Huffman KM, Slentz CA, Elliot-Penry L, AbouAssi H, White PJ, 
Bain JR, Muehlbauer MJ, Ilkayeva OR, Stevens RD, Porter Starr KN, Bales CW, Volpi E, 
Brosnan MJ, Trimmer JK, Rolph TP, Newgard CB, Kraus WE. Impact of combined resistance 
and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and 
insulin sensitivity in overweight humans. Diabetologia. 2015;58(10):2324-35. Epub 2015/08/10. 
doi: 10.1007/s00125-015-3705-6. PubMed PMID: 26254576; PMCID: PMC4793723. 
219 
 
28. Nowak C, Hetty S, Salihovic S, Castillejo-Lopez C, Ganna A, Cook NL, Broeckling CD, 
Prenni JE, Shen X, Giedraitis V, Arnlov J, Lind L, Berne C, Sundstrom J, Fall T, Ingelsson E. 
Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance. 
Sci Rep. 2018;8(1):8691. Epub 2018/06/08. doi: 10.1038/s41598-018-26701-0. PubMed PMID: 
29875472; PMCID: PMC5989236. 
29. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, Haring HU, Schleicher ED, Xu G, 
Lehmann R. Changes of the plasma metabolome during an oral glucose tolerance test: is there 
more than glucose to look at? Am J Physiol Endocrinol Metab. 2009;296(2):E384-93. Epub 
2008/12/11. doi: 10.1152/ajpendo.90748.2008. PubMed PMID: 19066319. 
30. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, 
Gerszten RE, Mootha VK. Metabolic profiling of the human response to a glucose challenge 
reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008;4:214. Epub 2008/08/07. doi: 
10.1038/msb.2008.50. PubMed PMID: 18682704; PMCID: PMC2538910. 
31. Van Pelt DW, Guth LM, Wang AY, Horowitz JF. Factors regulating subcutaneous 
adipose tissue storage, fibrosis, and inflammation may underlie low fatty acid mobilization in 
insulin-sensitive obese adults. Am J Physiol Endocrinol Metab. 2017;313(4):E429-E39. Epub 
2017/07/07. doi: 10.1152/ajpendo.00084.2017. PubMed PMID: 28679624; PMCID: 
PMC5668599. 
32. Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA. Obesity 
and insulin resistance in humans: a dose-response study. Metabolism. 1990;39(5):452-9. Epub 
1990/05/01. PubMed PMID: 2186255. 
33. Overmyer KA, Evans CR, Qi NR, Minogue CE, Carson JJ, Chermside-Scabbo CJ, Koch 
LG, Britton SL, Pagliarini DJ, Coon JJ, Burant CF. Maximal oxidative capacity during exercise 
is associated with skeletal muscle fuel selection and dynamic changes in mitochondrial protein 
acetylation. Cell Metab. 2015;21(3):468-78. Epub 2015/03/05. doi: 10.1016/j.cmet.2015.02.007. 
PubMed PMID: 25738461; PMCID: PMC4350023. 
34. Lorenz MA, Burant CF, Kennedy RT. Reducing time and increasing sensitivity in sample 
preparation for adherent mammalian cell metabolomics. Anal Chem. 2011;83(9):3406-14. Epub 
2011/04/05. doi: 10.1021/ac103313x. PubMed PMID: 21456517; PMCID: PMC3094105. 
35. Badawy AA, Morgan CJ, Turner JA. Application of the Phenomenex EZ:faasttrade mark 
amino acid analysis kit for rapid gas-chromatographic determination of concentrations of plasma 
tryptophan and its brain uptake competitors. Amino Acids. 2008;34(4):587-96. Epub 2007/12/12. 
doi: 10.1007/s00726-007-0012-7. PubMed PMID: 18071842; PMCID: PMC2797848. 
36. Fiehn O, Kopka J, Trethewey RN, Willmitzer L. Identification of uncommon plant 
metabolites based on calculation of elemental compositions using gas chromatography and 




37. Thonusin C, IglayReger HB, Soni T, Rothberg AE, Burant CF, Evans CR. Evaluation of 
intensity drift correction strategies using MetaboDrift, a normalization tool for multi-batch 
metabolomics data. J Chromatogr A. 2017;1523:265-74. Epub 2017/09/21. doi: 
10.1016/j.chroma.2017.09.023. PubMed PMID: 28927937; PMCID: PMC5788449. 
38. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, Wishart DS, Xia J. MetaboAnalyst 
4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018. 
Epub 2018/05/16. doi: 10.1093/nar/gky310. PubMed PMID: 29762782. 
39. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data 
Analysis. Curr Protoc Bioinformatics. 2016;55:14 0 1- 0 91. Epub 2016/09/08. doi: 
10.1002/cpbi.11. PubMed PMID: 27603023. 
40. Nowak C, Salihovic S, Ganna A, Brandmaier S, Tukiainen T, Broeckling CD, 
Magnusson PK, Prenni JE, Wang-Sattler R, Peters A, Strauch K, Meitinger T, Giedraitis V, 
Arnlov J, Berne C, Gieger C, Ripatti S, Lind L, Pedersen NL, Sundstrom J, Ingelsson E, Fall T. 
Effect of Insulin Resistance on Monounsaturated Fatty Acid Levels: A Multi-cohort Non-
targeted Metabolomics and Mendelian Randomization Study. PLoS Genet. 
2016;12(10):e1006379. doi: 10.1371/journal.pgen.1006379. PubMed PMID: 27768686; PMCID: 
PMC5074591 report that no other competing interests exist. 
41. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin 
sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol 
Endocrinol Metab. 2008;294(1):E15-26. Epub 2007/10/25. doi: 10.1152/ajpendo.00645.2007. 
PubMed PMID: 17957034. 
42. Esteban I, Aguado C, Sanchez M, Knecht E. Regulation of various proteolytic pathways 
by insulin and amino acids in human fibroblasts. FEBS Lett. 2007;581(18):3415-21. Epub 
2007/07/06. doi: 10.1016/j.febslet.2007.06.043. PubMed PMID: 17610878. 
43. Yoon MS. The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance 
and Metabolism. Nutrients. 2016;8(7). Epub 2016/07/05. doi: 10.3390/nu8070405. PubMed 
PMID: 27376324; PMCID: PMC4963881. 
44. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, 
Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS, Jr., Eisenson H, 
Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-
related metabolic signature that differentiates obese and lean humans and contributes to insulin 
resistance. Cell Metab. 2009;9(4):311-26. Epub 2009/04/10. doi: 10.1016/j.cmet.2009.02.002. 
PubMed PMID: 19356713; PMCID: PMC3640280. 
45. McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten RE, Clish CB, 
Mootha VK, Grinspoon SK, Fleischman A. Circulating branched-chain amino acid 
concentrations are associated with obesity and future insulin resistance in children and 
221 
 
adolescents. Pediatr Obes. 2013;8(1):52-61. Epub 2012/09/11. doi: 10.1111/j.2047-
6310.2012.00087.x. PubMed PMID: 22961720; PMCID: PMC3519972. 
46. Krebs M, Krssak M, Bernroider E, Anderwald C, Brehm A, Meyerspeer M, Nowotny P, 
Roth E, Waldhausl W, Roden M. Mechanism of amino acid-induced skeletal muscle insulin 
resistance in humans. Diabetes. 2002;51(3):599-605. Epub 2002/03/02. PubMed PMID: 
11872656. 
47. Chakrabarti P, Kim JY, Singh M, Shin YK, Kim J, Kumbrink J, Wu Y, Lee MJ, Kirsch 
KH, Fried SK, Kandror KV. Insulin inhibits lipolysis in adipocytes via the evolutionarily 
conserved mTORC1-Egr1-ATGL-mediated pathway. Mol Cell Biol. 2013;33(18):3659-66. Epub 
2013/07/17. doi: 10.1128/MCB.01584-12. PubMed PMID: 23858058; PMCID: PMC3753874. 
48. Burns TW, Terry BE, Langley PE, Robison GA. Insulin inhibition of lipolysis of human 
adipocytes: the role of cyclic adenosine monophosphate. Diabetes. 1979;28(11):957-61. Epub 
1979/11/01. doi: 10.2337/diab.28.11.957. PubMed PMID: 226442. 
49. Mittelman SD, Bergman RN. Inhibition of lipolysis causes suppression of endogenous 
glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab. 
2000;279(3):E630-7. Epub 2000/08/19. doi: 10.1152/ajpendo.2000.279.3.E630. PubMed PMID: 
10950832. 
50. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, Yang E, Farrell L, 
Fox CS, O'Donnell CJ, Carr SA, Vasan RS, Florez JC, Clish CB, Wang TJ, Gerszten RE. Lipid 
profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes 
prediction in humans. J Clin Invest. 2011;121(4):1402-11. Epub 2011/03/16. doi: 
10.1172/JCI44442. PubMed PMID: 21403394; PMCID: PMC3069773. 
51. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD. Role of fatty acid uptake 
and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. 
Biochim Biophys Acta. 2010;1801(1):1-22. Epub 2009/09/29. doi: 10.1016/j.bbalip.2009.09.014. 
PubMed PMID: 19782765. 
52. Muoio DM, Koves TR. Lipid-induced metabolic dysfunction in skeletal muscle. Novartis 
Found Symp. 2007;286:24-38; discussion -46, 162-3, 96-203. Epub 2008/02/14. PubMed PMID: 
18269172. 
53. Muoio DM, Neufer PD. Lipid-induced mitochondrial stress and insulin action in muscle. 
Cell Metab. 2012;15(5):595-605. Epub 2012/05/09. doi: 10.1016/j.cmet.2012.04.010. PubMed 
PMID: 22560212; PMCID: PMC3348508. 
54. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP. 
Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a 
marker of glucolipotoxicity. Obesity (Silver Spring). 2010;18(9):1695-700. Epub 2010/01/30. 
doi: 10.1038/oby.2009.510. PubMed PMID: 20111019; PMCID: PMC3984458. 
222 
 
55. Soeters MR, Sauerwein HP, Duran M, Wanders RJ, Ackermans MT, Fliers E, Houten 
SM, Serlie MJ. Muscle acylcarnitines during short-term fasting in lean healthy men. Clin Sci 
(Lond). 2009;116(7):585-92. Epub 2008/10/24. doi: 10.1042/CS20080433. PubMed PMID: 
18945215. 
56. Hoppel CL, Genuth SM. Carnitine metabolism in normal-weight and obese human 
subjects during fasting. Am J Physiol. 1980;238(5):E409-15. Epub 1980/05/01. doi: 
10.1152/ajpendo.1980.238.5.E409. PubMed PMID: 7377339. 
57. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological 
and clinical aspects. Clin Pharmacokinet. 2012;51(9):553-72. Epub 2012/07/19. doi: 
10.2165/11633940-000000000-00000. PubMed PMID: 22804748. 
58. Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, Pierce K, Deik A, 
Gerszten RE, Thadhani R, Rhee EP. A plasma long-chain acylcarnitine predicts cardiovascular 
mortality in incident dialysis patients. J Am Heart Assoc. 2013;2(6):e000542. Epub 2013/12/07. 
doi: 10.1161/JAHA.113.000542. PubMed PMID: 24308938; PMCID: PMC3886735. 
59. Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH, DeJesus VR, 
Vockley J, Arslanian SA. Metabolomic profiling of fatty acid and amino acid metabolism in 
youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes 








60. Lehmann R, Zhao X, Weigert C, Simon P, Fehrenbach E, Fritsche J, Machann J, Schick 
F, Wang J, Hoene M, Schleicher ED, Haring HU, Xu G, Niess AM. Medium chain acylcarnitines 
dominate the metabolite pattern in humans under moderate intensity exercise and support lipid 
oxidation. PLoS One. 2010;5(7):e11519. Epub 2010/07/17. doi: 10.1371/journal.pone.0011519. 
PubMed PMID: 20634953; PMCID: PMC2902514. 
61. Le Borgne F, Ben Mohamed A, Logerot M, Garnier E, Demarquoy J. Changes in 
carnitine octanoyltransferase activity induce alteration in fatty acid metabolism. Biochem 
Biophys Res Commun. 2011;409(4):699-704. Epub 2011/05/31. doi: 
10.1016/j.bbrc.2011.05.068. PubMed PMID: 21619872. 
223 
 
Chapter 5: Discussion 
 
Significance of Research Findings 
The importance of nutrition to health 
Nutrition science is one of the most important and impactful areas of biomedical research 
because the energy content and composition of the diet has important and profound effects on 
disease risk (1). Diets that score highly using indexes of quality such as the Healthy Eating 
Index, the Alternative Healthy Eating Index, and the Dietary Approaches to Stop Hypertension  
are associated with significant reductions in diseases such as cancer, type 2 diabetes, 
cardiometabolic diseases, and overall mortality (2, 3). Macronutrient overconsumption is an 
important and very controllable factor for controlling these causes of death (4).  Specifically, 
overconsumption of calories has been associated with cardiovascular diseases and type 2 
diabetes mellitus (5, 6), though total nutrient intake seems to be more important when 
considering the causative association between obesity and diabetes.   
Current methods for knowing dietary intake 
In order to make recommendations concerning dietary intake, policy makers must first 
understand the consumption patterns of populations and individuals. Current information about 
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macronutrient intake depend on large epidemiological studies such as the report from the 
National Health and Examination Survey (NHANES) entitled ‘What We Eat in America’ 
(WWEIA) which is composed of data that is produced using memory-based dietary assessment 
method (MBDA) (7-10). Consumption data from these studies are the basis for dietary guidelines 
such as the Dietary Guidelines for Americans (DGA), which outlines American federal nutrition 
policy and recommendations (11). Health researchers and practitioners draw associations 
between nutritional intake and disease based on data produced from MBDAs (12, 13).  However, 
data obtained from MBDA is questionable due to misreporting of energy and macronutrient 
intake (14-22).  The inaccuracies of MBDA are due to errors in subject recall, subject reactivity, 
or misrepresentation of diet due to social desirability (16, 23-26).  The use of misreported dietary 
information could potentially lead to misrepresentation of the effects of diet on health (27-31).  
Despite their limitations, MBDAs remain the most highly used and least biased tools for 
researchers to know dietary intake (9, 10, 19). However, given these limitations, developing an 
objective tool to assess dietary intake would provide a significant improvement to nutrition 
research and the ability to make health recommendations concerning nutritional intake (32) 
Metabolomics as an objective measure of dietary intake 
Metabolomics is a technology that uses high throughput methods to study small 
molecules present in biological samples paired with advanced statistical to derive insights into 
biological processes (33, 34). These small molecules are collectively referred to as the 
“metabolome” and reflect the downstream precursors and products of metabolism (33-35). Given 
the need to find a more objective measure of dietary intake than the more subjective MBDA (36-
41), it has been proposed that metabolomics could  answer to this problem (36, 37, 39, 41).  The 
use of metabolomics as a form of dietary analysis in humans is relatively new and focuses on 
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three areas: understanding diet using large epidemiological studies (42), identifying specific 
metabolomic patterns related to dietary intake (43), and to identifying compounds specific to the 
consumption of specific foods (44-46(47, 48). Recently, metabolomics been employed to analyze 
dynamic changes in the metabolome due to diet.  Frahnow and associates used metabolomics, 
specifically lipidomics, to identify patterns of changes in lipid classes after 1 and 6 weeks of a 
high fat diet in a controlled feeding study (47). Similar to our study, they found that the lipidome 
is rapidly altered by diet and should be controlled in clinical association studies (47). They were 
further able to classify specific classes of lipids into patterns of change such as monotonous 
reactions, time dependent increase or decrease, and counter regulation (47).   
A study by Pellis, et al., identified acute changes in the metabolome during the 6 hours 
following consumption of a standardized dairy shake containing 59% lipids, 30% carbohydrates, 
and 12% protein (49). Finally, Wellington, et al.,  identified trajectories of change in metabolites 
following a two-week prescribed “Western” rich in trans fats, red meats, sweetened beverages, 
and processed foods or “Prudent” diet pattern which included a greater intake of fruits, 
vegetables, lean meats, and whole grains (43).  
 The main goal of this dissertation was to examine, identify, and provide insight into 
dynamic changes in the metabolome due to changes in macronutrient intake, both long term and 
acute. Furthermore, this study strives to provide the first steps toward an objective identification 
of macronutrient intake using the tools of metabolomics.  
Summary of Research Findings 
 The goals of this dissertation can be divided into three distinct aims: 1a) determine 
dynamic changes in the lipidome due to high carbohydrate and high fat diets, 1b) using the 
results from aim 1a develop lipidomic biomarkers which differentiate between high fat and high 
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carbohydrate diets, 2) compare the recalled macronutrient intake with actual macronutrient 
intake of participants in a controlled feeding study, and 3) compare the metabolomic profile of 
obese yet metabolically healthy and lean individuals during a hyperinsulinemic-euglycemic 
clamp. In order to address aim 1a and 1b, these studies used two distinct research populations to 
investigate dynamic changes in the metabolome using high throughput metabolomics. We used 
two feeding studies with extreme macronutrient diets to illuminate these changes. The first 
feeding study (PUFA/CHO) involve feeding participants (n=12) a eucaloric high PUFA diet for 
21 days followed by a eucaloric high CHO diet for 21 days. The second study was a high 
fat/high carbohydrate-controlled feeding study called the Metabolomic Analysis of Diet Study 
(MEAL).  Participants in this study (n=23) were provided prepared diets which were consumed 
throughout the experiment  Participants consumed  a standard diet for 3 days, and then 
randomized to either a very high fat diet or a very high carbohydrate diet for the following 21 
days.   
Aim 1a sought to identify the dynamic response of the lipidome on very high fat enriched in 
polyunsaturated fatty acids followed by a very high carbohydrate diet.  Aim 1b used 
discriminating lipids from Aim 1a to identify diets from the plasma samples from the MEAL and 
PUFA/CHO studies as well as samples from a control study. A set of 12 discriminating lipids 
which we named “Sentinel Lipids” were found to be effective at discriminating between high fat 
and high carbohydrate diets after 2 days through 21 days of diet. To demonstrate the 
effectiveness of the sentinel lipids, a population of community members provided cross-sectional 
plasma samples as well as diets well characterized by 7 consecutive days of dietary journals were 
successfully identified as consumers of either high fat or high carbohydrate diets.  
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Aim 2 for this dissertation sought to investigate the differences between actual (provided) diets 
with reported diet using the 24H$ during the MEAL study.  We collected 24HR during the 
MEAL study after the standard diet and at random times during each of the 3 weeks of the 
experimental diets.  Proportions of macronutrients (proteins, fats, and carbohydrates) as well as 
energy intake (EI) of provided foods were compared to these same measures reported via 24HR.  
Aim 3 sought to compare the dynamic changes in the metabolome and metabolomic profiles in 
obese yet metabolically healthy individuals as well as lean controls. We collected plasma 
samples as these participants underwent an acute intravenous glucose and insulin infusion during 
a hyperinsulinemic-euglycemic clamp. The obese participants differed based on their status as 
either more insulin resistant or insulin sensitive.  
Summary of Dynamic Changes in the Metabolome Due to Diet 
 Chapter 2 focused on the lipidomic analysis of the dietary feeding study also used in 
Chapter 3.  Participants ate a standard diet for 3 days followed by either a very high fat diet or a 
very high carbohydrate diet for 21 days.  We collected plasma from all participants before the 
study began (baseline), after 3 days of a standard diet (standard), and again at days 2, 7, 14, and 
21 of the experimental diets.  We also included a more extreme feeding study which was 
conducted in our lab several years ago.  In this study, participants ate a high polyunsaturated 
fatty acid diet for 21 days followed immediately by a high carbohydrate diet for another 21 days. 
While this diet was more extreme in the unsaturated fatty acid profile of foods consumed, it was 
comparable to our study and provided more samples in order to identify differences between 
high fat and high carbohydrate eaters.  We had three specific aims to this paper: 1) identify how 
the lipidome reacts to 3 days of a standard diet, 2) identify specific dynamic changes and 
differences in the lipidome due to high fat or high carbohydrate diet, and 3) identify “sentinel 
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lipids” which can be used to discriminate between high fat and high carbohydrate eaters. To 
further aim 3 we also tested the plasma of free-living individuals with known diets against our 
sentinel lipids to evaluate the real-world efficacy of our test.  
 Aim’s 1a and 1b presented in Chapter 2 were similar in scope and used overlapping 
populations.  For aim 1a we successfully showed that the variability between free-living baseline 
lipidome signatures was less after eating 3 days of a standard diet. Furthermore, the variability 
was less after participants then went on the experimental diets.  This indicates that the lipidome 
is dynamic and changes in a very short period.  Furthermore, it suggests that researchers 
conducting nutrition-based metabolomics studies should strongly consider 3 days of a standard 
diet in order to produce a homogenous lipidome in their participants before introducing 
experimental diets.   
 The dynamic change shown in the lipidome was the focus of aim 1a and it used plasma 
samples from the MEAL study and the PUFA study to identify differences between the plasma 
lipidome of high fat and high carbohydrate diets and to describe the dynamic changes seen in 
lipid patterns.  We showed that PUFA diet was more than the MEAL diet showing more changes 
and larger differences in lipids at all experimental time points.  In particular, both diets resulted 
in differences in the levels of TG, CER, DG, PE, and PC.  We were able to show that the 
lipidome change was quite rapid, with more than half of the lipids species changing within 2 
days of starting either a high fat or high carbohydrate diet.  However, LPCs, LPEs, PlsChos, and 
PlsEths slowly changed. There was also a pattern present in the phosphatidylethanolamine 
plasmalogens, which is present in both diets, but most pronounced in the MEAL study (Figures 
2.1 & 2.2).  We identified in both diets what appears to be an adaptive response, e.g. more and 
more pronounced differences in lipid species were observed after 2 days of diet but many of 
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these returned to near baseline after 21 days of diet.  This was especially apparent in longer 
chained polyunsaturated TGs.   
 Aim 1b was to identify and use “sentinel lipids” as a diagnostic test to discriminate high 
carbohydrate and high fat diets. We identified 54 sentinel lipids that were significantly different 
at any experimental time point between high fat and high carbohydrate diets in the MEAL study 
and were identified in both the MEAL and PUFA study.  These sentinel lipids were used in an 
online R package called Metaboanalyst (www.metaboanalyst.ca) using the multivariate 
biomarker analysis feature.  From these sentinel lipids we identified 12 discriminating features. 
Receiver operator curves (ROC) were generated using Monte-Carlo cross validation using 2/3 of 
the participants to evaluate features of importance and the other 1/3 to test.  This was iterated 100 
times to characterize the ROC, which indicated a very high discrimination between high fat and 
high carbohydrate diets using the sentinel lipids.   
 To test our sentinel lipids on a free-living sample and inform generalizability from the 
laboratory, we used plasma sampled from free-living participants from the community 
(Community).  The participants (n=102) provided a cross-sectional sample of blood after 7 days 
of food diaries.  A carbohydrate/fat ratio was produced to indicate the macronutrient pattern 
consumed by these participants.  Using a supervised machine learning method (SVM) in the 
online R Metaboanalyst package (www.metaboanalyst.ca) these unknown samples were given a 
probability score to indicate their identity as high carbohydrate (0.0 – most confidence to 0.5 – 
least confidence) or high fat (0.5 – least confidence to 1.0 – most confidence).  When probability 
scores were graphed versus carbohydrate: fat ratio from participants’ food journals, there was a 
non-statistically significant pattern with a lower ratio (more carbohydrate) being identified as 
high carbohydrate and higher ratio (more fat) as high fat.  
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 Aim 1 has many strengths that set it apart from traditional nutritional science studies 
(Table 5.1). First, the use of state of the art untargeted shotgun lipidomic and targeted 
metabolomic profiling to determine and describe dynamic changes due to diet. Because all of 
these results of these studies conducted on free-living human populations are potentially 
translatable to the larger human population. Secondly, Aim 1 used three human study 
populations (PUFA/CHO, MEAL, and Community) which enhances generalizability of these 
findings. The PUFA/CHO and MEAL studies used well characterized diets designed by trained 
clinical dietitians in the metabolic kitchen. The use of the Community population to test the 
ability of the sentinel lipids in Aim 1b to identify high fat and high carbohydrate diets is a 
particular strength of this dissertation. The diets of the Community population were well known 
and characterized using 7 consecutive days of food journals which diminishes day to day 
variation inherent in the use of single day food journals and 24HR (9, 10). 
 While Aim 1 had several strengths, there were several limitations as well (Table 5.1). 
When determining lipid differences between high fat and high carbohydrate diets in  
Aim 1a, we correctly chose to use an FDR correction for multiple comparisons. However, the 
lipids compared were very highly correlated (Figure S2.4).  The use of the highly stringent FDR 
correction may be obfuscating true statistical differences and a less stringent nominal p-value 
from a Student’s T-test may be more appropriate. As with many human studies, in order to have 
good generalizability, this study suffers from a limited population due to financial, time and 
ethical reasons. This reduces the strength of our findings and indicates that a larger study should 
be conducted to reduce variability and other issues associated with small populations. Secondly, 
the diets used in both of these feeding studies used extreme macronutrient proportions that are 
rarely consumed by the population at large. Finally, all of these studies were conducted in 
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healthy, young adult volunteer participants who were primarily undergraduate and graduate 
students at the University of Michigan. The demographics of our populations do not reflect the 
population of the United States as a whole and this reduces the generalizability of our results 
 
Summary of Dietary Analysis Study 
 Chapter 3 was focused on the discrepancies in controlled feeding studies between 
reported dietary intake and actual dietary intake. The literature suggests that 24HR often under-
report energy intake as well as macronutrient intake (14-20), but this is poorly in the laboratory 
setting.  Unlike the literature, during the standard diet we found that energy, carbohydrate, and 
fat intake were well reported by our participants by the 24HR.  During the experimental diet, 
participants tended to over-report whichever macronutrient was provided in excess of the 
standard diet and under-report that which was provided at a lower level than the standard diet.  In 
other words, if participants were on a high fat diet, they under-reported fat and over-reported 
carbohydrate.  We also found that protein intake over-reported by participants regardless of diet, 
furthermore, during the standard diet, high carbohydrate, and fat diet all participants reported 
eating more animal protein than they were provided. One possible reason for this misreporting of 
macronutrients could be due to the motivation and education level of our participants.  Our 
participants were, for the most part, graduate students at the University of Michigan and their 
performance is consistent with previous findings that higher education is associated with less 
bias in the 24HR (14). Furthermore, while the 24HR were unannounced, the participants were 
aware of pending interviews.  Perhaps the knowledge that their 24HR were observed and 
recorded by the research team might have decreased recall bias in our participants. This is 
consistent with the findings of several studies showing decreased misreporting when participants 
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are aware their diets are observed (50-52). Finally, the food for our studies was provided on a 
cycle of 4 possible meals for breakfast, lunch, and dinner and may have increased the recall 
accuracy of our study.   
 Regardless of the reasons for the accuracy of our participants 24HR, we did find that 
subjects misreported macronutrient intake on the high fat and high carbohydrate diets and under-
reported animal protein.  Participants provided very high fat diets under-reported fat intake and 
participants provided very high carbohydrate diet under-reported carbohydrate intake. The 
results of our study suggest that, while 24HR may have its limitations in epidemiological studies 
and large population-based studies, perhaps energy recall can be trusted in controlled feeding 
studies.  However, in studies in which fat and carbohydrate intake are extreme, subjects may 
under report macronutrients that are provided in proportions that are very high compared to 
habitual intake. Conversely, participants may over report macronutrients that are provided in 
proportions that are very low compared to habitual intake. Misreporting of protein, due to under 
reporting of animal protein, must be considered when planning and analyzing feeding studies. 
 
Summary of Hyperinsulinemic-euglycemic Clamp Study 
Chapter 4 in this dissertation focused on metabolomic differences between obese healthy 
individuals who were either more insulin resistant, more insulin sensitive, and lean controls.   We 
found that metabolomic differences were primarily due to innate insulin resistance measured 
with glucose infusion rate rather than obesity. These differences were in metabolites associated 
with lipolysis (fatty acids), amino acids (BCAAs and glutamate), and short and medium chain 
acylcarnitines.  BCAAs and glutamate were significantly lower in participants who were more 
insulin resistant than those who were more insulin sensitive regardless of obesity.  Also, lipolysis 
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shown in levels of fatty acids was impaired in those who were more insulin resistant.  
Interestingly, long change acylcarnitines did not show a clearance while we saw a suppression of 
long chain fatty acids.  We concluded that this discrepancy is perhaps due to a differential 
clearance of acylcarnitines by carbon chain length.  
Strengths of this study start with the use of state of the art targeted metabolomic profiling. These 
subjects were compared based on glucose infusion rate but were metabolically healthy. This 
provides some insight into the etiology and development of insulin resistance and the role of 
innate glucose infusion rate rather than obesity in this development. We chose to include lean 
controls as a negative control comparison with the obese subjects of varied insulin resistance. 
The use of these lean controls highlighted the role of glucose infusion rate and diminished the 
role of obesity in the metabolomic changes and differences seen during the clamp in branched 
chain amino acids and fatty acids. Finally, the use of plasma samples collected throughout the 
time course of the clamp allowed for identification of dynamic changes in the metabolome not 
previously found in the literature. This was a cross sectional study and was small study (n=18) 
but the results are important and warrant a further look. Further work should follow obese 
participants using both insulin resistance and metabolomics to see how these factors change over 
time. More participants should be included in further studies to increase the power of results. 
Future Directions and Applications 
The results of this dissertation, especially in the development of an objective measure to identify 
high fat and high carbohydrate diet, were very promising.  However, these results also lead to 
several questions that lead to future directions and possible studies.  
The fat and carbohydrate percentages chosen for our HC and HF diets in the MEAL  
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Study were extreme, with both approaching 3 standard deviations above and below that reported 
by the American public (53). While our sentinel lipids performed very well on these extreme 
diets and seemed to do a reasonable job at identification of high carbohydrate and high fat 
consumption in our control population, they do not represent diets consumed by the “average” 
consumer (53). Future controlled feeding studies with incrementally decreasing/increasing 
carbohydrate and fat concentrations to further refine our model are called for. Our participants 
were all healthy individuals and within a limited range of BMI and ages. Further studies with a 
broader range of participants should be conducted as well including increasing the range of 
ethnicities, ages, BMIs, and health conditions.   
 The development of objective biomarkers of macronutrient intake is promising and leads 
us to ponder a future study in which participants habitual diet is determined using food journals 
or 24HR.  Plasma samples could be collected at baseline and analyzed to determine the baseline 
lipidome. Participants would then be provided 3 days of diet with macronutrient proportions 
matching the reported habitual intake identified at baseline. Lipidomics before and after this 
macronutrient feeding could be compared for agreement. This study would further establish our 
understanding of the strength of using lipidomics as an objective measure of dietary intake in 
coordination with memory based dietary assessments.  
 Our diets (PUFA/CHO and MEAL) manipulated fat and carbohydrate concentrations but 
kept protein concentrations constant at 15%.  However, we know that while protein intake is 
consistent within individuals, there is variations (9,10,53). We would like to continue the work 




 One of the limitations of these human feeding studies was that they were conducted in 
healthy, young populations of mostly graduate students. This does not reflect the population of 
the United States as a whole. We would like to expand these studies to include a range of ages, 
body compositions regional locations, races, and ethnicities to reflect and enhance 
generalizability to the larger US population. 
 We identified 55 sentinel lipids, which discriminated very high fat and very high 
carbohydrate consumers.  There was a very high level of intercorrelation between the sentinel 
lipids and we suspect that a smaller subset of sentinel lipids may produce a more refined model 
for identification of macronutrient intake.  
 For the HEIC study, this was a very small population (n=18) and was cross-sectional.  
We were not aware of the prior obesity status of these individuals nor was there follow-up on 
these participants to identify their metabolic status to determine risk. While the results are 
interesting and provide novel identification of differential acylcarnitine clearance, these results 
warrant a much larger study, which includes a larger range of participants. Also, a longitudinal 
study which follows participants over several years would provide more insight into the 
metabolomic differences we see between insulin resistant and insulin sensitive individuals 
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Table 5.1:  Dissertation Strengths and Limitations for all Aims 






 PUFA/CHO and MEAL were 
well-controlled longitudinal 
feeding studies 
 The MEAL study included a 
standard diet that 
demonstrates lipidomic 
convergence after only 3 days 
 Aims 1a & 1b used state of 
the art untargeted shotgun 
lipidomic methodologies 
 Unsupervised machine 
learning provides unbiased 
prediction of dietary intake 
 The Community study has 
well-characterized diets and 
provides insight into the 
efficacy of the use of sentinel 
lipids to identify 
macronutrient intake 
 Aim 2 compared actual diet 
with reported diet giving 
insight into true sources of 
misreporting 
 
 Fairly small sample sizes 
o PUFA/CHO (n=12) 
o MEAL (n=23) 
 Diets were extreme with no 
natural progression to 
approximate “real-world” 
diets 
 Lipids have a very high level 
of intercorrelation and the use 
of the FDR may be too 
stringent hiding true 
associations 
 Conducted in healthy, young, 
well-educated populations 
which may not reflect the 
population of the country as a 
whole 
Aim 3 
 State of the art targeted 
metabolomics 
 Subjects were metabolically 
healthy which could provide 
insight into the development 
of insulin resistance 
 Lean subjects provide a 
negative control group with 
respect to obesity 
 Time course study within the 
hyperinsulinemic-euglycemic 
clamp helps elucidate 
dynamic changes in 
metabolites in response to an 
acute glucose feed 
 
 Cross-sectional study design 
does not provide insight into 
the progression of insulin 
resistance or prior health 
status of these subjects 
 Small sample size (n=18) 
 Targeted metabolomics 
identified only specific 
metabolites while unexpected 





Figure 5.1 Summary of Aim 1 PUFA/CHO and MEAL Study Findings  
 
Schematic of the findings of Aim 1 from the PUFA/CHO and MEAL studies. The Lipidome 
converged after 3 days of a standard diet then diverged to high fat/low carbohydrate and low 
fat/high carbohydrate phenotypes. The 54 sentinel lipids are listed on the right with 12 final 
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